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“Therefore, since I myself have carefully investigated 
everything from the beginning, it seemed good also to me to 
write an orderly account” 
 
Luke Ch1 v 3 
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Summary 
 
Background: Outcomes in the management of early rheumatoid arthritis (RA) have been 
significantly improved through the use of composite disease activity measures (such as the 
DAS28) and aggressive DMARD escalation until a lower disease activity target has been 
achieved. Imaging studies suggest that the DAS28 may be insensitive to low levels of subclinical 
active disease that is associated with an increased risk of flare and progressive joint damage. 
Further, in some cases, elevations of the DAS28 may not necessarily be related to on going 
active synovitis. In both instances, relying upon the DAS28 assessment alone may lead to 
patients being considered for an inappropriate treatment decision since, patients with active 
subclinical disease may not be considered for further DMARD escalation whilst patients with non-
inflammatory causes of DAS28 elevation may be offered additional DMARD therapy that is either 
ineffective or potentially toxic. There is emerging evidence that musculoskeletal ultrasound 
(MSUS), gene expression profiles and inflammatory protein microarrays might provide useful 
additional disease activity information that allows clinicians to reach a treatment decision that is 
targeted at an individual patient’s specific needs 
 
Objectives: 
 
1. To determine whether using MSUS assessment of global disease activity in addition to the 
DAS28 produces significantly better short-medium term clinical and radiological outcomes 
2. To determine whether grouping early RA patients by either RA phenotype or disease 
activity level is associated with evidence of differential gene expression between the 
comparator groups 
3. To determine the degree of correlation and agreement between the Multi-Biomarker 
Disease Activity (MBDA) test, the DAS28 and a MSUS disease activity assessment 
 
Methods 
 
111 patients with either clinical diagnoses of early RA (symptom duration < 1 year) or anti-CCP 
antibody positive inflammatory arthritis were recruited to the Targeting Synovitis in Early 
Rheumatoid Arthritis (TaSER) study. Clinical consultations occurred monthly for 18 months and 
all participants were treated using the same step-up DMARD-biologic escalation protocol. 
Participants were randomised to either a DAS28 or MSUS assessment group. In the DAS28 
group, DMARD therapy was escalated until DAS28 low disease activity (LDAS – DAS28 <3.2) 
had been achieved. In the MSUS group, MSUS assessment was indicated for instances of 
DAS28 LDAS or DAS28 moderate disease activity (3.2≤	 DAS28 <5.1) with minimal clinical 
synovitis (28SJC ≤1). During MSUS assessment, the bilateral radiocarpal, index and middle 
MCP, index and middle PIP and 2nd and 5th MTP joints were examined for the presence of gray 
scale synovial hypertrophy and Power Doppler (PD) signal. Active disease was defined as the 
presence of grade 1 or higher PD signal in 2 or more joints. DMARD therapy was not changed if 
there had been significant escalation within the preceding 3 months. Intra-articular and intra-
muscular corticosteroid injections were administered generously during periods of active disease. 
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Blinded clinical outcomes were collected at baseline and every 3 months until study completion. 
Plain x-rays of hands and feet and MRI of the dominant wrist and hand were performed at 
baseline and study completion and will be graded by 2 independent radiologists who are blinded 
to participant’s randomisation group. Primary outcomes comprised: 1. mean change in DAS44 
from baseline and 18 months, 2. mean change in MRI RAMRIS erosion score between baseline 
and 18 months. Secondary outcome measures included: between group comparisons of the 
DAS44 and ACR-EULAR remission rates, EULAR response criteria, HAQ, EURO-QoL 5D, CRP, 
ESR, 10cm pain visual analogue score, mean change in plain x-ray Sharp score (van der Heijde 
modification) and mean change in MRI RAMRIS synovitis and bone marrow oedema scores.  
 
79 Participants donated additional blood samples for nested biomarker analysis at baseline, 
follow-up months 3 and 18. Baseline and 3 month PAXgene RNA samples were analysed with 
the assistance of the Systems Biology Group, Institute of Cardiovascular and Medical Sciences, 
University of Glasgow using an Illumina HumanHT-12v4 Beadchip microarray. Baseline, 3 month 
and 18 month serum samples were analysed by Crescendo Biosciences using their in house 
MBDA microarray. Additional whole blood, serum and plasma samples remain available for future 
polyomic analyses. For the gene expression analysis, participants were segregated into 
comparator groups based upon baseline and 3 month RA phenotypic and disease activity data. 
Comparator groups were intended to represent common clinical scenarios. Between group 
comparisons of gene expression were conducted in the R software package using the Linear 
Models for Microarray Data (Limma) plug-in. An adjusted p value <0.05 was considered to 
represent evidence of differential gene expression. For the MBDA analysis, the degree of 
correlation (Spearman’s rank correlation) between DAS28 and MBDA score was calculated at 
each time point and for all time points pooled together. The percentage agreement between 
MBDA, DAS28 and MSUS disease activity state categorisations was also calculated. 
 
Results 
 
111 participants were recruited and 101 (91%) completed follow-up. 95 (86%) participants fulfilled 
1987 ACR RA classification criteria and 107 (96%) fulfilled 2010 ACR-EULAR RA classification 
criteria. The presenting features appeared typical of an early RA cohort and, excepting gender, 
there were no statistical differences in baseline characteristics between the groups 
 
414 MSUS assessments were performed, 369 MSUS assessments coincided with DAS28 LDAS, 
of which 92 (25%) identified active synovitis. 271 MSUS assessments coincided with DAS28 
remission, of which 66 (24%) identified active synovitis. 45 MSUS assessments coincided with 
DAS28 moderate disease activity of which 15 (33%) identified active synovitis. Overall 71% of 
paired DAS28 and MSUS assessments agreed on the disease activity state 
 
MSUS-driven DMARD escalation was not associated with significant improvements in clinical 
outcomes.  Both groups experienced a similar mean change in DAS44 between baseline and 18 
months (DAS28 -2.51 vs MSUS -2.76, p 0.39). There were no statistically significant between 
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group differences in the ACR core set variables at any of the time points, nor their mean change 
from baseline. Over the follow-up period, the MSUS assessment group demonstrated incremental 
increases in the proportion of participants with EULAR good responses and DAS44 remission 
and a significantly higher rate of DAS44 remission at study completion (DAS28 44% vs MSUS 
65%, p=0.045). The impact of MSUS-driven DMARD escalation on radiological outcomes, 
medium-long term outcomes and adverse event rates remains to be determined. 
 
At baseline, gender (61 genes), RhF status (5 genes) and current smoking (1 gene) were 
associated with evidence of differential gene expression. The expression patterns of 19 genes 
changed following commencement of DMARD monotherapy. However, it was not possible to 
demonstrate evidence of differential gene expression in relation to disease activity level or 
phenotypic extremes at either time point. Up-regulation of 3 genes at baseline was associated 
with requiring DMARD escalation at 3 months. Otherwise, baseline gene expression was not 
predictive of 3 month disease activity state nor disease course over 12 months. Mean baseline 
interferon response gene score was not predictive of response to step-up DMARD therapy 
 
The MBDA test score correlated positively with DAS28 at a single time point (rs=0.58, p<0.0001) 
and the change correlated positively with corresponding changes in DAS28 (rs=0.56, p<0.0001). 
The MBDA test categorised a higher proportion of participants with moderate and high disease 
activity than the DAS28; however, a notable proportion of high (58%) and moderate (59%) MBDA 
assessments were not associated with MSUS evidence of synovitis.  
 
Conclusions 
 
MSUS and MBDA assessments of global disease activity identified active disease more 
frequently than corresponding DAS28 assessments. Compared to DAS28 driven therapy, MSUS 
driven step-up DMARD escalation was not associated with significantly better clinical outcomes 
but was associated with a higher rate of DAS44 remission at study completion. At present, there 
is no evidence to support the routine of MSUS to assess global RA disease activity; however, this 
position may change once the radiological and medium-long term outcomes are available. 
Peripheral blood gene expression analysis does not appear to contribute clinically useful 
additional information to the assessment of early RA. The MBDA test may provide an additional 
measure of disease activity; however, issues relating to specificity and its impact on clinical 
outcomes remain to be clarified. 
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1. Introduction 
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Rheumatoid arthritis (RA) is a chronic, immune-mediated, inflammatory polyarthropathy, 
predominantly affecting the peripheral synovial joints, which can be associated with significant 
extra-articular and systemic comorbidities. If left either untreated, or inadequately treated, 
patients accumulate an increasing burden of erosive joint damage, progressive joint deformity, 
disability, socio-economic decline and premature mortality. Modern drug therapies and treatment 
regimens have significantly improved clinicians’ ability to control the inflammatory process, so 
retarding, but not always preventing, structural and functional decline. Unfortunately, a significant 
subset of patients continue to experience persistently active disease and/or progressive joint 
damage. Recent advances in imaging technologies and understanding of RA pathogenesis offer 
new ways of 1. identifying persistent synovitis and 2. identifying those patients likely to be at an 
increased risk of either persistently active disease and/or progressive joint damage 
 
1.1 Clinical Features 
Population studies performed in European and North America suggest that the prevalence of RA 
is between 0.5 and 1% (1,2). At onset, and during active phases of the disease, patients describe 
pain, stiffness and loss of function of the affected joints. Pain and stiffness are typically worse in 
the morning, or after resting, and are improved by repeated movements. Any synovial, diathrodial 
joint can be involved, though typically patients present with a persistent, symmetrical peripheral 
polyarthritis affecting the metacarpophalangeal joints (MCPj) and/or proximal interphalangeal 
joints (PiPj) of the hands, the wrists and the metatarsophalangeal joints (MTPj) of the feet. (3,4). 
Larger joints (e.g elbows, shoulders, knees and hips) may also be affected but less commonly so. 
Patients may describe less specific systemic features such as lethargy, loss of appetite and 
weight loss. Clinical examination will identify the pattern of affected joints and confirm the 
presence of synovitis (the clinical expression of the inflammatory process). Synovitis is 
characterised by soft tissue swelling, with or without effusion, and tenderness related to the joint. 
It is often associated with loss of usual joint function. At presentation, joint deformities are 
unusual; however, patients with longstanding – or particularly aggressive – RA may exhibit 
subluxation and ulnar deviation of the wrists and MCPj, subluxation of the MTPj and characteristic 
hand deformities, such as swan necking and Boutonniere’s deformity. As a systemic inflammatory 
condition, the clinical features of RA are not confined to the joints; a subset of patients may also 
develop extra-articular features, such as rheumatoid nodules, pulmonary fibrosis, pulmonary 
nodules, pleural and pericardial inflammation, pericardial effusions, splenomegaly and Felty’s 
syndrome, vasculitis, mononeurtitis multiplex and/or inflammatory eye lesions,  
 
1.1.1 Diagnosis 
Traditionally, the diagnosis of RA was made on clinical and radiographic grounds by the 
identification of a symmetrical, peripheral inflammatory polyarthropathy affecting the small joints 
of the hands and feet and often in association with a positive, disease appropriate autoantibody 
(rheumatoid factor and/or anti-cyclic citrillunated peptides) and/or a characteristic extra-articular 
feature (such as rheumatoid nodules). However, this approach alone could lead to a delayed, or 
inappropriate diagnosis, in a significant subset of patients, since: 
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I. The classical, clinical presentation can be emulated by other inflammatory conditions, 
such as psoriatic arthritis or polyarticular gout 
II. In the very early stages after symptom onset, a significant subset of patients will present 
with an asymmetric, inflammatory oligoarthritis which does not fit the classical clinical 
picture  
III. Rheumatoid factors (RF) and anti-cyclic citrillunated peptide antibodies (anti-CCP) can be 
detected in serum for several years before the onset of clinical disease (5-7) 
IV. RF has been identified in patients with a number of other rheumatological (e.g. Sjogren’s 
syndrome, connective tissue disease, idiopathic inflammatory myopathies) and non-
rheumatological disorders (e.g. chronic infection – notably subacute bacterial 
endocarditis, hepatitis B and hepatitis C – fibrotic pulmonary disorders, malignancy and 
primary biliary cirrhosis)(8,9) and also in healthy subjects  
V. RF and anti-CCP assays have only moderate sensitivity (48% and 54% respectively) 
(10); thus reliance on the presence of autoantibodies will misclassify a significant subset 
of patients  
 
The role of disease classification criteria 
A number of classification criteria have been proposed to try and encourage uniformity of RA 
diagnosis in patients recruited to clinical trials. These criteria may estimate long-term prognosis 
based upon presenting features and may also facilitate early diagnosis by identifying those 
patients at an increased risk of progressing to rheumatoid arthritis from amongst all patients with 
undifferentiated inflammatory arthritis. 
 
i. The 1987 American College of Rheumatology (ACR) Classification Criteria for RA (11) were 
developed to distinguish RA from other rheumatological conditions. They comprise: 
 
1. early morning stiffness lasting more than one hour,  
2. arthritis (soft tissue swelling) around three or more joint areas,  
3. arthritis of hand joints – swelling in at least one area from wrist, MCP and PIP  
4. symmetrical distribution of arthritis,  
5. rheumatoid nodules,  
6. presence of RF,  
7. radiographic erosions, and/or periarticular osteopenia, affecting the hand and wrist 
joints on plain x-ray.  
 
RA is confirmed by the presence of four or more of the criteria with criteria 1 – 4 having been 
present for at least 6 weeks. However, the criteria’s ability to identify the early often non-erosive 
stages of RA is limited since they are prejudiced against patients with asymmetric, oligoarticular 
presentations and certain components (most notably radiographic erosions) are more commonly 
associated with longstanding RA. Whilst periarticular osteopenia and erosions are common in the 
early stages of RA (12) they are not specific for RA, having been described in association with 
other inflammatory arthritidies (particularly psoriatic arthritis). Further, it is increasingly recognised 
that the 1987 ACR criteria are limited since they differentiate patients with established RA from 
patients with other inflammatory arthritidies, an approach that runs contrary to the current 
consensus of early diagnosis and treatment (13) 
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ii. The 2010 Joint ACR and European League Against Rheumatism (EULAR) Classification 
Criteria for RA (13) were developed as a way of identifying those patients with undifferentiated 
inflammatory synovitis whose presenting features suggested that they were at a sufficiently high 
risk of developing either persistent inflammatory and/or erosive disease that they could be 
classified as having RA and commenced upon prompt immunomodulatory therapy (13). The 
classification algorithm requires the presence of at least one clinically swollen joint and then 
baseline clinical (symptom duration and distribution of clinical joint involvement), immunological 
(serology (RF and anti-CCP titres) and acute phase (CRP and ESR)) factors are scored 
depending upon their degree of involvement. A symptom duration of 6 weeks or greater gains 
additional weighting to allow differentiation from other, self limiting causes of inflammatory 
arthritis. When applied to the presenting features of a population of patients with undifferentiated 
inflammatory synovitis the 2010 ACR/EULAR Criteria classified a greater proportion of patients as 
RA, and allowed earlier introduction of disease modifying anti-rheumatic drug therapy (DMARD) 
than the 1987 ACR Criteria (14). 
 
iii. The ‘Visser Criteria’ (15): prospective observation of 524 patients with early arthritis lead to the 
development of a statistical model which uses baseline presenting clinical (symptom duration, 
morning stiffness, arthritis in 3 or more joint groups, positive metatarsal squeeze test), 
immunological (IgM-RF and anti-CCP status) and radiological (presence of erosions on hand or 
foot xrays) factors to 1. determine the risk of a patient developing persistent arthritis (compared to 
self-limiting) and then 2. determine the risk of a patient with persistent arthritis developing erosive 
joint damage over 2 years follow-up. Receiver operating characteristic curve analysis 
demonstrated that this model’s ability to discriminate persistent from self-limiting and erosive from 
non-erosive arthritis (i.e features supportive of the need for DMARD therapy) was significantly 
greater than the 1987 ACR Classification Criteria. The presumption being that persistent 
inflammatory arthritis, with a high risk of developing erosions, was highly likely to be RA 
 
iv. The ‘Leiden Prediction Rule’ (16) comprises nine baseline demographic (age, sex) clinical 
(distribution of joint involvement, morning stiffness 100mm VAS, tender joint count, swollen joint 
count) and laboratory factors (C-reactive protein level, RF and anti-CCP status) that logistic 
regression analyses have shown to be independently predictive of the 1 year risk of developing 
RA in patients presenting with undifferentiated inflammatory arthritis. Higher scores are 
associated with a greater probability of developing RA. A subsequent validation exercise 
demonstrated that this prediction rule retained excellent discriminative ability to determine the 
likelihood of progressing to RA when applied to three geographically distinct European 
undifferentiated arthritis cohorts (17) 
 
However, not all patients with undifferentiated inflammatory arthritis (UIA) will develop RA. 
Prospective observation of several inception cohorts has shown that approximately 60% of 
patients with UIA will spontaneously remit, approximately 30% will progress to RA and 
approximately 10% will develop an alternative inflammatory arthritis (18,19). The diagnostic and 
classification criteria described above serve as a means of differentiating those patients with very 
early RA, who may not yet exhibit classical clinical features but still require early DMARD therapy, 
from all other UA patients. In this way, patients with very early RA should not experience any 
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delay to the introduction of DMARD therapy and patients with UIA that is likely to remit will avoid 
the inherent risk of adverse effects associated with unnecessary therapy.  
 
1.1.2 Clinical Course 
Following diagnosis, RA does not follow a uniform, or predictable clinical course. Spontaneous 
remission, without pharmacological intervention, is rare. Clinical course varies markedly between 
patients; some will experience a mild, virtually self-limiting condition whereas others may 
experience severe, rapidly progressive joint disease associated with significant systemic 
inflammation (4). Furthermore, the duration and magnitude of a positive response to an individual 
DMARD varies considerably between patients and, even with DMARD treatment, many patients 
will experience persistently active disease, progressive erosive joint damage and eventually 
functional decline (4,20). Three broad, long-term disease trajectories have been postulated 
(4,21): 
 
1. Persistently active disease – persistent synovial and systemic inflammation causes 
progressive joint destruction, loss of functional ability and disability 
2. Intermittently active disease – affects approximately 15-30% of patient. The level of 
synovial and systemic inflammation fluctuates and, with therapy, patients may experience 
prolonged periods of clinical remission. However, acute relapses may occur, involve new 
joint groups and may not be associated with an obvious precipitant. The risk of erosive 
progression is highest during an acute relapse 
3. Prolonged clinical remission – is experienced by approximately 10% of patients. Patients 
may still experience occasional acute relapses; however, the long term risk of progressive 
joint damage and functional decline is low 
 
The impact of disease activity and structural damage on functional capacity 
In many patients functional capacity often declines steadily over the disease course (22,23). 
However, at any given time point, the functional limitations imposed by RA are caused by a 
combination of the burden of inflammatory disease activity and the level of structural joint damage 
that has accumulated until that point. Over the long term course of RA, the balance, and relative 
importance, of these factors often shifts from the initial symptoms of active joint inflammation (i.e 
disease activity) to the limitations caused by irreversible bone erosions and joint deformity (i.e. 
structural damage) (24). 
  
Prospective observational studies have attempted to describe the impact, and relationship 
between, disease activity and structural damage on functional capacity in patients with newly 
diagnosed RA.  
 
• Drossaers-Bakker et al described the functional outcomes in 138 females with newly 
diagnosed RA over 12 years of therapy (23). Functional capacity (Health Assessment 
Questionnaire (HAQ)) declined slowly over the follow-up period (baseline 0.63 (median); 12 
years 0.87). Disease activity (44 joint Disease Activity Score (DAS44)) remained relatively 
stable (baseline = 2.9 (median); year 3 = 3.1; year 6 = 2.8; year 12 = 2.5) with a statistically 
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significant positive correlation between DAS44 and HAQ at each of the time points 
(Spearman’s Correlation Coefficients: baseline = 0.68, year 3  = 0.51, year 6 = 0.52, year 12 = 
0.61; p<0.001 each correlation). Structural damage (modified Sharp Score) declined 
throughout the study (total score: baseline = 0 (median); year 3 = 29; year 6 = 56; year 12 = 
145) and was positively correlated with HAQ at each time point. A multivariate regression 
model demonstrated that DAS44 was the main determinant of functional capacity over the 
duration of the study and explained 51% of the variance in HAQ. Structural damage’s 
contribution to the HAQ was of a lesser magnitude and, when added to the same multivariate 
regression model, explained an additional 12% of the variance in HAQ. 
 
• Welsing et al observed 378 patients with early RA (< 1 years duration) for 9 years (24). 
Functional capacity (HAQ disability index (HAQ-DI)) declined over the follow-up period 
(baseline = 0.47 (median); 9 years = 0.63) at a decrement rate of 0.02 units per year. Disease 
activity levels (DAS44) improved initially and then remained constant. Correlation analyses 
demonstrated a statistically significant positive correlation between DAS44 and HAQ-DI at 
baseline, 3 and 6 years but not at 9 years (Pearson’s Correlation Coefficients: 0.4, 0.4, 0.7 
and -0.02 respectively). Structural damage (modified Sharp Score) worsened throughout the 
study (baseline = 11 (median); 9 years = 83.8), however did not exhibit a statistically 
significant positive correlation with HAQ-DI until 6 and 9 years of follow-up (Pearson’s 
Correlation Coefficients: 0.15, 0.06, 0.75, 0.57). Furthermore, multiple linear regression 
analyses demonstrated that at 6 and 9 years follow-up structural damage modified, and down-
played, the influence of DAS44 on HAQ.  
 
Taken together, these results suggest that disease activity has the greatest impact on functional 
capacity in the early years after disease onset; whilst in the later years structural damage exerts a 
greater influence. However, disease activity and structural damage are not mutually exclusive. 
Clearly, there may be an inter-relationship between the total amount of inflammation a patient has 
been exposed to and the level of structural damage that they subsequently develop. Wick et al, 
demonstrated that joint destruction was a result of cumulative exposure to inflammation by 
constructing a mathematical model based upon the clinical and radiological outcomes of 76 
patients with early RA (25). Cumulative inflammatory burden (area under the curve for DAS28) 
correlated positively with the observed joint destruction (modified Larsen Score) and was 
modified by a constant factor for each patient. Furthermore, whilst studies of plain radiographs 
(26-28) and MRI (29,30) have demonstrated that erosive structural damage is present in the very 
early stages of RA it is rare for bone marrow oedema (a marker for future erosions on MRI) to 
occur in the absence of synovitis (i.e active disease). 
  
Predicting long-term prognosis in early rheumatoid arthritis 
Determining prognosis in RA is closely associated with trying to predict a patient’s likelihood of 
response to disease modifying therapy and therefore their likely long-term inflammatory disease 
burden. Prognosis is not precisely defined, but most commonly refers to a continuum of disease 
outcomes beginning with the likelihood of a patient responding to disease modifying therapy, 
developing progressive joint erosions, joint deformity loss of function and eventually long-term 
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disability (Figure 1).  
 
Identifying patients with poor prognostic features (i.e. those at the highest risk of persistently 
active and progressive disease) may allow tailoring of therapy to individual patient’s needs. 
Based on presenting features, patients considered to have a comparatively poor long-term 
prognosis could be identified at outset and ‘triaged’ to receive a more aggressive initial treatment 
regimen compared to those with a more favourable prognostic profile.  
 
A number of demographic and disease related factors have been shown to have prognostic 
properties and can be divided into those that are fixed and those that are potentially modifiable 
(31,32): 
 
Fixed predictors of prognosis 
Age and Gender – It is well established that there is a higher incidence and prevalence of RA 
amongst women than men (33-35). A large, cross-sectional cohort study in 6004 patients has 
demonstrated that women consistently exhibit higher scores for disease activity (ACR Core set: 
DAS28, 28 tender and swollen joint counts, ESR, global health VAS, pain VAS and physician 
global estimate), lower remission rates, worse functional ability (HAQ) and have a higher 
prevalence of erosions compared to men (36). Furthermore, several longitudinal studies of 
patients with newly diagnosed, and untreated, RA have demonstrated that women tend to 
experience persistently higher overall measures of disease activity, lesser rates of remission and 
greater degrees of functional decline even though disease characteristics at presentation are 
similar to men (37-40).  
 
Considering mortality, younger age at symptom onset (< 55 years) has been associated with a 
higher risk of death from cardiovascular disease (41,42). However, the influence of age at onset 
on RA outcomes is less clear and the evidence is often conflicting. Prospective follow-up (median 
3.6 years) of 400 patients with newly diagnosed RA demonstrated that those with late onset 
disease (age > 65 years) experienced similar changes in disease activity, radiographic 
progression and functional ability, and higher remission rates, compared to those with early onset 
disease (age < 65 years) (43). However, conversely, step-wise regression analysis of a six year 
study of 332 patients with early RA showed that older age at presentation was predictive of higher 
disease activity measures, higher rates of radiographic progression and worse functional ability 
over the follow-up period (44). Camacho et al investigated the inter-relationship between age at 
presentation and gender on RA prognosis by examining the disease activity and functional ability 
outcomes of 3666 patients with recent onset inflammatory polyarthritis (45). At presentation 
women of all ages had similar levels of functional impairment and, overall, women generally had 
higher levels of functional impairment than men at any given follow-up time point. However, 
beyond 5 years of follow-up women with very late-onset disease (age > 75 years at presentation) 
experienced a more rapid acceleration in functional decline than those presenting at an earlier 
age. These results suggest that the impact of sex on RA disease activity is evident at 
presentation; however, the impact of age at presentation on functional ability, and therefore 
prognosis, may not become evident until much later in the follow-up period 
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Figure 1 – Prognostic continuum in rheumatoid arthritis 
 
Auto-antibody Status – Rheumatoid factors (RhF) and anti-citrillunated protein antibodies (ACPA) 
are important diagnostic indicators for RA and feature prominently in the 2010 ACR/EULAR RA 
Classification Criteria (13,46,47). RhF seropositivity has been associated with an increased rate 
of extra-articular manifestations (e.g. rheumatoid nodules, rheumatoid vasculitis) (48), increased 
mortality (49,50) and faster rates of destructive radiographic progression over 3–10 years follow-
up (47,51). Equally, possession of ACPA antibodies has consistently been shown to be 
associated with higher measures of disease activity and rates of radiographic damage 
progression over time. (1,8,51-53). Whilst presenting clinical disease activity measures and 
radiographic findings were similar for patients with ACPA-positive and ACPA-negative RA, van 
der Helm-van Mil et al demonstrated, that on longitudinal follow-up, ACPA-positive patients 
exhibited persistently higher swollen joint counts (a surrogate for clinical synovitis) and 
significantly higher scores for radiological damage (total Sharp-van der Heidje Score; p < 0.001) 
(52). Similarly, Ronnelid et al showed that, over 5 years follow-up, ACPA-positive patients had 
experienced persistently, statistically significant, higher levels of disease activity (ESR, swollen 
joint count, DAS28) and higher rates of radiological progression (change in Larsen Score (mean): 
9.7 vs 6.9; p = 0.01) compared to ACPA-negative patients who had otherwise similar presenting 
features and received a similar intensity of immunomodulatory therapy (1). 
 
Radiographic Evidence of Structural Damage – Patients with evidence of structural joint damage 
on presenting plain x-rays of hands and feet are at an increased risk of accumulating further 
damage in the future (3,5,54). Post-hoc analysis of 870 patients recruited to the ASPIRE study 
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found that patients with evidence of structural damage at baseline were at a greater risk of 
developing further damage after 1 year than those with no structural damage (5). Furthermore, 
patients were more likely to develop worsening of whichever radiographic finding (i.e. joint space 
narrowing or erosions) was particularly prevalent on the baseline radiographs.  
 
Genetic Factors – Multiple studies have identified specific genes associated with RA 
susceptibility. There has been far less research into whether or not specific genes are associated 
with treatment outcome and prognosis. A meta-analysis of 29 studies did demonstrate that, in 
most populations, possession of the shared epitope (HLA-DRB1) was associated with a 
significantly higher risk of developing plain x-ray erosions (OR 2.0; 95% CI 1.8-2.2) (8). 
Furthermore, several studies have shown that possession of specific genetic polymorphisms is 
associated with the likelihood of a positive treatment response (and thereby indirectly imply 
prognosis) to either methotrexate (55) or anti-TNF alpha blocking therapy (56,57). 
Pharmacogenetic analysis of the BeST Study has shown that, in early RA, carriage of the AMPD1 
34T, ATIC 347CC, and/or ITPA 94CC alleles is associated with a good clinical response 
(achieving DAS44 < 2.4 after 6 months therapy) to methotrexate monotherapy which is 
particularly evident when all three alleles are present (OR 27.8; 95% CI 3.2-250) (55). In 
established RA, possession of specific single nucleotide polymorphisms (SNPs) within specific 
candidate genes, relating to the Toll-like receptor and NFκB signalling pathways, have shown a 
positive association with the absolute change in clinical disease activity (CHUK, IKBKB, MyD88, 
NFκB1A, TLR-2, TLR-4) and likelihood of achieving a moderate-good EULAR response (CHUK, 
IKBKB, MyD88, TLR-2, IRAK3, NFκB-2, NFκBIB, PTGS2, TLR10/1/6), following commencement 
of anti-TNFα blocking therapy (56). Furthermore, in a similar population, possession of SNP 
variants in two RA susceptibility genes (AFF3, CD226) has also been shown to have a 
statistically significant association with the observed clinical response to anti-TNFα blocking 
therapy (57); thus suggesting that particular susceptibility alleles might also have implications for 
treatment response and feasibly prognosis 
 
Potentially modifiable predictors of prognosis 
Modifiable predictors of prognosis relate to either those external factors which have been strongly 
linked to RA pathogenesis, and can potentially be removed through lifestyle / environmental 
adjustment (most notably smoking), or those disease specific factors that therapeutic intervention 
aims to influence 
 
Tobacco Smoking – Tobacco smoking has implications for both RA susceptibility and long-term 
prognosis following clinical disease onset. Compared to never-smokers, those who smoke more 
than 25 cigarettes per day are at 32% increased risk of developing RA (OR 1.32; 95% CI 1.19-
1.46) and a 44% increased risk of developing RhF-positive RA (OR 1.44; 95% CI 1.23-1.65) (58). 
In the same analysis, longer periods of cigarette smoking exposure exerted a greater influence on 
the likelihood of developing both RA and RhF-positive RA than the quantity of cigarettes being 
smoked. Furthermore, there is a strong gene-environmental interaction evident in cigarette 
smokers who may already be genetically predisposed to develop RA. Individuals who are 
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homozygous for the HLA-DRB1 shared epitope and are cigarette smokers are at a significantly 
increased risk of developing ACPA-positive RA compared to shared epitope positive non-
smokers (OR 17.8; CI 10.8-29.4)(59,60).  
 
Cohort studies have also demonstrated that cigarette smoking increases an individual’s risk of 
developing RA that exhibits other poor prognostic features. Once RA is established, cigarette 
smoking has been associated with an increased risk of extra-articular disease (most notably 
rheumatoid nodules and pulmonary complications), lower measures of functional ability and a 
higher burden of radiological joint damage (61,62). Furthermore, cigarette smoking may influence 
longer-term prognosis by modulating a patient’s treatment response to both conventional DMARD 
and biologic therapy. A prospective study of 225 patients with early RA (<2 years duration) 
demonstrated that cigarette smoking was the only factor significantly associated with the 
likelihood of a patient not achieving ACR50 response after 6 months of combination DMARD 
therapy (OR 3.91; 95% CI 1.41–10.81) (21). Additionally, of 1430 patients with early arthritis, 
those who smoked were significantly less likely to achieve a EULAR good response after 3 
months of therapy with either methotrexate (n = 873; 27% vs 36%, p = 0.05) or anti-TNFα 
blocking therapy (22). Taken together, all of these results suggest cigarette smoking is likely to be 
a poor prognostic factor since it increases the likelihood of developing RA (particularly in 
individuals who are already at an increased genetic risk), is associated with an increased risk of 
developing poor prognostic features and is associated with lesser treatment responses 
 
Time to Initiation of DMARD Therapy – Following onset of clinical disease a therapeutic window 
has been proposed when the emerging inflammatory process is considered most amenable to 
intervention and therefore most likely to respond positively to therapy. Certainly, delays in 
commencement of DMARD therapy have consistently been associated with lesser treatment 
responses and poorer long-term clinical and functional outcomes (7,63). Pooling outcome data 
from 14 randomised clinical trials of DMARD therapy in RA (1435 patients in total) demonstrated 
that there is an incremental decline in treatment response the longer after symptom onset that 
therapy is initiated (mean ACR response rates: <1 year duration 53%, 1-2 years 43%, 2-5 years 
44%, 5-10 years 38%, >10 years 35%; p = 0.001) (64). Similarly, longer disease durations prior to 
commencing DMARD therapy have been associated with significantly lesser chances of 
achieving clinical remission (65,66) and lesser improvements in functional ability during therapy 
(67). Whilst delays in commencement of DMARD therapy adversely affect short-term therapeutic 
response, they also have important prognostic implications since they are often eventually 
associated with worse long-term radiological outcomes. Meta-analysis of 12 randomised clinical 
trails of DMARD therapy in early RA has demonstrated that early initiation of DMARD therapy 
resulted in a 33% lesser rate of radiographic progression compared to delayed therapy (mean 
delay = 9 months) (26). 
 
Disease activity at presentation – Long-term cohort studies have demonstrated that patients who 
present with low levels of inflammatory disease activity and lesser degrees of functional 
impairment have comparatively better prognoses than those who present with high levels of 
inflammatory disease activity. Gossec et al prospectively followed 191 patients with early 
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rheumatoid arthritis for 5 years. Those patients who presented with lower clinical measures of 
disease activity (DAS44 < 4; RAI < 17), lesser degrees of functional impairment (HAQ < 1.25) and 
lower laboratory measures of inflammation (CRP < 14.5mg/l) were significantly more likely to 
have achieved clinical remission by 3 years follow-up and sustained remission after 5 years 
follow-up (29). By inference, those patients who present with high measures of disease activity, 
functional impairment and/or acute phase response would be expected to have a comparatively 
poorer treatment response and thus prognosis. To some extent this has been borne out. Follow-
up of 191 early RA patients has shown that high baseline measures of CRP and ESR (surrogates 
for disease activity) were independently predictive of the degree of functional impairment (HAQ) 
evident after 5 years of treatment (31). 
 
Longitudinal disease activity – As a chronic inflammatory disease, RA is subject to fluctuations in 
overall disease activity. Indeed, treated patients remain at risk of acute flares following either loss 
of treatment effect, and/or exposure to an external precipitating factor. Even taking into account 
the factors described in the preceding sections, long-term prognosis will still depend heavily upon 
how much persistent inflammatory disease activity that a patient is exposed to over time. 
Therefore, cumulative inflammatory disease burden, a reflection of overall treatment response 
which does not relate to a specific treatment regimen, will be an important determinant of 
prognosis but may not be immediately evident based upon presenting features alone. Persistent 
elevation of acute phase reactants (ESR and CRP), thereby suggesting persistent inflammatory 
disease activity, has been associated with progressive accumulation of erosive radiographic 
damage (33,35). Furthermore, persistent elevation of clinical disease activity measures has also 
been associated with functional decline and radiographic progression (37,68). Using a cohort of 
194 early RA patients treated with step-up DMARD therapy, Conaghan et al demonstrated that a 
higher proportion of patients with persistently high DAS28 (>5.1) and persistently moderate 
DAS28 (>3.2 and < 5.1) experienced declines in functional ability (HAQ) over 12 months follow-
up compared to those patients who had persistently low DAS 28 (<3.2) (percentage with 
deterioration in HAQ; high DAS28 46.7, moderate DAS28 21.4, low DAS28 10.9) (37). Similarly, 
Salaffi et al have demonstrated that over three years follow-up persistent elevation of disease 
activity (DAS28-CRP) was predictive of progressive radiographic damage (41). At each time 
point, compared to patients without radiographic progression, those patients who exhibited the 
greatest rate of radiographic progression consistently exhibited significantly higher levels of 
inflammatory disease activity and a greater cumulative inflammatory disease burden (AUC: 
DAS28-CRP). 
 
Biological markers of prognosis 
Multiple studies have identified biological markers, often associated with abnormal immunological 
and inflammatory processes, that are either predictive of treatment response and/or long term 
prognosis. However, few of these markers are used in routine clinical practice and the majority 
require additional validation exercises. The preceding sections have described the potential 
prognostic properties of commonly measured immunological (RhF and ACPA) and acute phase 
response (CRP and ESR) markers. The following sections will describe the potential prognostic 
properties of several investigational biological markers. In many cases, individual markers have 
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been identified through exploratory studies attempting to identify predictive markers of response 
to specific biologic agents and their prognostic properties in early RA must be inferred (69). 
 
Immunological Factors – several additional antibodies have demonstrated diagnostic properties 
which allow either clear differentiation of RA from other causes of inflammatory arthritis or 
suggest RA in patients who are seronegative for RhF and/or ACPA (70). Amongst these a 
number have also demonstrated some relationship to treatment response: 
 
i. Anti-epidermal filaggrin antibodies (anti-keratin and anti-perinucler factor) have been associated 
with persistent disease activity, and therefore treatment resistance, in early RA but do not appear 
to be associated with subsequent radiographic progression (46,47). 
 
ii. Anti-mutated citrillunated vimentin antibodies (anti-MCV; anti-Sa) may be linked to 
inflammatory disease activity since anti-MCV titres have been shown to correlate strongly with 
disease activity measures (DAS28; r = 0.5334; p = 0.0003) and allowed stratification of patients 
into groups based upon disease activity (71). Furthermore, patients with early RA who express 
anti-MCV antibodies have been shown to experience a significantly lesser treatment response 
and a greater overall inflammatory disease burden (DAS28 AUC) compared to RA patients who 
are anti-MCV negative (49). 
 
iii. Increased levels of IgG lacking galactose (termed Gal 0 glycoforms) have been associated 
with RA and have been correlated to disease activity. In female RA patients, who subsequently 
become pregnant, Gal 0 Glycoform levels are elevated in the pre-partum period, fall with 
pregnancy associated disease remission and re-increase in the post-partum period (72) 
 
Genetic Factors – particular characteristics of an individual’s genotype may influence their risk of 
developing RA and may also bear upon its long term severity once joint disease has manifest: 
 
i. Shared Epitope – Possession of specific HLA-DR allele variants (particularly HLA DR4) is 
associated with an increased risk of developing RA in the future. Furthermore, possession of the 
shared epitope has prognostic has been associated with an increased risk of developing joint 
erosions (8) and of possessing ACPA antibodies (53); both of which have independently been 
shown to be poor prognostic markers 
 
ii. Matrix Metalloproteinase Genotype – The matrix metalloproteinases are a group of enzymes 
that contribute to erosion formation through the degradation of collagen and cartilage. Possession 
of a specific polymorphism in the matrix metalloproteinase-3 gene (MMP3 6A/6A) appears to 
have prognostic implications since in a single longitudinal study of 103 early RA patients it was 
positively associated with a greater degree of erosive joint damage at presentation and a 
significantly higher rate of radiographic progression over 4 years follow-up (73). 
 
iii. Interleukin-10 Promotor Genotype – A single prospective study in 283 RA patients 
demonstrated that specific polymorphisms of the interleukin-10 promotor gene, may have 
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prognostic implications. Patients possessing alleles which coded for high levels of IL-10 
production (-2849 AG/GG) had higher titres of RA associated autoantibodies, and experienced 
greater degrees of radiographic progression over 2 years follow up, compared to those who 
possessed alleles coding for low levels of IL-10 production (-2849 AA) (54). 
 
Acute Phase Reactants – the potential prognostic role for commonly used measures of the acute 
phase response, CRP and ESR, has been discussed in the preceding section 2.1.2.2.2. 
Interleukin-6 (IL-6) is released by inflamed synovial membrane into blood and has several 
systemic effects through; regulation of platelet production, development of the anaemia of chronic 
disease and stimulation of the liver to synthesise acute phase proteins. However, whilst plasma 
IL-6 levels correlate positively with measures of the acute phase response, it is unlikely that IL-6 
has any prognostic properties since no apparent relationship between plasma IL-6 levels and the 
rate of radiographic progression has been demonstrated (74). 
 
Tissue Specific Markers – Since inflamed synovium can damage several different tissue layers of 
an affected joint it is feasible that the expression levels of markers related to metabolism / 
degradation within each of these tissue compartments might also have prognostic properties. 
However, their use in routine practice remains unclear since measurement of the marker often 
requires percutaneous biopsy procedures to harvest the target tissue 
 
i. Synovial Membrane Markers: hyaluronan is a glycosaminoglycan released by inflamed synovial 
membrane that can leak into the circulation and be measured in high levels in the serum of RA 
patients. Hyaluronan may be a marker of on going joint damage since, in a prospective study of 
40 RA patients, serum levels correlated positively with radiographic damage scores at 
presentation and remained elevated in patients who demonstrated progressive radiological joint 
destruction over 12 years follow-up (75). Matrix metalloproteinases (MMP) are released by 
inflamed synovium and contribute to joint damage by mediating cartilage degradation. Therefore, 
it is feasible that their persistent activity (or persistent elevation) could have implications for long-
term prognosis. In 98 patients with untreated RA, baseline levels of MMP-1 and MMP-3 
correlated positively with CRP (as a measure of baseline disease activity) and with the rate of 
change of radiographic damage (Larsen Index) and functional decline (HAQ) after 12 months 
follow-up (76). Furthermore, a logistic regression analysis identified baseline MMP-3 levels as the 
strongest predictor of developing radiographic damage in patients who initially had non-erosive x-
rays. 
 
ii. Cartilage-Specific Markers: elevated levels of markers of cartilage metabolism have been 
shown to have both negative and positive prognostic implications. Using hip joint destruction as a 
marker of radiographic progression, all patients with rapid radiographic progression exhibited 
elevated levels of cartilage oligometric matrix protein (COMP). Patients with slow radiographic 
progression had significantly lower levels of COMP but higher levels of chondroitin sulphate 
epitope 846, a marker of cartilage aggrecan synthesis (77). Elevated baseline urinary excretion of 
crosslinked c-terminal peptides from type II collagen (CTX-II) and degradation products of the 
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helical region of type II collagen (Helix-II), have been shown to correlate positively with changes 
in radiographic damage over 12 months follow-up (CTX-II r = 0.3, p = 0.007; Helix-II r = 0.22, p = 
0.05) (78). Furthermore, patients who exhibited elevated levels of both markers experienced 
higher rates of radiographic progression than those who exhibited elevation of either one or 
neither marker. 
 
iii. Bone-Specific Markers: several markers, specific to bone metabolism, have been linked  to the 
development of progressive joint destruction in RA. Synovial fluid, but not serum, levels of bone 
sialoprotein, a protein released by osteoblasts in juxta-articular bone, have correlated positively 
with increasing degrees of joint destruction on knee radiographs (79). However, this finding is not 
confined to RA and was also demonstrated in patients with osteoarthritis. Prospective studies 
have shown that elevated serum and urinary levels of cross-linked carboxyterminal telopeptides 
of type I collagen (ICTP) both correlate positively with measures of RA disease activity and 
appear predictive of future radiographic progression (46,80). Furthermore, persistent elevation of 
serum ICTP levels despite 6 months of DMARD treatment has been associated with increased 
rates of radiographic progression compared to those patients whose serum levels fall with 
treatment (81). 
 
iv. Vascular Markers – Whilst RA predominantly causes pathological changes within the synovial 
membrane of affected joints it is also a systemic disease and specific, pathological changes have 
been frequently described within the systemic vascular bed. Hence, markers of RA-related 
vascular inflammation might also have prognostic implications for the overall disease process. 
Vascular endothelial growth factor (VEGF) is expressed at increased levels in serum and synovial 
fluid in RA patients. In early RA, serum VEGF levels have been shown to correlate positively with 
clinical measures of disease activity (swollen and tender joint counts) and reflect treatment 
response since they decrease significantly in patients who achieve moderate-good EULAR 
response rates after DMARD therapy (59). Furthermore, baseline serum VEGF levels positively 
correlated with, and therefore may be predictive of, subsequent changes in radiological damage 
scores (Spearman’s r = 0.579, p = 0.004) 
 
To date studies attempting to identify biological markers of prognosis have tended to focus on 
single candidates or families of markers related to activity within a single inflammatory process or 
tissue compartment. However, for a disease with such a widely heterogeneous phenotype and 
clinical course as RA, it is quite possible that relying upon a single marker to provide prognostic 
information for all patients will prove inadequate. Alternatively, combining and comparing the 
expression of several biological markers, with known prognostic properties and representing the 
different genetic and cellular layers of the inflammatory disease process, might give a more 
accurate, and nuanced, indication of an individual patient’s long term disease course and 
likelihood of responding to therapy. 
 
• Proteomic analysis of serum from 44 patients with established RA identified a panel of 
proteins (IL-6, IL-2, oncostatin M, macrophage colony-stimulating factor (M-CSF), tumour 
necrosis factor receptor superfamily member 9 (TNFRSF9), CCL23, transforming growth 
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factor-alpha (TGF-alpha), CXCL13) which correlated positively with traditional disease 
activity measures and were differentially expressed between patients with RA judged to 
have either active or inactive disease (82). Furthermore, multivariate analysis created a 
statistical model comprising 5 markers (CXCL13, CCL23, TGF-alpha, TNFRSF9, M-CSF) 
which accurately predicted the disease activity level (DAS28) at the time of testing.  
 
• In a longitudinal analysis of 118 patients with early RA receiving DMARD therapy, Young-
Sim et al investigated the ability of baseline traditional clinical and laboratory disease 
activity measures in combination with serum and urinary levels of candidate markers for 
synovial inflammation and cartilage turnover to predict progression of radiographic damage 
after 2 years follow-up (83). Multivariate logistic analysis identified elevated baseline levels 
of serum MMP3 and urinary CTX-II as being the only two factors which were independently 
predictive of subsequent radiographic progression (PPV 62.1 and 57.7 respectively).  
 
1.1.3 The Pre-symptomatic Stages of Rheumatoid Arthritis 
It is not possible to make the diagnosis of RA until patients develop clinical signs and symptoms 
that suggest inflammatory joint disease (i.e. clinical synovitis). In many cases, the diagnosis is 
made on the basis of clinical features ‘fitting’ the typical description of RA and the presence of 
particular autoantibodies lends weight to the clinically suspected diagnosis. In cases where 
patients have evidence of inflammatory joint disease but do not ‘fit’ the typical description of RA, 
the presence of either RhF and/or ACPA antibodies can be used to estimate the likelihood that 
the patient is displaying an atypical or early presentation of RA or to estimate their risk of 
progressing to RA in the future. Several observational cohort studies have clearly demonstrated 
that subjects who eventually develop RA display evidence of abnormal immune activation and 
auto-antibody production for several years before the development of symptomatic joint disease 
(6,7,22,84-86). There is also a dynamic element to the autoantibody production; prior to the onset 
of symptomatic joint disease subjects exhibit a sharp increase in the overall titre of serum ACPA 
antibodies (7) and a marked expansion in the number of citrillunated epitopes that are recognised 
by ACPA antibodies (epitope spreading) (87-89). In addition to the presence of ACPA antibodies 
a number of other factors have also been suggested to increase the risk of a an at-risk subject 
eventually developing RA: 
 
Tobacco Smoking – Tobacco smoke exposure is an important component of a complex gene-
environmental interaction whereby subjects who smoke are at increased risk of developing RA, 
particularly if they already posses a genetic predisposition (60,90). Epidemiological studies of 
monozygotic twins and large prospective cohorts had previously recognised that subjects who 
smoked were more likely to develop RA than those who didn’t smoke (58,91), with the stronger 
determinant being duration of smoking, rather than volume. Several linked studies have 
demonstrated that the risk is particularly prevalent in smokers who also possess a genetic 
predisposition to the development of RA, such as the shared epitope of HLA-DRB1 or 
polymorphisms of the PTPN22 gene (60,90,92,93). Indeed, current smokers, who are 
homozygous for the HLA-DRB1 shared epitope have been found to have a 15-23 times increased 
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risk of developing RA compared to non-smokers who do not possess the shared epitope gene. 
As previously discussed, tobacco smoke exposure has consistently been shown to increase the 
risk of developing seropositive (RhF and/or anti-CCP antibody) RA. Recently it has been 
postulated that the influence of tobacco smoke on development of RA is mediated through 
abnormal immune activation, and particularly the development of autoreactivity to citrillunated 
peptides, at mucosal surfaces; such as the gums (94-96) or bronchial epithelium (97,98) 
 
Infection – The initial trigger for autoreactivity and ACPA antibody production prior to the 
development of clinical RA is incompletely understood. There is increasing evidence that the 
initial immune event may be independent of the synovium, particularly since RhF and ACPA 
antibodies are frequently detected in the absence of synovial inflammation (99). Further, there is 
an emerging consensus that infective and immune episodes that occur at mucosal sites (such as 
the gum and/or respiratory epithelium) may play a role in the initial synthesis of ACPA antibodies 
(94,98,100). Recently, it has been recognised that the presence of certain bacteria (particularly 
porphyromonas gingivalis) within the oral biofilm, and the development of periodontitis, is a risk 
factor for both the production of ACPA antibodies (94,96) and the future development of 
autoantibody positive RA (101) 
 
Hormonal Factors – The potential influence of hormonal factors on the subsequent development 
of RA is well recognised. Women are more frequently affected than men (102), the peak 
incidence occurs after the menopause and periods of hormonal flux, such as the post-partum or 
peri-menopausal periods, are frequently associated with the development of RA (103,104). There 
is conflicting evidence about the link between hormonal exposure and the development of auto-
antibodies in the pre-clinical stages of RA. Some observational studies have suggested that 
increased hormonal exposure (such as early menarche or oral contraceptive pill use) may 
increase the risk of developing anti-CCP antibodies (105), whereas alternative studies have 
suggested that oral contraceptive pill use was protective against the development of rheumatoid 
factors (106). There is little published research describing the link between hormonal factors and 
future risk of RA in asymptomatic subjects who express RA associated auto-antibodies  
 
Obesity –Obesity is often considered a state of chronic low grade inflammation and being obese 
has been associated with the development of several different inflammatory conditions. Large 
scale epidemiological studies have observed that there may be a link between body mass index 
and risk of developing RA because there were higher proportions of obese patients within the RA 
group than the unaffected control groups (107,108). However, interestingly, recent studies of the 
presenting characteristics of new RA patients have suggested that patients with auto-antibody 
negative RA have significantly higher body mass indices than those with auto-antibody positive 
RA (105,109). The risk association between body mass index and later development of RA in 
asymptomatic, anti-CCP positive individuals has not yet been described 
 
Alcohol Intake – Several, independent case-control studies have demonstrated that the level of 
alcohol consumption in unaffected control subjects is statistically higher than in incident RA 
patients; the inference being that alcohol may have a protective effect on the development of 
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RA(105,107,110). Further, a retrospective analysis conducted using blood samples donated to 
the Nurses Health Study has suggested that daily alcohol consumption was associated with lower 
levels of pro-inflammatory markers (IL-6, sRNFRII), though not anti-CCP titres, in the 
asymptomatic stages before the onset of clinical RA 
 
1.2 Current Approaches to the Management of Early 
Rheumatoid Arthritis 
 
1.2.1 Core Principles 
It is now widely accepted that DMARD therapy should be commenced as soon as possible after 
the clinical diagnosis of rheumatoid arthritis can be made in order to retard the development of 
early, irreversible joint damage and long term functional impairment (111,112). Several core 
principles underpin most commonly accepted RA treatment strategies 
 
Early Commencement of DMARD Therapy 
In the early stages of RA there appears to be a therapeutic window when the nascent 
inflammatory process is most likely to respond to therapy (the proposed window of opportunity) 
(113). The timing and duration of any therapeutic window will likely vary between individual 
patients. Both relatively short delays in the commencement of DMARD therapy, and 
presentations with longer symptom durations, have consistently been associated with lesser 
treatment responses and poorer functional outcomes. Importantly, short-term delays in therapy 
have long-term adverse consequences and, similarly, early control of inflammatory disease 
activity appears to have long-term benefits. However, despite several studies reporting similar 
results the observation remains an association, rather than a causal relationship. A number of the 
older studies may have been confounded by either not correcting for disease severity at 
presentation and/or the use of low-intensity DMARD regimens that are contrary to current treat-
to-target principles. 
 
• The FINRACo trial (FINnish Rheumatoid Arthritis Combination therapy trial), and its follow-
up studies, assessed the short, medium and long-term impact of different initial DMARD 
regimens in 195 patients with newly diagnosed RA (65,114,115). Patients were 
randomised to receive either sequential DMARD monotherapy (initially sulfasalazine) or 
combination DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine and 
prednisolone) with both groups aiming for clinical remission (ACR definition). After 2 years 
follow-up, in the sequential DMARD monotherapy arm, significantly fewer patients with a 
longer symptom duration prior to commencing treatment had achieved remission than 
those with a shorter symptom duration (ACR remission rate; symptom duration < 4 months 
= 35%, symptom duration > 4 months = 11%; p = 0.021) (65). Symptom duration prior to 
DMARD commencement did not affect the likelihood of achieving remission in the 
combination therapy arm suggesting that the adverse impact of delayed therapy might 
potentially be attenuated by using a more aggressive treatment regimen at outset 
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• Green et al investigated the apparent relationship between presenting disease 
characteristics and the likelihood of persistent disease activity in 63 patients with 
undifferentiated inflammatory arthritis (51% fulfilled 1987 ACR RA classification criteria) 
(66). A regression analysis, incorporating multiple clinical and laboratory disease activity 
variables, demonstrated that disease duration prior to receiving treatment was the only 
factor independently associated with the likelihood of patients experiencing persistent 
disease activity after 6 months follow-up (median symptom duration (IQR): persistent 
disease activity group = 20 weeks (12-32), disease remission = 10 weeks (8-20), p < 0.05) 
 
• Nell et al performed a case-control study comparing clinical and radiological outcomes in 
patients with early (< 3 months) and late (3 – 12 months) presentations of RA (116). At all 
time points over a 36 month follow-up period, patients who presented with early symptoms 
experienced significantly greater treatment responses (ΔDAS28, ACR20/50/70 responses) 
lesser measures of disease activity (DAS28), greater improvements in functional ability 
(HAQ) and lower radiographic damage scores (Larsen Index). Almost identical outcomes 
were observed when a second early RA cohort were followed over a similar period 
 
• Analysis of patients referred to the Leiden Early Arthritis Clinic has demonstrated that those 
who had longer symptom durations prior to commencement of DMARD therapy (ie delayed 
therapy), were less likely to achieve remission, and were more likely to experience 
radiographic deterioration than those with shorter symptom durations (117). Of 598 
patients with RA, 412 (86%) were assessed after 12 weeks of symptom onset and were 
considered to have received delayed DMARD therapy. Over a 6 year follow-up period, 
those patients who received delayed DMARD therapy exhibited significantly higher scores 
for radiographic damage at all time points, regardless of the favoured DMARD regimen. 
Furthermore, patients in the delayed therapy group were significantly less likely to achieve 
sustained, drug-free remission (hazard ratio: 1.8 [95% CI 1.17-3.0], p = 0.009). Older age 
at onset, gradual symptom onset, small joint involvement, presence of RhF and anti-CCP 
antibodies and low CRP levels were each independently associated with delay in review by 
a rheumatologist; however, their individual relationship to observed outcomes was not 
described  
 
Early Tight Control of Disease Activity 
If cumulative total exposure to inflammatory disease activity (ie the inflammatory burden) is 
associated with worse clinical and radiological outcomes it is reasonable to assume that an RA 
patient’s longer-term prognosis can be positively influenced by DMARD treatment regimens 
which aim to minimise overall exposure to inflammation by being intolerant of persistently active 
inflammatory disease. To some extent this presupposition has been borne out by several 
strategic RA treatment studies which used persistent evidence of inflammatory disease activity to 
trigger escalation in a patient’s DMARD therapy. 
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• The Tight Control of Rheumatoid Arthritis Trial (TICORA) demonstrated that newly 
diagnosed RA patients who underwent regular review (monthly), formal quantification of 
global disease activity (DAS44) and whose initial step-up DMARD treatment strategy was 
escalated aggressively if disease activity assessment exceeded a predefined threshold 
(DAS44 > 2.4), experienced significantly greater clinical improvements and less 
radiological progression compared to similar patients who underwent less frequent review 
and received a less aggressive DMARD treatment strategy that was guided by clinical 
findings rather than a defined disease activity target (118). 111 patients with newly 
diagnosed RA were randomised to either an intensive or routine treatment and follow-up 
strategy. At all follow-up time points, patients in the intensive group exhibited significantly 
lower disease activity scores and an overall greater improvement in all measures of 
disease activity, quality of life and functional ability. Furthermore, after 18 months follow-up 
patients in the intensive strategy group had experienced significantly lesser changes in 
radiographic erosion and total Sharp scores and lesser (not statistically significant) 
changes in joint space narrowing scores. It is worth noting that whilst presenting clinical 
and demographic features for both groups were similar the mean disease duration was 19 
months; therefore, the relatively late presentation and commencement of therapy for all 
patients may actually have had a negative impact on the impressive outcome results. 
 
• The Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA) study  (119) 
had a similar design to TICORA though utilised percentage change in disease activity 
rather than a composite disease activity measure. Two hundred and ninety-nine patients 
with early RA (symptom duration < 2 years) were randomly assigned to either an intensive 
or conventional treatment strategy group. Patients in the intensive strategy group were 
reviewed monthly and treatment escalation decisions were based upon the output of a 
computer based decision making tool which analysed the change in clinical and laboratory 
disease measures. Patients in the conventional strategy group were reviewed monthly and 
DMARD escalation decisions were at the discretion of the treating clinician. Over a 2 year 
follow-up period, patients in the intensive strategy group experienced faster falls in clinical 
and laboratory disease activity measures, a higher chance of attaining clinical remission 
(50% vs 37%; p = 0.029) and significantly longer periods of remission (mean duration: 11.6 
vs 9.1 months; p=0.025). Of the patients who did demonstrate radiographic change, 
progression rates tended to be higher in the conventional group. 
 
Taken together the results of the TICORA and CAMERA studies demonstrate that patients’ early 
response to DMARD therapy can be significantly improved through frequent reviews, formalised 
assessment of global disease activity and aggressive escalation of DMARD therapy in the 
presence of persistent disease activity. Importantly, these benefits were observed in patients who 
would now be considered to have presented relatively late (i.e outwith the proposed window of 
opportunity).  
 
Follow-up analyses of the FINRaCo trial have demonstrated that good short-term treatment 
responses have a positive medium-longer term impact. After 5 years follow-up and unrestricted 
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DMARD therapy, disease activity measures in the initial combination therapy and sequential 
therapy groups were similar, however patients in the combination therapy group demonstrated 
lower radiographic damage scores (median Larsen Index: 11 vs 24; p = 0.001) and a significantly 
lesser accrual of radiographic damage (114). After 11 years follow-up, the benefits from initial 
early aggressive therapy remained evident. Functional ability scores were similar between 
treatment groups (mean HAQ: combination therapy = 0.34, sequential therapy = 0.38); however, 
the combination therapy group demonstrated significantly higher remission rates (ACR remission 
rate: combination therapy = 37%, sequential therapy 19%), a significantly higher proportion had 
achieved minimal disease activity (combination therapy = 3%, sequential therapy = 43%, p = 
0.016) and had a greater overall chance of ever attaining ACR remission at any time point 
endpoint (115) 
 
Predefined Disease Activity Target 
The treatment regimens employed by the FINRaCO, TICORA and CAMERA studies all 
incorporated a formalised assessment of global disease activity and a threshold measure above 
which escalations in DMARD therapy would be considered. The FINRaCO study threshold was 
less than 50% improvement in any two of three criteria (swollen joint count, tender joint count, 
ESR or CRP) (120) . The TICORA study threshold was moderate disease activity (DAS44 > 2.4) 
or higher. The CAMERA study threshold was monitored by a computer programme and 
comprised less than 20% improvement in swollen joint count and less than 20% improvement in 
two out of a further 3 criteria (ESR, tender joint count, general well being VAS). In each study, 
DMARD escalation decisions for the comparator group were based upon the treating physicians 
clinical impression of global disease activity and, as previously described, were consistently 
associated with worse outcomes. This is hardly surprising since clinical examination alone for 
features of active inflammatory joint disease present is relatively insensitive (121,122). Hence, the 
effectiveness of initial step-up DMARD treatment regimens appears to be improved through 
formalised clinical assessments of global disease activity 
 
The Behandel-Strategieen (BeST) Study has further demonstrated the value of strategies which 
aim for a predefined disease activity level (123). 508 patients with untreated RA (median 
symptom duration 23 weeks) were randomly allocated to receive one of four different approaches 
to DMARD therapy; 1. sequential monotherapy, 2. step-up combination therapy, 3. combination 
DMARD therapy with tapering steroid and 4. combination DMARD and tumour necrosis factor-
alpha (TNFα) antagonist therapy. In each treatment arm therapy was escalated until low disease 
activity (DAS44 < 2.4) was achieved. Patients who received the most aggressive initial treatment 
regimens (groups 3 and 4) experienced the fastest initial improvements in measures of disease 
activity and functional impairment and longer periods of sustained remission. However, at 12 
months follow-up and after a greater number of treatment changes, patients in groups 1 and 2 
(i.e. less aggressive initial treatment strategies), had attained similar disease activity levels and 
overall response rates to those in groups 3 and 4. Radiographic progression rates were 
significantly lesser for groups 3 and 4 and it is possible that this could partly be explained by the 
earlier attainment of low disease activity in the more aggressively treated groups. That is, even 
though the final disease activity levels were similar, the groups that experienced the fastest 
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improvement in inflammatory disease activity (and the lesser cumulative inflammatory burden) 
also demonstrated lesser rates of radiographic damage progression 
 
To date, all strategic DMARD trials have employed low disease activity as a treatment escalation 
threshold rather than clinical remission. Therefore, current RA treatment guidelines state low 
disease activity (DAS28 < 3.2; DAS44 < 2.4) as the preferred disease activity target  
(124,125). However, attaining even lower levels of disease activity should be associated with 
better outcomes since the total overall inflammatory burden will have been lesser: 
 
• Cohen et al compared 3 and 5 year radiological and functional ability outcomes between 
30 patients in persistent remission (3 and 5 year DAS44 < 1.6) to 104 who had not 
achieved persistent remission (Mean 5 year DAS44 = 2.49 (i.e moderate disease activity)) 
(126). Compared to non-remitting patients, those who achieved sustained remission 
experienced greater improvements in functional ability (mean ΔHAQ: -0.97 vs -0.65) and 
lesser rates of radiographic progression (mean Δ total Sharp Score: 4.37 vs 15.01). 
 
• A post-hoc analysis of The Active-Controlled Study of Patients Receiving Infliximab for the 
Treatment of Rheumatoid Arthritis of Early Onset trial (the ASPIRE trial) compared 14 and 
54 week radiographic outcomes in patient’s who received either methotrexate and placebo 
or methotrexate and infliximab who were stratified according to their disease activity level 
(127). At all disease activity levels, patients who received methotrexate and infliximab 
combination therapy exhibited significantly less rates of radiographic progression than 
those who received methotrexate monotherapy; though anti-TNFα blockers such as 
infliximab are one of the few available therapies that have been shown to positively 
influence the development of radiographic damage. After 54 weeks follow-up, and 
regardless of the treatment group, the level of radiographic progression was positively 
associated with the measured disease activity level, since there was a step-wise increase 
in the amount of radiographic damage accumulated from the lowest to highest disease 
activity groups (mean Δ total Sharp Score: methotrexate group – remission 1.1, low SDAI 
2.2, moderate SDAI 3.9, high SDAI 5.8; methotrexate and infliximab group – remission -
0.2, low SDAI -0.4, moderate SDAI 0.6, high SDAI 2.1; p values for trend not quoted) 
 
To date, strategic studies have chosen various definitions of either low disease activity 
(118,123,128) or remission (119,120) as the target for DMARD therapy. Increasingly, consensus 
statements and international guidelines are advocating that DMARD therapy should be steered to 
achieve either clinical remission (111,124) and/or imaging remission (129), the presumption being 
that complete abrogation of inflammatory activity will be associated with the lowest likelihood of 
progressive disease. However, it is important to consider that there remain several different 
methods of classifying remission, that are not interchanageable and do not recognise identical 
disease states (130). Further, the risk:benefit balance of achieving modern definitions of 
remission remains to be determined and it may be that pursuing increasingly lower levels of 
disease activity is associated with either minimal additional clinical benefits and/or a higher risk of 
treatment associated adverse effects. 
  42 
 
1.2.2 DMARD Treatment Regimens 
The preceding section describes general principles that underpin an aggressive management 
approach that aims to optimise early treatment responses in newly diagnosed RA. However, they 
do not specify either which specific DMARDs to prescribe or the order in which they can be used. 
Diagrammatic representations of different DMARD treatment strategies are shown in Figure 2. 
‘Step-up’ strategies initially commence DMARD monotherapy and additional agents are added if 
disease activity levels remain above a treatment escalation threshold. Conversely, in ‘parallel and 
step-down’ strategies several DMARDs are commenced simultaneously and once disease activity 
levels are persistently below a predefined threshold, doses are gradually reduced until the 
disease activity level appears stable on the lowest intensity combination of DMARDS possible. 
Several clinical trials have attempted to demonstrate the efficacy of both these approaches: 
 
Step-Up DMARD Combination Therapy – formed the basis of the DMARD strategies 
underpinning the TICORA and CAMERA studies. Clinical studies have demonstrated that adding 
hydroxychloroquine, sulfasalazine, hydroxychloroquine and sulfasalazine (131), ciclosporin 
(132,133), leflunomide (134) or parenteral gold (135) to methotrexate produces additional 
improvements in disease activity measures. Initial DMARD monotherapy remains a popular first 
choice amongst rheumatologists (136) since a significant proportion of patients will respond 
adequately to monotherapy alone (137,138) and it avoids the theoretical risks of additional 
adverse effects when several DMARDs are commenced simultaneously. Further, patients who 
respond promptly to DMARD monotherapy can experience a sustained clinical response. 
Analysis of the Swedish Pharmacotherapy (SWEFOT) trial demonstrated that the majority of 
patients who experienced a satisfactory response (DAS28 < 3.2) to initial methotrexate 
monotherapy continued to exhibit sustained low disease activity over the subsequent 1 (73%) and 
2 year (69%) follow-up periods (139). However, despite the group level clinical response some 
methotrexate responders did still exhibit deterioration in all measures of radiographic damage. 
Furthermore, during the initial monotherapy stage patients who will ultimately require combination 
therapy will remain exposed to a period of persistent disease activity which is contrary to the 
principle of achieving tight control as early as possible. 
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Figure 2 – Diagrammatic representation of different approaches to DMARD initiation regimens in 
early rheumatoid arthritis  
(Reproduced from Dale and Porter, Best Pract Res Clin Rheum 2010; 443-455) 
PDAS = persistent disease activity state (DAS28 > 3.2); LDAS = low disease activity state 
(DAS28 < 3.2) 
 
Parallel and Step-Down Combination Therapy – Theoretically, commencing two or more 
DMARDs with differing modes of action simultaneously could generate improved outcomes if the 
agents interact synergistically. However, clinical studies of parallel DMARD regimens have often 
had conflicting results which could partly be explained by the choice of agents and variable use of 
corticosteroids.  
 
• The previously described FINRaCO study demonstrated that parallel therapy 
(methotrexate, sulfasalazine, hydroxychloroquine and low dose prednisolone) enabled 
significantly more patients to attain ACR remission (37% vs 18%, p=0.003) and ACR50 
response targets than those treated with sequential monotherapy (initially sulfasalazine) 
(120) . Both groups experienced radiographic progression though the accumulation of new 
erosive damage (median change in eroded joint count: 2 vs 3, p=0.006) and overall rate of 
change (median change in Larsen score 2 vs 10, p=0.002) was significantly higher in the 
monotherapy group.  
 
• Hetland et al compared the efficacy and safety of a parallel treatment strategy comprising 
methotrexate and cyclosporine (140). The Cyclosporine, Methotrexate, Steroid in RA 
(CIMESTRA) trial randomised 160 patients with untreated early RA (median disease 
duration 3.2 – 3.9 months) to receive either methotrexate and cyclosporine combination 
therapy or methotrexate monotherapy. Over the course of the study, cumulative intra-
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articular steroid doses were similar between both groups. After 52 weeks follow-up, 
response rates favoured the combination therapy group with a significantly greater number 
demonstrating an ACR20 response (85% vs 65%; p=0.02). The proportion of patients 
achieving ACR50 and ACR70 responses was higher in the combination therapy group but 
did not achieve statistical significance. There was no significant radiographic progression 
observed within or between either treatment group. Furthermore, a greater proportion of 
the combination therapy group experienced either hypertrichosis (33% vs 8%, p<0.001) or 
a greater than 30% increase in serum creatinine (19%vs 6%, p=0.03). 
 
In contrast, two earlier randomised trials demonstrated no, or modest, benefit of methotrexate 
and sulfasalazine combination therapy over either agent as monotherapy: 
 
• Haagsma et al compared 12 month clinical outcomes between 105 untreated, early RA 
patients (<12 month’s duration) randomised to receive either methotrexate monotherapy, 
sulfasalazine monotherapy or methotrexate and sulfasalazine combination therapy (141). 
Overall, patients who received combination therapy tended to experience slightly higher 
improvements in measures of clinical disease activity and functional ability. However, there 
were no statisticaly significant between group differences and patients in the combination 
therapy group did experience a higher rate of gastrointestinal intolerance 
 
• Dougados et al compared 12 month clinical and radiological outcomes between 205 
untreated, early RA patients (<1 year’s duration) randomised to receive either methotrexate 
monotherapy, sulfasalazine monotherapy or methotrexate and sulfasalazine combination 
therapy (142). Patients who received combination therapy experienced significantly greater 
improvements in DAS44 scores (mean change: SASP -1.15, MTX -0.87, MTX+SASP -
1.26, p=0.019) and tender joint counts (mean change in RAI: SASP -7.1, MTX -4.1, 
MTX+SASP -9.4, p=0.001) but not any other disease activity measure. Follow-up x-rays 
demonstrated a similar rate of radiographic progression between all groups. Patients within 
the combination therapy group experienced significantly higher rates of gastrointestinal 
intolerance and liver function test abnormalities. 
  
Having commenced parallel combination therapy it is logical to consider eventually either 
reducing the dose, or withdrawing at least some of the compoent DMARDs to minimise the 
number of medications a patient requires. The Combinatietherapie Bij Reumatoide Artritis 
(COBRA) trial was the first to systematically investigate the efficacy of this approach (143). One 
hundred and fifty-six patients with early, active RA (median duration 4 months) were randomised 
to receive either methotrexate, sulfasalazine and high-dose tapering prednisolone parallel therapy 
or sulfasalazine monotherapy. In the parallel therapy group prednisolone, and then methotrexate, 
doses were tapered to cessation at set time points rather than whenever disease activity 
thresholds were attained. Within the first 28 week follow-up period, and particularly whilst they 
remained on prednisolone, patients within the parallel therapy group experienced significantly 
greater improvements in all measures of disease activity. However, the discontinuation of 
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prednisolone coincided with a gradual coming together of both groups’ outcomes such that there 
were no significant clinical difference between either group after 56 weeks follow-up. The initial 
rapid improvement in disease activity measures experienced by the parallel therapy group was 
associated with initial slowing in radiographic damage progression. Over the first 28 week follow-
up period (during parallel therapy) the parallel therapy group experienced a significantly slower 
rate of radiographic damage progression (median Δ total Sharp Score: 1 vs 4, p<0.0001) which 
persisted, though the difference was less marked, over the second 28 week follow-up period 
(median Δ total Sharp Score: 1 vs 2.5; p=0.04).  
 
Both the FINRaCO and COBRA trials demonstrated an apparent benefit of parallel therapy over 
sulfasalazine monotherapy, and both incorporated prednisolone into the initial DMARD 
combination. In the COBRA study the initial apparent clinical benefits of parallel therapy was lost 
after the discontinuation of prednisolone. Furthermore, in the trials reported by Haagsma et al and 
Hetland et al parallel therapy with methotrexate and sulfasalazine together was only marginally 
better than monotherapy with either agent. Therefore, it is possible that the initial, benefits of 
parallel therapy demonstrated in the FINRaCO and COBRA trials are in fact related to the rapid 
immunomodulatory effects of corticosteroids rather than the theoretical synergistic effects of 
using simultaneous DMARDs 
 
Compared to DMARD monotherapy, any treatment strategy that includes DMARD combination 
therapy (whether as initial parallel therapy or as a step-up option) could feasibly be associated 
with an increased risk of adverse effects from the overlapping actions of the component 
DMARDs. A meta-analysis which used the results from 36 randomised DMARD trials of early and 
established RA has in fact demonstrated a slightly different outcome (144). Compared to DMARD 
monotherapy, combination DMARD therapy was shown to be significantly more effective (RR 
0.35; 95% CI 0.28, 0.45). Furthermore, whilst pooled results for all DMARD combinations 
demonstrated a slightly higher risk of adverse effects (RR 1.37; 95% CI 1.16-1.62), combining 
methotrexate with either sulfasalazine and/or antimalarials (the most commonly prescribed 
DMARD combination) was not associated with an increased risk. 
 
Relative Efficacy of Different DMARD Introduction Regimens 
Rather than focus on specific drug combinations several studies have performed head-to-head 
comparisons of different DMARD introduction regimens in an attempt to demonstrate the relative 
efficacies of each approach. 
 
• The BeST Trial randomised 508 patients with active, early RA (median symptom duration 
23 – 26 weeks) to one of four different DMARD introduction treatment strategies and 
compared functional ability and radiographic outcomes after 1 years follow-up (123,145). 
The treatment groups were: group 1 sequential monotherapy (starting with methotrexate), 
group 2 step-up combination therapy (starting with methotrexate), group 3 combination 
therapy (methotrexate and sulfasalazine) with tapering high dose prednisolone, group 4 
methotrexate and infliximab combination therapy. In each group, the DMARD regimen 
would be changed, and in most cases intensified, if DAS44 remained greater than 2.4 
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(moderate disease activity). Patients who received the most intensive initial therapy (i.e. 
groups 3 and 4) required the fewest therapy adjustments, experienced earlier and faster 
improvements in functional ability and clinical disease activity measures and were more 
likely to have achieved sustained low disease activity. Furthermore, high proportions of 
patients in group 3 (78%) and group 4 (50%) had been able to discontinue their most 
potent immunomodulatory therapy (group 3 prednisolone, group 4 infliximab) because of 
sustained low disease activity. After 1 and 2 years follow-up, there were no significant 
between-group differences in HAQ scores, ACR20 and ACR70 response rates and the 
proportion of patients achieving clinical remission, suggesting that, within a treatment 
strategy aiming for low disease activity (i.e. tight control), step-up non-biologic DMARD 
strategies can eventually be as effective as initial combination strategies that incorporate 
powerful immunomodulatory agents. However, despite the apparent similarities in clinical 
response, initial parallel combination therapy was associated with superior radiographic 
outcomes. Plain radiographs of patients who received parallel combination therapy 
demonstrated significantly less progression of the total radiographic damage score (mean 
change in modified-Sharp score: 9.0 vs 5.2 vs 2.6 vs 2.5, p=0.005), erosions score (mean 
change: 4.7 vs 3.1 vs 1.1 vs 1.3, p<0.001) and joint space narrowing score (mean change: 
4.3 vs 2.1 vs 1.5 vs 1.2). Furthermore, fewer patients demonstrated severe radiographic 
progression (change in modified-Sharp score > 20: 18 vs 7 vs 1 vs 1). 
 
• Like the BeST trial, the Triple Therapy in Early Active Rheumatoid Arthritis trial compared a 
step-up DMARD introduction strategy to initial parallel combination therapy; however, the 
observed outcomes were noticeably different (146). Patients with newly diagnosed (mean 
duration 10–13 months), untreated RA were randomised to receive either step-up DMARD 
therapy (sulfasalazine monotherapy >> sulfasalazine and methotrexate >> sulfasalazine, 
methotrexate and hydroxychloroquine) or initial parallel combination therapy (all three 
agents). Patients were reviewed monthly (unlike BeST where patients were reviewed 3 
monthly), received combinations of intra-articular and intra-muscular corticosteroid 
injections and DMARD regimens were steadily intensified until low disease activity 
(DAS28<3.2) was achieved. After 12 months follow-up, both groups had experienced 
similar improvements in measures of disease activity and functional ability and, whilst there 
was a trend in favour of step-up therapy, there were no statistically significant differences in 
either the EULAR response rates or clinical remission. Radiological outcomes differed from 
those reported by the BeST trial. Patients in both groups experienced a similar, small 
amount of radiological progression (mean change in total Sharp score: step-up 6.0 vs 
parallel 6.6, 95%CI -3-2) with no significant between-group difference in the change in total 
Sharp score, erosion score (mean change: 1.1 vs 1.7, 95%CI -1.5,0.3) or joint space 
narrowing score (mean change: 4.9 vs 4.8, 95%CI -2,2). 
 
Two further randomised, strategic trials have recently described whether different variations of 
approach to step-up therapy, in patients who had experienced an inadequate response to 
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methotrexate monotherapy, might have significant impacts upon patients short-medium term 
outcomes 
 
• The Swedish Pharmacotherapy (SWEFOT) trial investigated whether the components of 
step-up DMARD combinations might influence clinical outcomes in patients who have 
experienced an inadequate response to initial methotrexate monotherapy (147). 487 
patients with early (symptom duration < 1 year), untreated RA were initially treated with 
methotrexate monotherapy. 258 patients (53%), who did not achieve an adequate 
response to methotrexate monotherapy (DAS28 > 3.2), were then randomised to ‘step-up’ 
to combination therapy with either methotrexate, sulfasalazine and hydroxychloroquine or 
methotrexate and infliximab. After 12 months further follow-up, adding infliximab allowed 
significantly more patients to achieve an EULAR good response than adding sulfasalazine 
and hydroxychloroquine (47% vs 32%, p=0.0107). After 24 months follow-up there was no 
significant between group differences for clinical measures of treatment response (EULAR 
Good response: 31% vs 38%, p=0.204) though patients who received infliximab did 
demonstrate significantly lower rates of radiographic progression (mean Δ total Sharp 
score: DMARD group 7.23 vs Infliximab group 4.0, p=0.009). Short and medium functional 
ability measures have not yet been reported. 
 
• Moreland et al investigated whether delaying commencement of combination DMARD 
therapy would have any negative impact on clinical and radiological outcomes in patients 
who had an initial inadequate response to methotrexate monotherapy (148) (149). 755 
patients with early RA (mean duration 3.6 months) were randomised to receive either 
methotrexate monotherapy or parallel combination therapy (methotrexate, sulfasalazine 
and hydroxychloroquine or methotrexate and etanercept). After 24 weeks, the threshold for 
stepping up to combination therapy was persisting moderate to high disease activity 
(DAS28 ≥3.2). Twenty eight percent of patients in the methotrexate monotherapy group 
achieved low disease activity and therefore did not require combination therapy. Over the 2 
years follow-up period, and following commencement of combination therapy, the clinical 
and radiographic outcomes of patients who received delayed combination therapy were 
virtually indistinguishable from those who had received immediate combination therapy.  
 
Taken together the results of the preceding four studies suggest that a pragmatic approach to the 
use of DMARD therapy in early RA would use a step-up introduction strategy, aiming for at least 
low disease activity, and based along tight control principles. The BeST and TEAR trials both 
demonstrate that the initial clinical response to step-up combination therapy is similar to initial 
parallel therapy. Patients in both parallel treatment groups of the BeST study did exhibit better 
radiological outcomes than those who received initial step-up therapy. This might partly be 
explained by the initial rapid improvements in measures of inflammatory disease activity; 
however, it is not possible to correct for the direct disease modifying effects of the associated 
prednisolone and infliximab. The available results from the trial conducted by Moreland et al 
suggest that delaying introduction of combination therapy does not necessarily disadvantage 
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those patients who fail to respond to methotrexate monotherapy. Delayed combination therapy 
also avoids overtreatment of the significant proportion of patients who will experience an 
adequate initial response to DMARD monotherapy. The timing of biologic therapy remains 
unclear. In the BeST study, patients who received combination DMARD and tapering 
prednisolone achieved similar clinical and radiological outcomes to those who initially received 
methotrexate and infliximab. In the SWEFOT study, patients who failed to respond to 
methotrexate monotherapy achieved significantly better 1 year clinical outcomes if infliximab was 
added instead of additional conventional DMARDs though clinical response rates after 24 months 
treatment were similar. However, the trial reported by Moreland et al comments that the results 
for both immediate combination therapy groups were similar. Further, such early use of biologic 
therapies may prove excessively expensive and be restricted by individual countries prescribing 
authorities. Importantly, neither the SWEFOT trial nor Moreland et al’s trial have yet reported 
whether patients who experienced an initial adequate clinical response to methotrexate 
monotherapy also experienced similar medium-long term clinical, radiological and functional 
outcomes to those patients who received a more aggressive treatment regimen. 
 
1.3 Global Disease Activity Assessment 
As a chronic, inflammatory condition, which has the potential to affect any of a large number of 
synovial joints, the clinical presentation and course of RA can be highly variable. Traditionally, 
decisions regarding the need to change DMARD therapy were based upon largely subjective 
interpretations of the level of active disease present; such as, the patient’s description of recent 
symptoms, identification of clinically synovitic joints and relative changes in laboratory markers of 
the acute phase response. It is now routine for clinical trials in RA to describe changes in global 
RA disease activity through the use of composite scores, which integrate several commonly 
recorded patient reported measures, clinical examination findings and laboratory results, to 
generate a single numerical value. Furthermore, several of the previously described DMARD 
treatment strategy trials have used composite disease activity measures as either thresholds to 
trigger changes in DMARD therapy and/or outcome targets. Thus, increasingly, most RA 
treatment guidelines recommend the regular assessment of composite disease activity measures 
and their use has gradually filtered into routine clinical practice (111,112,125). 
 
1.3.1 Clinical examination 
Until DMARD strategy trials started to demonstrate the benefit of using composite measures of 
disease activity, treatment change decisions were informed by clinicians either identifying the 
presence of synovitis during clinical examination, or judging that the symptoms, signs and 
laboratory findings evident at a single time point represented ‘active’ RA. Unfortunately, in many 
instances, clinical examination alone has proven to be relatively insensitive (i.e. misses some 
areas of active disease), non-specific (i.e. misclassifies or misinterprets clinical findings) and 
could lead to erroneous treatment decisions. In the TICORA trial, DMARD escalation decisions in 
the routine therapy group were based on the clinician’s interpretation of their examination findings 
(118) and it was clearly shown that this approach lead to worse clinical and radiological 
outcomes. It’s worth noting that, whilst the intensity of follow-ups visit was lesser, the treatment 
escalation protocols were the same for both routine and intensive treatment groups. 
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Imaging studies have shown that identification of synovitis through clinical examination alone is 
insensitive, usually underestimates the amount of synovitis present, and, by extension, could 
leave patients at risk of persistently active, low-level synovitis (i.e. undertreatment in the presence 
of active disease): 
 
• Wakefield et al performed simultaneous clinical and musculoskeletal ultrasound (MSUS) 
examination on 80 patients with untreated inflammatory oligoarthritis (mean duration = 18 
weeks) (122). Compared to clinical examination, MSUS examination identified a higher 
overall number of joints with ultrasonographic evidence of synovitis (clinical examination 
evidence of synovitis = 12.6% vs MSUS evidence of synovitis = 27.5%) and demonstrated 
that 13% of clinically asymptomatic joints also had evidence of subclinical synovitis. MSUS 
evidence of subclinical synovitis, indicating wider spread joint involvement than suspected 
on clinical grounds, lead to the majority (58%) of patients with clinically diagnosed 
monoarthritis being reclassified as either oligoarthritis (35%) or polyarthritis (23%) 
 
• Szkudlarek et al compared the ability of clinical examination, MSUS and MRI to identify 
evidence of inflammation in the 2nd to 5th MCPj and 2nd to 5th proximal interpahalngeal 
(PIPj) joints of 40 RA patients (150). MRI was considered the gold standard for identifying 
synovitis. Of the 480 joints examined, there was complete agreement between clinical and 
MSUS findings in 371 (77%) joints. Clinical examination identified 18 (4%) additional joints 
which had evidence of inflammation, whereas MSUS identified a further 91 (19%) joints 
with ultrasonographic evidence of inflammation. 
 
• Filer et al performed systematic clinical and MSUS examinations of 58 patients presenting 
with untreated inflammatory arthritis and at least one clinically synovitic joint (151). Once 
again, it was shown that clinical examination alone underestimated the number of joints 
involved since, in every joint region examined (PiPj, MCPj, wrist, elbow, shoulder, knee, 
ankle), MSUS consistently identified a significantly greater proportion of joints with 
ultrasonographic evidence of inflammation. 
 
Furthermore, clinical examination is a largely subjective skill that may be influenced by systematic 
differences in technique between individual examiners. Thus, differences of technique and 
interpretation between examiners may also introduce a further level of variability and inaccuracy: 
 
• Salaffi et al compared the inter-examiner agreement of two rheumatologists who 
independently conducted clinical examinations of 44 early RA patients (disease duration < 
2 years) (152). Examination findings demonstrated a variable (predominantly fair to 
moderate) level of agreement for identification of tender (κ = 0.31 – 0.62) and swollen (κ = 
0.20 – 0.65) joints depending on the joint area being examined. Once again, systematic 
MSUS assessment performed on the same patients identified significantly more joints with 
ultrasonographic evidence of inflammation compared to those that were clinically swollen 
(mean number = 19.1 vs 12.6, p = 0.01) 
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• Stone et al determined the inter-examiner agreement of five rheumatologists conducting 
clinical examinations on 5 patients with RA and 5 with psoriatic arthritis (153). Different 
factors related to clinical examination demonstrated different levels of inter-examiner 
agreement. Visual identification of joint swelling showed moderate-substantial agreement 
(κ = 0.55 – 0.63); however, there is likely to be less disagreement when overt inflammation 
is evident. Palpation of swelling (i.e. low grade inflammation) showed only slight-fair 
agreement (κ = 0.19-0.41). Identification of joint tenderness, a relatively non-specific 
clinical sign, showed moderate agreement (κ = 0.41-0.58). 
 
The hallmark clinical examination findings for joint inflammation are joint tenderness and/or joint 
swelling and these are important components of the most commonly used composite disease 
activity scores. Unfortunately, these findings may also be present when RA overlaps with other 
conditions associated with joint pain. Thus clinicians may potentially misattribute clinical findings 
to RA activity and use this to erroneously justify DMARD escalation decisions. Such decisions 
may have little clinical/symptomatic benefit but still place the patient at risk of adverse effects (i.e. 
an adverse risk:benefit ratio). Wolfe and Michaud have proposed that a significant minority 
(17.1%) of patients develop an overlap syndrome between RA and fibromyalgia, a chronic pain 
condition associated with increased levels of pain, disability and fatigue (154). In two similar 
clinical, established RA cohorts, Pollard et al have reported a prevalence of fibromyalgic-RA 
between 12% to 17% (155). Fibromyalgic-RA patients were identified by disproportionately 
elevated tender joint counts (difference between tender and swollen joint counts > 7) and 
exhibited measures of pain, fatigue and functional ability that were consistently worse than a non-
fibromyalgic-RA comparator group. Furthermore, patients with fibromyalgic-RA exhibited 
significantly higher DAS28 scores (mean: 5.7 (95%CI 5.3-6.1) vs 4.0 (95%CI 3.7-4.3)) based 
largely upon higher tender joint counts (mean: 16 (95%CI 14-18) vs 4 (95%CI 3-5) and global 
visual analogue (mean: 61 (95%CI 53-68) vs 37 (95%CI 31-42) scores but similar swollen joint 
counts (mean: 3 (95%CI 2-4) vs 4 (95%CI 3-4) and ESR (mean: 33 (95%CI 22-43) vs 28 (95%CI 
24-32). Hence, if the physical examination findings to calculate the DAS28, and using this as part 
of a tight-control DMARD treatment strategy aiming for low disease activity, had been used to 
justify DMARD escalation a significant minority of patients would face being treated with higher 
doses, or increasingly complex combinations, of potentially toxic DMARDs which were unlikely to 
be effective in treating their painful joint symptoms. 
 
1.3.2 Acute Phase Reactants 
Theoretically, the laboratory measures of the acute phase response (e.g C-reactive protein 
(CRP), erythrocyte sedimentation rate (ESR)) could prove useful additional measures of RA 
disease activity since they remove any potential bias associated with the subjective interpretation 
of physical examination findings. However, acute phase markers are inherently non-specific and 
can be influenced by external factors such as intercurrent illness. Furthermore, acute phase 
markers are of limited value in the substantial subset of patients (approximately 30-40%) who 
have clinically active disease but fail to mount a measurable elevation in acute phase reactants 
(156,157). Cohort studies have demonstrated that elevation of inflammatory markers is 
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associated with elevation of other disease activity measures and an increased risk of radiographic 
progression: 
 
• Dixon et al compared the levels of various acute phase markers (CRP, ESR, haptoglobin, 
fibrinogen) to clinical measures of global disease activity (articular index) in 105 RA 
patients treated with a variety of older non-biologic DMARDs (158). Serial levels of all 
markers fell significantly in response to commencement of therapy and, for each treatment 
group, showed moderate to strong positive correlations with corresponding clinical articular 
index scores (mean correlations: 0.774 – 0.954, p<0.01 - <0.001) 
 
• Van Leeuwen et al demonstrated that time-integrated acute phase reactant levels correlate 
positively with radiographic progression over the same period (68). 110 patients with early 
RA (mean symptom duration < 26 months) underwent monthly measurement of acute 
phase reactant levels and 6 monthly radiographs of hands and feet for 36 months. At all 
follow-up time points, cumulative CRP and ESR levels correlated positively with the 
observed amount of radiographic progression (Spearman’s correlation coefficient: CRP 0-
12 months r=0.599; 0-24 months r=0.607; 0-36 months r=0.638; p<0.001. ESR 0-12 
months r=0.522; 0-24 months r=0.498; 0-36 months r=0.507, p<0.001). Thus, persistent 
elevation of inflammatory markers is associated with ongoing radiographic progression 
 
1.3.3 Composite Disease Activity Measures 
Individual clinical and laboratory variables have been shown to perform poorly as single markers 
of global disease activity since they each correlate only moderately with other disease activity 
markers (159). In the same analysis, combining several of the individual variables into a 
composite measure greatly enhanced the validity of the resultant disease activity score (mean 
Pearson correlation coefficient: DAS44 0.63; Mallaya Index 0.65, Riel Index 0.61). Several 
composite scores have been proposed (summarised in Table 1) and each lends differing weight 
to various combinations of patient reported outcomes, clinical findings and laboratory results to 
generate a numerical score that attempts to objectively represent global RA disease activity (160-
167). The numerical output of each measure allows disease activity levels at a single time point to 
be categorised according to severity (remission, low, moderate and severe) and allows serial 
measurements to ‘track’ fluctuations in disease activity levels over time, or in response to a 
therapeutic intervention. As one component of a tight control treatment strategy, composite 
disease activity measures have been shown to contribute significantly to improved clinical 
outcomes in early RA (118,128). Indeed, all recent national and international early RA 
management guidelines have recommended the use of some form of composite disease activity 
measure(112,124,168-170). However, despite these recommendations, a recent survey of 335 
American Rheumatologists has shown that whilst the majority of respondents felt composite 
measures were useful in clinical practice (48-75%), only a minority were actually using composite 
measures regularly (DAS44 5.4%, DAS28 27.8%, SDAI 6.6%, CDAI 15.2%, PAS 6.9%, PAS-II 
1.8%, RAPID3 29.25%, RADAI5 1.19%) (165) 
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Composite disease activity scores can be categorised based upon the types of variables they 
employ: 
 
Patient Reported Composite Outcome Measures – patient reported outcomes are based solely 
upon patient’s own assessments of their symptoms and functional ability. Hence, they are 
generally easy to use, quick to perform and provide a patient focussed measure of disease 
activity. However, they do not incorporate a clinical assessment of disease activity (notably the 
presence/absence of clinical synovitis) and therefore may be influenced by external factors not 
directly related to RA disease activity (e.g secondary degenerative joint disease, comorbidities). 
Furthermore, responsiveness to change and long-term predictive power have often not yet been 
established 
 
• Patient Activity Scores (PAS / PASII) (171) – are calculated using patient reported 10cm 
visual analogue scores for pain and global health and either HAQ or HAQ-II (PAS-II) 
questionnaires. The PAS-II has been validated in a wide range of rheumatological 
conditions where as the PAS has only been validated in RA. PAS-II correlates fairly with 
DAS28 (κ = 0.29) and CDAI (κ = 0.40) (172); however, the longitudinal performance of 
either measure in response to changes in disease activity has not yet been studied 
 
• Routine Assessment Patient Index Data (RAPID3) (173) – The RAPID3 measure is the 
most commonly used of the proposed RAPID measures and comprises patient reported 
10cm visual analogue scores for pain and global health and the MD-HAQ questionnaire. At 
a single time point, RAPID3 scores correlate moderately-strongly with DAS28 (Spearman’s 
correlation coefficient: 0.39 – 0.61) and CDAI (Spearman’s correlation coefficient: 0.54 – 
0.77) (174); however, its responsiveness to changes in disease activity has not yet been 
studied 
 
• RA Disease Activity Index (RADAI) (7,175) – The RADAI questionnaire uses quite different 
components to other patient reported disease activity measures. Patients respond to 5 
questions focussed on their perception of RA symptoms over the preceding 6 months. 
RADAI correlates positively with other composite disease activity measures at a single time 
point (Spearman’s correlation coefficients: DAS28, SDAI, CDAI = 0.64-0.74; p<0.001) 
(176). Similarly, changes in RADAI correlate strongly with corresponding changes in 
DAS28 (R2 = 0.70, p<0.0001) (177). 
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Table 1 – Summary of components of RA composite disease activity measures and scoring 
ranges 
VAS – 10cm Visual Analogue Scale, RAI – Ritchie Articular Index, SJC – Swollen Joint Count, 
TJC – tender joint count  
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Patient and Clinician Composite Outcome Measures  
 
• Clinical Disease Activity Index (CDAI) (178) (179) – The CDAI is calculated using clinical 
examination findings and patient reported outcomes and, since it does not include 
laboratory variables, can be available immediately at the point of care. Indeed, the CDAI 
was derived by demonstrating that acute phase reactants only contributed a small 
proportion to the variance of other composite disease activity measures (DAS28 15%; 
SDAI 5%). CDAI scores correlate strongly with other composite disease activity measures 
(DAS28 R=0.89-0.90; SDAI R = 0.90-0.91) and demonstrate a similar relationship to HAQ 
as other composite measures (R = 0.45-0.47). Longitudinal assessments have 
demonstrated that changes in CDAI disease activity are similar to changes in DAS28 and 
SDAI disease activity and that changes in CDAI scores correctly categorise patients into 
appropriate ACR response groups. Furthermore, CDAI appears to have similar predictive 
properties for radiographic progression to DAS28 and SDAI since time-averaged scores for 
each measure showed similar correlations to changes in radiographic damage after 36 
months follow-up (R coefficient between time averaged measure and change in Larsen 
score: DAS28 0.58 (95%CI 0.37-0.73); SDAI 0.59 (95%CI 0.39-0.74); CDAI 0.54 (95%CI 
0.32-0.70)) (178) 
 
Patient, Clinician and Laboratory Composite Outcome Measures  
 
The Disease Activity Scores and Simplified Disease Activity Index utilise similar clinical, 
laboratory and patient reported measures to generate numerical outputs. Both use tender and 
swollen joint counts, patient global health 10cm visual analogue scores and a measure of the 
acute phase response. The Simplified Disease Activity Index also includes a physician global 
health 10cm visual analogue score. The Disease Activity Scores employ complex mathematical 
calculations to apply differential weightings of importance to individual variables whereas the 
Simplified Disease Activity Index is simply the sum of the component variables and therefore is 
relatively simple to calculate. 
 
• Disease Activity Scores- The 28 and 44 joint Disease Activity Scores (180) (DAS28 and 
DAS44 respectively) are the most commonly used composite measures of RA disease 
activity. They have been extensively validated both as clinical trial outcome measures and 
tools to measure response to therapeutic intervention (161) with the DAS28 often being 
considered quicker and more convenient to administer. Whilst both scores employ slightly 
different variables and scoring ranges, for given patients their outputs show strong 
correlation (R=0.97) (180). For calculation purposes, either the CRP or ESR can be used to 
represent the level of acute phase response; however, the outputs are not interchangeable 
since DAS28-CRP scores tend to be lower than equivalent DAS28-ESR scores (181). 
Acute phase reactants contribute significantly to the final DAS28 value which, in some 
instances, can lead to erroneous categorisation of disease activity since reactants levels 
may fall in response to therapy but patients may still exhibit swollen, synovitic joints (182). 
Conversely, external factors may stimulate increased acute phase reactant levels that 
contribute to an apparently elevated DAS28 score that is not related to active RA. At a 
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single time point, and over time, persistent elevation of DAS44 scores are the largest 
contributor to functional decline (HAQ) (183). Additionally, persistent elevation of DAS28 
over time correlates positively with radiological progression (Change Larsen Score: R=0.58 
(95CI0.37-0.73), p<0.001) (178) 
 
• Simplified Disease Activity Index (SDAI) – The SDAI (184) is simpler to calculate than the 
DAS28, though comprises similar variables. Balanced weighting of individual variables 
generates an output which correlates positively with DAS28 (R=0.8-0.92; p<0.0001) (185) 
though a SDAI score less than 3.3 dictates a more stringent description of remission. 
Hence, SDAI remission is one of two definitions of remission proposed in the recent 
ACR/EULAR Boolean Definition of Remission for Clinical Trials (186). Following treatment, 
changes in SDAI reflect corresponding changes in other disease activity measures and 
persistent elevation of SDAI is positively associated with an increased risk of experiencing 
radiographic progression (184). Whilst SDAI (sensitivity 90%; specificity 86%) levels 
outperform DAS28-ESR (sensitivity 87%; specificity 70%) and DAS28-CRP (sensitivity 
86%; specificity 78%) at predicting which patients require DMARD therapy changes (187), 
the effectiveness of SDAI to ‘steer’ DMARD therapy has not yet been formally assessed in 
a ‘treat-to-target’ treatment strategy study.  
 
Despite each of the composite measures utilising similar components of the ACR core-set 
variables, different mathematical constructs can lead to each measure categorising patients 
differently. Overall, DAS28 and SDAI appear to categorise patient’s disease into similar disease 
activity level groups (130,188). In a longitudinal study of 200 early RA patients receiving DMARD 
therapy, DAS28 showed good agreement with both SDAI and CDAI at identifying low disease 
activity (i.e the treatment target) during follow-up visits (κ = 0.68 and 0.67 respectively) whilst 
SDAI and CDAI showed excellent agreement (κ = 0.97) (130). In the same study, DAS28, SDAI 
and CDAI demonstrated lesser agreement at identifying clinical remission (κ = 0.48 and 0.52 
(moderate) respectively), whereas SDAI and CDAI still demonstrated excellent agreement (κ = 
0.97). In fact, the SDAI provides the most stringent definition of clinical remission since patient’s 
swollen joint count cannot exceed 2. By contrast, patients can be categorised as meeting DAS28 
remission criteria but still display up to 10 swollen joints (189,190). Indeed, comparison of 
different definitions of clinical remission from 2754 patients with RA demonstrated that 85% 
fulfilling SDAI clinical remission criteria had no swollen joints whereas only 70% of patients 
fulfilling DAS28 clinical remission criteria had no swollen joints (191). Taken as a surrogate for 
clinical synovitis, persistence of swollen joints, despite meeting clinical remission criteria, does 
appear to have a significant bearing on whether or not patients have actually achieved inactive 
RA. In a study of 114 patients treated with methotrexate monotherapy with sustained clinical 
remission (DAS28 < 2.6 consistently for 6 months); those patients with residual joint swelling 
(swollen joint count ≥	 2) tended to experience greater degrees of radiographic progression than 
those with one or no swollen joints (mean change in Sharp/van der Heijde Score: 2.2 vs 0.2; 
p=0.11)(192). Once again, the effectiveness of SDAI at truly categorising inactive disease was 
demonstrated; a much smaller proportion of patients fulfilled SDAI remission criteria (46%) and, 
overall, this group experienced virtually no radiographic progression (mean change in Sharp/van 
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der Heijde Score = -0.07). Interestingly, attaining DAS28 remission and having no swollen joints 
appeared analogous to attaining SDAI remission since both subgroups demonstrated virtually 
identical rates of radiographic progression. However, whilst attainment of remission (by which 
ever measure) is clearly desirable, clinical scores may not fully exclude active disease. Of 93 
patients who attained persistent ACR remission (a very strict definition), 13 (14%) demonstrated 
clinically significant erosive progression and 14 (15%) developed erosions in previously 
unaffected joints (193) 
 
1.4 The Role of Musculoskeletal Ultrasound in the 
Assessment of Rheumatoid Arthritis 
 
Incorporation of systematic measurement of global disease activity into regular clinical 
assessment has undoubtedly improved short-medium term outcomes in early RA. To date, most 
treatment strategy trials have used an objective score, representing global disease activity, to 
‘steer’ DMARD therapy until a predefined, acceptable lower level has been achieved. Studies 
have expressed their chosen target using either conventional composite scores - such as DAS44 
(118) or DAS28 (128,194) – laboratory markers of the acute phase response (195,196) or a 
computer-performed analysis of several commonly recorded ACR core-set variables (119). 
However, as previously described, despite meeting existing remission criteria a subset of patients 
can still exhibit swollen joints (i.e clinically evident synovitis) and may be at risk of undertreatment 
if composite disease activity measures alone are used to guide DMARD therapy. Conversely, 
another subset of patients may return inappropriately elevated composite disease activity scores 
that are not directly related to underlying inflammatory activity but could feasibly lead to 
inappropriate DMARD escalation.  
 
1.4.1 Persistent Disease Activity Despite Clinical Remission 
Composite disease activity scores provide a useful measure of a patient’s total RA disease 
activity at a single time point, are a useful means of objectively assessing a patient’s response to 
DMARD therapy changes and tracking their overall progress. However, they may be insensitive 
to persisting low disease activity, so leading to some patients being classified as having remission 
- and by extension no inflammatory disease activity - when active synovitis can be demonstrated 
using additional imaging modalities. Imaging studies have consistently demonstrated that despite 
fulfilling composite disease activity measure remission criteria a significant subset of patients still 
exhibit imaging evidence of active synovitis: 
 
• Twenty-two patients with established RA underwent standardised clinical and MSUS 
examinations of their knees to determine differences in detection rates for common 
inflammatory knee lesions (197). MSUS consistently out performed clinical examination by 
identifying a significantly higher number of suprapatellar bursitis (39% vs 16%), knee joint 
effusions (61% vs 36%) and Baker’s cysts (24% vs 5%). Hence, MSUS appears more 
sensitive than clinical examination at identifying inflammatory knee lesions. 
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• Eighty patients with new diagnoses of inflammatory arthritis underwent clinical and 
ultrasonographic assessment for the presence of synovitis (122). During targeted scanning 
of 459 painful, but not clinically synovitic, joints MSUS identified subclinical synovitis in 150 
joints (33%). In blanket scanning of 826 asymptomatic, non-synovitic joints, MSUS still 
identified subclinical synovitis in 107 joints (13%). Of the 80 patients examined, MSUS 
identified a higher burden of joint involvement than clinical examination in 51 (64%) 
patients and led to 36 (29%) patients being reclassified from an oligoarthritis to a 
polyarthritis. 
 
• Presence of musculoskeletal ultrasound (MSUS) and magnetic resonance imaging (MRI) 
evidence of inflammatory joint disease was reported in 107 established RA patients 
(median disease duration 7 years) whose rheumatologist classified as being ‘in remission’ 
(121). Sixty one patients (57%) fulfilled DAS28 remission criteria; of whom 48 (79%) 
demonstrated MSUS evidence of synovial hypertrophy; 29 (48%) demonstrated MSUS 
evidence of increased Power Doppler (PD) signal; 51 (84%) demonstrated MRI evidence of 
synovitis and 28 (46%) demonstrated MRI evidence of bone marrow oedema, a precursor 
of bone erosions. Furthermore, 31 (29%) patients met a very stringent definition of 
remission (asymptomatic patients with no tender, swollen or painful joints) but still 
displayed imaging evidence of inflammatory joint disease with 22 (73%) demonstrating 
MSUS synovial hypertrophy; 13 (43%) demonstrating increased PD signal; 25 (96%) 
demonstrating MRI synovitis and 13 (46%) demonstrating MRI bone marrow oedema. 
 
• Szkudlarek et al compared the relative sensitivities, specificities and accuracy of clinical 
examination, MSUS and plain radiography to identify inflammatory joint lesions and 
damage when using MRI as a gold standard. The second to fifth metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joints of 40 patients with established RA 
(median disease duration 5 years) (150) were examined independently using each 
modality. Out of 480 joints examined, clinical examination identified synovitis in 121 (25%) 
joints, MSUS identified synovitis in 194 (40%) joints, of which 91 (75%) weren’t clinically 
inflamed. Furthermore, 18 (4%) joints were classified as having clinical evidence of 
synovitis which could not be identified by MSUS. Compared to MRI findings in 
corresponding joints, the sensitivity, specificity and accuracy of clinical examination at 
identifying synovitis were 0.40, 0.85 and 0.72 respectively. For MSUS, the sensitivity, 
specificity and accuracy were 0.70, 0.78 and 0.76 respectively. 
 
• A small study of 10 patients with new diagnoses of early RA (median disease duration 10 
months) described the longitudinal changes in clinical and MSUS examination findings in 
response to commencing infliximab therapy (198). Prior to treatment, 142 (51%) of 280 
clinically examined joints appeared swollen (i.e clinically synovitic); 264 (64%) of 416 
MSUS examined joints demonstrated grey scale (GS) synovial hypertrophy and 139 (33%) 
demonstrated positive PD signal. Following treatment, all clinical and MSUS measures 
improved significantly with only 7 (2.9%) clinically swollen joints remaining after 8 weeks. 
However, despite the clinical improvements, follow-up MSUS assessments still identified 
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MSUS evidence of active synovitis.  After 8 weeks, 35% of clinically normal joints 
demonstrated GS synovial hypertrophy and 7% demonstrated positive PD signal. After 22 
weeks, 178 (49%) of 364 joints examined by MSUS demonstrated GS synovial hypertrophy 
and 23 (7%) demonstrated positive PD signal. Nine of the treated patients achieved clinical 
remission; however, none achieved complete absence of MSUS abnormalities, albeit most 
were graded low-to-moderate activity.  
 
• Balsa et al performed systematic clinical and ultrasonographic examinations on 97 RA 
patients judged to be in clinical remission on the basis of no clinical signs of active disease 
(199). Despite the clinical judgement, 92 (95%) patients had evidence of GS synovial 
hypertrophy and 41 (42%) had evidence of positive PD signal in at least one joint. Patients 
were then segregated depending on whether they met DAS28 and/or SDAI remission 
criteria (74% and 44% respectively). Fulfillment of SDAI remission criteria was more likely 
to identify patients with totally inactive inflammatory disease during MSUS assessment 
since, compared to DAS28 remission, these patients had significantly lower levels of PD 
signal and total PD scores. 
 
It is has been well demonstrated that, at low levels of inflammatory disease activity, clinical 
examination alone may be falsely reassuring and under represent the total active disease burden. 
Furthermore, evidence is emerging that fulfilling existing remission criteria does not necessarily 
equate with inactive disease. Longitudinal studies of patients fulfilling remission criteria have 
demonstrated disease progression thus implying that existing remission definitions do not 
necessarily equate to inactive disease 
 
• Molenaar et al observed the clinical and radiographic progress of 187 established RA 
patients (median duration 7 years) who fulfilled ACR remission criteria at recruitment (193). 
After 2 years follow-up, 97 (52%) patients remained in persistent clinical remission; 
however, overall there was a significant increase in radiographic damage scores (median 
Sharp/van der Heidje score: baseline = 21, 2 years = 25, p <0.001). Progression rates were 
higher in patients who experienced an acute RA flare compared to those who remained in 
persistent clinical remission (median progression score: 1 vs 0, p<0.001). However, 7 (7%) 
patients in persistent clinical remission demonstrated clinically relevant progression of 
radiographic damage scores and 14 (15%) developed new erosions in previously 
unaffected joints 
 
• A longitudinal observational study of 102 established RA patients (median duration 7 
years), deemed to be in clinical remission, described how MSUS and MRI evidence of 
active synovitis predisposes to subsequent disease progression (200). The definition of 
remission was based upon clinician’s judgement rather than specific criteria; however 56% 
of participants did meet the DAS28 definition of remission. At baseline, imaging techniques 
demonstrated high levels of joint inflammation. On MSUS 89% of patients demonstrated 
synovial hypertrophy and 63% demonstrated PD signal. On MRI, 92% demonstrated 
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synovitis and 53% demonstrated bone marrow oedema. After 1 years follow-up, 19% of 
patients demonstrated significant deterioration in radiographic joint damage scores.  
 
• Composite disease activity scores provide an overall representation of total disease 
activity. However, the influence of elevation in a single component (especially swollen joint 
counts as a surrogate for clinical synovitis) may be attenuated if all other components are 
normal. Clinical outcome data for 864 RA patients (mean duration 2.4 years) treated with 
methotrexate monotherapy was pooled from the control arms of several recent randomised 
trials of biologic therapy (192). One hundred and fourteen patients (13%) were classified as 
exhibiting sustained DAS28 remission (DAS28<2.6 for 6 months), of these 77 (68%) 
demonstrated radiographic progression. Patients in sustained remission with one or no 
swollen joints (i.e minimal clinical synovitis) demonstrated lower changes in radiographic 
progression scores than those with two or more swollen joints (mean change Sharp/van 
der Heidje Score: 0.2 vs 2.6, p=0.11). Thus, even if clinical remission criteria are fulfilled, 
the persistent of clinically swollen joints is still associated with radiographic disease and 
may be an additional marker of active disease. 
 
1.4.2 Inappropriate Elevation of Disease Activity Measure 
The characteristic symptoms of RA joint involvement are pain, stiffness, swelling and loss of 
function. However, these symptoms are relatively non-specific and in RA patients their presence 
may not always be directly related to on-going, active inflammation. Joint pain and loss of function 
can be caused in RA patients by other, coexistent illnesses and therefore careful evaluation is 
necessary to discriminate which is the predominant cause in each individual patient’s case. 
Coexisting painful conditions (such as fibromyalgia or osteoarthritis) can confound the outputs of 
composite disease activity measures, whereby elevated tender joint counts and patient reported 
global health visual analogue scores generate apparently elevated disease activity scores in the 
absence of clinical synovitis and/or an elevated acute phase response. Equally, acute phase 
reactants may be elevated for other reasons; for example, ESR may be elevated in the elderly or 
cases of dysproteinaemia (201), whereas CRP is often elevated in patients with other chronic 
inflammatory conditions (202). Presuming that all joint pains are related to RA could feasibly lead 
to inappropriate escalation of DMARD therapy, when in fact inflammatory disease is quiescent. 
This would be unlikely to relieve a patient’s symptoms but may increase their risk of experiencing 
treatment side effects. Several studies have demonstrated that patients with RA might develop 
persistent elevation of disease activity measures despite adequate treatment of their arthritis: 
 
• Five year follow-up of 525 newly diagnosed RA patients recruited during four different time 
periods between 1985 and 2005 showed that more recently recruited patients experienced 
a relatively milder early disease course with significantly lower mean disease activity 
scores for their respective follow-up periods (mean DAS28 over 5 years: 1985-1990 = 4.1; 
1990-1995 = 3.1; 1995-2000 = 3.4; p<0.0001) (203). However, despite the apparent 
improvements in measures of inflammatory disease activity there were no significant 
differences reported between pain outcomes regardless of which period patients first 
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commenced DMARD treatment (mean pain 10cm VAS after 5 years: 1985-1990 = 32.3; 
1990-1995 = 35.5; 1995-2000 = 33.9; p=0.3493) 
 
• Leeb et al compared the DAS28 outputs for 62 RA patients with age and sex matched 
fibromyalgia patients (204). Overall, there were no significant between group differences 
for final DAS28 scores (RA 4.23 vs fibromyalgia 4.04; p>0.05). However, the individual 
variables, which contributed to the final score, did vary significantly between the diagnostic 
groups. RA patients exhibited significantly higher mean swollen joint counts (3.84 vs 0.04; 
p<0.0001) and ESR levels (24.16 vs 8.42; p<0.0001); whereas, fibromyalgia patients 
returned significantly higher mean tender joint counts (6.08 vs 12.38; p<0.0001) and global 
health visual analogue scores (43.72 vs 64.21; p<0.0001). These results emphasise the 
importance of determining the underlying cause of joint pain prior to making treatment 
decisions based on composite disease activity measures since, based upon current 
DMARD escalation recommendations, many of the fibromyalgia patients would have been 
eligible for DMARD therapy if DAS28 scores alone had been used to inform treatment 
decisions. 
 
• Wolfe et al have proposed that a substantial subset of RA patients develop an overlap with 
fibromyalgia which contributes to them experiencing persistent joint pain and fatigue (154). 
11,866 RA patients completed the Regional Pain Scale and a 10cm fatigue VAS to 
determine the incidence of co-existing fibromyalgia. 1731 (17.1%) respondents fulfilled 
criteria for fibromyalgia, were more likely to be work disabled (54.5% vs 26.4%), reported 
more severe symptoms across all outcome measures and had higher direct medical costs. 
 
• Pollard et al defined ‘fibromyalgic RA’ as a difference of at least 7 between the tender and 
swollen joint counts and sought to determine its influence on the DAS28 (155). In two 
independent cohorts 12 – 17% of patients were identified as fibromyalgic-RA. Using 
DAS28, fibromyalgic RA patients returned higher overall disease activity scores (5.7 vs 4.0 
and 6.1 vs 4.4) and were more likely to classified as having active disease  (OR 14.3, 
95%CI 5.5-37.1). Whilst tender joint counts (16 vs 4 and 18 vs 5) and global health VAS 
(61 vs 37 and 63 vs 46) were significantly higher for fibromyalgic RA patients, swollen joint 
counts (3 vs 4 and 6 vs 5) and ESR levels (33 vs 28 and 32 vs 33) were similar compared 
to non-fibromyalgic RA patients. These results further support the view that 
disproportionate elevations in tender joint counts and global health VAS may return 
elevated composite disease activity scores that do not necessarily reflect the level of active 
inflammatory disease present 
 
• A recent questionnaire assessment of 2795 European and American patients with 
established RA (mean disease duration 9.9 years) demonstrated striking discrepancies 
between patient’s perceptions of their RA disease control and experience of pain (205). All 
patients, at all levels of RA disease activity, experienced pain in some form and levels of 
pain were positively associated with the severity of RA disease activity. Whilst the majority 
of patients with mild RA reported mild pain levels (Europe 62%; USA 63%) a significant 
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minority were still experiencing moderate pain (Europe and USA both 36%). Furthermore, 
patients being treated for depression were more likely to report severe pain though the 
data is not sufficient to elucidate the inter-relationship between depression and self 
reported pain levels 
 
• In the subset of RA patients who develop an overlap with fibromyalgia, having a diagnosis 
of fibromyalgia is an independent predictor of subsequent DAS28 scores. In a cross-
sectional study of 270 patients with established RA, 32 (13%) also fulfilled ACR 
classification criteria for fibromyalgia (206). Compared to RA patients, fibromyalgic-RA 
patients exhibited significantly higher mean DAS28 scores (5.36 vs 4.03, p<0.001), tender 
joint counts (9.5 vs 3.0, p<0.001), disease activity VAS (56.5 vs 32.0, p<0.001), pain VAS 
(76.0 vs 40.0, p<0.001) and HAQ scores (2.0 vs 1.12, p<0.001) but similar ESR (29 vs 25, 
p=0.343) and swollen joint counts (3.5 vs 2.0, p=0.119). Furthermore, fibromyalgic-RA 
patients were less likely to be categorised as either clinical remission (0 vs 17%), low 
disease activity (3% vs 15%) and were more likely to be categorised as high disease 
activity (59% vs 22%). A multivariate regression analysis suggested that the additional 
diagnosis of fibromyalgia was an independent predictor of DAS28 score associated with a 
mean adjusted increase of 0.885 points. 
 
• A substantial proportion of patients who satisfy existing definitions of remission still 
experience significant levels of pain suggesting either: 1. there is persisting subclinical 
synovitis or 2: pain is being mediated by an alternative, non-inflammatory process (e.g 
central sensitisation). Out of 157 patients in persistent remission (DAS28-CRP<2.6) 11.9-
12.5% still reported clinically significant pain (MDHAQ pain ≥ 4) at each timepoint (207). 
Furthermore, high pain scores were positively associated with high scores for several other 
non-specific symptoms, including patient global assessment, fatigue, poor sleep quality, 
self-efficacy and quality of life. Inflammation related features, such as swollen joint counts, 
auto-antibody status, C-reactive protein levels and radiographic damage scores, did not 
show an association with pain scores suggesting that additional, non-inflammatory factors 
may be contributing to these patient’s symptom experiences 
 
• RA patients who first present with high total pain scores are at a greater risk of 
experiencing persistently high levels of pain compared to those who present with low-
moderate pain scores. Mcwilliam et al analysed data from 1189 patients from the Early 
Rheumatoid Arthritis Network to describe the relationship between changes in pain and 
other disease activity measures over one year (208). Despite patients experiencing an 
improvement in disease activity measures with DMARD therapy (mean DAS28 baseline = 
4.8 vs 1 year = 3.8; p<0.001) many (58%) continued to report incomplete improvement in 
Bodily Pain scores (median score: baseline = 41 vs 1 year = 51; p<0.001). Female sex and 
a high baseline DAS28-P (a measure of non-inflammatory factors comprising joint 
tenderness and global health VAS) were identified as independent predictors of lesser 
improvements in pain scores 
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• There is now increasing evidence that RA disease processes are associated with alteration 
in nociceptive responses which, in the presence of chronic painful stimuli, could feasibly 
lead to abnormal or altered pain sensations. Leffler et al tested pain responses around an 
inflamed joint and a pain-free area in patients with early (<1 year duration) and established 
(>5 year duration) RA (209). Both groups demonstrated allodynia to pressure around the 
inflamed joints. The established RA group demonstrated sensory abnormalities - reduced 
sensation of light touch and hyperaesthesia to minor painful stimuli (e.g innocuous cold) – 
that were not evident in the early RA group, suggesting the development of altered 
peripheral sensory processing. Furthermore, there was evidence of altered central 
somatosensory processing as the established group also demonstrated allodynia in non-
painful areas 
 
Taken altogether these results suggest that in a substantial subset of patients pain scores and 
traditional composite disease activity measures may not be accurate measures of the total 
inflammatory burden since: 1. changes in pain symptoms don’t always follow the same trend as 
corresponding changes in disease activity scores, 2. additional, non-inflammatory factors may 
contribute to patient’s pain symptoms and examination findings (especially tender joint counts 
and global health VAS) and 3. RA patients exhibit evidence of altered somatosensory function 
that may contribute to on going painful symptoms. Thus relying upon the DAS28 alone to guide 
treatment escalation decisions may not be appropriate since apparent elevations in certain 
contexts – especially when the tender joint counts and global health VAS are disproportionately 
elevated – may not be related to on-going inflammatory disease. In these circumstances, patients 
would be unlikely to benefit from further intensification of DMARD therapy and could be placed at 
an increased risk of experiencing adverse treatment effects but little symptomatic improvement. 
 
1.5 The Significance of Inflammatory Lesions 
Identified by Musculoskeletal Ultrasound 
 
To a point, clinical examination and composite disease activity scores do provide a useful, 
objective measure of global disease activity which allows longitudinal monitoring and assessment 
of response to changes in therapy. However, in certain circumstances relying upon clinical 
measures alone may be either insufficiently sensitive and/or specific to allow treatment decisions 
to be tailored to a patient’s specific needs. As the preceding sections describe two important 
subgroups of patients have emerged:  
 
1. patients fulfilling clinical remission criteria with persistent subclinical synovitis since they 
are potentially at risk of being undertreated in the presence of demonstrably active 
disease 
2. patients with disease activity scores elevated above DMARD escalation thresholds 
without active inflammatory disease since they are at risk of receiving unnecessarily 
intensive therapy with a poor chance of symptomatic benefit but an increased risk of drug 
associated adverse effects 
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In these situations musculoskeletal ultrasound (MSUS) may offer an additional measure of global 
inflammatory disease that allows treatment decisions to be tailored specifically to the needs of 
individual patients. MSUS is being increasingly recognised as an adjunct to clinical examination 
since it is relatively inexpensive, reproducible, acceptable to patients (without the need for 
ionising radiation) and allows assessment of different joint areas during the same consultation. 
MSUS examination allows direct visualisation of articular and periarticular joint structures to 
confirm the presence or absence of inflammatory joint lesions (such as synovitis), or an 
alternative lesion, as the cause of a patient’s symptoms. In contrast, for composite disease 
activity scores, several either relatively insensitive (swollen joint count) or non-specific (tender 
joint count, global health VAS, ESR) variables are used to generate an output that is only 
indirectly associated (or not) with the underlying disease process. 
 
1.5.1 MSUS appearances of synovitis 
Compared to physical examination MSUS allows direct visualisation of articular and peri-articular 
structures and localisation of the specific lesions that may be contributing to a patient’s on-going 
symptoms. Importantly, it specifically allows clinicians to confirm or exclude, the presence of 
active synovitis in patients with continuing joint pain. Histological studies have demonstrated that 
active synovial inflammation consists of inflammatory cell infiltration, angiogenesis / vascular 
proliferation and propagation of the synovial membrane (210). MSUS depicts these different 
characteristics using grey scale and Doppler imaging techniques. Grey scale ultrasound shows 
the relationship of articular structures to periarticular soft tissues and allows assessment of the 
size and shape of synovial hypertrophy. Colour and Power Doppler imaging allows assessment of 
tissue vascularity and therefore allows differentiation between active (presence of PD signals) 
and inactive (absence of PD signals) synovitis when applied to areas of synovial hypertrophy. 
 
Several studies have demonstrated that MSUS representations of synovitis are accurate 
representations of histologically and/or MRI identified inflammatory processes.  
 
• A small study of 10 RA patients and 10 osteoarthritis (OA) patients was one of the first to 
compare MSUS appearances to corresponding histological findings (211). All patients were 
undergoing an elective total knee replacement and underwent MSUS evaluation prior to 
surgery. Inflammatory pannus was identified histologically in 9 patients, 8 of whom had RA. 
Grey scale MSUS was less sensitive than histological assessment since both sonographers 
failed to identify synovial hypertrophy in all the patients with histologically evident pannus. 
Furthermore, grey scale imaging was less specific than histological examination with both 
sonographers identifying synovial hypertrophy in 4 OA patients without pannus. For both 
sonographers, colour Doppler sonography findings correlated much more closely to 
histological findings. Sonographer 1 identified colour Doppler signals in 8 of the 9 patients with 
histological pannus whereas sonographer 2 identified colour Doppler signals in all the patients 
with pannus. Furthermore, 4 patients, who displayed colour Doppler evidence of increased 
synovial perfusion, in the absence of pannus, did have histological evidence of active 
inflammation with synovial proliferation and increased vascularity 
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Figure 3 - Examples of MSUS depictions of active and inactive synovitis  
a + b – gray scale images; c + d – gray scale images with PD 
 
• PD assessment of knee synovium vascularity has been shown to correlate positively with 
histological analysis of vascularity in linked tissue specimens. Walther et al compared MSUS 
PD and immunohistochemical assessments of knee synovial membrane vascularity in 10 RA 
and 13 OA patients about to undergo total knee replacement (212). Representative PD 
images and tissue samples underwent additional digital image analysis to control for the 
subjective influence of the examiner. Strong positive correlation was demonstrated between 
the MSUS PD scores and the pathologists grading of vascularity (Spearman’s ρ 0.89, p<0.01). 
Furthermore, strong positive correlations persisted when comparing vascularity grades for 
digitally analysed PD images and tissue samples (Pearson’s correlation coefficient r=0.81, 
p<0.01) 
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• Koski et al have demonstrated that a positive synovial Doppler signal is an indicator of active 
synovial inflammation on histological specimens (213). MSUS and histological findings from a 
range of different synovial sites were compared from 44 patients with a variety of different 
inflammatory arthritidies. Histological examination was considered the gold standard and 
identified abnormal synovial appearances in 43 (98%) samples, of which, 35 (79%) showed 
active synovitis. Combined grey-scale and PD MSUS scanning identified synovial 
abnormalities in 43 (98%) joints. A positive PD signal was detected in 34 of the 43 (79%) joints 
which showed any pathological appearances and in 29 of the 35 (83%) joints with active 
histological inflammation. Grades of PD signal correlated positively with levels of synovial 
infiltration by polymorphonuclear leucocytes (r = 0.397, p<0.01) and fibrin deposition (r = 
0.328, p<0.05) but did not correlate significantly with either the overall histopathological score 
(r = 0.239, p NS) or the vascularity grade (r -0.03, p NS). Thus the presence of PD signal 
strongly favours active synovial inflammation whereas its absence doesn’t necessarily exclude 
it. 
 
• MSUS and MRI show reasonable overall agreement for the identification of synovial 
hypertrophy and synovitis in the small joints of the hand (150). 40 RA patients underwent 
systematic grey scale MSUS assessment and gadolinium-enhanced MRI scanning of their 
dominant hand. Overall agreement between both imaging modalities was 71% with MSUS and 
MRI showing evidence of synovitis in 106 (38%) joints and its absence in 92 (33%) joints. 
Synovial hypertrophy, which was not evident on MRI, was identified by MSUS in 55 additional 
joints. Whereas, MRI identified synovitis in 24 joints that was not detected by MSUS. In early 
RA patients, MSUS was actually more sensitive than MRI at identifying synovial hypertrophy 
(88 vs 57 joints). Unfortunately, the paper does not report the degree of agreement between 
MSUS Doppler signal and post-gadolinium enhancement on MRI 
 
• During MRI examination, administration of intravenous contrast (gadolinium), allows 
differentiation between areas of active and inactive inflammation. Active synovial inflammation, 
demonstrates post-contrast enhancement, whereas chronic synovial fibrosis does not 
enhance but may appear enlarged. Increased intra-articular MSUS Doppler signals appear 
comparable to post-contrast MRI evidence of synovial inflammation. Terslev et al compared 
CD signal and post-contrast MRI findings in the finger and wrist joints of 29 established RA 
patients (mean duration 7 years) (214). Colour Doppler MSUS and MRI agreed on the 
presence or absence of active inflammation in 157 joints (overall agreement 75%, kappa value 
0.45). MSUS identified additional CD signals in 11 joints not evident on MRI; whereas, MRI 
identified enhancing synovitis in an additional 38 joints. Furthermore, CD MSUS quantitative 
measures of intra-articular vascularisation showed statistically significant correlations with 
post-contrast MRI measures of synovial thickening (MRI vs CD colour fraction r=0.59, 
p<0.001; MRI vs mean resistance index r=-0.54,p<0.001). Thus, whilst both modalities employ 
different descriptors of synovial inflammation, their respective outputs have sufficient parallels 
to be considered at least similar. However, since the respective descriptors are related to 
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different underlying disease processes, the inevitable inconsistencies will prevent the outputs 
being fully interchangeable. 
 
• Klauser et al have demonstrated that Colour Doppler (CD) signal is not present in the joints of 
healthy individuals (215). The finger joints of 46 early RA patients (disease duration < 6 
months) and 10 healthy controls were graded semi-quantitatively for clinical evidence of joint 
inflammation and intra-articular vascularization using CD MSUS scanning. None of the joints 
of the healthy control subjects demonstrated detectable intra-articular CD flow signals. By 
contrast, 70 (25%) of joints in RA patients demonstrated some intra-articular CD flow signals. 
The proportion of joints demonstrating intra-articular CD flow increased as the clinical grade of 
inflammation increased (inactive 8%, moderately active 52%, active 58%). Administration of 
an intravenous bubble contrast agent significantly increased the proportion of joints in RA 
patients demonstrating intra-articular CD signal but had no impact on detection in healthy 
volunteers 
 
1.5.2 Power Doppler signal corresponds to active synovitis 
Thus, an argument emerges that MSUS may provide an additional means of assessing global 
disease activity in RA patients based upon direct visualisation of the inflammatory lesion rather 
than inference from indirect clinical measures. Several overlapping strands (summarised in the 
preceding sections) underpin this argument: 
 
1. at low levels of disease activity composite disease activity measures may not be sensitive 
enough to identify persistently active disease 
2. some patients who fulfil clinical remission criteria do not have inactive disease and will 
exhibit evidence of disease progression 
3. in a substantial subset of patients composite disease activity measures lack specificity 
and may remain elevated above a treatment escalation threshold even though there is no 
residual inflammatory disease activity 
4. MSUS is more sensitive than clinical evaluation at identifying features of synovial 
inflammation 
5. MSUS findings of synovial hypertrophy, on Grey scale scanning, and increased synovial 
vascularisation, on either Colour or Power Doppler scanning, compare favourably to 
corresponding features of synovial inflammation on histological analysis and MRI 
scanning 
 
Overall, the presence of positive MSUS Doppler signals within a synovial membrane appears to 
differentiate well between on-going synovial inflammation and chronic fibrous synovial 
hypertrophy. Several studies have demonstrated that persistent Doppler signals are positively 
associated with observed fluctuations in clinical disease activity and predict future adverse 
changes in either clinical disease activity (e.g acute flare) or radiographic progression. 
 
• The previously described longitudinal study by Brown et al compared baseline MSUS and 
MRI findings to clinical and radiological outcomes in 102 patients with established RA in 
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clinical remission (200). Clinical remission was based upon clinician’s judgements; at 
baseline 61% fulfilled DAS28 remission criteria and 45% fulfilled ACR criteria. Over the 12 
months follow-up period, patients remained in relatively stable remission with no significant 
changes in disease activity measures and only 5% of patients required any therapy 
escalation. At baseline, 89% patients had MSUS evidence of synovial hypertrophy and 
63% had evidence of increased synovial PD signal. Overall, 19% of patients experienced a 
significant deterioration in radiographic damage scores and the risk of radiographic 
progression was positively associated with the presence of PD signal at baseline. 
Univariate regression analyses demonstrated that the total PD score in the dominant hand 
MCP joints was significantly, positively associated with radiographic progression in any 
hand or foot joint (OR 1.36, 95CI 1.02-1.81, p=0.036). Within the MCPj, the presence of 
any positive PD signal (OR 12.21, 95CI 3.34-44.73, p<0.001), the total Grey scale synovial 
hypertrophy score (OR 2.31, 95CI 1.06-5.52, p=0.032) and the PD score (OR 4.4, 95CI 
1.98-8.08, p<0.001) were each significantly associated with the likelihood of developing 
radiographic damage. Furthermore, clinically asymptomatic joints which still exhibited 
positive PD signal were significantly more likely to demonstrate radiographic progression 
than those that had no PD signal (29% vs 4%; OR 8.77 95CI 1.54-49.89, p=0.014). 
 
• Peluso et al compared MSUS Grey scale and PD findings to subsequent clinical outcomes, 
in 48 early RA patients (mean duration 6.9 months) and 46 established RA (mean duration 
118.9 months) with stable DAS44 remission (DAS44<1.6 over 6 months), and 
demonstrated that positive synovial PD signal predicted an acute clinical flare over a 12 
months follow-up period (216). Once again, high proportions of both patient groups had 
MSUS evidence of synovial inflammation (positive PD signal: early RA 41.7%; established 
RA 30.4%). 29.8% of patients experienced a clinical flare (criteria not clearly defined) over 
the 12 month follow-up period. A significantly higher proportion of the patients who 
demonstrated positive PD activity at baseline experienced an acute flare compared to 
those who had no PD activity (47.1% vs 20%, p=0.009). Furthermore, patients who 
demonstrated an overall increase in DAS44 tended to have higher scores for synovial 
hypertrophy (mean 5.2 vs 2.6, no between group comparison quoted) and PD activity 
(mean 3.1 vs 1.1, no between group comparison quoted) compared to those who remained 
in clinical remission.  
 
• Scire et al have demonstrated that positive intra-articular PD signal is the strongest 
predictor of subsequent disease flare in early RA patients who have already achieved 
DAS44 remission (217). 106 patients with early RA (mean duration 3.8 months) were 
treated using conventional DMARDs in a step-up tight control regimen and underwent 
regular clinical and MSUS evaluation for 24 months. Forty three patients achieved the 
studies definition of remission (DAS44<1.6 on 2 occasions 3 months apart); of these 41 
(95%) patients still showed MSUS evidence of synovial hypertrophy and 18 (41%) showed 
a positive PD signal. After achieving DAS44 remission, 14 (33%) patients experienced an 
acute relapse over the subsequent 6 months and exhibited significantly higher PD scores 
(median 1 vs 0, p<0.05) and synovial hypertrophy scores (median 6 vs 2, p<0.05) than 
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those with stable disease. Univariate logistic regression analysis demonstrated that 
positive PD activity in any joint was the strongest predictor of future relapse (OR 12.8, 95CI 
1.6-103.5, p<0.05). The positive predictive value for an acute flare of PD activity was 
calculated as 70.6%; however, its negative predictive value of 92.3% implies that its 
absence is unlikely to be associated with an early acute flare 
 
• Saleem et al used MSUS to prospectively monitor 93 RA patients who had achieved 
clinical remission (physician’s assessment) using conventional DMARD therapy for 12 
months (218). Twenty four patients experienced an acute flare and the presence of intra-
articular PD signal at study recruitment was identified as the single biggest predictor of 
subsequent flare (OR 4.08, 95CI 1.26-13.19, p=0.014). Baseline MSUS findings were not 
quoted in the original paper. 
 
Repeatedly demonstrating an association between MSUS evidence of subclinical joint 
inflammation and a subsequent increased risk of acute disease flare, and/or progression, does 
strongly support the presumption that the MSUS findings of active synovial inflammation (and 
particularly positive PD signal) do represent active disease. Further evidence to support the link 
between MSUS findings and disease activity can be found by demonstrating the response of 
MSUS representations of active synovial inflammation to changes in immunomodulatory therapy 
(i.e MSUS findings improve following commencement of effective therapy) 
 
• A small study of 5 established RA patients, with clinically active disease despite DMARD 
therapy, demonstrated that MSUS findings of synovial inflammation improve significantly 
after one month’s therapy with etanercept and in line with corresponding improvements of 
clinical and laboratory measures of disease activity (219). Patients underwent MSUS 
examination of all MCP joints before, and after 28 days of, treatment. Published results 
only relate to the right second MCPj since this showed baseline evidence of involvement in 
all patients. The mean number of synovial CD signals (quantitatively assessed by computer 
aided image interpretation) fell significantly following the administration of etanercept 
(mean colour signals/region of index: 23,602 to 2907, p<0.001) and the change in CD 
findings correlated well with the observed clinical change (Spearman correlation coefficient  
R=0.85) 
 
• A small observational study of 11 established RA patients (mean duration 10 years) 
demonstrated a significant fall in CD evidence of synovial vascularization shortly after 
initiating etanercept (220). MSUS was performed on the clinically worst affected joint 
identified during the baseline assessment. After 2 weeks treatment, all clinical and 
laboratory measures of disease activity had improved significantly (p<0.01 – p<0.05) and 
corresponded to significant improvements in two separate CD measures of vascularisation 
in the target joints (median number colour pixels per region of interest: 0.10 to 0.04, 
p<0.01; mean resistance index: 0.82 to 1.06, p<0.01). 
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• Terslev et al have also described the changes in MSUS findings of synovial inflammation 
immediately before, and one month after, 51 patients with established RA (mean duration 
12 years) underwent intra-articular corticosteroid injections into a single, clinically inflamed 
joint (221). Overall, local clinical and global clinical and laboratory measures of joint 
swelling and disease activity improved significantly following intra-articular injection. The 
majority of patients also demonstrated improvement in MSUS measures of synovial 
inflammation. Synovial membrane volume (assessed quantitatively using pixel counting 
software) reduced in 38 (75%) patients (mean total pixel count: 14721 to 10169, p<0.01). 
41 (80%) patients exhibited a significant fall in CD signal volume (assessed quantitatively 
using colour pixel counting software) (mean colour pixel fraction: 0.21 to 0.10, P<0.001) 
though only 32 (63%) patients experienced a corresponding increase in resistance index 
(mean resistance index: 0.71 to 0.79, p<0.01). 
 
• Thirteen patients with established RA who had experienced an acute disease flare 
underwent MSUS examination of the most symptomatic either index or middle MCPj 
immediately before, and shortly after (within 72 hours) receiving a bolus of intravenous 
methylprednisolone (222). Before treatment all patients demonstrated synovial hypertrophy 
and increased synovial vascularisation. The majority demonstrated a significant reduction 
in PD signal shortly after treatment (mean percentage change in PD quantity 71%) which 
mirrored corresponding changes of clinical and laboratory measures and correlated 
significantly with the observed improved in HAQ (p=0.012, correlation coefficient not 
quoted) 
 
• Taylor et al have demonstrated that patients with RA who respond to treatment with 
infliximab demonstrate improvements in MSUS grey scale and PD findings which are not 
evident in patients who receive placebo (223). Twenty four patients with early RA (duration 
less than 3 years) with persisting clinical synovitis despite methotrexate therapy were 
randomised to receive either intravenous infliximab or placebo. Clinical and 
ultrasonographic (MCP 1-5 bilaterally) assessments were compared at baseline and after 
18 months therapy. Baseline disease characteristics and disease activity measures were 
comparable between groups. Greater improvements in clinical disease outcome measures 
were evident in the infliximab-treated group (median change DAS28: 1.21 vs 0.39, 
p=0.157). Patients who received infliximab demonstrated significantly greater 
improvements in grey scale measures of synovial thickness (percentage change: 54.5 vs 
13.7, p=0.014) and Colour Doppler signal (percentage change: 78.6 vs 26.6, p=0.017). 
Additionally, the volume of MCP synovial hypertrophy (r=0.69, p=0.02) and PD signal 
(r=0.78, p=0.005) present at baseline correlated strongly with progression of radiographic 
damage after 54 weeks follow-up in the placebo group. By contrast, patients in the 
infliximab group demonstrated non-significant, weakly negative correlations between 
baseline MCP synovial hypertrophy (r=-0.23, p=0.479) and PD signal (r=-0.28, p=0.372) 
and radiographic progression suggesting that the reduction in the volume of active MSUS 
evident synovitis represented a true reduction in overall disease activity as evidenced by 
virtually no new joint damage. 
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Taken together these results suggest that MSUS could have an important role to play in refining 
DMARD escalation decisions in carefully selected patients. MSUS allows the identification of on-
going subclinical synovitis to support decisions to escalate DMARD therapy in patients with either 
few clinically swollen joints, or in those who meet clinical remission criteria. Likewise, the 
exclusion of active synovitis in symptomatic patients should reduce patient’s risk of treatment 
failure and/or adverse effects by discouraging unnecessary DMARD escalations. However, 
treatment decisions taken at a similar time point are unlikely to influence patient’s long-term 
outcomes. It is possible that regularly assessing patient’s global disease activity using MSUS 
could allow patients to achieve significantly better medium-long term disease outcomes through 
prompt identification and treatment of persistent or recurrent subclinical synovitis (even before the 
onset of clinical flare) and prevention of unnecessary treatment escalations when inflammatory 
joint disease is quiescent. Compared to patient’s assessed using clinical composite disease 
activity measures, patients who undergo regular disease activity assessment by MSUS as part of 
a tight control, step-up DMARD escalation strategy, could have their DMARD regimens more 
closely tailored to their individual needs. Hypothetically, they should display significantly better 
clinical, functional and radiological outcomes (through early, aggressive suppression of persistent 
subclinical synovitis) and fewer DMARD associated adverse effects (through prevention of 
inappropriate DMARD escalation). 
 
1.5.3 Implication of MSUS Disease Activity Assessment 
There is an increasing momentum within published evidence that MSUS assessment of disease 
activity may improve rheumatologists’ ability to treat inflammatory joint disease in RA. Indeed, 
recent international consensus statements advocate the use of MSUS disease activity monitoring 
within a tight control, treat-to-target DMARD escalation regimen (129). However, before MSUS 
disease activity assessment is wholesale incorporated into routine practice a number of important 
issues should be considered: 
 
1. So far, the bulk of published evidence supporting the use of MSUS has been 
observational rather than interventional. It is highly likely that, compared to DAS28, the 
routine use of MSUS to assess disease activity will identify a higher instance of active 
disease that leads to patients receiving more intensive DMARD therapy. However, so far, 
there have been no interventional studies that demonstrate aggressively treating 
subclinical disease provides improved clinical outcomes, without significantly increasing 
the risk of adverse events 
 
2. MSUS is more sensitive than clinical examination for the identifying of synovial 
hypertrophy and active synovitis. However, as MSUS machines become more advanced 
and more sensitive, they may also become less specific. Earlier studies (e.g. Klauser et 
al) had shown that healthy subject’s joints do not exhibit intra-articular PD signal (215). 
By contrast, several recent studies have shown that it is possible to identify physiological 
intra-articular Doppler signals within the joints of healthy subjects (214,224). 
Physiological Doppler signals may also be present in RA patients and, in the context of 
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RA, are likely to be interpreted as disease related rather than physiological, thus leading 
to the disease activity state being misclassified as active rather than quiescent and 
potentially leading to further DMARD escalation. 
 
3. Unlike clinical examination, MSUS disease activity assessment requires additional 
equipment and time to perform. Regardless of the joints examined, performing MSUS in 
addition to clinical examination will require longer clinic appointments and therefore may 
limit the rheumatologist’s ability to see as many patients within a given session. 
Furthermore, in addition to the initial cost of purchasing highly sophisticated equipment, 
the increased identification and treatment of clinical synovitis could potentially be 
associated with higher treatment costs since it is possible that the use of combination 
DMARD therapy and/or biologic therapy will be higher amongst patients assessed using 
MSUS that those assessed using DAS28 
 
4. MSUS has the potential to become an extension of clinical examination and therefore, 
like all examination techniques, must be taught and practised. Since the interpretation of 
MSUS images is highly subjective there is potential for variability between individual 
sonographers. In fact, several validation exercises have suggested that, in experienced 
operators, there is moderate-good agreement between sonographers, particularly when 
standaridised assessment methods are followed and examination is confined to easily 
accessible peripheral joints (152,225,226) 
 
1.6 Assessment of Rheumatoid Arthritis Disease 
Activity and Prognosis Using Multilevel 
Biomarker Profiles 
 
Patients who develop a new inflammatory arthritis can receive diagnoses of RA through either a 
‘typical’ clinical presentation or through fulfilment of classification criteria. However, despite the 
similarities in clinical phenotypes, several clinical observations suggest that the diagnostic label of 
RA is an umbrella term representing a heterogenous group of underlying disease processes: 
 
1. Characteristic autoantibodies (e.g rheumatoid factors, anti-CCP antibodies) are only 
detectable in approximately 70% of new RA diagnoses  
2. Joint involvement is not uniform at presentation. For example, whilst the majority of 
patients present with a symmetrical inflammatory polyarthropathy, a subset can present 
with an asymmetrical oligoarthritis and still fulfil RA clasification criteria 
3. Response to immunomodulatory therapy is heterogenous. For example, biologic 
therapies, targeted at core inflammatory mediators, have an average response rate of 
approximately 60-70% 
4. Disease course after commencing DMARD therapy is highly variable even between 
patients with similar presenting disease characteristics and demographics 
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The abnormal pathogenetic and inflammatory processes which culminate in the clinical 
expression of an inflammatory polyarthropathy, and ultimately lead to the fulfilment of RA 
classification criteria, are becoming increasingly better described. Specific abnormalities relating 
to the development and perpetuation of RA have been described at genetic (DNA and RNA), 
molecular (cytokine, protein and lipid) and cellular levels both within the synovial and systemic 
environments (69,227). Feasibly, the heterogeneity of clinical presentation and response to 
DMARD therapy will be reflected by specific differences in the expression of markers relating to 
the activity of the underlying pathogenetic and inflammatory pathways. Ultimately, careful 
characterisation of an individual RA patient’s disease signature (i.e how they express specific 
cellular and molecular markers) could allow further sub-categorisation of their illness and provide 
an additional means of determining their likely risk of progressive or persistently active disease 
and their likelihood of responding to particular immunomodulatory agents; thus, allowing highly 
individualised tailoring of their therapy. High through-put microarray technologies allow rapid and 
comprehensive characterisation of profiles at genetic, genomic (e.g RNA expression), protein and 
metabolic levels in a variety of different target tissues. A number of exploratory studies have 
described how well particular profiles correlate to specific clinical phenotypes. Broadly, profiles 
may provide useful additional mechanistic information relating to underlying disease processes, 
or may provide prognostic information estimating a patient’s likely clinical course, however, their 
specific role in routine clinical care remains to be clarified 
 
1.6.1 Expression Analysis  
The transcription of messenger RNA (mRNA) from host DNA is dynamic and can be influenced 
by environmental, systemic and disease related factors. At any given time point the pattern of an 
individual tissue’s mRNA expression will provide a snapshot of which metabolic, immunological 
and cellular pathways are being either promoted or repressed. Microarray expression analysis 
experiments expose fixed genetic probes to mRNA isolated from target cells or tissue. Binding 
between genetic probes and tissue mRNA confirms the presence of specific mRNA segments 
and produces a hybridisation pattern which, when compared to a reference pattern, can be used 
to infer the relative up or down-regulation of specific genes. Comparing mRNA expression 
patterns between individuals with similar clinical phenotypes will demonstrate the degree of 
heterogeneity in their respective immunological and aetiological pathways. Conversely, 
comparing mRNA expression profiles at a group level should highlight those common patterns, or 
pathways, which are especially associated with a particular clinical phenotype and therefore 
might have either diagnostic and/or prognostic properties. To date, expression analysis 
experiments in RA have attempted to either 1. link mRNA profiles to specific pathgenetic 
processes or 2. identify mRNA profiles associated with specific clinical phenotypes  
 
Common autoimmune diseases (RA, SLE, MS, type 1 diabetes mellitus) demonstrate similarities 
in gene expression profiles which allow them to be differentiated from normal controls (228). In 
RA specifically, several studies have attempted to link gene expression data, using a variety of 
different target tissues, to corresponding clinical data to either gain insight into possible 
pathogenetic mechanisms, describe the relationship between gene expression profile and clinical 
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phenotype and/or identify additional markers associated with favourable/unfavourable treatment 
responses.  
 
• Van der Pouw et al performed gene expression analyses using synovial tissue collected 
from 15 RA patients during joint replacement surgery (229). Unsupervised hierarchical 
clustering demonstrated that the patients could be subdivided into two distinct groups 
based upon their gene expression profiles. In the first group, ten patients (Group RA-I) 
demonstrated increased expression of 121 genes broadly related to inflammation. This 
group could be further subdivided based on which specific aspect of inflammation-related 
gene expression was up-regulated: group RA-Ia comprised four patients with high 
expression of genes relating to adaptive immunity; group RA-Ib comprised 6 patients with 
increased expression of genes relating to classical complement pathway activation. In the 
second group, five patients exhibited increased expression of 39 genes relating to 
fibroblast differentiation but relatively low expression of genes relating to inflammation and 
complement activation. A crude comparison to clinical data was reported and it’s notable 
that each subgroup contained a small number of patients. All patients fulfilled 1987 ACR 
RA classification criteria which led the authors to conclude that the distinct differences in 
gene expression profiles groupings reflected the degree of heterogeneity in RA 
pathogenetic processes. Statistical between-group comparisons were not reported; 
however, compared to other groups, Group RA-Ia exhibited higher mean ESR (38 vs 27 vs 
25) and prevelance of erosive disease (100% vs 83% vs 80%) whilst Group RA-1b had a 
slightly lower rate of rheumatoid factor positivity (100% vs 83% vs 100%). 
 
• Olsen et al compared gene expression profiles in peripheral blood mononuclear cells 
(PBMC) between 11 early RA patients (mean duration 1.1 years), 8 established RA 
patients (mean duration 10.5 years) and 11 control subjects with asthma or allergic disease 
(230). Between group comparisons identified a gene expression pattern which was present 
in early RA but neither in established RA nor the control group. There was a degree of 
overlap between early RA expression profiles and those of patients with other autoimmune 
disorders (most notably SLE) suggesting that these two clinically distinct diseases might 
share a common pathogenetic pathway. In this study expression profiles were not 
compared to corresponding clinical data. 
 
• Devauchelle et al investigated whether synovial tissue gene expression profiles could 
differentiate between 5 patients with established RA (mean duration 14 years) and 10 
patients with osteoarthritis (OA) (231). Overall, 63 genes exhibited significant differential 
expression between RA and OA patients. In RA patients, 15 of the genes had higher 
expression levels and 48 had lower expression levels. Thirty six percent of the identified 
genes had known functions being related to cell cycle, signal transduction, metabolism or 
protease activity. Unsupervised clustering analyses correctly classified all RA and OA 
samples separately. Furthermore, a small validation analysis using the 63 selected genes 
correctly identified 2 further RA and 3 further OA patients  
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• Batliwalla et al demonstrated that patients with active RA exhibit different PBMC gene 
expression patterns to controls (232). Comparisons were performed between 29 patients 
with established RA (mean duration 12 years) and 21 control subjects. Hierarchical 
clustering analyses identified 81 genes with significantly different expression values 
between each group. This clustering incorporated all RA patients and three control subjects 
(false positives). Furthermore, a significant proportion of the up-regulated genes were 
related to monocyte function. How gene expression profiles were distributed amongst 
different RA phenotypic groupings was not described.  
 
• Since B-cells are strongly implicated in the pathogenesis of RA, Szodoray et al compared 
gene expression profiles of peripheral B-cells between 8 early RA patients (mean duration 
1.6 years) with active disease and 8 age- and sex-matched controls (233). In RA patients 
there was apparent increased expression of 305 genes and reduced expression of 231 
genes. Pathway analysis software identified functional clustering of the differentially 
expressed genes within pathways often associated with B cell function; such as, cell 
activation, proliferation apoptosis, autoimmunity, cytokine function and angiogenesis. 
 
The previously described gene expression studies utilised between group comparisons of either 
different stages of RA or between a cohort of RA patients and an unaffected control cohort. In 
each case, it was inferred that the observed differences in gene expression profile were related to 
the phenotypic variable used to define each group (e.g. RA vs control or early RA vs established 
RA). All of these studies used relatively small cohort groups and therefore may not fully reflect the 
broad heterogeneity of RA. Only one study reported a follow-up validation analysis. A number of 
recent studies have taken an alternative approach whereby all participants have established 
diagnoses of RA and are subdivided into comparison groups using clinically relevant variables 
such as disease activity level or response to a specific intervention. The majority of these studies 
have examined the value of gene expression profiles as markers of response to biologic therapy 
 
• Thirty three patients with DMARD resistant, established RA (mean duration 11.3 years) 
were treated with intravenous infliximab and provided whole blood, for PBMC gene 
expression profiling, immediately before, and 3 months after, commencing treatment (234). 
Patients were classified as being treatment responders if DAS28 fell by at least 1.2 after 3 
months treatment. Differential expression analyses identified 41 gene transcripts with 
statistically significant (p = 0.05) levels of expression between responders and non-
responders. Quantitative Real Time-PCR reliably quantified 20 of the 41 candidate 
transcripts and a hierarchical clustering analysis showed that these 20 transcripts would 
correctly classify the treatment response in 75% of patients. Subsequent analyses 
identified a combination of 8 gene transcripts which were at least as accurate as the panel 
of 20 transcripts for classifying patient’s treatment response through hierarchical clustering. 
Time integrated analyses comparing changes in gene expression levels between baseline 
and 3 months of treatment demonstrated that in responders 18 of 20 candidate gene 
transcripts tended towards to higher expression levels at 3 months. By contrast, in non-
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responders, 19 of 20 gene transcripts exhibited a reduction in expression levels which 
reached statistical significance for 8 transcripts. 
 
• Lindberg et al compared before and after treatment changes in gene expression profiles in 
synovial biopsy samples taken from 10 RA patients receiving intravenous infliximab (235). 
Patients were grouped based upon their fulfilment of EULAR response criteria after three 
months treatment (3 good responders, 5 moderate responders, 2 non-responders). For 
baseline samples, step-wise comparisons between each responder group identified 279 
differentially expressed genes when good and non-responders were compared. However, 
there were no statistically significantly expressed genes when good responders were 
compared with moderate and non-responders. Following infliximab therapy, comparisons 
between baseline and 3 month gene expression profiles in good responders identified 115 
genes whose expression levels changed significantly following therapy (i.e. a dynamic 
change in expression levels led to them being differentially expressed). 
Immunohistochemical analyses identified TNFα in four synovial biopsy samples, of which 
all were taken from either good (3) or moderate (1) responders. Comparing these samples 
to the TNFα negative biopsies identified 12 differentially expressed genes. Furthermore, 
comparisons between gene expression profiles for the TNFα positive patients with those 
from all non-responders identified 685 differentially expressed genes; thus suggesting that 
the presence of TNFα has pathogenic significance and may serve as an important 
predictor of successful infliximab treatment 
 
• The relationship between pre-treatment gene expression profiles in synovial tissue and 
response to infliximab therapy has been reported in 18 patients with DMARD-resistant 
established RA (236). Response was defined as a reduction in DAS28 of at least 1.2 after 
16 weeks of therapy. Hierarchical clustering analyses, using the 189 genes which exhibited 
at least a 1.4 fold between group difference in expression levels, identified a panel of 
genes which had clearly increased expression levels in responders and reduced levels in 
non-responders. These transcripts contained a number of specific genes (e.g CD163, 
S100A8, HLA Class II, immunoglobulin, integrins and chemokines) which have already 
been associated with high levels of inflammation in RA tissue 
 
• Sekiguchi et al described how changes in serial PBMC gene expression profiles correlated 
to clinical changes and treatment response over time in 18 patients with DMARD-resistant 
RA treated with intravenous infliximab (237). Achieving an ACR50 response (i.e at least 
50% improvement in core set variables) was defined as a treatment response. The 
investigators performed gene expression analyses using a custom made, low density (747 
genes) microarray which incorporated genes known to be related to inflammatory blood cell 
activation. In total, 18 genes were differentially expressed (>1.5-fold change) between the 
responder and non-responder groups; of which, the top ten were related to interferon. In 
the responder group, successful treatment with infliximab caused persistent reduction in 
the expression levels of several interferon related genes. By contrast, in the non-responder 
group, infliximab therapy caused an early, transient fall in interferon-related gene 
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expression levels that returned to baseline levels on follow-up testing. Subsequent 
quantitative real-time PCR analyses confirmed the findings of the microarray analysis. 
Interestingly, time course analyses showed that interferon-related gene expression levels 
followed a very similar pattern to corresponding fluctuations in DAS28 and, in most cases, 
individual gene expression levels correlated strongly with corresponding DAS28 scores (R2 
0.6115 – 0.8929). These preliminary results do suggest that changes in gene expression 
profiles may reflect changes in RA disease activity and that cut-down, customised cDNA 
microarrays might provide an additional means of longitudinally monitoring response to (at 
least) infliximab therapy. 
 
• Nineteen patients with DMARD resistant, established RA provided whole blood PBMCs 
immediately before, and 3 days after, commencing treatment with etanercept to determine 
whether very early changes in gene expression profile were predictive of treatment 
response (238). Once again, a good response was defined as at least a 1.2 reduction in 
DAS28 3 months after commencing therapy and was achieved by 12 patients. Three days 
after receiving etanercept, 42 genes showed a differential change in expression levels 
between the responder and non-responder groups. Of these, 36 genes demonstrated were 
down-regulated comparing responder to non-responders. Pathway analyses demonstrated 
that successful etanercept therapy produced early down regulation of genes involved in 
pathways related to TNFα signalling, NFκB-independent signalling and regulation of 
cellular and oxidative stress. These early changes were associated with, and therefore may 
be predictive of, at least 3 month response to etanercept. Interestingly, pre-treatment gene 
expression profiles were not predictive of 3 month etanercept response whereas the 
dynamic changes in gene expression profiles after 3 days were 
 
• The previously described study by Batliwalla et al (232) showed that there was significant 
correlation between disease activity levels and the expression levels of genes relating to 
monocyte function. Stuhlmuller et al progressed these findings by attempting to determine 
whether a single, monocyte-related biomarker was predictive of anti-TNFα response in RA 
(239). Monocytes were purified from blood samples donated by 77 RA patients (mean 
disease duration 8.7 years), who were participating in a randomised control trial of 
adalumimab monotherapy, and 23 healthy controls. Response to adalumimab was defined 
as achievement of an ACR20 response. Pairwise comparisons between RA patients and 
healthy controls identified 51 genes with differential expression. Hierarchical clustering 
analyses performed using three candidate genes correctly classified treatment response in 
all patients. Following adalumimab treatment, there were 117 genes which exhibited 
differential expression levels between responders and non-responders. Three genes 
(FAM3C, ITGAX (CD11c), TMEM45A) were differentially expressed in all pairwise 
comparisons between responders and non-responders. Follow-on real time reverse 
transcription PCR quantification using monocytes from an independent cohort of 27 RA 
patients showed a strongly positive (r=0.651), statistically significant (p<0.0001) correlation 
between CD11c expression levels and ACR response to adalumimab which correctly 
predicted the likelihood experiencing a good treatment response. Receiver operating 
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characteristic analyses suggested the sensitivity for detecting responders was 100% and 
the specificity was 91.7%. However, the predictive utility of CD11c was only evident in 
patients receiving adalumimab monotherapy since it did not appear predictive of response 
to either methotrexate monotherapy or methotrexate/adalumimab combination therapy.  
 
Despite their disparate designs, taken together the previously described studies do suggest that 
gene expression profiles might have a number of useful diagnostic and prognostic properties in 
relation to assessment and management of RA: 
 
1. RA patients can be distinguished from healthy controls, and/or osteoarthritis sufferers, 
through specific differences in gene expression profiles (231-233,240). Furthermore, 
specific difference in gene expression profiles have been demonstrated between early 
and established RA patients (230) 
 
2. Pre-treatment gene expression profiles correctly classify, and therefore may be predictive 
of, subsequent response to biologic therapy. Specifically, good clinical responses to 
either infliximab (234,236,237,241), adalumimab (239) or etanercept (238) have each 
been associated with specific pre-treatment differences in gene expression profiles 
between responders and non-responders 
 
3. Treatment with biologic therapy induces a dynamic pattern change in gene expression 
profiles (235,237,238) which may reflect observed changes in clinical disease activity 
(and therefore treatment response) 
 
To date, most transcriptomic studies in RA have attempted to compare relatively early changes in 
gene expression profiles to the clinical impact of a single intervention. Most commonly, this has 
been the introduction of biologic therapy (usually an anti-TNFα agent) in patients with DMARD-
resistant established RA. However, as previously discussed, the time period when therapeutic 
intervention is most likely to have the greatest long-term benefit appears to be during the early 
months following symptom onset. Currently, most treatment guidelines advocate using 
aggressive non-biologic DMARD regimens to suppress the emerging inflammatory process and 
using clinical disease activity measures, with their attendant lingering concerns regarding 
sensitivity and specificity, to guide treatment changes. Biologic agents, the single treatment group 
proven to consistently retard erosive joint progression, remain reserved for those patients who 
demonstrate DMARD resistance through persistently active disease and, in many cases, 
progressive irreversible joint damage. Furthermore, the previously described transcriptomic 
studies are starting to identify specific gene expression patterns, and indeed differences in 
expression of single genes, which might in fact increase the overall efficacy of biologic therapy 
further by ensuring that specific therapies are targeted at those patients most likely to experience 
a beneficial response. However, the majority of newly diagnosed RA patients will not initially 
receive biologic therapy; therefore, the potential role for using gene expression profiles in the 
often rigidly dictated assessment and management of early RA remains to be described. If similar 
relationships to those demonstrated between anti-TNFα treatment response and gene expression 
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profile are also evident when applied to non-biologic DMARD treatment response it might be 
possible to identify specific gene expression profile patterns which either predict response or non-
response to non-biologic DMARD therapy (either singularly or as a group). Ultimately, it may be 
possible to use gene expression information at presentation to screen newly diagnosed RA 
patients’ blood for the presence of specific gene expression patterns to predict their likelihood of 
responding to a particular treatment, or regimen. In this way, specific treatments, or regimens, 
can be targeted at the patients most likely to respond to the treatment and, theoretically, patients 
should avoid the unnecessary (and uncomfortable) delays associated with receiving ineffectual 
therapy. Similarly, since both gene expression and disease activity levels appear to be dynamic, if 
strong correlations can be identified between specific disease activity states and specific gene 
expression patterns, it may be possible to use blood gene expression as an additional measure of 
global disease activity      
 
1.6.2 Metabolomics 
Metabolomics uses high-throughput technologies, such as nuclear magnetic resonance 
spectroscopy and liquid gas chromatography, to describe the relative concentrations of 
metabolically active, low molecular weight compounds in individual tissues or organs (162). 
Evident differences in the metabolomic expression patterns between individuals with a specific 
illness and unaffected controls can provide important insights into the underlying disease 
processes. Important metabolomic signatures, with either diagnostic and/or prognostic properties, 
have been identified in studies of cancer (bladder, colorectal, prostate, stomach, renal, brain and 
lung), type 1 and type 2 diabetes mellitus, cardiovascular disease, neurological diseases 
(Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer’s disease and schizophrenia), 
asthma and coeliac disease (162). To date, relatively few descriptions of the diagnostic and/or 
prognostic properties of metabolomic profiling in RA have been published though it is feasible that 
phenotypic variations in RA may also exhibit characteristic metabolomic signatures. 
 
• Madsen et al described the potential diagnostic properties of metabolomic profiling to 
distinguish RA patients from either psoriatic arthritis patients or healthy controls (242). 
Firstly, the plasma metabolomic profiles of 25 RA patients (early and established disease) 
were compared to 20 psoriatic arthritis patients. Combining the results for gas 
chromatography-mass spectrometry and liquid chromatography mass spectrometry 
identified 83 metabolites with differential expression levels between RA and psoriatic 
arthritis. A follow-on validation analysis used a subset of these differentially expressed 
metabolites to attempt to distinguish between 14 different RA patients and 20 healthy 
controls. This model correctly identified RA patients with a sensitivity of 93% and specificity 
of 70%. Whilst this specificity is clearly less than that offered by ACPA testing, analysing 
metabolomics profiles did correctly identify several patients with clinical diagnoses of RA 
but negative autoantibody statuses 
 
• Hugle et al have recently reported on the diagnostic value of using metabolomic profiles to 
distinguish between septic and non-septic arthritis and between degenerative and 
inflammatory arthritidies (243). Synovial fluid from 59 patients with a broad range of 
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rheumatological diagnoses was examined using nuclear magnetic resonance 
spectroscopy. Overall, synovial fluid from patients with septic arthritis demonstrated a 
distinctive metabolomic profile. However, there was no distinct differences observed 
between patients with osteoarthritis and inflammatory arthritidies (including RA). 
 
• Van Wietmarschen have described which differences occur in urinary and plasma 
metabolomic profiles when a patient’s RA is classified according to Chinese medicine 
theory (244). Thirty nine RA patients completed a detailed symptoms questionnaire and 
were classified as having either Heat RA or Cold RA by Chinese medicine practitioners. 
Urinary and plasma metabolomic profiles were determined by liquid chromatography mass 
spectrometry. The authors report panels of 11 urinary metabolites and 8 plasma 
metabolites that discriminated between the Heat and Cold RA groups. Heat RA patients 
exhibited higher urinary levels of several metabolites related to carnitine synthesis and the 
authors suggest that Cold RA patients may exhibit either lower muscle mass or lesser rates 
of muscle breakdown. However, a clinical correlation to body habitus is not reported. 
Furthermore, Heat RA patients exhibited higher DHEAS levels than Cold RA patients 
suggesting that Cold RA patients may experience greater rates of suppression of 
hypothalamaic-pituitary-adrenal axis function. Once again, a comparison with formal 
assessments of endocrine function is not reported. 
 
Clearly, there hasn’t been the same degree of investigation into the role of metabolomic 
signatures in the assessment of RA as has been reported for transcriptomic profiling. The 
available studies do seem to suggest that metabolomic profiling may at least have a role in 
supporting the diagnosis of seronegative RA and differentiating septic arthritis from other 
inflammatory arthritidies. However, it is unlikely that Chinese Medicine Theory models of disease 
will ever be incorporated into the standard assessment portfolio of Western rheumatologists. 
Either way, further larger scale studies are required to better describe how metabolomic profiling 
performs as either 1. a diagnostic and/or prognostic tool in the assessment of patients with 
suspected inflammatory arthritidies and 2. an additional measure of global disease activity able to 
accurately represent response to DMARD therapy changes. 
 
Overall, high throughput technologies do show some promise as additional means of assessing 
patients with inflammatory arthritidies. On the basis of available evidence it’s possible that high 
throughput technologies (particularly transcriptomic profiling) may distinguish between different 
causes of inflammatory arthritis and different disease activity states and might also provide 
additional prognostic information regarding a patient’s likely response to a particular therapy. 
However, these presumptions are mostly inferred from relatively small clinical studies with a 
heterogeneous range of study designs. Furthermore, the majority of treatment response studies 
have been conducted on the subset of patients receiving biologic therapy rather than those 
receiving non-biologic DMARDs. Such technologies will require careful, prospective validation in 
much larger patient cohorts to systematically describe their diagnostic, prognostic and disease 
activity properties before they might be incorporated into routine clinical practice. At present, most 
gene expression studies in RA have been conducted using either peripheral blood and/or 
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synovial tissue samples. In a clinical setting, the most readily available tissue for analysis remains 
peripheral blood and this is often collected during a patient’s routine consultation. In most centres, 
the collection of synovial tissue is not routine, since additional facilities and training are required 
to perform percutaneous biopsy and many patients consider the procedure excessively invasive. 
If high through-put technologies were to identify a useful additional prognostic and/or disease 
activity profile, it will be most clinically useful if it were to be identified in peripheral blood 
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1.7 Objectives  
The programme of research described in the following chapters has the following objectives: 
 
1. To identify and recruit a cohort of patients with newly diagnosed rheumatoid arthritis to a 
prospective study of DMARD treatment strategy and novel disease activity assessment 
methods 
 
2. To prospectively gather a broad range of clinical, laboratory and radiological outcome 
measures to be used to describe response to DMARD therapy at an individual and group 
level 
 
3. To determine the value of adding musculoskeletal ultrasound assessment to standard 
clinical assessments of RA global disease activity and what impact this will have on 
DMARD escalation decisions. To also determine whether patients who undergo regular 
assessment of global disease activity by musculoskeletal ultrasound, in addition to DAS28, 
exhibit significantly better clinical, functional and radiological outcomes compared to those 
patients who undergo global disease activity assessment by DAS28 alone 
 
4. To determine whether phenotypic variations in RA can be distinguished by distinct 
differences in peripheral blood gene expression profile 
 
5. To describe the relationship between peripheral blood gene expression and response to 
DMARD therapy to determine whether peripheral blood gene expression profiling provides 
useful prognostic and/or disease activity information 
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1.8 Hypotheses 
 
1. Regular assessment by musculoskeletal ultrasound, in addition to DAS28, will identify a 
higher burden of active, inflammatory joint disease than clinical assessment alone 
 
2. Patients who undergo regular global disease activity assessment by musculoskeletal 
ultrasound, in addition to DAS28, will have DMARD therapy tailored more appropriately to 
their specific needs and experience a better benefit:risk ratio than those who undergo 
clinical assessment alone. Specifically, using musculoskeletal ultrasound to influence 
DMARD escalation decisions will produce significantly better clinical, functional and 
radiological outcomes than using clinical assessment alone 
 
3. Specific RA phenotypic variations will be associated with specific peripheral blood gene 
expression profile signatures 
 
4. Specific perturbations in peripheral blood gene expression profile will be associated with 
positive or negative treatment responses and therefore may have clinically useful predictive 
properties 
 
5. Fluctuations in RA disease activity in response to DMARD therapy will be reflected by 
corresponding changes in peripheral blood gene expression profile. Hence, peripheral 
blood gene expression profiling might serve as an additional measure of global RA disease 
activity 
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2. Methods 
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2.1 Introduction 
The research described herein has been conducted on a single cohort of 111 patients with newly 
diagnosed RA who provided the necessary clinical and radiological outcome data, and additional 
blood samples, during monthly attendances at specially set-up rheumatology research clinics. 
The clinical and radiological outcome data collected as part of the musculoskeletal ultrasound 
research study will also be used to inform the analysis of the gene expression and multi-
biomarker disease activity (MBDA) test datasets. Hence, the gene expression and MBDA 
analyses are considered to be nested within the main clinical study. This approach has allowed 
very detailed, longitudinal descriptions of individual patient’s, and patient group’s, response to 
step-up DMARD therapy at clinical, functional, radiological, gene expression and biochemical 
levels. The description of methods will be presented in sequence with specific subsections 
relating to relevant aspects of the musculoskeletal ultrasound and gene expression analyses 
included where appropriate. 
 
2.2 Identification of Study Cohort 
In order to conduct longitudinal research into early RA treatment a mechanism must exist to allow 
recruitment and follow-up of potential participants in a timely manner. This process must facilitate 
early identification and review of patients, such that the screening process used to determine 
whether a patient is suitable to participate in a clinical trial does not produce unacceptable delays 
in diagnosis or commencement of appropriate treatment. Furthermore, patients who undergo 
screening and either decline, or are deemed unsuitable, to participate must not experience any 
compromise in delivery of appropriate care. The following sections will describe how patients who 
participated in this research project were identified, screened for participation and the reasoning 
behind the final cohort size 
 
2.2.1 Screening Arrangements 
 
Research Sites  
Specific research clinics were established at three hospital sites in Glasgow (Gartnavel General 
Hospital, Glasgow Royal Infirmary and Stobhill Hospital) for screening and follow-up of patients. 
Research clinics ran 4-5 times weekly at Gartnavel General Hospital, twice weekly at Glasgow 
Royal Infirmary and once weekly at Stobhill Hospital. Each clinic was staffed by a Clinical 
Research Fellow (Dr James Dale – JD) and an experienced Rheumatology Research Nurse / 
Metrologist (Sister Anne Stirling – AS). The balance between new patient reviews (1 hour) and 
return slots (30 minutes) was varied according to the stage and recruitment status of the study. In 
addition to the three main hospital sites potential participants could also be referred for screening 
from Rheumatology Departments based at other hospital sites within Greater Glasgow and Clyde 
(including the Victoria Infirmary, Inverclyde Royal Hospital, Royal Alexandria Hospital, Nuffield 
Health Glasgow Hospital and BMI Ross Hall Hospital) with follow-up being arranged at the 
research clinic most convenient for the participant 
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Referral Sources 
In order to maximise the rate of recruitment, potential participants could be referred for screening 
by a variety of different routes:  
 
1. Patients who had already undergone outpatient rheumatology clinic review and had 
recently been given presumptive diagnoses of RA were referred directly to Dr Dale by the 
base hospital rheumatology team. These referrals were made by either telephone, email or 
directly face-to-face 
 
2. At Gartnavel General Hospital and Stobhill Hospital, new patient referrals from Primary 
Care or other specialities that were suggestive of RA were forwarded to Dr Dale and 
provided with early first review appointments at the research clinics. Patients who fulfilled 
inclusion criteria, and who agreed to participate, continued to attend the research clinics 
whereas those who either declined to participate, or did not fulfil inclusion criteria, had 
appropriate follow-up arranged within their base rheumatology unit 
 
3. Acute general medical admissions with severe, debilitating first presentations of RA were 
referred to Dr Dale for screening and early follow-up 
 
For each participating site, the referral of potential participants for screening was encouraged by 
displaying recruitment posters in outpatient clinics and day-wards, sending regular recruitment 
emails and updates to colleagues (consultants, trainees and specialist nurses) and by Dr Dale 
attending each Rheumatology Department’s academic meetings to present the aims, design and 
treatment protocol for the study. A copy of the recruitment poster can be found in Appendix B 
 
Screening Process 
All potential participants underwent a standardised screening process conducted by Dr Dale and 
Sister Stirling. The aims of this process were to 1. ensure that potential participants had the 
correct diagnosis and fulfilled the inclusion criteria, 2. ensure that potential participants neither 
met any of the exclusion criteria nor exhibited any other contraindication to taking part, 3. provide 
participants with ample opportunity to discuss their diagnosis, the nature of their treatment and 
the implications of taking part in clinical research and 4. collect all of the necessary baseline 
clinical, laboratory and radiological outcome data. During the screening process the following 
standardised assessments were performed: 
 
• Clinical 1. Comprehensive clinical history (JD) – including history of presenting 
complaint, past medical history, medication history and social circumstances 
 
2. Clinical examination (JD) – including general systemic examination and 
musculoskeletal examination  
 
• Laboratory 1. Biochemistry – Urea + electrolytes (UE), liver function tests (LFT), C-
reactive Protein (CRP), calcium, glucose, non-fasting lipid profile (total 
cholesterol, HDL, triglycerides and cholesterol:HDL), thyroid function tests 
(TFT) 
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2. Haematology – Full blood count (FBC), Erythrocyte sedimention rate 
(ESR) 
 
3. Immunology – Rheumatoid factor (RF), anti-cyclic citrillunated peptide 
antibodies (anti-CCP), anti-nuclear antibody (ANA) 
 
• Radiological 1. Chest X-ray 
 
2. Plain X-ray hands and feet (AP projection) 
 
3. Musculoskeletal ultrasound of hands and feet (JD) – scanning of limited 
joint set (bilateral radiocarpal, MCP2+3, PIP 2+3 and MTP 2+5) with grading 
of synovial hypertrophy and PD signal  
 
• Disease Activity 1. DAS28 (JD) – comprising 28 swollen joint count, 28 tender 
joint count, patient global health 10cm visual analogue score and 
ESR 
 
2. DAS44 (AS) – comprising 44 swollen joint count, Ritchie 
articular index, patient global health 10cm visual analogue score 
and ESR 
 
3. Total pain 10cm visual analogue score 
 
• Functional Assessment 1. Health assessment questionnaire (AS) 
 
2. Euro-QOL 5D questionnaire (AS) 
 
Due to the generally accepted requirement that there must elapse at least 24 hours between the 
initial discussion of participating in clinical research and the provision of written consent the 
screening process required most patients to attend for two separate visits which were usually 
scheduled within 7 days of each other. The short delay between screening and recruitment visit 
also allowed the return of any outstanding blood test results that might otherwise have precluded 
the patient’s participation. All potential participants were provided with a standardised Patient 
Information Leaflet describing the nature of the project and all who agreed to participate were 
required to provide written consent. Examples of the Patient Information Leaflet and Patient 
Consent Form are reproduced in Appendices C and D. Any patients who either declined to 
participate, did not fulfil the inclusion criteria, or did fulfil the exclusion criteria, underwent a full 
clinical evaluation and - during the follow-up review - were commenced on appropriate treatment 
(as indicated) with onward follow-up being arranged at their base rheumatology unit.   
 
2.2.2 Inclusion Criteria 
The inclusion criteria are similar to criteria used in a number of other studies of RA treatment 
strategy and were designed to ensure that only patients with the correct diagnosis and presenting 
characteristics were offered participation in the research 
 
Patient with newly diagnosed RA or CCP-positive Undifferentiated Inflammatory Arthritis (with 3 
or more swollen joints 
Since the research aimed to be applicable to modern clinical practice a pragmatic approach to 
recruitment was undertaken. In order to identify a cohort of patients that was comparable to that 
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encountered in daily practice, patients who could justifiably be given a clinical diagnosis of RA 
were considered for recruitment. Furthermore, given the very high specificity of positive anti-CCP 
antibodies for RA (10), the evidence that inflammatory arthritis in anti-CCP positive patients has a 
very high risk of evolving into RA (245,246) and that anti-CCP positivity is considered a poor 
prognostic marker (53,247), patients with clinically undifferentiated inflammatory arthritis who 
were anti-CCP positive were also considered for participation. However, since anti-CCP 
antibodies can be detected in blood for many years before the onset of clinical inflammatory joint 
disease (7), and since many anti-CCP positive individuals may experience arthralgia without 
having evident inflammatory joint disease, anti-CCP positive patients needed to exhibit at least 3 
clinically swollen joints to ensure that their symptoms could be attributed to the presence of 
synovitis.   
 
Symptom duration less than 12 months 
Clinical observations have demonstrated that different temporal stages of RA may react 
differently to immunomodulatory therapy, with the greatest chance of achieving a prolonged, 
beneficial response being during the very earliest stages of symptom onset before immune 
plasticity is lost (113,116). Thus, whilst early and established RA are on the same pathological 
and clinical continuum it is possible that they may require different therapeutic approaches. 
Hence, since the opportunity to maximise long-term treatment outcomes appears to be within the 
early stages after symptom onset, this research has focussed on ‘early RA’.  
 
During the period of drafting of the research protocol (April – June 2009) there was no consensus 
over the definition of ‘early RA’ based on duration of symptoms. International guidelines available 
at the time all stated different time intervals: 
 
 Scottish Intercollegiate Guidelines Network  symptom duration < 5 years (248) 
 British Society of Rheumatology   symptom duration < 2 years (168) 
 European League Against Rheumatism  no comment (169) 
 American College of Rheumatology  disease duration < 6 months (112) 
 
Furthermore, even the recent publication of the 2010 ACR/EULAR Classification Criteria failed to 
clarify the definition since they stated RA should be considered whenever arthritis has persisted 
for more than 6 weeks but did not distinguish between early and established disease (13). For 
ease of use, and so as not to limit recruitment, an arbitrary symptom duration of up to 12 months 
was chosen for this research. Symptom duration was chosen in preference to disease duration 
(i.e. the time from diagnosis) to account for any prolonged delays in seeking medical review that 
might have resulted in some patients first presenting to the rheumatology clinic with established 
disease (249). Symptom duration was timed from the point that participants first experienced 
consistent and persistent joint symptoms (pain, swelling and/or stiffness) that, in the opinion of 
the clinician, were attributable to RA.  
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Active Disease (DAS44 ≥ 2.4) 
A patient’s diagnosis of RA is independent of their level of disease activity provided they present 
with an appropriate history and display supportive examination and investigation findings. At low 
disease activity levels (DAS44 < 2.4) the initial treatment approach may be less aggressive than 
in those patients with clearly more active disease. A moderate disease activity threshold for 
inclusion should ensure that only patients with active disease are considered for participation and 
that the potential benefits of receiving aggressive, rapidly escalating doses of DMARD therapy 
outweigh the potential risks of experiencing treatment adverse effects 
 
DMARD Naïve or DMARD Monotherapy for less than 6 weeks 
Since the research described herein focuses heavily on optimising the very early stages of 
DMARD therapy it is logical to only include patients at the very start of their therapy. Otherwise 
any participants who were already established on DMARD therapy may either be already 
experiencing an early benefit (thereby negatively biasing the scale of their overall treatment 
response) or may appear to have prolonged courses of initial DMARD monotherapy (which would 
be against the ethos of early tight disease control). Furthermore, since the parallel research aim 
is to describe changes in biomarker signatures with treatment it is logical to only consider patients 
in whom there is only a small chance that an additional external factor (such as DMARD therapy) 
might have biased the observed findings. Since some patients were referred by external 
rheumatology departments to the research clinics, and since the researchers were occasionally 
unavailable to arrange rapid reviews, up to 6 weeks DMARD monotherapy was accepted in order 
to maximise the recruitment rate and avoid any unacceptable delays in externally referred 
patients commencing appropriate therapy.  
 
Aged 18 or over 
A lower age limit of 18 years is a standard inclusion criterion in most interventional studies in 
rheumatology generally and RA treatment strategies generally. An upper age limit was not 
applied 
 
2.2.3  Exclusion Criteria 
Assuming a potential participant fulfilled the inclusion criteria, the exclusion criteria were used to 
ensure that participants would not be placed at an increased risk of adverse effects from the 
treatment protocol’s DMARD escalation regimen. Essentially, the exclusion criteria are common 
contraindications to receiving aggressive, rapidly escalating DMARD therapy - especially 
methotrexate which forms the crux of the DMARD regimen 
 
Significant liver disease and/or abnormality of liver function tests (baseline AST/ALT > twice 
upper limit of normal or alkaline phosphatase > 2.5 times upper limit of normal) 
Both methotrexate and sulfasalazine can cause aberrations of liver function that may require 
either dose reduction or complete cessation of therapy; hence, potentially hepatotoxic therapies 
are often avoided in patients with pre-existing liver disease. Further, both methotrexate and 
sulfasalazine undergo extensive hepatic metabolism; hence, significant liver disease can lead to 
the accumulation of their metabolites and an increased risk of adverse effects. Thus, patients with 
pre-existing liver disease might be placed at an unacceptably high risk of developing worsening 
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liver function through participation in the study. Furthermore, failure to utilise the proposed 
DMARD regimen in a subset of patients might lead to their RA appearing to be inadequately 
treated (within the limits imposed by their co-morbidities) and therefore could negatively bias the 
observed outcomes. Fluctuations in liver function test results are important indicators of evolving 
liver dysfunction; however, regular monitoring can prove extremely difficult if patient’s liver 
function tests appear abnormal prior to commencing DMARD therapy 
 
Significant renal impairment (baseline serum creatinine > 200 µmol/l; eGFR < 30) 
Both methotrexate and sulfasalazine (and their derivatives) are primarily excreted in urine. Thus, 
significant renal failure, and a loss of excretory renal function, can potentially lead to the 
accumulation of non-excreted metabolites and an increased risk of adverse effects 
 
Significant cytopenia (baseline white cell count < 4.0 x 109/l; haemoglobin < 10 g/l, platelet < 150 
x 109/l) 
Both methotrexate and sulfasalazine can cause suppression of blood cell counts, through either 
direct myelotoxicity or an anti-metabolite effect. These effects are often unpredictable and can 
relate to either an isolated cell line or whole blood. In either case, exacerbating a pre-existing 
cytopenia would place the affected patient at an even greater risk of becoming symptomatic (e.g. 
worsening leucopenia = risk of opportunistic infection; worsening anaemia = risk of constitutional 
symptoms and cardiorespiratory compromise; worsening thrombocytopenia = risk of spontaneous 
or uncontrolled haemorrhage). DMARD monitoring relies upon a change in full blood count 
parameters to signal the development of possible DMARD associated adverse effects. However, 
accurate monitoring can become difficult, and potentially unsafe, when patients have pre-existing 
full blood count abnormalities that might prevent any additional abnormalities being highlighted. 
 
Pregnancy, planned pregnancy or breast feeding 
Use of methotrexate whilst pregnant leads to a high risk of either birth defects or spontaneous 
termination. Furthermore, low concentrations of methotrexate are excreted in breast milk and 
could feasibly be consumed by a suckling infant. Thus, the Federal Drug Agency (FDA) 
(pregnancy category X) and American Academy of Paediatricians consider methotrexate use to 
be strongly contraindicated during pregnancy and breast feeding. Since methotrexate forms the 
crux of this research’s DMARD treatment regimen it would not be appropriate to offer participation 
to any patient (who otherwise meets inclusion criteria) who is either pregnant, currently 
breastfeeding or considering pregnancy since it would not be possible to fully investigate the 
impact of the intervention under investigation and could place the participant and their child at an 
unacceptably high risk of harm. Sulfasalazine use during pregnancy appears to be safe (FDA 
pregnancy category B) and only very small concentrations appear to be excreted in breast milk. 
The FDA have not formally assigned hydroxychloroquine to a pregnancy category. Cohort data 
suggests the risk of exposing unborn foetuses to hydroxychloroquine is equivalent to the risk of 
foetuses born in mothers with similar medical conditions who do not take hydroxychloroquine. A 
very small concentration of hydroxychloroquine is excreted in breast milk. To date, no consistent, 
significant evidence of harm to the infant has been demonstrated and overall the benefits of 
breast feeding are felt to outweigh the risk associated with hydroxychloroquine. The FDA have 
classified etanercept as pregnancy category B; however, there is very little data available from 
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human pregnancy studies. There is little longitudinal data to describe the potential risk of 
etanercept during breastfeeding. Since it has a high molecular weight and is not orally absorbed, 
only very small quantities will be expressed in breast milk and it is unlikely to affect the suckling 
infant. Regardless, until more detailed safety data is available the manufacturers (Pfizer) advise 
avoiding use of etanercept during pregnancy and breastfeeding.  
 
Contraindication to MRI  
Magnetic resonance imaging (MRI) of dominant wrist and MCP joints is the primary radiological 
outcome measure. However, since MRI uses a high energy magnetic field scanning is 
contraindicated in any patients whose body contains any ferromagnetic object for fear that the 
object may cause local trauma through becoming dislodged or heated by induction. If a potential 
participant were unable to undergo MRI they would not be able to contribute to one of the 
research’s main outcome measures and therefore their omission could bias the observed results. 
Common contraindications to MRI include: implantable cardiac pacemakers and defibrillators, 
vagus nerve stimulators, cochlear implants, deep brain stimulators, particular cerebral aneurysm 
clips, particular surgical prostheses and retained metal fragments. The MRI scanner usually 
requires patients to lie prone in a narrow, horizontal corridor with most of their upper body 
surrounded by the scanning machinery. Some patients find this a very unpleasant and oppressive 
experience; hence, severe claustrophobia is also considered a relative contraindication to MRI 
 
Other co-morbid condition that in the opinion of the investigator would preclude the use of 
combination DMARD therapy 
Whilst it was hoped that the previously described exclusion criteria would capture most of the 
common contraindications to participating in the research it was acknowledged that there would 
be a small number of patients who did not fulfil the exclusion criteria in whom participation would 
still be considered inappropriate because of additional external factors. Thus, this final exclusion 
criterion was included to allow the researchers a degree of clinical judgement when considering 
potential participants with either multiple medical co-morbidities or significant psychological 
and/or social difficulties 
 
2.2.4 Sample Size Estimation 
A sample size calculation was conducted to ensure adequate power to demonstrate a statistically 
significant difference in the primary clinical outcomes between the intervention groups in the 
treatment strategy arm of this research. The previously described TICORA (118) and TEAR (146) 
studies had been conducted in a similar geographical population with similar designs. Both of 
these studies had performed sample size calculations to ensure sufficient patients were recruited 
to demonstrate a statistically significant between-group difference. The parameters that formed 
the basis of these calculations are described in Table 2 
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 Comparator Minimum 
Important 
Change 
Standard 
deviation 
Alpha 
value 
Power Group 
Size 
TICORA 
 
Mean fall in 
DAS44 
 
Percentage 
EULAR 
Good 
ΔDAS44 ≥ 
1.1 
0.7 p < 0.01 95% 53 
TEAR 
 
Mean fall in 
DAS28 
ΔDAS28 ≥ 
1.1 
1.46 p < 0.05 90% 37 
Table 2 – Summary of sample size calculation parameters for TICORA and TEAR studies 
 
In contrast to the TICORA and TEAR studies, this study used mean change in DAS44 and MRI 
RAMRIS scoring as co-primary outcome measures. At the time of study design available 
published data had shown the standard deviation of RAMRIS synovitis score at the wrist to be 
±1.64 (250) but there were no published values for the minimum clinically important difference. 
Presuming that the sample size estimate for the TICORA study DAS44 outcome would still hold 
true the following calculation was performed to infer what difference in RAMRIS synovitis scores it 
might be able to detect using similarly sized groups: 
 
Thus, groups comprising at least 53 patients would be able to detect a minimum change in 
RAMRIS synovitis score of 0.90 at power of 80% and alpha value p<0.05.  
 
2.3 DMARD Treatment Protocol 
 
Since the interventional component of the TaSER study aimed to be clinically relevant a DMARD 
escalation protocol was devised that closely reflected current clinical practice and was supported 
by a sound evidence base. Patients in both treatment groups would progress through exactly the 
same treatment steps if their measured disease activity levels were greater than the escalation 
threshold. However, the method of global disease activity assessment used, and thus the 
threshold for DMARD escalation, would be clearly different 
 
2.3.1  Overview of DMARD Escalation Protocol 
A previously published description of the prescribing habits of UK rheumatologists demonstrated 
that the vast majority (97%) prefer to commence newly diagnosed RA patients on DMARD 
monotherapy and ‘step-up’ to combination DMARD therapy if measures of disease activity fail to 
improve (136). This step-up DMARD escalation approach forms the basis of practice in the 
majority of NHSGGC early arthritis clinics. Indeed, several treatment strategy studies have 
If n per group = 2 x σ2 x f(α,β)   Where  (µ2-µ1) = minimum difference 
       (µ2-µ1)2   σ = standard deviation = 1.64 
      α = probability of type 1 error = 0.05 
      β = probability of type 2 error = 0.2 
      f(α,β) = 7.9 
 
53 = 2 x (1.64)2 x 7.9 
    (µ2-µ1) 
 
(µ2-µ1)2 = 2 x (1.64)2 x 7.9 è (µ2-µ1) = 0.90 
            53 
   
  92 
demonstrated that early step-up DMARD therapy can produce short term clinical outcomes which 
are at least equivalent to more aggressive forms of initial combination therapy (123,145,146,251) 
and that short term delays in commencement of combination therapy, which allow a trial of 
DMARD monotherapy, do not excessively disadvantage clinical and radiological 
outcomes(148,252). This step-up approach has the additional advantage of preventing those 
good prognosis patients who respond adequately to initial monotherapy having to take 
unnecessary medications that in some cases can be extremely complicated and potentially toxic. 
The evidence base behind the DMARD escalation protocol is discussed in detail in Section 2.3.3 
 
General Principles 
• Patients will attend for monthly clinical reviews for a total duration of 18 months 
 
• During each review, implementation of some or all of the following aspects of a complex 
therapeutic intervention will be considered: 
 
1. Optimisation of DMARD therapy dose 
2. Administration of intra-articular and/or intramuscular corticosteroids 
3. Prescription and optimisation of appropriate level of analgesia: including NSAIDs, 
opioid and non-opioid analgesics and adjuvant analgesics 
4. Provision of appropriate orthoses and joint support devices 
5. Referral for assessment and treatment by members of the AHP multidisciplinary team. 
All patients undergoing screening will be referred for initial review by the 
physiotherapists and occupational therapists. During the study follow-up period it may 
become necessary to arrange referral to some, or all, of the following AHPs: 
physiotherapists, occupational therapists, podiatrists and/or dieticians 
6. Referral for assessment by members of the Orthopaedic Surgery team (as necessary) 
7. Referral for assessment and treatment of other co-morbidities by clinicians within 
other specialities (as necessary) 
 
Participants in the control and intervention groups followed the same DMARD escalation 
steps and were offered all other aspects of the complex therapeutic intervention without 
bias.  
 
• DMARD therapy was escalated until an individual participant’s assigned global disease 
activity measure fell, and remained, below a predefined lower disease activity target 
(discussed in more detail in following sections) 
 
• The effectiveness of individual DMARDs was optimised by attempting to increase each 
agent to either the optimum dose for each patient’s weight or the maximally tolerated dose 
not associated with adverse effects 
 
• Participant’s DAS28 was assessed at every monthly visit. Decisions to escalate DMARD 
therapy were deferred until at least 3 months had elapsed following transition to each 
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DMARD step. This duration provided sufficient time for the full impact of the new DMARD 
regimen to become fully apparent 
 
• Participants attended for monthly clinical appointments throughout the follow-up period. 
This frequency allowed optimisation of DMARD doses, early intervention for adverse 
effects and frequent administration of intra-articular and/or intra-muscular corticiosteroid 
injections in participants who continued to exhibit active inflammatory disease. In the 3 
months following progression to each DMARD escalation step, doses were optimised but 
no new DMARD agents were added 
 
• This research aimed to be directly applicable to routine clinical practice and reflect the 
practicalities of implementing an aggressive DMARD escalation protocol. Therefore, 
participants who failed to tolerate an individual agent, or who declined DMARD escalation 
even if indicated by the study protocol, continued to be followed up via the research clinics 
and were not deemed treatment failures 
 
• The metrologist (AS) scoring the clinical, functional and radiological outcome data was 
blinded to each participant’s treatment group for the duration of the research. Dr Dale, who 
was responsible for the clinical assessment and management of each patient, was not 
blinded to participant’s treatment group since he was required to perform the relevant 
clinical and MSUS assessments of global disease activity for each participant and to 
decide when DMARD escalation was indicated. The collection of any blinded outcome data 
was not used to influence any decision to escalate DMARD therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Diagrammatic representation of DMARD escalation protocol 
 
  
2. DMARD Combination Therapy 
3. Combination Therapy with s/c Methotrexate  
1. DMARD Monotherapy 
4. Anti-TNFα Blocking Therapy 
Disease activity measure 
exceeds DMARD 
escalation thershold 
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DMARD Escalation Steps 
Figure 4 provides a diagrammatic representation of the DMARD escalation protocol.  
 
Step 1 – DMARD Monotherapy 
Methotrexate 7.5mg/wk with folic acid 5mg/wk 
  Increased monthly to target dose - 7.5 mg/wk è 15 mg/wk è 20 mg/wk 
 
  OR 
 
Sulfasalazine 500mg/d 
  Increased weekly to target dose (approximately 400mcg/kg/d) 
 
Step 2 – Combination DMARD Therapy 
Triple therapy Methotrexate, sulfalasalazine and hydroxychloroquine 
 
  OR 
 
Dual therapy Patients who are intolerant of a single agent will receive the other two agents in  
combination 
 
Step 3 – Combination Therapy with Parenteral Methotrexate 
Conversion of oral methotrexate to equivalent subcutaneous dose. If oral methotrexate escalation 
was limited by intolerance, attempts will be made to escalate subcutaneous methotrexate dose to 
maximum (25mg/wk) or maximum tolerated dose 
 
Step 4 - Anti-TNFα Therapy 
Addition of subcutaneous etanercept (50mg/wk) to combination DMARD therapy 
 
Step 5 - Anti-TNFα Therapy Withdrawal 
Patients who achieve remission with etanercept (Control group - DAS28<2.6, MSUS group – no 
PD signal) at three consecutive monthly assessments will have etanercept discontinued after 6 
months of treatment. In event of a clinically evident acute flare etanercept will be restarted 
indefinitely 
 
Corticosteroid Therapy 
Corticosteroid therapy has a rapid onset, immunomodulatory effect which can often provide 
patients with short-term symptomatic respite whilst longer, and slower, acting DMARD therapy is 
being established. Multiple studies have attempted to describe the potential benefits of 
corticosteroids as treatment for RA; however, in many cases the results are often contradictory. 
Eitherway, treatment guidelines consistently recommend that corticosteroids in some form be 
administered in combination with DMARD therapy in patients with early RA 
(111,112,124,169,170). Theoretically, the rapid immunomodulatory effect of corticosteroids 
should produce profound, early improvements in measures of inflammatory disease activity which 
will serve to restrict an individual patient’s overall cumulative inflammatory burden. In the 
management of early RA, corticosteroid therapy has been shown to produce the following 
improvements in outcome: 
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1. Rapid anti-inflammatory effect. Significantly greater improvements in measures of disease 
activity and higher remission rates have been demonstrated when corticosteroids are given 
concomitantly with DMARDs compared to DMARD monotherapy (253) (254) (255) 
 
2. Short-term disease modifying effects. Initial co-prescriptions of corticosteroids and DMARDs 
are consistently associated with reduced rates of radiographic progression compared to 
DMARD therapy alone. (254,256-258) 
 
3. Stable disease remission. Patients treated with corticosteroids and DMARD combinations 
are significantly more likely to achieve, and maintain, clinical remission than those receiving 
DMARD therapy alone (259) 
 
Within NHSGGC rheumatology departments corticosteroids have traditionally been administered 
either parenterally (particularly intra-muscularly) or as direct intra-articular injections in isolated 
joints. This pragmatic practice ensures patients still experience the rapid initial 
immunomodulatory effects of corticosteroids, whilst limiting the overall systemic dose and 
avoiding the need for complicated drug regimens comprising multiple tablets and frequent dose 
changes. Indeed, a recent study of treatment strategy has suggested that short term clinical 
outcomes in early RA are equivalent in patients prescribed either oral or intramuscular 
corticosteroids (260). Until disease activity levels fall consistently below DMARD escalation 
thresholds this studies treatment protocol will aim to actively administer corticosteroid therapy in 
addition to the escalating DMARD regimen. The corticosteroid treatment offered will be guided by 
the following principles: 
 
1. Corticosteroid therapy to be considered whenever clinically active, inflammatory disease is 
evident 
 
2. Corticosteroid therapy to be preferentially administered as either intra-muscular and/or 
intra-articular injections of triamcinolone acetonide (or equivalent) and up to 120mg given 
at each clinical review 
 
3. Intra-articular steroid injections to be considered for any clinically swollen joint if that joint 
has not been injected within the preceding 3 months 
 
4. Short, tapering courses of oral corticosteroids to be reserved for any patients who 
demonstrates persistently active moderate-high disease activity despite multiple attempts 
at intra-muscular and/or intra-articular steroid injection 
 
2.3.2 Clinical Factors Relating to Individual Agents 
The following section describe practical and clinical issues relating to the individual DMARDs that 
make up this research’s DMARD escalation regimen. The individual dosing schedules for each 
agent were based on those employed by NHSGGC rheumatology departments at the time the 
protocol was devised. The monitoring requirements are broadly in keeping with those suggested 
by the British Society of Rheumatology (261). In each case, attempts were made to escalate new 
DMARDs in the stages described below to either the target, or highest tolerated, dose. In many 
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cases intervening clinical factors – such as intolerance or adverse effects – lead to a less than 
target dose being accepted long term 
 
Methotrexate – is an antimetabolite. Structurally, it is a weak dicarboxylic acid which closely 
resembles, and therefore competitively inhibits, dihydrofolic acid 
 
Mechanism – the exact method by which methotrexate exerts its immunomodulatory effect in RA 
is not known. Methotrexate inhibits folic acid metabolism through directly inhibiting several intra-
cellular enzymes, most notably dihydrofolate reductase. This leads to reduction in purine and 
pyrimidine synthesis, reduced nucleic acid synthesis, inhibition of inflammatory cytokine 
production and cellular adhesion molecule expression, promotion of cell apopotosis and extra-
cellular adenosine release (262). Ultimately, there is suppression of T-lymphocyte activation and 
proliferation 
 
Dosing and escalation regimen 
Month 1  MTX 7.5mg/wk with folic acid 5mg/wk 
Month 2  MTX 15mg/wk with folic acid 5mg/wk 
Month 3+  MTX 20mg.wk with folic acid 5mg/wk 
 
Monitoring requirements - fortnightly FBC, U+E and LFT until both methotrexate dose and blood 
monitoring have been stable for at least 6 weeks; thereafter, monthly monitoring of FBC, U+E and 
LFT 
 
Adverse Effects – nausea, abdominal pain and anorexia (especially post-dose), ulcerative 
stomatitis and mouth ulcers, fatigue, macrocytosis and cytopenias (including leucopenia, 
anaemia, thrombocytopenia or panycytopenia), acute hepatitis, acute pneumonitis and pulmonary 
fibrosis 
 
Cautions 
 
i. Alcohol intake – restricted to 4-6 units per week to reduce risk of hepatotoxicity 
ii. Drug interactions – increase serum methotrexate concentration and therefore increase 
risk of toxicity; co-trimoxazole, trimethoprim, phenytoin, probenecid, tolbutamide, NSAID 
(especially diclofenac) 
iii. Renal impairment – significant renal impairment will restrict methotrexate excretion and 
therefore increase the risk of toxicity 
 
Sulfasalazine - comprises sulfapyridine and 5-aminosalicyclic acid joined by an azo bond.  
 
Mechanism – sulfasalazine’s immunomodulatory mode of action is not clearly understood. 
Following ingestion, sulfapyridine and 5-aminosalicyclic acid are separated by intestinal bacteria. 
5-aminosalycyclic acid is considered the active component. Sulfasalazine suppresses folic acid 
metabolism through the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase (263), promotes extra-cellular adenosine release (264) and inhibits release of pro-
inflammatory cytokines (265) 
 
  97 
Dose and escalation regimen – daily dose is increased every week in 500mg steps until daily 
target dose (approximately 400mcg/kg/d) is achieved.  
Monitoring requirements - monthly FBC and LFTs for 3 months; thereafter 3 monthly 
 
Adverse Effects – nausea, vomiting, abdominal pain, anorexia, diarrhoea, headache, rash, oral 
ulceration, macrocytosis and cytopenia (leucopenia, anaemia, thrombocytopenia and/or 
pancytopenia) acute hepatitis 
 
Cautions 
i. Sulphonamide hypersensitivity 
ii. Glucose-6-phosphate dehydrogenase deficiency – increase risk of haemolysis 
iii.  Renal impairment – increase risk of crystalluria 
 
Hydroxychloroquine – is an anti-malarial agent which has also been used to reduce 
inflammation in a variety of inflammatory disorders 
   
Mechanism – hydroxychloroquine accumulates within intra-cellular lysosomes to cause significant 
increases in inter-lysosomal pH, a reduction in proteolysis and a reduction in secretion of pro-
inflammatory mediators. Furthermore, hydroxychloroquine restricts the activation of pro-
inflammatory lymphocytes through interfering with antigen presentation by MHC class II proteins 
(266) 
 
Dose and escalation regimen – dosing is based upon the patient’s weight (upto 6.5mg/kg). There 
is no dose escalation schedule 
 
Weight ≤ 46kg  hydroxychloroquine 200mg/d 
 46 kg < Weight ≤ 62kg hydroxychloroquine 300mg/d (400 / 200mg alternate days) 
Weight > 62 kg  hydroxychloroquine 400mg/d  
 
Monitoring requirements – specific blood monitoring is not required. The Royal College of 
Ophthalmologists recommend pre-treatment visual screening and annual formal assessment of 
visual acuity using standardised reading charts. Referral for an ophthalmologist’s opinion is 
indicated if either patients: 1. are unable to complete baseline visual screening or 2. develop 
worsening visual acuity whilst prescribed hydroxychloroquine (267) 
 
Adverse Effects – rash, pruritus, anorexia, nausea, vomiting, diarrhoea, lethargy, cytopenias 
(leucopenia, anaemia, thrombocytopenia and/or pancytopenia), irreversible retinal toxicity, 
skeletal and cardiac muscle myopathy 
 
Cautions 
 
i. Epilepsy – hydroxychloroquine may lower seizure thresholds 
ii. Psoriasis – hydroxychloroquine may cause acute exacerbations of skin plaques 
iii.  Drug interactions – hydroxychloroquiune may cause increased serum concentrations 
of digoxin, methotrexate and ciclosproin 
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Etanercept – is a fusion protein produced by DNA engineering which links the gene coding for 
soluble TNFα receptor 2 to the gene coding for the Fc component of human immunoglobulin G1 
(268). 
 
Mechanism – etanercept suppresses active inflammation by acting as a decoy receptor that binds 
and neutralises circulating TNFα. This mimics the action of naturally occurring, soluble TNFα. 
receptors. TNFα is a potent, pro-inflammatory cytokine that promotes the proliferation, 
differentiation and migration of pro-inflammatory cells into areas of active inflammation. Inhibition 
of TNFα activity restricts the influence of a major positive feed back loop that would otherwise 
perpetuate inflammation 
 
Dose – etanercept 50mg/wk subcutaneously for 6 months, usually self-administered by the 
patient. There is no dose escalation and all other non-biologic DMARDs are continued without 
dose adjustment. It is preferable for patients to remain on methotrexate throughout the course of 
etanercept 
 
Monitoring requirements – etanercept is normally co-prescribed with non-biologic DMARDs, 
therefore the monitoring of the non-biologic DMARDs will take precedence over, and account for, 
any monitoring requirements for the etanercept 
 
Adverse Effects – injection site reactions, pruritis, allergic reaction, increased risk of typical (e.g. 
upper respiratory tract, skin and soft tissue, urinary tract) and atypical (e.g. tuberculosis) infection, 
reactivation of latent infection (especially tuberculosis), psoriaform rash, lupus-like syndrome, 
leucopenia, demyelination 
 
Pre-treatment Screening – due to the increased risk of infection, tuberculosis reactivation and 
demyelination in patients treated with any of the anti-TNFα agents, all patients who fulfil criteria 
for etanercept will be subjected to the same pre-treatment screening procedures as all other 
NHSGGC patients who are considered for anti-TNFα blocking therapy 
 
i. Safety questionnaire – including tuberculosis risk factor assessment, risks for intercurrent 
infection (indwelling catheter, previous history of septic arthritis), family history of demyelinating 
illness and previous history of cancer 
 
ii. Chest X-ray – for evidence of previous tuberculosis exposure 
 
iii. Blood T-spot Test – interferon-gamma release assay which detects the presence of effector T-
lymphocytes sensitised against Mycobacterium tuberculosis and therefore identifies patients with 
previous, currently inactive, tuberculosis (i.e. latent disease) 
 
If any of the methods used during pre-treatment screening identify that a participant has either 
been previously exposed to tuberculosis, or has evidence of latent disease, a 3-month course of 
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isoniazid chemoprophylaxis will be commenced prior to commencement of treatment with 
etanercept 
 
2.3.3 The Evidence Supporting the DMARD Escalation Regimen 
The following sections will summarise the evidence base behind the use of each DMARD agent 
and the sequence of escalation steps used within the treatment protocol 
 
Step 1 DMARD Monotherapy 
Most of the data comparing the head-to-head effectiveness of individual DMARDs is limited to 
single studies where there will often been variability in the structure and quality of study design. A 
systematic review of published DMARD strategies has suggested that, in head-to-head 
comparisons, there is no significant difference in the efficacy of either methotrexate, sulfasalazine 
or leflunomide (137). Within NHSGGC Rheumatology departments, leflunomide is not a 
commonly used initial DMARD and there is less evidence available to support its use in 
combination with other DMARDS. Thus for the purposes of this research leflunomide was 
excluded from the DMARD protocol. Two randomised studies have compared the efficacies of 
methotrexate and sulfasalazine head-to-head and a large cohort study has described the impact 
of both agents on all cause mortality: 
 
• Haagsma et al randomised 105 patients with untreated early RA (symptom duration < 12 
months) to receive treatment with either sulfasalazine (SASP) monotherapy, methotrexate 
(MTX) monotherapy or both in combination (COMB) (141). After 1 year’s follow-up, there 
were no statistically significant differences in clinical outcomes between any of the 
treatment groups. Similar mean changes in DAS44 (SASP -1.6 vs MTX -1.7 vs COMB -
1.9), fulfilment of ACR response criteria (SASP 25 vs MTX 25 vs COMB 28) and fulfilment 
of EULAR good criteria (SASP 14 vs MTX 15 vs COMB 14) were reported. Furthermore, 
overall adverse event rates were similar between groups though a higher number of 
patients treated with sulfasalazine withdrew because of adverse events. Radiographic 
progression scores were not reported 
 
• Dougadas et al randomised 209 patients with untreated, active (DAS44 > 3.0) seropositive 
early (disease duration < 12 months) RA to receive either sulfasalazine monotherapy, 
methotrexate monotherapy or both agents in combination (142). Overall, patients in all 
treatment groups experienced similar improvements in most disease activity measures; 
however, patients receiving combination therapy did exhibit a significantly greater mean 
improvement in Ritchie Articular Index (SASP -7.1 vs MTX -4.2 vs COMB -9.4; p = 0.001) 
and a significantly better improvement in DAS44 (SASP -1.15 vs MTX -0.87 vs COMB -
1.26; p = 0.019). ACR and EULAR good response rates were similar across the three 
treatment groups (ACR: SASP 59% vs MTX 59% vs COMB 65%; EULAR good SASP 34% 
vs MTX 38% vs COMB 38%). Compared to methotrexate monotherapy, patients treated 
with sulfasalazine monotherapy tended to experience slightly greater mean improvements 
in Ritchie Articular Index (-7.1 vs -4.2), 44 swollen joint count (-4.5 vs -3.9), ESR (-30 vs -
24) and DAS44 (-1.15 vs -0.87). Whilst methotrexate monotherapy patients tended to 
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exhibit slightly greater mean improvements in duration of morning stiffness (-53 minutes vs 
– 46 minutes) and CRP (-16 vs -8). However, statistical comparisons between the 
monotherapy group outcomes are not reported. All three treatment groups demonstrated 
comparable rates of progression in measures of radiographic progression (mean change 
modified Total Sharp Score: SASP 4.64 vs MTX 4.50 vs COMB 3.46; p>0.05). Total 
adverse event rates were higher in the monotherapy groups but significantly higher in the 
combination therapy group (SASP 75% vs MTX 75% vs COMB 91%; p=0.025).  
 
• Choi et al have described the impact of different DMARDs on all cause mortality in a large 
cohort (n=1240) of RA patients who have been prospectively followed-up from the time of 
diagnosis (269). Over the follow-up period, 588 patients had ever received methotrexate, 
191 patients died, of whom 72 had received methotrexate. Cardiovascular disease was the 
most common cause of death (44%). Even correcting for the presence of poor RA 
prognostic factors, methotrexate use was associated with a significant reduction in the risk 
of all cause mortality (hazard ratio 0.4 (CI 0.1-0.7)) and the risk of cardiovascular mortality 
(hazard ratio 0.3 (CI 0.2-0.7)). Furthermore, this positive impact on mortality outcomes was 
not demonstrated with any another DMARD (hazard ratios: MTX 0.2 vs SASP 0.9 vs 
penicilamine 0.8 vs hydroxychloroquine 0.7 vs IM gold 1.9) 
 
Taken together these results do seem to suggest that, when used as DMARD monotherapy, 
there is little to separate the clinical efficacy of methotrexate and sulfasalazine since they are both 
associated with the same degree of improvement in clinical outcome measures and similar rates 
of radiographic progression. However, methotrexate does appear to be better tolerated than 
sulfasalazine and has a clear influence of mortality outcomes that is not apparent with 
sulfasalazine. Thus, whilst patients participating in this study will be offered either methotrexate or 
sulfasalazine as initial DMARD monotherapy, the adverse effects profiles and mortality benefits 
lend a strong weighting towards methotrexate.  
 
Step 2 Combination DMARD Therapy 
Several studies have demonstrated that adding either ciclosporin (132), leflunomide (134) or 
parenteral gold (135) to established methotrexate monotherapy can produce additional 
improvements in clinical outcomes. However, these are combinations that are often associated 
with adverse events, are not commonly used in local practice. Given the potential number of 
drugs that have either proven disease modifying properties, or have traditionally been considered 
DMARDs, there are theoretically a vast number of DMARD combinations possible. Most of the 
recent RA treatment strategy studies have focussed on triple DMARDs combinations that 
incorporate methotrexate (MTX), sulfasalazine (SASP) and hydroxychloroquine in varying 
sequences and doses. Table 3 summarises the differences in use of triple DMARD therapy in 
these studies. Importantly, studies of DMARD escalation strategies following methotrexate failure 
have not shown any inferior clinical outcomes when stepping-up to triple DMARD therapy 
compared to stepping-up to methotrexate and biologic (123,149). In particular, patients in Group 
2 (step-up combination therapy) of the BeST study demonstrated equivalent improvements in the 
primary outcome measure (change in HAQ) compared to those in Group 4 who were initially 
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treated with biologic therapy (145). There were some advantages to biologic therapy since a 
greater proportion of Group 4 patients did achieve persistent low disease activity (Group 2 = 21% 
vs Group 4 = 40%) and exhibited lesser rates of radiographic progression (mean change total 
Sharp score: Group 2 5.2 vs Group 4 2.5; mean change in erosion score: Group 2 3.1 vs Group 4 
1.3). In the SWEFOT study, patients who stepped-up to triple DMARD therapy after methotrexate 
failure exhibited statistically similar ACR (all levels) and EULAR Good response rates compared 
to those stepped-up to methotrexate and infliximab (147). Both groups exhibited evidence of 
radiographic progression but there was no statistically significant difference in the degree of 
progression observed between either group. 
 
 Step 1 Step 2 Step 3 
TICORA (118) SASP 
 
MTX – SASP – HCQ  
TEAR (UK) – Control (146) SASP 
 
MTX – SASP - HCQ  
TEAR (UK) – Triple 
 
MTX – SASP - HCQ Optimise MTX dose  
BEST - Group 2 (145) MTX 
 
MTX - SASP MTX – SASP – 
HCQ 
SWEFOT – Group A (147) MTX 
 
MTX – SASP - HCQ  
  Table 3 – Summary of DMARD escalation steps in early RA treatment strategy 
studies 
 
Several, older, randomised controlled trials, which were not necessarily conducted in early RA, 
have demonstrated that triple DMARD therapy tends to be more effective than any combination of 
dual DMARD therapy.  
 
• O’Dell et al randomised 102 patients with active RA, despite DMARD monotherapy to 
switch to either methotrexate monotherapy, sulfasalazine-hydroxychloroquine dual therapy 
or triple therapy with all three agents (270). 50 patients fulfilled the primary outcome criteria 
by achieving at least 50 percent improvement in disease activity measures after 9 months 
and sustaining it over 2 years of follow-up. A statistically significant greater proportion of 
patients receiving triple therapy (77%) achieved the primary outcome compared to those 
receiving either dual therapy (40%) or methotrexate monotherapy (33%). Furthermore, 
patients receiving triple therapy exhibited lower tender joint counts (mono 7 vs dual 7 vs 
triple 3), swollen joint counts (mono 5 vs dual 7 vs triple 2) and ESR (mono 16 vs dual 16 
vs triple 10) but not an increased rate of adverse effects. 
 
• Calguneri et al randomised 180 patients with active, untreated RA to receive treatment with 
either monotherapy (MTX or SASP or HCQ), dual therapy (MTX-SASP or MTX-HCQ) or 
triple therapy (MTX-SASP-HCQ) (271). Results for each group were pooled rather than 
being reported for each of the potential combinations. After 2 years therapy, patients in all 
groups experienced significant improvements in clinical and laboratory outcome measures. 
The magnitude of response observed was related to the intensity of the DMARD regimen 
with patients receiving triple therapy exhibiting significantly greater responses than the dual 
therapy group who exhibited significantly greater responses then the monotherapy group 
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(Improvement >50%: mono 49.1% vs dual 73.2% vs triple 87.9; p<0.001 for all 
comparisons. ACR remission rates: mono 31.5% vs dual 44.6% vs triple 60.3%: p=0.007 
for all between group comparisons). Rates of radiographic non-progression were 
significantly higher in both combination therapy groups (mono 24.5% vs dual 64.2% vs 
triple 68.9) 
 
• 171 patients with active RA despite DMARD monotherapy were randomised to receive 
either methotrexate-sulfasalazine dual therapy, methotrexate-hydroxychloroquine dual 
therapy or methotrexate-sulfasalazine-hydroxychloroquine triple therapy (131). After 2 
years follow-up, ACR20 response rates were significantly higher for patients receiving triple 
therapy (78%) compared to patients receiving either methotrexate-hydroxychloroquine 
(60%; p=0.05) or methotrexate-sulfasalazine (49%; p=0.002) dual therapy. Triple therapy 
produced significantly higher ACR50 response rates (55%) compared to methotrexate-
sulfasalazine (29%; p=0.005) but not methotrexate-hydroxychloroquine (40%; p=0.10). 
Furthermore, there were no statistical between group distances for the ACR70 response 
rates (26% vs 18% vs 16%). Drug toxicity rates were similar across all treatment groups. 
Radiological progression rates were not reported 
 
Thus, this study has chosen that patients who exceed DMARD escalation thresholds after at least 
3 months of DMARD monotherapy, will step-up to triple DMARD therapy, since this appears to be 
produce greater improvements in clinical outcomes compared to any of the available dual therapy 
combinations. Whilst combining multiple DMARDs with multiple modes of action should 
theoretically improve the likelihood of achieving a beneficial treatment response, it could also 
increase the risk of drug associated adverse effects. Individual DMARD combination therapy trials 
have tended not to demonstrate an increased risk of adverse effects compared to DMARD 
monotherapy with the constituent agents. A large meta-analysis of 36 DMARD strategy studies 
concluded that whilst combination therapy per se appeared more effective than monotherapy (RR 
0.35; 95%CI 0.28, 0.45; p=0.00001) there was also a higher risk of toxicity (RR 1.37; 95%CI 1.16, 
1.62; p=0.0001) (144). However, importantly, combinations incorporating methotrexate, 
sulfasalazine and/or hydroxychloroquine were not shown to have a greater risk of toxicity 
compared to monotherapy (RR 0.81; 95%CI 0.52, 1.27; p=0.66)  
 
Step 3 Combination Therapy with Subcutaneous Methotrexate 
Current British Society of Rheumatology Guidelines require RA patients to have tried 2 or more 
non-biologic DMARDS, for at least 6 months each, before they can be offered anti-TNFα blocking 
therapy (272). The DMARD protocol for this study aims to aggressively escalate DMARD therapy 
every 3 months if active disease persists. Thus, if followed in their entirety, the BSR anti-TNFα 
prescribing criteria, could potentially leave patients with persistently active disease ‘waiting’ for 6 
months to elapse following escalation to triple DMARD therapy until they became eligible for 
biologic therapy. This delay is contrary to the principle of tight, early disease control and 
minimisation of cumulative exposure to inflammatory disease that this study is hoping to optimise. 
If DMARD escalation thresholds continue to be exceeded after at least 3 months of triple DMARD 
therapy, switching from oral to subcutaneous methotrexate may allow optimisation of the efficacy 
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of the DMARD therapy whilst also satisfying the BSR guidelines for duration of DMARD therapy 
(273). 
 
Pharmokinetic studies have demonstrated that low dose oral methotrexate preparations have a 
highly variable bioavailability, ranging between 25% to 100% of the ingested dose (274). In 
contrast, the bioavailability of parenteral methotrexate (subcutaneous or intra-muscular) is much 
more predictable and has consistently been shown to be greater than an equivalent oral dose 
(275,276). Thus, in some patients switching to an equivalent dose of subcutaneous methotrexate 
may improve RA disease control, since the consistent improvement in bioavailability leads to 
patients receiving an effectively higher dose. The authors of 2 small, retrospective cohort studies 
have observed loss of disease control when patients were switched to equivalent doses of oral 
methotrexate following a worldwide shortage of parenteral methotrexate (277,278). Subsequently, 
2 randomized and blinded clinical trials have systematically described the relative efficacies of 
oral and parenteral methotrexate: 
 
• Sixty four patients with active (mean DAS28 = 5.6), established (mean duration = 9.7 
years) RA despite oral methotrexate (dose 15-20mg/wk) were switched to intramuscular 
methotrexate (15mg/wk) (279). After 6 weeks of intramuscular methotrexate, the observed 
clinical benefits were modest: the mean improvement in DAS28 was 0.42 and only 4 
patients had achieved DAS28 <3.2. The remaining 54 patients, who continued to display 
active disease (DAS28 > 3.2), were randomised to either continue 15mg/wk intramuscular 
methotrexate or escalate the weekly dose to 45mg/wk. After a further 16 weeks follow-up, 
the observed clinical improvements remained modest and the response rates were 
identical for both groups. Within each group, 1 further patient achieved DAS28<3.2, 1 
further patient achieved ACR20 response, 5 patients exhibited improvement in DAS28>1.2 
and no patients achieved a EULAR Good response. Minor adverse events were reported 
slightly more frequently in the dose escalation group. Thus, increasing beyond 15mg/wk 
subcutaneous methotrexate is unlikely to provide additional clinical benefits but may place 
patients at a slightly higher risk of minor adverse effects. 
 
• Braun et al have demonstrated that patients with RA who are treated with subcutaneous 
methotrexate achieve significantly better clinical outcomes than those treated with oral 
methotrexate (280). 384 patients with active (DAS28 > 4) predominantly early (median 
disease duration 2.1-2.5 months) RA were randomised to receive either 15mg/wk oral or 
15mg/wk subcutaneous methotrexate. After 24 weeks follow-up, patients treated with 
subcutaneous methotrexate exhibited significantly higher ACR20 (sc 78% vs oral 70%; 
p<0.05) and ACR70 (sc 41% vs oral 33%; p<0.05) responses. A significantly higher 
proportion of patients with delayed presentations (> 1 year disease duration) of RA who 
received subcutaneous methotrexate achieved an ACR20 response compared to similar 
patients treated with oral methotrexate (sc 89 vs oral 63; p<0.05). Furthermore, the study 
demonstrated that the overall effectiveness of methotrexate could be improved further if 
patients switched to a subcutaneous preparation and then subsequently increased the 
dose further. Of 52 patients who failed to achieve an ACR20 response with oral 
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methotrexate, 16 (30%) subsequently achieved an ACR20 response by switching to 
subcutaneous methotrexate, and 12 (23%) gained an ACR20 response by increasing the 
weekly subcutaneous methotrexate dose. Adverse event rates were similar for both 
groups; though subcutaneous methotrexate was associated with a lower rate of diarrhoea. 
 
Whilst there have been no randomised clinical trials describing the value of parenteral 
methotrexate in combination with other DMARDs it is feasible to presume that switching to 
subcutaneous methotrexate, in patients receiving triple DMARD therapy, may increase the overall 
efficacy of the combination by optimising the therapeutic contribution of the methotrexate 
component. The study by Lambert et al reported very modest improvements when oral 
methotrexate was switched to a subcutaneous preparation. However, the initial assessment point 
was after 6 weeks of subcutaneous therapy, thus may have been too early to detect clinical 
improvement. Furthermore, in a number of patients the weekly methotrexate dose was actually 
reduced from 20mg/wk to 15mg/wk. The much larger study by Braun et al has clearly shown that 
subcutaneous methotrexate produces better clinical outcomes than equivalent oral doses and 
therefore may be a more effective way of initiating methotrexate therapy. Furthermore, a 
significant minority of patients who had failed to respond to oral methotrexate experienced 
improved clinical outcomes by first switching to subcutaneous methotrexate and later optimising 
their weekly dose.  
 
Step 4 Combination Therapy with Anti-TNFα Blocking Therapy 
Anti-TNFα blocking therapy can produce profound clinical benefits and arrest erosive progression 
in RA patients who experience persistently active disease despite non-biologic DMARD therapy. 
Since a substantial subset of patients will experience adequate responses to non-biologic 
DMARD therapy, most recent RA treatment guidelines restrict the use of anti-TNFα blocking 
drugs until after non-biologic DMARD treatment failure is evident (111,125,272). In this way, 
potentially expensive, and occasionally toxic, therapies are reserved for those patients who have 
demonstrated the greatest need for aggressive treatment. In reality, there are 5 anti-TNFα 
blocking agents available (adalumimab (Abbot), certoluzimab (UCB), etanercept (Pfizer), 
golimumab (Centocor) and infliximab (Schering Plough)); however, since this research has been 
funded by a research grant from Pfizer UK, those patients who exceed DMARD escalation 
thresholds despite at least 3 months of subcutaneous methotrexate-DMARD combination therapy 
will be prescribed etanercept.  
 
Etanercept is a soluble tumour necrosis factor alpha (TNFα) receptor fusion protein which binds, 
and inactivates, the pro-inflammatory cytokine TNFα. Randomised, placebo controlled studies 
have demonstrated that patients with persistently active RA despite DMARD therapy experience 
significant clinical improvements, and lesser rates of radiographic progression, when etanercept 
is added to their existing DMARD therapy (160,164). Furthermore, etanercept used in 
combination with methotrexate has been shown to produce significantly greater clinical 
responses, and lesser rates of radiographic progression, than using either agent alone (166). 
Several studies have demonstrated the effectiveness of adding etanercept to non-biologic 
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DMARD therapy in persistently active, established RA (160,164,166,167),  and its specific value 
in the treatment of active, early RA has been described in a number of other clinical studies:  
 
• Bathon et al randomised 632 patients with recent diagnoses (mean disease duration 11-12 
months) of RhF positive, erosive and active RA to receive either etanercept monotherapy 
(10mg or 25mg twice a week) or oral methotrexate (281). After 12 months follow-up it was 
evident that the patients who had received 25mg etanercept twice weekly had experienced 
a more rapid improvement in clinical disease activity measures, significantly greater 
treatment responses and lesser deterioration in measures of erosive and total radiographic 
damage compared to patients receiving either methotrexate or 10mg etanercept twice 
weekly. Patients receiving methotrexate experienced higher rates of all types of infection 
and laboratory monitoring abnormalities than patients in either etanercept group. 
 
• In the COMET study, 528 patients with active (mean DAS28 = 6.5), early (mean disease 
duration 9.0 months) RA, who had not received either methotrexate or biologic therapy, 
were randomised to receive either methotrexate monotherapy or methotrexate-etanercept 
combination therapy (282). After 52 weeks follow-up, head-to-head comparisons showed 
that methotrexate-etanercept combination therapy produced more rapid, and statistically 
greater, improvements in disease activity measures (DAS28). A significantly higher number 
of etanercept treated patients achieved DAS28 remission (DAS28<2.6: MTX 28% vs MTX-
ETAN 50%; p<0.0001), radiographic non-progression (MTX 59% vs MTX-ETAN 80%; 
p<0.0001) normalisation of functional ability (HAQ DI < 0.5: MTX 39% vs MTX-ETAN 55%; 
p=0.0004) and were able to remain in their usual employment (MTX 9% vs MTX-ETAN 
24%; p=0.004) 
 
The majority of clinical studies of anti-TNFα blocking therapies in early RA have tended to 
compare the relative efficacies of either commencing newly presenting patients on immediate 
anti-TNFα blocking therapy or commencing anti-TNFα blocking once a short trial of DMARD 
monotherapy has proven ineffective. However, the British Society of Rheumatology biologic 
prescribing guidelines require patients to have tried, and failed, at least two non-biologic 
DMARDs before they can be considered for anti-TNFα blocking therapy. Hence, in reality, many 
patients will have tried several different DMARDS, and many will be taking combination therapy, 
prior to commencing anti-TNFα blocking therapy. Therefore, in order to reflect usual clinical 
practice, and satisfy the ethos of the BSR prescribing guidelines, this research has chosen to 
place anti-TNFα blocking therapy as the final stage of the step-up DMARD escalation. Hopefully, 
this approach will determine how much further leeway there is available to optimise the efficacy of 
step-up DMARD escalation using traditional, cheaper non-biologic DMARDs and won’t delay 
patients with aggressive RA from receiving timely anti-TNFα blocking therapy if they demonstrate 
persistently active disease. 
 
Anti-TNFα blocking therapies undoubtedly produce profound, often rapid, improvements in RA 
and, since many patients have struggled to receive adequate responses with any other agents, 
treatment is traditionally continued indefinitely. However, continued treatment is also associated 
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with continued concerns relating to the long-term risks of powerful, immunomodulatory therapy; 
such as, infection, autoimmune phenomena and cancer. Furthermore, patients with early RA who 
experience a profound response to anti-TNFα blocking therapy may also experience a 
fundamental change in the immunopathogenetic processes underlying their RA which may not 
require them to continue aggressive long-term therapy.  
 
• Quinn et al tested the effectiveness of remission induction with anti-TNFα blocking therapy 
by randomising 20 patients with early (median symptom duration = 6 – 7.4 months) 
untreated RA to receive either methotrexate monotherapy or methotrexate-infliximab 
combination therapy (283). Infliximab was discontinued after 12 months and patients were 
followed for a further 12 months. As expected, patients treated with infliximab experienced 
a rapid initial improvement in clinical disease activity measures and significantly higher 
treatment response rates (ACR70: 70% vs 30%). Importantly, following the discontinuation 
of infliximab, 70% of patients sustained the initial on-treatment clinical responses and did 
not require therapy escalation. 
 
• Follow-on subgroup analysis of the BeST study described the progress of patients 
randomised to Group 4 (initial MTX-infliximab combination therapy) who achieved 
persistent low disease activity (DAS44<2.4 for at least 6 months) and subsequently 
discontinued infliximab (284). From the initial 120 patients treated with infliximab, 77 (64%) 
achieved low disease activity and discontinued treatment. Of these patients, 67 (56% of the 
whole group; 87% of the discontinuing group) remained in persistent low disease activity 
and did not need to recommence infliximab. The median duration of infliximab therapy prior 
to discontinuation was 9.9 months. Of the patient’s who experienced a clinical flare, the 
median interval between treatment cessation and recommencement was 3.7 months 
 
Sheehy et al randomised 24 patients with untreated, early (mean symptom duration 6.3 
months) RA to receive either methotrexate monotherapy or methotrexate-etanercept 
combination therapy (285). Etanercept was discontinued after 24 weeks if patients had 
achieved clinical remission (DAS28<2.6). Remission rates after 24 weeks treatment were 
significantly higher in the etanercept group (MTX 35% vs MTX-ETAN 85%). Sixty percent 
of the patients who had achieved clinical remission with etanercept remained in remission 
after a further 24 weeks follow-up; whereas, only 30% of the methotrexate treated patients 
were able to sustain remission 
 
These data suggest that short courses of anti-TNFα blocking therapy may have remission 
inducing properties, since a significant proportion of patients (56-70%) were able to receive short 
courses of treatment (6-9 months), achieve the pre-defined disease activity target and then 
discontinue anti-TNFα blocking therapy without any loss of RA disease control. This approach 
may optimise the clinical and cost-effectiveness of anti-TNFα blocking therapies by allowing 
patients to experience the benefits of anti-TNFα blocking therapy whilst avoiding prolonged and 
costly courses of treatment which might, in some cases, prove hazardous. Thus, since this 
studies DMARD escalation protocol could lead to participant’s qualifying for etanercept at much 
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lower levels of disease activity than currently sanctioned by any treatment guidelines, patients 
who do qualify for etanercept will initially receive a time limited treatment course. If remission is 
achieved and sustained, etanercept will be discontinued after 6 months. If, after discontinuing 
etanercept, patients subsequently experience a clinically apparent, acute flare of RA etanercept 
will be restarted indefinitely. 
 
2.4 DMARD Escalation Thresholds 
Since the intervention under investigation is the potential efficacy of MSUS to assess global 
disease activity and guide DMARD escalation decisions, participants are randomly assigned to 
groups that only differ in the methods used to assess global disease activity. All other aspects of 
their treatment, and particularly the sequence of DMARD escalation, are identical for both groups. 
 
2.4.1  Randomisation Process 
Participants were randomised at the point they consented to participate in the research and 
remained within the same intervention group for the duration of their participation. The 
randomisation process aimed to distribute common demographic and disease-associated factors 
equally between both groups, so as to remove any confounding influence they might otherwise 
have exerted on the final outcomes 
 
The randomisation process was administered by the Robertson Centre for Biostatistics at the 
University of Glasgow and was conducted using a telephone-based Interactive Voice Response 
(IVR) system. Participants were randomly assigned to either a Control (DAS28) or Intervention 
(MSUS) group; however, the randomisation was adaptive to ensure an equal balance of disease 
related factors between both groups.  
 
Control Group – global disease activity assessment and DMARD escalation threshold based on 
DAS28 score at time of assessment. 
 
Intervention Group – global disease activity assessment and DMARD escalation threshold based 
upon combination of DAS28 and MSUS findings 
 
Adaptive stratified randomisation (minimisation) techniques - based upon participant’s rheumatoid 
factor status, baseline erosive status and baseline DAS28 – were used to ensure an equal 
balance (and therefore influence) of these factors between both groups. Essentially, 
mathematical modelling describes the overall level of imbalance between each group for all these 
factors; new participants are allocated to the group that is most likely to correct (or reduce) the 
degree of imbalance. Randomisation was based upon RhF status rather than anti-CCP 
antibodies since, at the time of design, NHSGGC Immunology Laboratory were unable to 
guarantee that anti-CCP antibody testing would be available for the duration of the recruitment 
process 
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Blinding: participants and Dr Dale - who applies the DMARD escalation protocol for both groups - 
were aware (i.e unblinded) of which intervention group the participant has been assigned to. All 
other members of the research team, and particularly those responsible for scoring the clinical 
and radiological outcomes, were blinded to each participant’s intervention group and level of 
DMARD therapy. Hence there is single blinded assessment of research outcomes 
 
2.4.2  DMARD Escalation Thresholds for Each Group 
As previously discussed, most current RA treatment guidelines recommend regular disease 
activity assessment using a composite disease activity score (such as DAS28) aiming for a 
predefined disease activity level (111,112,124,125,168). For this study, the ‘gold standard’, to 
which the additional impact of MSUS assessment will be compared, was considered to be 
disease activity assessment and DMARD steering using the DAS28. The reasoning underpinning 
the chosen DMARD escalation thresholds is described in detail in the following sections; 
furthermore, a diagrammatic representation of the potential decision paths for each group is 
shown in Figure 8  
 
Control Group 
The numerical value of a patient’s DAS28 score at a given time point allows their overall disease 
activity to be categorised into the following levels (161,165): 
 
High disease activity  DAS28 >5.1 
Moderate disease activity 3.2 ≥ DAS28 ≤ 5.1 
Low disease activity  2.6 ≤ DAS28 < 3.2 
Clinical remission  DAS28 < 2.6 
 
The thresholds for DAS28 and DAS44 groupings were developed from the consensus opinion of 
groups of rheumatologists who were asked to decide whether certain patient profiles qualified for 
DMARD escalation (180). High disease activity was defined as clinical profiles that, in the opinion 
of the participating rheumatologists, qualified for DMARD escalation. Low disease activity was 
defined as clinical profiles that would allow DMARD tapering and/or cessation. The discriminatory 
ability of individual variables, and groups of variables, to differentiate between high and low 
disease activity states was then determined and these weightings form the basis of the current 
DAS28 and DAS44 calculations (180,286). Whilst DAS28 and DAS44 scores provide useful, 
easily understood numerical measures of global disease activity a number of important points 
relating to their derivation must be considered:  
 
1. the initial definition of high and low disease activity was based on the clinical judgements of 
a group of rheumatologists. Clinical practice and interpretation of clinical findings varies 
significantly between individual clinicians; thus, the assumptions underpinning current 
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DAS28 and DAS44 disease activity definitions – and all subsequent treatment response 
criteria - were inherently subjective, and at risk of inter-observer variability, even before 
specific values had been derived 
 
2. a specific definition of moderate disease activity was not described. Moderate disease 
activity is inferred in patients who achieve DAS28 and DAS44 scores that fall between the 
numerical thresholds for either high or low disease activity. By extension this should refer 
to those patients who, in the opinion of the assessing rheumatologists, neither required 
DMARD escalation nor reduction. However, in practice this assumed definition is not 
entirely accurate since patients with moderate disease activity are usually considered to 
have some degree of active inflammatory disease and therefore do require DMARD 
escalation 
 
For the purposes of this study, the control group DMARD escalation threshold will be a DAS28 
greater than, or equal to, 3.2 (i.e at least moderate disease activity) at least three months after 
DMARD escalation. This threshold is in keeping with current practice in existing NHSGGC early 
arthritis clinics and is equivalent to similar thresholds employed by several preceding early RA 
step-up DMARD strategy studies (118,145,146,252). 
 
Musculoskeletal Ultrasound Group 
Currently, there remains no consensus regarding which joints need to be examined by MSUS to 
adequately assess global disease activity (i.e the minimal joint set); nor is there an agreed MSUS 
definition of active synovitis. The following section will describe the development of this studies 
MSUS joint set and thresholds for DMARD escalation: 
 
Definition of MSUS Pathology 
The Outcome Measures in Rheumatology (OMERACT) and EULAR MSUS Working Parties have 
published consensus definitions to improve accuracy and description of MSUS findings (287). 
These definitions are widely used and were adopted by this study: 
 
Synovial Fluid – abnormal hypoechoic or anechoic intra-articular material that is displaceable and 
compressible; does not exhibit Doppler signal 
 
Synovial Hypertrophy – abnormal hypoechoic intra-articular tissue that is non-displaceable and 
poorly compressible; may exhibit Doppler signal 
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Tenosynovitis – hypoechoic or anechoic thickened tissue, with or without fluid within the tendon 
sheath, that is seen in two perpendicular planes; may exhibit Doppler signal 
 
Enthesopathy – abnormally hypoechoic (loss of normal fibrillar architecture) and/or thickened 
tendon, or ligament, at its bony attachment seen in two perpendicular planes; may exhbit Doppler 
signal and/or bony changes, including enthesophytes, erosions or irregularity 
 
Bone Erosion – an intra-articular discontinuity of the bone surface that is visible in two 
perpendicular planes 
 
Since comparative studies of MSUS findings, synovial histology and clinical outcomes have 
demonstrated that the presence of intra-articular Doppler signal is strongly associated with active 
inflammatory disease (whether by demonstration of an active inflammatory infiltrate, radiographic 
evidence of erosive progression or increased frequency of acute flare – see Section 1.5) active 
synovitis in a single joint requires demonstration of intra-articular Doppler signal. Equally, since 
the primary articular lesion of RA is synovitis, and since this study is primarily focussed on 
assessing measures of global inflammatory disease activity (and not their erosive sequlae), 
MSUS assessment will focus on findings of synovial hypertrophy (and/or effusion), and intra-
articular Doppler signal and exclude tenosynovitis, enthesopathy and bone erosions. In this way, 
the MSUS assessment method will be deliberately focused on identifying evidence of active 
inflammatory disease, quicker to apply and potentially easier to apply during normal clinical 
practice 
 
Grading of MSUS Findings 
Without the use of time-consuming digital image analysis software grading of MSUS findings 
during routine clinical practice remains largely subjective; being dependent upon the examiners 
ability to both acquire and interpret the individual components of each MSUS image. Several 
semi-quantitative grading systems have been proposed whereby standard definitions of the 
extent of MSUS findings attach a numerical value to the observed findings (288,289). However, 
there is not yet a universal consensus on which is the correct grading system, nor has their ability 
to influence outcomes in longitudinal clinical research been described. At the time that this 
protocol was being devised, the grading system proposed by Szkudlarek et al was most widely 
used (288). This grading system was originally based on MSUS findings in MCP and MTP joints; 
though for the purposes of this research the grading principles were extended to the radiocarpal 
and PIP joints as well (see below). 
 
Synovial Hypertrophy – non-compressible hypoechoic intra-articular area (synovial thickening – 
see Figure 5) 
Grade 0  no synovial thickening 
Grade 1 minimal synovial thickening; filling the angle between the periarticular bones, 
without bulging over the line linking tops of the bones 
Grade 2 synovial thickening bulging over the line linking tops of the periarticular bones but 
without extension along the bone diaphysis 
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Grade 3 synovial thickening bulging over the line linking tops of the periarticular bones 
and with extension to at least one of the bone diaphysis 
 
Joint Effusion – compressible anechoic intra-articular area (see Figure 6) 
Grade 0 no effusion 
Grade 1 minimal amount of joint effusion 
Grade 2 moderate amount of joint effusion (without distension of the joint capsule) 
Grade 3 extensive amount of joint effusion (with distension of the joint capsule) 
 
Doppler Signal – extend of Power Doppler signal identified within the synovium (see Figure 7) 
Grade 0 no flow in the synovium 
Grade 1 single vessel signals 
Grade 2 confluent vessel signals in less than half the area of the synovium 
Grade 3 vessel signals in more than half the area of the synovium 
 
 
 
 
 
 
 
 
 
 
  
  
Grade 0 Grade 1 
Grade 2 Grade 3 
Figure 5: Grading of Synovial Hypertrophy 
From: Szkudlarek et al. Arthritis and Rheumatism 2003; 48: 955-962 
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Grade 0 Grade 1 
Grade 2 Grade 3 
Figure 6: Grading of Joint Effusion 
From: Szkudlarek et al. Arthritis and Rheumatism 2003; 48: 955-962 
 
  
  
Grade 0 Grade 1 
Grade 2 Grade 3 
Figure 7: Grading of Power Doppler Signal 
From: Szkudlarek et al. Arthritis and Rheumatism 2003; 48: 955-962 
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Development of Minimal MSUS Joint Set 
In order for MSUS to be directly applicable to clinical practice, the methods used need to be both 
reliable and efficient. Whilst scanning large numbers of joints in detail will produce findings which 
most accurately reflect global RA disease activity, it is also likely to be time consuming and 
impractical in a busy clinical setting. Thus it is important to identify and test the minimum number 
of joints requiring MSUS examination to balance both accuracy and practicalities. Several clinical 
studies have described how different permutations of minimised joint sets correlate to larger, 
more comprehensive joint sets and their various findings will form the basis of the joint set used 
throughout this research: 
 
• Scheel et al systematically examined the clinically more affected 2nd to 5th MCP and PIP joints 
of 46 patients with RA for evidence of synovial hypertrophy and joint effusion (290). The 
presence of Doppler signal was not reported. Synovial hypertrophy and joint effusion were 
graded as a single finding using a semi-quantitative system (grade 0-3) adapted from that 
proposed by Szkudlarek et al (288). Total scores for different combinations of joints were 
compared using receiver operating characteristic (ROC) and area under the curve (AUC) 
analyses. Scores generated using the findings at 2nd through 5th MCP joints produced the 
lowest AUC (0.69), sensitivity (45.7%) and specificity (90%). There was no statistically 
significant difference between the scores generated using all other joint combinations since 
each generated high AUC values: 2nd through 5th MCP and PIP joints (AUC 0.90, Sensitivity 
0.76, Specificity 0.90); 2nd through 4th MCP and PIP joints (AUC 0.90, Sensitivity 0.80, 
Specificity 0.90); 2nd and 3rd MCP and PIP joints (AUC 0.85, Sensitivity 0.61, Specificity 1.0) 
2nd through 5th PIP joints (AUC 0.90, Sensitivity 0.80, Specificity 1.0). 
 
• Naredo et al performed comprehensive MSUS examinations on 160 patients with active, 
established RA prior to, and after 6 months of, biologic therapy (226). Systematic examination 
of grey scale and Power Doppler signal findings was performed in 44 peripheral large and 
small joints and all findings were graded semi-quantitatively. Different combinations of reduced 
joint sets were produced based upon the frequency of finding synovial and Power Doppler 
abnormalities at baseline. A reduced 12 joint model was then produced using only those joints 
which detected at least 90% involvement by synovitis and Power Doppler signal. The reduced 
12 joint model comprised examining the elbow, wrist, 2nd and 3rd MCP, knee and ankle 
bilaterally for evidence of grey scale synovitis and Power Doppler signal.  The 12 joint set 
identified 100% of patients with grey scale synovitis on the full 44 joint set and 94.4% of 
patients with Power Doppler signal. Furthermore, a simplification which focussed solely on 
Power Doppler findings in the 12 joint set demonstrated strongly positive, and statistically 
significant correlations with the corresponding total Power Doppler scores and indexes found 
in the full 44 joint set (Pearson Correlation Coefficients: Joint Count = 0.89, p<0.0005; Joint 
Index = 0.90, p<0.0005). 
 
• Backhaus et al have proposed a 7 joint set of the clinically dominant hand and foot (291). This 
joint set comprises the dominant wrist, 2nd and 3rd MCP, 2nd and 3rd PIP and 2nd and 5th MTP 
joints. The derivation of the joint set is not explicitly described in the original publication. 
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Nevertheless, a validation exercise did demonstrate that the score correlates positively with 
clinical disease activity measures and is responsive to changes in therapy. One hundred and 
twenty patients with RA or psoriatic arthritis underwent MSUS examination of the 7 joint set 
immediately prior to, 3 months after and 6 months after a significant change in DMARD or 
biologic therapy. Grey scale and Power Doppler findings for synovitis, tenosynovitis and 
erosions were graded semiquantitatively (0-3). Mean baseline Power Doppler synovitis score 
was 3.3, suggesting a relatively low overall number of joints with active synovitis. Mean grey 
scale and Power Doppler scores for synovitis fell significantly 6 months after a therapy change 
(Grey scale synovitis: Baseline 8.1 to 5.5, p<0.05; Power Doppler synovitis: Baseline 3.3 to 
2.0, p<0.05). There were statistically significant, moderately positive correlations observed 
between the change in mean Grey scale and Power Doppler synovitis scores and 
corresponding changes in DAS28 after 6 months of treatment (Grey scale synovitis vs DAS28: 
r=0.38, p<0.05; Power Doppler synovitis vs DAS28: r=0.31, p<0.05). Furthermore, reliability 
analyses demonstrated moderate inter-reader agreement for both semiquantitative 
assessment of grey scale synovitis (κ=0.55) and Power Doppler synovitis (κ= 0.67) and 
moderate intra-reader agreement for semiquantitative assessments (κ= 0.64) 
 
A recent longitudinal clinical study has demonstrated that the 7 joint set is sensitive to changes 
in clinical and laboratory measures of RA disease activity in a large cohort of RA patients 
(292). Four hundred and thirty patients underwent clinical (DAS28), laboratory (CRP and ESR) 
and MSUS 7 joint set assessment of global disease activity prior to, 3, 6 and 12 months after 
changing their DMARD/biologic treatment. Twelve months after treatment changes, mean grey 
scale and Power Doppler synovitis scores had fallen significantly for all groups. Patients 
receiving first or second line DMARDs demonstrated a significant correlation between the 
change in grey scale and Power Doppler synovitis scores and the corresponding change in 
DAS28 (1st Line DMARD: GS r=0.419, p<0.001; PD r=0.459, p<0.001. 2nd Line DMARD: GS 
r=0.257, p=0.008, PD r=0.283, p=0.007). A significant, positive correlation between changes 
in MSUS findings and ESR and CRP levels was demonstrated for patients receiving first line 
biologic therapy (ESR: GS=0.207, p=0.011; PD 0.179, p=0.032. CRP: GS not quoted; PD 
r=0.312, p<0.001), though results for DAS28 were not reported. Overall, the magnitude of 
change in MSUS scores appeared greater than the corresponding change in DAS28.  
 
• Dougadas et al have reported the clinimetric properties and reliability of several MSUS joint 
sets to quantify global RA disease activity in 76 patients with active disease requiring biologic 
therapy (293). Overall, the joint sets chosen by Dougadas et al comprised substantially more 
joints (20-38) than those proposed by Scheel etal, Backhaus et al and Naredo et al. Each of 
the chosen joint sets (20 joints: 1st-5th MCP and MTP bilaterally. 28 joints: DAS28 joint set. 38 
joints: DAS28 joint set + 1st-5th MTPj bilaterally) demonstrated good intra-observer agreement 
(intra-class correlation coefficient range: Grey scale 0.85 – 0.97, Power Doppler 0.61 – 0.96), 
construct validity (Alpha Cronbach test: Grey scale 0.76 – 0.89, Power Doppler 0.81 – 0.86) 
and sensitivity to change after commencing TNF-alpha blocking therapy. These findings were 
comparable, if not better, than clinical assessments performed in similar joint sets though 
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unfortunately correlation analyses between the different examination methods and joint sets 
were not reported. 
 
• Filer et al performed a longitudinal clinical study of 58 patients with undifferentiated 
inflammatory arthritis to describe the ability of different MSUS joint set combinations to predict 
a future diagnosis of RA (146,151). Whilst this is a study of the diagnostic ability of MSUS joint 
sets, and there is no comparison to alternative disease activity measures, a number of 
important factors were illustrated. When used in conjunction with the Leiden predictive criteria 
for RA, MSUS grey scale and Power Doppler findings significantly improved the examiners 
ability to diagnose RA. Specifically, logistic regression analyses demonstrated that grey scale 
and Power Doppler involvement of the wrist, MCP and MTP joints and symmetrical 
involvement of the wrist and MTP joints provided additional, independent predictors of RA over 
and above the Leiden score. Moreover, combining MSUS findings into a 10 joint set, based 
upon the 12 joint set proposed by Naredo et al (see above) but with the knee joints excluded, 
further increased the AUC and sensitivity of the assessment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The previously described studies highlight several important factors that were taken into account 
when the joint set used by this study was being planned: 
  
Published 
Joint Sets 
 
Proposed 
Joint Set 
Backhaus et al Naredo et al 
Figure 8: Derivation of limited joint set 
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1. Minimised MSUS joint sets, often restricted to easily accessible peripheral small joints, are 
comparable to larger, global MSUS joint sets  
2. Minimised MSUS joint sets are sensitive to change following commencement, or escalation 
of DMARD and/or biologic therapy 
3. Simplified systems which focus on the presence of Power Doppler signal provide 
comparable findings to those which focus on Power Doppler signal and grey scale findings 
4. Bilateral involvement of wrist and MTP joints is predictive of RA 
 
Since there were no universally accepted minimal joint sets available, a joint set pragmatically 
combining the important properties of those that had already been proposed (Scheel et al, 
Backhaus et al, Naredo et al) and had undergone a degree of validation was developed (Figure 
8). RA classically presents with symmetrical joint involvement, and since Naredo et al (226), and 
later Filer at al (151), emphasised the importance of assessing bilateral joint involvement, this 
study also deliberately chose to use a symmetrical joint set. The joints chosen are the bilateral 
extrapolation of the unilateral set proposed by Scheel et al and Backhaus et al (290-292) and 
include several joints in common with the set proposed by Naredo et al. The joint set proposed by 
Naredo et al also included several large peripheral joints (elbow, knees, ankles). These were 
excluded since scanning of these regions is more complicated, potentially time consuming and 
requires a higher degree of MSUS expertise that might limit the adoption of the proposed joint set 
by less experienced rheumatology sonographers. Prior to commencement of the research period 
the components of the proposed 14 joint MSUS set, and MSUS definitions of active RA, were 
discussed with Professor Phillip Conaghan (Professor of Musculoskeletal Medicine, University of 
Leeds), a rheumatologist with a noted interest and reputation in the use of modern imaging 
techniques to assess disease activity in rheumatological conditions. Indeed, the proposed 14-joint 
count was recently tested alongside an alternative, similarly structured, 18-joint count currently 
being validated by the OMERACT-Ultrasound Task Force (the Global Synovitis Score) and was 
found to have similar metric properties (294) 
 
MSUS Disease Activity Assessment 
Whenever MSUS disease activity assessment was indicated the following joints were examined 
systematically: bilateral index and middle PIPj, index and middle MCPj, wrist, 2nd and 5th MTPj. 
Each joint was examined in the dorsal, longitudinal plane with the participant’s hands and feet 
resting in the neutral position. The presence of synovial hypertrophy and PD signal was graded 
using the semi-quantitative system proposed by Szkudlareck et al (288). The nature of unclear or 
equivocal findings was confirmed by examination in the transverse plane. If there was no PD 
signal evident during dorsal examination of the MCP and PIP joints the palmar aspect of the joint 
was also examined. Appendix D includes an example of how MSUS findings were recorded 
during each assessment 
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Ultrasound Machine Settings 
Interpretation of images gathered by MSUS is subject to a degree of subjective, inter-observer 
variability which can, in some cases, lead to erroneous interpretation of the final image. 
Furthermore, individual ultrasound machines differ in how they present the same image and the 
content of the final image can be influenced by variations in a machine’s standard settings. 
Therefore, the following steps were taken to try and minimise any additional inherent variability 
associated with the MSUS assessment and therefore restrict any variability this might 
subsequently introduce in DMARD escalation decision. 
 
1. A single, portable machine, and single linear probe with standardised settings, was used 
for all MSUS assessments.  
2. A single researcher (Dr James Dale) performed all MSUS assessments using a 
standardised technique 
3. For each assessment, predefined, standardised ultrasound machine settings were used.  
 
A portable Voluson I (GE Healthcare, UK) with a 10-16mHz linear probe (SP 10-16RS, GE 
Healthcare, UK) was purchased solely for use during this research. This machine and probe were 
used for every single MSUS assessment. For each assessment predefined, standardised 
ultrasound machine settings were used. In practice, these were identical to the pre-programmed 
settings provided by the manufacturer to optimise MCPj assessment. 
 
Gray Scale Settings 
 
Frequency 16.0-13.5 (high resolution setting) 
Focus point Single point – placed in line, or just below, region of interest 
Depth 2.2cm 
Power  100% 
Zoom  100% 
 
Gain Variable – adjusted to examiner’s preference to obtain subjective highest 
quality image 
Persistence  1 
Dynamic Contrast 4 
Edge Enhance  3 
Line Filter  2 
Quality   High 
Speckle Reduction Imaging (SRI II) High 
 
Power Doppler Settings 
 
Frequency   High 
Pulse Repetition Frequency 0.9kHz 
Wall Filter   Low 
Region of interest box – size and shape adjusted to incorporate the whole of the intra-
articular space, surrounding articular surfaces and shafts of bone and the upper margin of 
image 
 
Gain – variable and adjusted to examiner’s preference to obtain highest quality images with 
least evidence of artefact. PD gain was set at the level just below that which caused 
abnormal Doppler artefact to appear below the surface of bone 
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Musculoskeletal Ultrasound Definition of Active Disease and Thresholds for DMARD 
Escalation 
Timing of MSUS Assessment in Relation to Clinical Assessment 
The positioning of MSUS assessment in relation to DAS28 assessment, and when it’s most likely 
to positively influence DMARD escalation decisions, needs to be carefully considered. There will 
be some scenarios where the additional information provided by MSUS assessment is unlikely to 
influence treatment decisions since the decision can be reached on clinical grounds alone. 
Furthermore, there will be some scenarios where the additional information provided by MSUS 
will lead to a different treatment decision than that suggested by the clinical findings..  
 
The following clinical scenarios were used to consider how best to place MSUS assessment 
alongside DAS28 assessment: 
 
• DAS28 > 5.1 – corresponds to high disease activity. This level of disease activity is least 
likely to have been influenced by external factors and is most likely to represent active 
inflammatory disease. DMARD escalation is indicated based upon the clinical findings and 
therefore MSUS assessment is not indicated 
 
• 3.2≤	 DAS28 < 3.2 and at least 2 clinically swollen joints – a moderate disease activity 
score and demonstration of at least 2 clinically swollen joints provides strong clinical 
evidence of persistent inflammatory disease activity. Therefore, DMARD escalation is 
indicated based on clinical findings and MSUS is not required since it is unlikely to 
influence the clinical decision 
 
• 3.2 ≤	 DAS28 < 5.1 and one or no clinically swollen joints – in this scenario the DAS28 
score is elevated above the traditional DMARD escalation threshold, however, there is 
minimal clinical evidence of active synovitis. MSUS assessment is indicated to determine 
whether the clinical findings represent active subclinical synovitis and therefore require 
DMARD escalation. If subclinical synovitis is not identified it is highly probable that the 
clinical findings (and any on-going joint symptoms) are not related to active synovitis and 
would not respond to further DMARD escalation. Exclusion of subclinical synovitis should 
prompt an alternative treatment approach in any patients who remain symptomatic. 
Furthermore, symptomatic patients without active synovitis will avoid exposure to the 
potential risks of unnecessary additional DMARD therapy 
 
• DAS28 < 3.2 – corresponds to low disease activity and in many situations is the disease 
activity target at which DMARD therapy is aimed. MSUS assessment is indicated to identify 
persistent subclinical synovitis. Confirmation of subclinical synovitis should prompt further 
DMARD escalation, even in asymptomatic patients. Thus, MSUS findings have supported 
further intensification of DMARD therapy, over-and-above that suggested by the DAS28 
assessment.  
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MSUS Definition of Active RA 
Whilst RA is a systemic disease, MSUS assessment initially generates findings that represent the 
individual joints being examined rather than global disease activity. Findings for individual joints 
need to be collated into a single measure of global disease activity that can then be used to 
inform DMARD escalation decisions. Since there is not yet a universally accepted reduced joint 
set there is not (yet) a universally accepted MSUS definition of active RA. In the development of 
this research a number of presumptions were made which informed the development of a unique 
MSUS definition of active RA based on evidence discussed in the preceding sections: 
 
1. The proposed limited joint set will identify a greater burden of active synovitis than that 
suggested by clinical assessment 
2. The proposed limited joint set will exclude on-going synovitis in a subset of patients whose 
DAS28 assessment is biased by non-inflammatory joint disease 
3. The presence of intra-articular Power Doppler is abnormal and corresponds to the 
presence of active synovitis. Conversely, regardless of grade, grey scale synovial 
hypertrophy without Power Doppler signal represents chronic synovial hypertrophy rather 
than active synovitis 
4. An increase in global disease activity will be represented by abnormal MSUS findings, and 
specifically abnormal Power Doppler findings, in at least 2 or more of the joints comprising 
the reduced joint set 
5. Erosions represent the sequlae of preceding active synovitis; therefore, identification of 
synovial hypertrophy and intra-articular Power Doppler signal will provide a more accurate 
representation of global disease activity at a given time point 
 
Thus, the following definition of active RA, based upon MSUS findings from the proposed limited 
joint set, was adopted: 
 
“The presence of at least grade 1 or higher intra-articular Power Doppler signal in at least 2 joints 
examined by MSUS for grey scale synovial hypertrophy and Power Doppler signal” 
 
This definition was chosen because: 1. it was in keeping with recent evidence that RA patients in 
low disease activity who still exhibited 2 clinically swollen joints were at an increased risk of future 
erosive progression compared to patients with no swollen joints (192) 2. it suggests active 
synovitis is not confined to a single joint and 3. reduced the risk of PD artefact within a single joint 
being misinterpreted as active synovitis and contributing to erroneous DMARD escalation 
(224,295) 
  
  120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* MSUS Assessment – grey scale and power Doppler assessment of index and middle PIPj 
hands bilaterally, index and middle MCPj hands bilaterally, radio-carpal joint bilaterally and 2nd 
and 5th MTPj feet bilaterally 
 
** Ultrasound Synovitis – power Doppler signal ≥ 1 affecting 2 or more joints 
 
Figure 9: Diagrammatic representation of potential DMARD escalation decision pathways for 
Control (DAS28) and Intervention (MSUS) groups; based upon possible clinical and MSUS 
scenarios 
  
TASER Cohort 
Control Group 
DAS28 assessment 
 
Intervention Group 
MSUS assessment 
DAS28 
< 3.2 
DAS28 
> 3.2 
No change Escalate 
therapy 
DAS28 
< 3.2 
DAS28 
> 3.2 
DAS28 
> 5.1 
SJ <1 SJC ≥2 
14 Joint MSUS 
Assessment * 
Escalate 
therapy 
No 
ultrasound 
synovitis 
Ultrasound 
synovitis** 
Escalate 
therapy 
No change 
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2.5 Outcome Measures 
 
A broad range of clinical, laboratory and radiological outcome measures were collected at regular 
intervals throughout the follow-up period. Since only members of the MSUS group underwent 
MSUS intervention it was not possible to blind the participants to their randomisation group. 
However, Sister Anne Stirling, who collected all the clinical outcomes, and the 2 radiologists who 
will grade the radiological outcomes, were kept fully ignorant of each participant’s randomisation 
group so that the assessment and grading of the main clinical and radiological outcomes is 
considered to be ‘single blinded’. To avoid treatment bias, Dr Dale was not made aware of any of 
the outcome assessments until the study had fully completed. Furthermore, none of the outcome 
measures were used to influence a participant’s treatment decision. Table 4 summarises which 
outcomes were collected at each time point throughout the research. 
 
   Month 
 Assessor 
 
B
linded 
S
creening 
B
aseline 
1 2 3 4 5 6 7 8 9 10 
11 
12 
13 
14 
15 
16 
17 
18 
RF/CCP NHSGGC Y x                    
                       
DAS28  
JD 
 
N 
 x x x x x x x x x x x x x x x x x x x 
Ultrasound*     x   x   x   x   x    
                       
DAS44  
 
 
AS 
 
 
 
Y 
x x   x   x   x   x   x   x 
Pain VAS  x   x   x   x   x   x   x 
Physician 
global VAS 
 x   x   x   x   x   x   x 
HAQ score  x   x   x   x   x   x   x 
EQ5-D  x   x   x   x   x   x   x 
                       
Plain X-ray 
hands/feet 
 
Rad x 2 
 
Y 
x                   x 
MRI 
hand/wrist 
 x                  x 
                       
Biomarkers Lab Y  x   x         x       
                       
FBC/ESR  
NHSGGC 
 
Y 
x x x x x x x x x x x x x x x x x x x x 
U&E/LFT x x x x x x x x x x x x x x x x x x x x 
CRP x x x x x x x x x x x x x x x x x x x x 
                       
Adverse 
events 
JD N   x x x x x x x x x x x x x x x x x x 
Table 4: Timing of collection of each outcome measure 
(NHSGGC = NHSGGC Laboratory Services, JD = Dr James Dale, AS = Sr Anne Stirling, 
RADx2 = independent radiologists, Lab = collaborating scientists)            
 
2.5.1 Clinical Outcome Measures 
Sister Anne Stirling, rheumatology research nurse and metrologist, accompanied Dr Dale to 
research clinics at each of the participating hospitals and collected all clinical outcome data. 
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Sister Stirling assessed participants after Dr Dale in a clinic room sufficiently far from Dr Dale’s to 
prevent her overhearing any of the preceding treatment discussions. To ensure Sister Stirling 
remained blinded to assessment groups, participants were clearly instructed to avoid any 
discussions of their RA status, clinic consultation and whether or not they underwent ultrasound 
assessment. The ultrasound machine was present at every single consultation and Dr Dale 
attempted to ensure that all clinic visits were of approximately equal duration. The following 
assessments of clinical status and functional ability were collected at baseline and every three 
months thereafter until study completion 
 
44 Joint Disease Activity Score (DAS44) (286,296): The DAS44 is a composite measure of 
disease activity derived by imputing the values of the 44 swollen joint count (44SJC), Ritchie 
Articular Index (RAI), patient global health 10cm VAS and ESR into the following equation: 
 
DAS44 = (0.53938x√RAI) + (0.6465x44SJC) + (0.33xlnESR) + (0.00722xGlobalVAS)  
 
DAS44 values at a single time point allows global disease activity to be categorised into various 
levels of severity: 
 
 Remission   DAS44 < 1.6 
 Low disease activity  DAS44 ≤	 2.4 
 Moderate disease activity 2.4 < DAS44 ≤	 3.7 
 High disease activity  DAS44 > 3.7 
 
Furthermore, EULAR response criteria use the relationship between the net change in DAS44 
and the final DAS44 value to categorise qualitatively a patient’s apparent response to therapy 
(297): 
 
 Improvement in DAS44 
 
DAS44 at endpoint ≤ 1.2 > 0.6 and ≤ 1.2 ≤	 0.6 
≤ 2.4 Good Moderate 
Moderate 
None 
None 
None 
>2.4 and ≤ 3.7 Moderate 
Moderate >3.7   None 
Table 5: Derivation of EULAR response using DAS44 thresholds 
 
Health Assessment Questionnaire Disability Index (HAQ): The HAQ is widely considered as 
the gold standard measure of functional ability. It was originally developed in patients with arthritis 
(298) but since has been validated as a measure of functional ability in patients with a wide range 
of arthritic and chronic conditions (299). The HAQ is administered as a self, or assessor, 
completed questionnaire where statements relating to activity of daily living are graded using 
semi-quantitative Likert Scales (0 – without difficulty, 1 – with some difficulty, 2 – with much 
difficulty, 3 – unable to do). Scores are adjusted for requiring external assistance and the use of 
physical aids. The final score is between 0-3.0 with increasing scores representing worse 
functional ability. The minimally clinical important change is approximately 0.22 and functionally 
independent patients can report mildly elevated HAQs between 0.38 and 0.45 (300). Appendix E 
displays the HAQ questionnaire proforma.  
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EQ-5D-3L Questionnaire (Euro-QOL): The EQ-5D-3L questionnaire and EQ VAS provide a 
generic, highly simplified measure of health status (301). Domains relating to mobility, self care, 
usual activities, pain/discomfort and anxiety/depression are graded using a 3 level cardinal scale 
(1 – no problems, 2 – some problems, 3 – extreme problems). A 20cm vertical VAS provides a 
numerical depiction of the respondent’s general health (0 – the best health you can imagine; 100 
– the worst health you can imagine). For individual patients, EQ-5D-3L results can be 
represented as a health profile by listing the responses for each health domain with the numerical 
value of the global VAS. Alternatively, a numerical health index can be calculated by using 
predefined value sets to adjust for the weighting of each domain and global VAS. On a group 
level, the EQ-5D-3L can be summarised by the frequency of patients responding to the different 
levels of each domain or as a description of the range and central tendency of the global VAS 
and EQ-5D-3L health index 
 
Pain 10cm Visual Analogue Score: Ten centimetre pain visual analogue scores provide an 
easily understood, and commonly used, measure of a patient’s symptom burden at a single time 
point. Its change over time provides a numerical representation of the change in a patient’s 
symptoms in response to therapy. However, pain VAS are non-specific and are often influenced 
by other, non-RA related, causes of pain 
 
Taken together this group of clinical variables comprises the minimum, core-set recommended by 
the American College of Rheumatology to standardise descriptions of outcomes in longitudinal 
clinical studies (302) 
 
2.5.2 Laboratory Outcome Measures 
Acute Phase Measures: CRP and ESR were measured at each monthly visit and were analysed 
by the routine methods of NHSGGC Laboratory services. For reporting purposes, values 
corresponding to each of the 3 monthly clinical assessments will be reported 
 
Monitoring Blood Tests: To comply with national DMARD monitoring guidelines, samples for 
testing of U+E, LFT and FBC were analysed each month by NHSGGC Laboratory services. 
Whilst these blood tests can sometimes demonstrate abnormalities related to RA activity their 
values will not be reported as an outcome measure. 
 
2.5.3 Radiological Outcome Measures 
All images for radiological outcome analysis were collected at baseline and after 18 months using 
local NHSGGC radiology facilities and each department’s standard image acquisition methods. 
The degree of change in standardised radiological scores of joint damage will serve to describe 
the rate of erosive progression for each patient over the follow-up period of the study. There will 
be two independent radiological outcome measures collected: 
 
MRI Dominant Hand and Wrist: This will serve as the primary radiological outcome measure 
and images will be graded using the OMERACT Rheumatoid Arthritis MRI Scoring system 
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(RAMRIS) (250,303-305). MRI has several advantages over traditional plain radiographs: 1. MRI 
is more sensitive than plain radiographs at detecting erosions, 2. MRI allows direct visualisation 
of synovitis (and other peri-articular pathology) and 3. MRI evidence of bone marrow oedema has 
been consistently shown to predict future erosive joint damage (306). To reduce potential inter-
machine bias all MRI scans were performed using the same MRI machine (1.5T Siemans Avanto, 
Glasgow Royal Infirmary Department of Radiology) and scanning protocols that had been 
standardised by the local radiographers. The dominant wrist and 2nd-to-5th MCPj were imaged 
using the following sequences: T1-weighted - before and after intravenous gadolinium contrast –  
and T2-weighted fat saturated. In order to limit examination time, scanning was restricted to the 
dominant wrist since studies comparing unilateral and bilateral combinations of joints have not 
demonstrated any significant difference between either combination’s ability to detect structural 
progression (307) 
 
The OMERACT RAMRIS System: The RAMRIS system was developed by consensus to 
standardise acquisition and grading of MRI images for research purposes and to facilitate its use 
as an outcome measure (303). The RAMRIS system semi quantitatively grades the extent of MRI 
erosions, synovitis and bone marrow oedema affecting each joint region individually. Grading is 
standardised using an image reference atlas. The following definitions are used: 
 
Synovitis: “an area in the synovial compartment that shows above normal post-gadolinium 
enhancement of a thickness greater than the width of normal synovium.” Graded 0-3 based on 
proportion (in thirds) of enhancement of synovial tissue: 0 – normal, 1 – mild, 2 – moderate, 3 – 
severe 
 
Bone erosions: “a sharply marginated bone lesion, with correct juxta-articular localisation and 
typical signal characteristics, which is visible in two planes with a cortical break seen in at least 
one plane.” Graded 0-10 based on proportion (in centiles) of eroded tissue compared to total 
bone volume: 0 – normal, 1 – 1-10%, 2 - 11-20%, 3 – 21-30% etc 
 
Bone marrow oedema: “a lesion within the trabecular bone, with ill defined margins and signal 
characteristics consistent with increased water content.” Graded 0-3 based on proportion of bone 
displaying oedema: 0 – no oedema, 1 – 1-33% oedematous, 2 – 34-66% oedematous, 3 – 67-
100% oedematous. 
 
For each region examined, total scores for each component can be calculated by summing the 
individual scores for each individual joint (Table 5). Changes in total scores, and for individual 
joints, between baseline and follow-up scans can be used to describe the rate of improvement / 
progression in each component at an overall, or individual joint level. 
 
Validation studies with multiple independent readers have demonstrated that the RAMRIS system 
has high intra- and inter-reader agreement with high intra-class correlation coefficients for each of 
the individual components (median ICC: synovitis 0.69-0.90, bone erosion 0.73-0.91, bone 
marrow oedema 0.79-0.98) (250). The RAMRIS system has shown high sensitivity to change with 
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low smallest detectable differences (median SDD: synovitis 1.89, bone erosion 5.53, bone 
marrow oedema 3.18) and low minimal detectable changes (median MDC: synovitis 19.8, bone 
erosion 3.69, bone marrow oedema 7.07) demonstrated for each component (307). Furthermore, 
the RAMRIS system appears to identify a higher number of patients with erosive progression than 
standardised plain radiography scoring systems (307). 
 
 Wrist 2nd – 5th MCPj 
 
Total 
(Combined) 
Synovitis 
 
0-9 0 - 12 0 – 23 
Bone Erosion 
 
0 – 150 0 – 80 0 – 230 
Bone Marrow 
Oedema 
 
0 - 45 0 - 24 0 – 69 
Table 6: Potential range of scores for RAMRIS components for wrist and 2nd-5th MCPj separately 
and combined 
 
Plain X-ray Hands and Feet: The majority of RA interventional clinical trials have traditionally 
reported changes in plain x-ray findings as the primary radiological outcome. Acquiring plain 
radiography images is generally cheap, fast and facilities are usually available in most clinical 
settings. However, in early inflammatory arthritis there is an increasing recognition that plain 
radiography alone is a relatively insensitive method of detecting structural damage and 
progression since the frequency of plain radiographic erosions is relatively low (308). Hence, to 
maximise sensitivity MRI has been chosen as the primary radiological outcome measure; though 
plain radiographs of hands and feet will still be collected to allow comparison with previously 
published clinical trials.  
 
The Sharp / Van der Heijde Score (309): A recent survey of RA clinical trials identified the Sharp / 
Van Der Heijde Score as the most commonly reported plain radiographic outcome (310).  
 
The presence and extent of erosions is assessed in the following joints: Hands – 1st-5th MCPj, 2nd-
5th PIPj, IPj of thumb, 1st proximal metacarpal, distal radius and ulna, scaphoid, lunate, trapezium 
and trapezoid bones; Feet – 1st-5th MTPj and IPj of first toe. Erosions in the hands are graded 0-5: 
0 – no erosion, 1 – single discrete interruption of cortical surface, 2-4 – erosive change involving 
between 2-4 quadrants of the joint, 5 – confluent erosions involving full surface of the joint. In the 
feet, each side of the joint is graded independently 0-5 and then both scores are summed to 
provide a total score out of 10 for each joint.  
 
The presence of joint space narrowing is assessed in the following joints: Hands 1st-5th MCPj, 2nd-
5th PiPj, 3rd-5th carpometacarpal (CMC), radiocarpal joint, scaphoid-lunate and lunate-capitate 
joints; Feet – 1st-5th MTPj and IPj of first toe. Joint space narrowing for hands and feet are graded 
0-4: 0 – normal, 1 – focal or doubtful, 2 – involving ≤ 50% of joint surface, 3 – involving > 50% of 
joint surface or subluxation evident, 4 – bony ankylosis evident.  
 
Grades for erosions and joint space narrowing can be summed for all joints giving a maximum 
erosion score of 160 in the hands, 120 in the feet and 280 altogether; a maximum joint space 
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narrowing score of 120 in hands, 48 in feet and 168 altogether. The maximum overall Sharp / Van 
der Heijde Score is 448. The Sharp / Van der Heijde system has demonstrated good metric 
properties with high scores for inter-rater reliability (ICC 0.80-0.96) and intra-rater reliability (ICC 
0.94-0.99) for all components at single time points and in relation to detecting change (311,312). 
The smallest detectable difference between two radiographs is 7 (311). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Principles for Scoring of Radiological Analysis 
The following, over-arching principles will be applied to the grading of all plain radiography and 
MRI outcomes to ensure that the process is reliable and free from external bias. 
 
1. Baseline and follow-up images at each site will be acquired using the same imaging 
equipment 
2. Digital versions of all images will be reviewed and graded using the same image analysis 
platform (www.osirix-viewer.com) 
3. Each image will be reviewed independently by two musculoskeletal radiologists who are 
blinded to the participant’s identify and treatment group.  
4. For each image, the mean of the two independent gradings for each component will be 
used in the statistical analysis. However, if there is significant disagreement between the 
independent gradings for a particular image, the grading radiologists will be asked to 
discuss their assessments until a consensus is reached  
5. Images will be reviewed in chronological order to increase the sensitivity to detect change 
over time (313) 
 
2.5.4 Data Storage and Management 
To facilitate the later statistical analysis, all data generated by this research will be stored within a 
secure, password-protected, online eCRF hosted and administered by the Robertson Centre for 
Biostatistics, University of Glasgow. Access to the eCRF will be restricted to those individuals 
responsible for assessing and recording each of the different data types. Each individual will only 
be able to enter data into the fields relating to their contribution and will not have sight of any 
Figure 10: Illustration of joints of hands 
and feet scored for erosions () and joint 
space narrowing (I) by the modified (Van 
der Heijde) Sharp Scoring System  
[Illustration from Van der Heijde et al. 
Arthitis Rheum 1992. 35. P26-34] 
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other outcome data. Furthermore, to maintain the objectivity and blinding of the outcome 
assessors, each patient’s unique data entry pages will not display their randomisation group. 
Data queries will be administered by the Robertson Centre for Biostatistics whereby the relevant 
dataset will be downloaded from the ‘live’ eCRF since, to maintain data integrity, it will not be 
possible to analyse the data stored within the eCRF directly. 
 
2.6 Statistical Analysis 
Due to the frequency and breadth of clinical and radiological data being collected a very large 
range of within group and between-group comparisons were possible. Comparisons were made 
to determine whether there was a significant difference in a single variable between both groups 
at a single time point or whether there had been a significant within group change over time of a 
particular variable. Prior to each analysis the distribution of the relevant dataset was determined. 
Given the group sizes it was presumed that most datasets would not be normally distributed and 
therefore, unless otherwise stated, non-parametric analysis techniques were used. Data for each 
comparison were drawn from the eCRF administered by the Robertson Centre for Biostatistics. 
All analyses were performed using either SPSSv17 or Graphpad Prism v6 (www.graphpad.com). 
Unless otherwise stated, p<0.05 was considered the threshold for statistical significance.  
 
2.6.1 Description of Baseline Characteristics 
In order to ensure that the control and intervention group could be directly compared, and that 
they were representative of a ‘typical’ RA population, it was important to determine whether there 
were any significant imbalances in baseline demographic or RA-related characteristics. Table 7 
illustrates how each of the baseline variables were categorised, summarised and compared 
between the control and intervention groups. For the purposes of this illustration it is presumed 
that data will not be normally distributed and therefore, unless otherwise stated, data were 
analysed using non-parametric methods.  
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 Variable 
 
Categorisation Summary 
Statistic 
(range) 
Between Group 
Comparison 
Technique 
 
 
 
Demographic 
Data 
Sex 
 
Dichotomous Frequency / 
Percentage 
Chi-squared 
Age 
 
Continuous Median 
(IQR*) 
Mann Whitney U 
Weight / Height 
(BMI) 
 
Continuous Median 
(IQR) 
Mann Whitney U  
Smoking Status 
(current / ex / never) 
Nominal Frequency / 
Percentage 
Chi-squared 
 
 
 
 
 
Disease 
Characteristics 
Symptom Duration 
 
Continuous Median 
(IQR) 
Mann Whitney U 
RhF Status 
(positive or 
negative) 
Dichotomous Frequency / 
Percentage 
Chi-squared 
RhF Titre 
 
Continuous Median 
(IQR) 
Mann Whitney U 
Anti-CCP Status 
(positive or 
negative) 
Dichotomous Frequency / 
Percentage 
Chi-squared 
Anti-CCP Titre 
 
Continuous Median 
(IQR) 
Mann Whitney U 
Baseline Erosions 
(present / absent) 
Dichotomous Frequency / 
Percentage 
Chi-squared 
 
 
 
Disease 
Activity / 
Impact 
DAS44 
(including its 
constituent parts) 
Continuous Median 
(IQR) 
Mann Whitney U 
HAQ 
 
Continuous Median 
(IQR) 
2 sample t test 
CRP / ESR 
 
Continuous Median  
(IQR) 
Mann Whitney U 
Pain 10cm VAS 
 
Continuous Median 
(IQR) 
Mann Whitney U 
  Table 7: Baseline characteristics and proposed statistical analysis methods  
(*IQR – interquartile range) 
 
2.6.2 Assessment of Impact of MSUS Upon DMARD Escalation Decision 
Making 
Since a central theme of this research is related to how MSUS findings could potentially influence 
DMARD escalation decisions it was important to describe how often there was agreement and 
disagreement between clinical and MSUS disease activity assessment. In this way, it was 
possible to determine how often MSUS findings would influence DMARD treatment decisions and 
also the potential impact of regularly incorporating MSUS into a rheumatologist’s clinical work 
load. If there was a discrepancy in the assessment of disease activity, the MSUS findings took 
precedence over the DAS28 in determining whether or not DMARD escalation was indicated.  
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Definitions of Agreement and Disagreement 
The following definitions of agreement and disagreement were used: 
 
Agreement: DAS28 and MSUS both agree on the presence / absence of active inflammatory 
disease and lead to the same decision relating to DMARD therapy. This related to the following 
scenarios: 
 
1. Presence of active disease requiring DMARD escalation: DAS28 >3.2 with minimal 
clinical synovitis (e.g 0-1 swollen joints) AND MSUS identifies grade 1 (or higher) 
PDUS signal in at least two joints 
2. Absence of active disease requiring no change to DMARD therapy: DAS28<3.2 AND 
MSUS identifies PDUS findings in either one or no joints 
 
Disagreement: DAS28 and MSUS disagree on the presence / absence of active inflammatory 
disease and support opposing decisions relating to DMARD therapy. This related to the following 
scenarios: 
 
1. Low disease activity but subclinical synovitis requiring DMARD escalation: DAS28 <3.2 
BUT MSUS identifies grade 1 (or higher) PDUS signal in at least two joints 
2. Moderate disease activity but absent synovitis on MSUS assessment: DAS28 >3.2 with 
minimal clinical synovitis (e.g 0-1 swollen joints) BUT MSUS identifies PDUS findings 
in either one or no joints 
 
Since there was a three month gap between the decision to escalate DMARD therapy and the 
next opportunity to perform MSUS the amount of MSUS data available was limited. In order, to 
maximise the data available, all instances when there was paired sets of DAS28 and MSUS 
findings were pooled together. The following analyses were planned: 
 
1. Description of percentage agreement and disagreement: using the definitions of 
agreement and disagreement described in the preceding section the frequency and 
percentage of agreement between DAS28 and MSUS was calculated. Since DAS28 and 
MSUS assess RA disease activity by quite different methods and return quite different 
outputs it was not possible to calculate a traditional statistical measure of agreement (e.g 
Kappa statistic). Thus, the simpler percentage agreement between the findings was 
chosen as the preferred descriptor 
 
2. Frequency of joint involvement: the frequency of each joint displaying positive MSUS. 
findings was calculated to determine the relative contribution of individual joint areas to 
the final disease activity assessment. Findings for corresponding right and left hand sided 
joints were pooled to calculate the frequency of positive findings in each area. 
Subsequently, whether one or both of a particular joint displayed positive findings was 
determined. In this way it was possible to identify joint areas that could be excluded from 
the proposed global MSUS assessment tool without negatively affecting the overall 
sensitivity 
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3. Joint scores and counts: at a single sitting gradings from each of the MSUS findings were 
combined in the following ways to provide an overall summary of the assessment: 
 
i. Total MSUS Score – sum of all the gradings from each joint for a particular 
finding. Ranges: synovial hypertrophy 0-42, PDUS 0-42 
 
ii. MSUS Joint Count – number of examined joints exhibiting a particular MSUS 
finding, regardless of the finding’s grading. Ranges: synovial hypertrophy 0-14, 
PDUS 0-14. Patients exhibiting a PDUS index greater than or equal to 2 were 
eligible for DMARD escalation 
 
For each finding, changes in mean MSUS score and indices over time were used to describe how 
each MSUS finding fluctuated over the follow-up period and responded to increasing DMARD 
intensity. Furthermore, longitudinal changes in MSUS findings were compared to corresponding 
changes in clinical disease activity assessment to determine how well the measured clinical 
changes reflected changes visible in underlying synovitis 
 
2.6.3 Description of Treatment Intensity 
The specific details of each patient’s DMARD regimen (e.g doses and constituent agents) and 
corticosteroid requirements was collected during each monthly consultation and recorded in the 
online eCRF 
 
DMARD Therapy 
It was presumed that participants in the MSUS assessment group would receive more intensive 
DMARD therapy over the duration of the follow-up period; i.e more treatment escalation steps 
and a higher frequency, and earlier, use of combination DMARD and anti-TNFα blocking therapy. 
In order of ascending intensity, grading of treatment intensity was based upon the hierarchy 
suggested by the DMARD escalation protocol (section 2.3): 
 
i.  DMARD Monotherapy  Methotrexate, sulfasalazine or hydroxychloroquine 
iia. Dual Combination Therapy Methotrexate + sulfasalazine; methotrexate + 
hydroxychloroquine; sulfasalazine + hydroxychloroquine 
iib. Triple Combination Therapy Methotrexate + sulfasalazine + hydroxychloroquine 
iii. Subcutaneous methotrexate Subcutaneous methotrexate with one or both of 
sulfasalazine and/or hydroxychloroquine 
iv. Biologic therapy Etanercept with some or all of methotrexate (oral or 
subcutaneous), sulfasalazine and hydroxychloroquine 
 
The proportion of patients in each assessment group within each of these treatment intensity 
groups was calculated for each 3 monthly time point (0, 3, 6, 9, 12, 15, 18 months). Furthermore, 
the mean dose of each individual DMARD being administered at each 3 monthly time point was 
calculated. 
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Corticosteroid Treatment 
Since, corticosteroids have a rapid immunomodulatory action that can produce rapid, short-term 
fluctuations in measured disease activity it is feasible that unequal use of corticosteroids could 
account for some of the differences in outcome observed between each of the assessment 
groups. Whilst both assessment groups share the same indication for administering 
corticosteroids, it is feasible that an inadvertent treatment bias may be introduced which favours 
the MSUS assessment group. The intensity of corticosteroid treatment administered to each 
group was determined by: 
 
i. describing the mean number and cumulative dose of intra-articular and intra-muscular 
corticosteroids administered over the whole duration of the research, 
ii. describing the mean number and total dose of intra-articular and intra-muscular 
corticosteroids administered during each monthly review 
 
Individual joints were injected with differing doses of triamcinolone acetonide depending upon 
their size; thus, for comparison purposes the mean cumulative dose of intra-articular and intra-
muscular corticosteroid administered over the duration of the follow-up period will provide a more 
accurate representation of treatment intensity 
 
2.6.4 Description of Treatment Response 
A broad range of clinical and functional outcome measures were collected at 3 monthly intervals 
over the duration of the follow-up period and were in-line with the joint ACR-EULAR 
recommendations for reporting of clinical outcomes (314). This dense outcome data collection 
allowed each patient’s, and their assessment groups, overall treatment response to be described 
by a variety of different measures. Numerical changes in composite disease activity measures - in 
particular the DAS44 – between two time-points allowed treatment responses to be described as 
either the absolute change in value or whether or not a predefined target (such as low disease 
activity or remission) was achieved. Furthermore, both the relative change from baseline of the 
DAS44 (e.g EULAR response criteria), and its mean over the follow-up period, were used as a 
measure of overall disease control to determine whether either group had been exposed to a 
significantly greater inflammatory burden. Broadly, changes in outcome measures between 
baseline and 3 months were presumed to represent changes in response to initial DMARD 
monotherapy; whereas, changes between baseline and 18 months were presumed to represent 
overall response to intensive DMARD therapy 
 
DAS44 
The mean change in DAS44 from baseline was the primary clinical outcome measure. The 
numerical value of the DAS44 at each time point could also be manipulated by a variety of 
different additional methods to provide a measure of treatment response between different time-
points and also over the duration of the follow-up period.  
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Longitudinal change in DAS44: It is commonly accepted that a fall in DAS44 of 1.2 (or greater) 
represents a significant, positive treatment response (297). The between group difference in the 
mean change in DAS44 between baseline and month 18 was compared to determine whether 
either group experienced a statistically higher magnitude of change in disease activity. The mean 
DAS44 for each group at each 3 month time point was compared using the 2 sample t-test test to 
determine if there were any statistically significant between group differences in disease activity 
at any time point 
 
Disease activity level thresholds: at a given time point the absolute value of DAS44 allowed 
participant’s disease activity to be categorised according to well established criteria (286,296): 
 
Remission   DAS44 < 1.6 
 Low disease activity  DAS44 ≤	 2.4 
 Moderate disease activity 2.4 < DAS44 ≤	 3.7 
 High disease activity  DAS44 > 3.7 
  
The proportion of each assessment group falling within each of the DAS44 categorisation groups 
at each time point was calculated and compared using a Chi-squared test 
 
EULAR response criteria: between two time points, the absolute change in DAS44 and the final 
DAS44 values were used to determine the proportion of patients within each assessment group 
fulfilling the EULAR response criteria (297). EULAR responses were defined using the criteria 
described in Table 5 (reproduced below for ease) 
 
 Improvement in DAS44 
 
DAS44 at endpoint ≤ 1.2 > 0.6 and ≤ 1.2 ≤	 0.6 
≤ 2.4 Good Moderate 
Moderate 
None 
None 
None 
>2.4 and ≤ 3.7 Moderate 
Moderate >3.7   None 
Table 5: Derivation of EULAR response using DAS44 thresholds 
 
The proportion of patients in each assessment group meeting each of the EULAR response 
criteria at each time point were compared using the Chi-squared test. There was particular focus 
on the EULAR responses between baseline and 3 months follow-up (response to initial DMARD 
monotherapy) and baseline and 18 months follow-up (overall response to intensive 
management). 
 
Cumulative inflammatory burden: patient’s response to DMARD therapy is neither uniform nor 
predictable and month-by-month fluctuations in DAS44 may not give a clear indication of a 
patient’s overall exposure to active disease. For this study, each participant’s mean DAS44 was 
presumed to provide a truer representation of their overall disease course and cumulative 
inflammatory disease burden. Therefore, each participant’s mean-DAS44 period was calculated 
and then pooled within assessment groups. Median mean-DAS44 were compared between the 
assessment groups using the Mann-Whitney U test to determine whether or not there was a 
statistical difference in either group’s overall exposure to active disease.  
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Health Assessment Questionnaire 
The Likert responses to each of the HAQ questions was used to calculate a numerical HAQ score 
that represented a participants level of functional ability at each assessment time point (298,299). 
Between group comparisons of differences in functional ability were conducted by comparing 
each group’s median HAQ using the Mann Whitney U test at each 3 month assessment time 
point 
 
Euro-QOL 5D-3L Questionnaire 
The 5 domains of the EQ-5D questionnaire rate a patient’s ability to undertake specific 
descriptors of health status (mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression) using a 3 point Likert scale and a 20cm VAS (301). Whilst graded 1 to 3, the 
levels for each health status are cardinal variables with no numerical value. At each 3 monthly 
time point, each assessment group’s health profile will be described by reporting the proportion of 
patients who fall within each level of the individual domains. Between assessment groups, the 
proportion of patient’s within each level of individual domains will be compared using the Chi 
squared test and the median EQ-5D 20cm VAS will be compared using the Mann Whitney U test.  
 
Patient Global Health and Pain 10cm Visual Analogue Scales 
Ten centimetre VAS scales provide numerical representations of the patient’s overall health 
perception and experience of pain in the preceding week. At each 3 monthly time point, median 
values for global health 10cm VAS and pain 10cm VAS were calculated and between group 
comparisons were performed using Mann Whitney U test 
 
Acute Phase Reactant Levels 
Values for CRP and ESR, corresponding to each of the 3 monthly assessment time points, were 
recorded from the laboratory result systems of NHS GGC. Median values of each reactant were 
calculated for each group at each of the 3 monthly assessment time points and between group 
comparisons at each time point were performed using the Mann Whitney U test. Mean and area 
under the curve values could also be used for each reactant to provide an additional measure of 
cumulative inflammatory burden.  
 
Composite Measure of Treatment Response 
The clinical and laboratory outcome data collected as part of this research comprised the ACR 
core set variables and therefore the degree of change in each core set variable over the duration 
of the follow-up period was used to determine the ACR response rate for each group (302,315). 
Each of the ACR response definitions (ACR20, ACR50, ACR70) require a minimum amount of 
improvement in both tender and swollen joint count and a minimum amount of improvement in 3 
of the remaining 5 variables. The ACR core set variable comprise: 
 
1. Tender joint count    Ritchie articular index 
2. Swollen joint count    44 swollen joint count 
3. Patient pain assessment   Pain 10cm VAS 
4. Patient global assessment  Patient Global 10cm VAS 
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5. Physician global assessment Physician Global Likert Scale 
6. Assessment of physical function HAQ questionnaire 
7. Acute phase reactant value  ESR 
 
ACR response rates were calculated between baseline and 6 monthly time points using the 
following method 
 
1. At least 20/50/70% improvement in tender joint count AND swollen joint count 
 
AND 
 
2. At least 20/50/70% improvement in 3 out of the following 5 variables: 
 
i. pain 10cm VAS 
ii. patient global 10cm VAS 
iii. physician global likert scale 
iv. HAQ questionnaire 
v. ESR 
 
The proportion of patients within each assessment group meeting each of the ACR response 
definitions at each 6 monthly time point were compared using the Chi-squared test.  
 
2.6.5 Description of Change in Radiological Outcomes 
Changes in radiological measures over the follow-up period provide an additional measure of 
treatment success. The group with the least effective assessment strategy will be expected to 
exhibit either a greater frequency and degree of erosive progression and a greater persistence of 
active synovitis. Changes in MRI appearances are considered the primary radiological outcome; 
however, changes in plain x-ray appearances will also be reported since these remain the most 
commonly reported radiological outcome in RA clinical trials. At the time of writing, the formal 
grading of the radiological outcomes had not been completed; therefore it will not be possible to 
present the radiological outcome results within this thesis  
 
MRI Outcomes 
Baseline and 18 month MRI appearance of synovitis, erosions and bone marrow oedema will be 
graded using the previously described RAMRIS system (section 2.5.3). For each assessment 
group at each time point, median grades for each component will be reported for the wrist and 
MCPj individually and as a combined score. The mean change in the numerical value of the each 
component’s grade between baseline and 18 months will represent the impact of the assessment 
strategy on disease progression and treatment response. The group with the most effective 
assessment and treatment strategy will be expected to demonstrate a lesser increase in the 
erosion score and a greater reduction in the synovitis and bone marrow oedema scores. Median 
scores at each time point, and their change over the follow-up, will be compared between the 
assessment groups using either the Mann Whitney U test or Student’s t test as appropriate. Table 
6 (reproduced below for ease) summarises the range of scores for each component by 
anatomical area 
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 Wrist 2nd – 5th MCPj 
 
Total 
(Combined) 
Synovitis 
 
0-9 0 - 12 0 – 23 
Bone Erosion 
 
0 – 150 0 – 80 0 – 230 
Bone Marrow 
Oedema 
 
0 - 45 0 - 24 0 – 69 
Table 6 (reproduced): Potential range of scores for RAMRIS components for wrist and 
2nd-5th MCPj separately and combined 
 
Plain X-ray Outcomes 
 
Baseline and 18 month plain x-rays of the hands and feet will be graded using the Sharp / Van 
der Heidje Score (311). Mean changes between baseline and 18 months in the erosion, joint 
space narrowing and total scores will be used to represent the degree of radiographic 
progression evident in both groups. It is presumed that the group with the most effective 
assessment and treatment strategy will also exhibit a lesser increase in all components of the 
Sharp / Van der Heijde Scores. Median scores at each time point, and their mean change over 
the follow-up period, will be compared between assessment groups using either the Mann 
Whitney U test or Student’s t test as appropriate. Table 8 summarises the potential range of 
scores for each anatomical region 
 
 Erosions 
 
Joint Space 
Narrowing 
Total 
Hands 
 
0-160 0-120 0-280 
Feet 
 
0-120 0-48 0-168 
Total 
 
0-280 0-168 0-448 
Table 8: Potential range of scores for plain xray erosions and joint space narrowing in the hands 
and feet when graded using the Sharp / Van der Heijde Score 
 
To provide some indication of the burden of erosive disease at presentation the presence or 
absence of erosions on baseline hand and foot x-rays was recorded from the standard 
radiological reports issued by NHSGGC staff radiologists. These reports are provided by a wide 
number of radiologist with varying degrees of experience in reporting plain x-ray findings. Reports 
are descriptive and do not formally quantify the presence / absence of radiological features of RA. 
Consequently, the presence / absence of baseline x-ray erosions reported by this thesis is not 
standardised and subject to significant inter-reader variability. It is highly likely that the formal 
grading of plain x-ray images using the modified Sharp score will return findings that differ 
significantly from the values quoted by this thesis (especially the prevalence of erosive change at 
baseline) 
 
2.6.6 Adverse Event Rates 
Even though the treatment protocol comprises several DMARDs that are commonly used in 
combination in the treatment of RA, it is possible that the aggressive escalation strategy favoured 
by the MSUS assessment group could lead to a higher incidence of adverse effects. In fact, it 
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might become evident that the frequency of adverse effects observed when patients with 
asymptomatic, subclinical synovitis receive increasingly aggressive DMARD combinations tips 
the risk:benefit ratio in favour of not escalating DMARD therapy. Equally, the prevention of 
DMARD escalation by MSUS findings excluding on going synovitis in patients with elevated 
disease activity scores might also divert some patients away from the risk of increased risk of 
adverse effects associated with combination therapy. Until the frequency of adverse effects has 
been determined it will not be possible to comment on the potential safety implications of using 
MSUS to guide DMARD escalation. Throughout the duration of the study, the incidence, duration 
and nature of adverse events was carefully recorded using standardised preforms provided by 
the Robertson Centre for Biostatistics, University of Glasgow. The definition of an adverse event 
is based upon the standardised definitions published by the Medicines and Healthcare products 
Regulatory Agency (MHRA): 
 
Adverse Event: any untoward medical occurrence in a subject to whom a medicinal product has 
been administered, including occurrences which are not necessarily caused by or related to that 
product 
 
Adverse Drug Reaction: any untoward and unintended response in a subject to an investigational 
medicinal product which is related to any dose administered to that subject 
 
Unexpected Adverse Reaction: an adverse reaction the nature and severity of which is not 
consistent with the information about the medicinal product in question set out: 
 
i. in the case of a product with a marketing authorisation, in the summary of product 
characteristics for that product 
ii. in the case of any other investigational medicinal product, in the investigator’s 
brochure relating to the trial in question 
 
Serious Adverse Event / Unexpected Serious Adverse Reaction: any adverse event, adverse 
reaction or unexpected adverse reaction, respectively, that: 
 
i. results in death 
ii. is life threatening 
iii. requires hospitilisation or prolongation of existing hospitalisation 
iv. results in persistent or significant disability or incapacity 
v. consists of a congenital anomaly or birth defect 
 
Important medical events that may not be immediately life-threatening or result in death or 
hospitalisation but may jeopardise the patient or may require intervention to prevent one of the 
other outcomes listed in the definition above are also considered to be serious 
 
At the time of writing the adverse event data were not available for analysis. In due course, the 
total frequency of adverse events occurring within each assessment group will be reported for the 
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duration of the assessment period. Adverse events will be categorized according to severity 
(based on the preceding definitions) and also nature. 
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2.7 Biomarker Analysis 
 
A nested biomarker study was conducted in parallel to the clinical study. All participants recruited 
to the clinical study donated additional blood samples at set time points throughout the follow-up 
period. The ultimate aim was that these samples would undergo analysis using a variety of 
different molecular platforms so that changes in biomarker signature could be compared to 
corresponding changes in clinical measures of disease activity and treatment response. This 
clinical data was already being collected as part of the clinical study. Any samples that were not 
immediately analysed were stored as a research tissue bank and made available for future 
exploratory analyses in relation to the research cohort. 
 
2.7.1 Principles of Biomarker Analysis 
 
Collection and Storage of Samples 
Table 9 summarises which additional blood samples were collected and their intended use: 
 
Draw 
Order 
Vacutainer Fraction Quantity Proposed 
Analysis 
1 SST - Serum Separation 
Tube  
Serum 1 Immunoassay 
2 EDTA  Plasma 
 
2 Proteomics 
3 Lithium Heparin 
 
Plasma 2 Immunoassay 
4 BD P100 
 
Plasma 1 Proteomics 
5 PAXgene RNA 
 
Whole blood 1 RNA 
6 PAXgene DNA 
 
Whole blood 1 DNA 
Table 9: Vacutainer set and draw order 
 
PAXgene RNA and DNA samples were stored in the original vacutainers whereas all other 
aliquots were stored in polypropylene tubes. All samples were labelled using each participant’s 
unique study identifier and a code relating to the sample type and sampling time point. Table 10 
summarises the sample labelling system for (T00X – α – β). 
 
T00X - α - β 
Patient’s unique study 
identifier 
Chronological 0-111 
Sample time point  Sample type  
A – baseline S – SST 
B – 3 months E – EDTA 
C – prior to etanercept L – Lithium Heparin 
D – 3 months of etanercept P – BD P100 
E – 6 months of etanercept RNA – PAXgene RNA 
F – 18 months (study 
completion) 
DNA – PAXgene DNA 
Table 10: Illustration of biomarker sample labelling system for sample (T00X – α – β) 
 
In order to reduce any errors that could have been introduced by variations in sampling handling 
procedures all initial handling and aliquoting was performed by Dr James Dale following a 
standardised procedure based on each vacutainer’s manufacturer’s instructions and the advice of 
laboratory colleagues based at the Translational Medicine Research Collaboration, Dundee. Even 
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though the eventual biomarker analysis did not happen in collaboration with TMRC their 
recommendations for sample handling were continued for the duration of the study. Table 11 
summarises the initial sample handling procedures and storage arrangements for the different 
sample types from the point of collection to first storage. The target was that all samples should 
be placed within the storage freezers within 4 hours of initial collection. Samples were initially 
stored together in the freezers of the Glasgow Biomedical Research Centre, University of 
Glasgow though the collection has recently been transferred to the freezers of NHSGGC 
Biorepository and catalogued using the Laboratory Information and Management System (LIMS). 
 
Labelling  
Code 
Vacutainer Number of 
Inversions 
Transfer 
Temperature 
Centrifugation 
(1100g – 12 
minutes) 
Aliquots Final 
Storage 
Temperature 
S SST  5 Ice Yes 3-4 x 
500µl 
Serum 
-80oC 
E EDTA  8-10 Ice Yes 5-7 x 
500µl 
Plasma 
-80oC 
Li Lithium 
Heparin 
 
8-10 Ice Yes 5-7 x 
500µl 
Plasma 
-80oC 
P BD P100 
 
8-10 Ice Yes 5-7 x 
500µl 
Plasma 
-80oC 
RNA PAXgene 
RNA 
 
8-10 Room  No 1 x 
2.5ml 
Whole 
blood 
-80oC 
DNA PAXgene 
DNA 
 
8-10 Room No 1 x 
8.5ml 
Whole 
blood 
-80oC 
Table 11: Initial blood sample handling procedures 
 
Sampling Time Points 
 
Figure 11 illustrates at which points during the follow-up period participants were asked to donate 
additional blood for biomarker analysis. All patients who completed the full follow-up period had 
donated sample sets at baseline, after 3 and then 18 months of participation. The small subset of 
patients who qualified for etanercept therapy were also asked to donate additional sample sets at 
the point they commenced etanercept, after 3 months of etanercept and after 6 months 
(completion of etanercept). 
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Sample collected on 
all etanercept 
subgroup only 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Illustration of relationship between sample set collection time points 
and changes in disease activity 
 
The longitudinal clinical outcome data collection and the various sampling time points were 
chosen to explore how dynamic changes in clinical disease activity were reflected by changes in 
corresponding biomarker expression profiles. These timings allowed the following relationships to 
be explored: 
 
1. Clinical disease activity measure at a single time point VS corresponding biomarker 
expression signature: to determine degree of correlation between clinical and biomarker 
measures of disease activity, and thereby to determine whether particular biomarkers 
might act as additional measures of global disease activity 
2. Presenting phenotypic profile VS baseline biomarker signatures: to determine whether 
specific phenotypic groupings (e.g. rheumatoid factor status, anti-CCP antibody status) 
were associated with specific patterns of biomarker expression 
3. Baseline biomarker expression signature VS longitudinal disease activity outcome data: 
to determine whether baseline biomarker signature associate with, and were therefore 
predictive of, specific patterns of either disease activity, treatment response (e.g 
persistently active or inadequate treatment responders) and/or adverse events 
4. Three month clinical disease activity measure VS three month biomarker expression 
profile. This is a strategically crucial point in a patient’s treatment course since it marks 
the first time that the response to initial DMARD monotherapy, and therefore the need to 
possibly escalate DMARD therapy, is considered. At this point biomarker signatures 
could theoretically serve several overlapping, prognostic purposes: 1. identification of 
those who will achieve and sustain a good response to DMARD monotherapy (e.g. good 
prognosis); 2. identification of those who exhibit active disease and exceed DMARD 
escalation thresholds; 3. differentiation between patients with different classifications of 
disease activity (particularly the separation of patients with true remission from those with 
subclinical synovitis in the absence of clinically evident synovitis) 
0 3 6 9 12 15 18 
Disease 
Activity 
Measure Etanercept 
Subgroup 
Data Collection Time Point (months) 
Bl
Δ 0 – 3  
months 
Sample collected on 
all patients 
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5. Change between two points of clinical disease activity measure VS corresponding 
change in biomarker expression signatures. In this way it might be possible to identify 
specific changes in biomarker signatures that are related to specific clinical responses 
following DMARD changes. Changes between baseline and 3 months represent 
response to initial DMARD monotherapy whereas changes between baseline and 18 
months represent overall response to intensive step-up therapy 
 
2.7.2 Transcriptomic Analysis 
 
Grateful Acknowledgement 
 
The preparation and processing of the PAXgene RNA samples detailed in the following sections 
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(technician) of the Institute of Cardiovascular and Medical Sciences and Mrs Lynn Crawford 
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The following description of sample handling, purification and analysis is based upon the 
standard techniques currently used by the Systems Biology Group of the Institute of 
Cardiovascular and Medical Sciences at the University of Glasgow. In turn, these procedures are 
largely based upon the recommendations of the manufacturers (Preanalytix, Qiagen Group, 
Becton, Dickinson and Company, Franklin Lakes, New Jersy, USA) of the PAXgene RNA 
collection and purification equipment. The PAXgene RNA system allows reliable storage and 
transportation of human whole blood and integrates with an efficient method of intracellular RNA 
purification. Each PAXgene RNA tube contains a proprietary mixture of RNA stabilization 
compounds that minimise RNA molecule degradation by RNases and ex vivo shifts in gene 
expression. For this research, all RNA purification steps were performed manually. The PAXgene 
RNA manufacturer’s literature suggests that, on average, this technique yields at least 3µg of 
RNA from 2.5ml of whole blood on at least 95% of all samples. The necessary materials and 
equipment for conducting the analysis are listed in Appendix F 
 
2.7.2.1 RNA Concentration and Purification 
 
1. Baseline and 3 month PAXgene RNA samples identified, removed from -80 degree freezer 
storage and brought slowly back to ambient temperature. PAXgene RNA tubes were kept 
at ambient temperature for at least 2 hours prior to processing 
2. Centrifugation of PAXgene RNA tube (10 minutes; 3000-5000g using swing-out rotor); 
Supernatant was decanted by pipette and nucleic acids contained within pellet were 
washed and re-suspended using 4ml RNase-free water 
3. Protein digestion was triggered by incubating the re-suspended pellet with 40µl proteinase 
K, 350µl re-suspension and 300µl binding buffers. Incubated at 55oC for 10 minutes 
4. Lysate was pipetted into PAXgene Shredder spin column and centrifuged for 3 minutes at 
maximum speed (up to 20,000g) to homogenise the cell lysate and remove residual cell 
debris. 
5. 350µl ethanol (96-100% purity) was mixed with the supernatant.  
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6. 700µl of mixture was pipetted into the PAXgene RNA spin column and centrifuged at 8000-
20,000g for 1 minute. RNA binds to the PAXgene silica membrane and contaminants were 
extracted by flow through 
7. Repeated washes with wash buffer to remove any remaining contaminants. Between the 
first and second wash steps any residual bound DNA was removed by treating the silica 
membrane with DNase incubation mixture (10µl DNase I added to 70µl DNA digestion 
buffer). During each washing step the PAXgene RNA spin column was centrifuged (1 
minute; 8000-20,000g) with 350-500µl wash buffer; contaminants were contained within the 
flow through liquid which was discarded 
8. RNA was collected through elution by placing 40µl of elution buffer directly onto the 
PAXgene RNA spin column and centrifuging for 1 minute at 8000-20,000g. Elution solution 
was incubated at 65oC for 5 minutes to denature RNA 
 
2.7.2.2 cDNA Hybridisation and RNA Amplification 
RNA purified from whole blood must be amplified, via a cDNA hybridisation step, to generate 
sufficient nucleic acid material to allow application to the microarray chip. An Illumina Beadchip 
microarray was used for this research; therefore, the standardised Illumina TotalPrep RNA 
Amplification procedure (316) was followed. The broad steps are: 
 
Reverse Transcription to Synthesise First Strand cDNA 
1. Nuclease-free water was added to 500 ng of total RNA to make a volume of 11µl 
2. RNA solution was mixed with 9µl of Reverse Transcription Master Mix. Solution was 
centrifuged briefly to collect reaction at the bottom of the tube.  
- Reverse Transcription Master Mix comprises: 1µl T7 Oligo(dT) Primer, 2µl 10X First 
Strand Buffer, 4µl dNTP Mix, 1µl RNase Inhibitor, 1µl ArrayScript 
3. Solution was incubated at 42oC for 2 hours in a thermal cycler and then briefly centrifuged 
 
Synthesis of Double-Stranded DNA from Single-Stranded cDNA by DNA polymerase 
4. 80µl of Second Strand Master Mix was added to RNA / Reverse Transcription Master Mix 
solution and mixed thoroughly 
- Second Strand Master Mix comprises: 63µl Nuclease-free Water, 10µl 10X Second 
Strand Buffer, 4µl dNTP Mix, 2µl DNA Polymerase, 1µ RNase Hl 
5. Solution was incubated at 16oC for 2 hours in a thermal cycler.  
 
Purification of cDNA 
6. 250µl of cDNA Binding Buffer was added to each double-stranded DNA sample and mixed 
thoroughly. Mixture was briefly centrifuged (10,000g) to collect reaction at the bottom of the 
tube 
7. Double-stranded DNA mixture was pipetted onto the centre of the cDNA Filter Cartridge 
which was then centrifuged for 1 minute at 10,000g until the mixture has passed through 
the filter. All flow-through was discarded 
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8. 500 µl of wash buffer was added to cDNA Filter Cartridge and the mixture was centrifuged 
again at 10,000g for 1 minute until all the wash buffer had passed through the filter. All 
flow-through was discarded 
9. 20 µl of preheated (50-55oC) Nuclease-free water was applied to the centre of the cDNA 
Filter Cartridge.  
10. The cartridge was allowed to stand, at room temperature, for 2 minutes and was then 
centrifuged at 10,000g for 1 minute until all the Nuclease-free water had passed through 
the filter. The double-stranded DNA was present in the eluate (approximately 17.5µl) 
 
In Vitro Synthesis of cRNA from cDNA Templates 
11. 7.5 µl of IVT Master Mix was added to each double-stranded DNA sample, mixed and then 
incubated in a thermal cycler at 37 oC for 4-14 hours 
- IVT Master Mix comprises: 2.5 µl T7 10X reaction buffer, 2.5µl T7 enzyme mix, 2.5µl 
Biotin-NTP mix 
12. 75µl of Nuclease-free water was added to the cRNA mixture to halt the reaction. The total 
volume was 100µl 
 
Purification of cRNA 
13. 350µl of cRNA Binding Buffer and 250µl of ACS reagent grade 100% ethanol was added to 
each RNA sample 
14. cRNA – ethanol mixture was pipetted onto the centre of the cRNA Filter Cartridge which 
was centrifuged for 1 minute at 10,000g until all the mixture had passed through the filter. 
All the flow-through liquid was discarded 
15. 650µl wash buffer was applied to each cRNA Filter Cartridge, centrifuged for 1 minute at 
10,000g until all the wash buffer had passed through the filter. All the flow-through liquid 
was discarded 
16. 200µl of preheated (50-55oC) Nuclease-free water was added to the cRNA solution and the 
whole mixture was incubated at 55oC for 10 minutes 
17. The cRNA-water solution and cRNA Filter Cartridge were centrifuged at 10,000g for 1.5 
minutes until all the water had passed through the filter. The cRNA had eluted into the 
Nuclease free water 
 
Quality Control Analysis of cRNA  
RNA quantity was measured using Nanodrop 1000 spectrophotometry which determined that the 
mean concentration of cRNA synthesised per sample was 357.8ng/ul (SD ±100.6). Each sample 
was measured in either duplicate or triplicate (depending on the level of agreement between the 
first two samples) and then averaged prior to dilution to 45.45ng/µl.  
 
RNA quality was measured by passing all samples through an Agilent Technologies Bioanalyser. 
All samples achieved an RNA Integrity Number (RIN) of 6 or greater (range 6-9.5). Indeed, only 1 
sample returned a RIN value less than the accepted threshold of seven and 6 samples returned 
RIN values between 7.0 and 7.5. Hence, due to this extremely small number, and that there was 
only one opportunity to extract RNA, all samples were allowed to continue in the study 
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2.7.2.3 Illumina Beadchip Microarray Analysis 
Purified cRNA was hybridised onto commercially available Illumina HumanHT-12v4.0 Beadchip 
microarray chips (Illumina Inc, San Diego, California, USA). Each microarray chip allows 
simultaneous analysis of 12 separate samples. Broadly, each microarray well comprises 
microscopic polystyrene beads with each bead being associated with a specific genetic probe. 
Approximately, 25,400 genes are distributed over 47,321 probe positions, providing whole 
genome coverage. When purified cRNA is exposed to the microarray chip surface, individual 
cRNA fragments bind covalently to the complementary bead-bound genetic probe. Fluorescently 
labelled target probes are then added to determine the relative strength and frequency of binding 
between probe and cRNA fragment. The strength of the fluorescent signal emanating from each 
probe is dictated by the number of cRNA fragments binding to the probe and thus is proportional 
to the quantity of RNA present within the sample under examination. 
 
Standardised sample handling and processing procedures were followed throughout. Individual 
samples were allocated to specific chips and wells using the following blocking hierarchy: 
randomisation group – sex – anti-CCP status – RhF status – smoking status – baseline xray 
erosions – 3 month DAS28 – 12 month DAS28 – first DMARD. This blocking technique attempted 
to minimise any additional variations in the observed expression profile by ensuring that other 
common demographic and disease-related factors that could also feasibly influence expression 
profile were evenly distributed throughout the microarray chips. All microarray chips were 
analysed using a Beadarray reader  
 
Hybridisation of RNA 
18. cRNA samples were heated to 65oC for 5 minutes, pulse centrifuged (250g) and allowed to 
cool to room temperature. Hybridisation buffer and humidity control buffers were heated to 
58oC for 10 minutes and then also allowed to cool to room temperature. Beadchip 
microarrays were allowed to equilibrate with room temperature 
19. 750ng of cRNA was pipetted into each hybridisation tube. 5µl RNase-free water was 
pipetted into cRNA sample tube with 10µl of hybridisation control buffer 
20. The hybridisation chambers were assembled by fitting the Beadchip hybridisation chamber, 
chamber gasket and chamber insert together. 200µl of humidity control buffer was pipetted 
into each of the hybridisation chambers 
21. Each Beadchip microarray was fitted into its hybridisation chamber insert. 15µl of cRNA 
sample was pipetted onto the centre of each inlet port to ensure that all sections of the 
stripe were covered 
22. Sample laden Beadchip microarrays were loaded into each hybridisation chamber which 
was then sealed and incubated at 58oC for at least 14 hours (i.e overnight) 
 
Washing of Beadchip Micorarrays 
23. Hybridisation chambers were removed from the incubator and individual Beadchip 
micorarrays were submerged face-up in a beaker containing 3ml E1BC buffer diluted with 
1L RNase-free water. The Beadchip microarray’s coverseal was removed whilst still 
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submerged in the E1BC buffer solution and Beadchip microarrays were transferred to a 
staining dish containing 250ml of Wash E1BC solution 
24. High temperature wash: Beadchip microarrays were incubated with High-Temperature 
Wash Buffer in a Hybex waterbath for 10 minutes 
25. First room temperature wash: using a slide rack handle, Beadchip microarrays were 
plunged in-and-out of a staining dish containing 250ml Wash E1BC solution 10 times. The 
staining dish and Beadchip microarray were then shaken at a medium-low setting on an 
orbital shaker for 5 minutes 
26. Ethanol wash: Beadchip microarray was plunged in-and-out of a staining dish containing 
250ml 100% ethanol 10 times. The staining dish and Beadchip microarray were then 
shaken at medium-low setting on an orbital shaker for 10 minutes 
27. Second room temperature wash: using a slide rack handle, Beadchip microarrays were 
plunged in-an-out of a staining dish containing 250ml Wash E1BC solution 10 times. The 
staining dish and Beadchip microarray were then shaken at a medium-low setting on an 
orbital shaker for 2 minutes 
28. Block: a Beadchip wash tray was placed on a rocker mixer and filled with 4ml Block E1 
buffer. Beadchip microarrays were transferred into individual wash trays, coated with Block 
E1 buffer and rocked at medium speed for 10 minutes 
 
Detection of Signal 
29. 2ml of Block E1 buffer was mixed with 1:1,000 dilution of Cy3-Streptavidin and added to a 
Beadchip wash tray. The Beadchip was placed in the wash tray, covered and placed on a 
rocker-mixer, at medium setting, for 10 minutes 
30. Third room temperature wash: using a slide rack handle, Beadchip microarrays were 
plunged in-an-out of a staining dish containing 250ml Wash E1BC solution 5 times. The 
staining dish and Beadchip microarray were then shaken at a medium-low setting on an 
orbital shaker for 5 minutes 
31. After washing, racks of Beadchips were dried by immediately centrifuging them at 1400 
rpm at room temperature for 4 minutes 
32. BeadArray Reader Assessment: Beadchips were placed into the BeadArray Reader tray, 
registered using each Beadchip’s unique barcode. Eight Beadchip’s were imaged during 
each run of the BeadArray Reader. Beadchips were scanned using the BeadArray 
Reader’s standard scanning protocol. During each run a lazer is shone across the 
Beadchips to excite the fluor of the hybridized single-stranded product attached to each 
bead. Light emissions from each fluor are recorded as high-resolution images which 
correspond to individual Beadchip sections 
 
2.7.2.4 Data Processing and Analysis 
 
Grateful Acknowledgement 
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All data handling and comparisons were conducted using R (www.r-project.org) a freely available, 
text based statistical analysis and computation environment. Certain steps within the analysis 
pipeline are performed using additional, open-source R add-on packages 
 
Pre-comparison Data Handling 
1. Quantile Normalisation: In order to fulfil the accepted presumption that most genes are 
neutrally expressed, with approximately similar distributions, and to eliminate systematic 
(i.e non biological and artefactual) variability, the raw BeadArray data underwent quantile 
normalisation using beadarray, a R add-on package (www.bioconductor.org/package/2.11/ 
bioc/html/beadarray) designed for the pre-processing and analysis of Illumina BeadArray 
raw data  
 
2. ComBat Transformation: Principle component analyses demonstrated that the raw Illumina 
BeadArray data clustered into two distinct groups that related to the microarray chip batch. 
In order to minimise the potential influence of this evident batch effect on the variability of 
the observed results the data underwent ComBat transformation using the Surrogate 
Variable Analysis (sva) R add-on package (317). This method of reducing batch effect by 
using surrogate variables has been shown to reduce error rates and improve reproducibility 
in differential expression analysis experiments  
 
3. Differential Gene Expression Analysis: Each of the following between group comparisons 
were conducted using the R add-on package Limma (Linear Models for Microarray Data – 
www.bioconductor.org/packages/2.12/bioc/html/limma) (318). Limma provides a suite of 
functions that are widely used to interrogate microarray data and assess differential gene 
expression between pre-determined groups. Its analysis methods are based along 
empirical Bayesian principles and correct for wide ranges in gene expression variability, 
even after normalisation steps have been performed. This approach limits the chance of 
generating false positive findings through multiple testing methods 
 
Identifying Differences of Gene Expression Between Different Phenotypic Groups 
Simply assuming that all instances of statistically significant differences in expression levels (i.e. 
the fold change) of particular genes are disease related may exclude biologically important genes 
and doesn’t allow for artefactual outliers. Also, given the large number of genes on each 
microarray natural variability will make it likely that some genes will by chance exhibit statistically 
significant differences of expression between the comparator groups. Thus, between group 
comparisons performed by Limma consider both fold change and variability to generate a p value 
which estimates how likely the results could have occurred by chance alone. Further, calculating 
the false discovery rate corrects the p value in proportion to the number of multiple tests 
performed and thus limits the likelihood of identifying false positives (319). For this analysis, the 
adjusted p value significance threshold for each comparison was determined on an individual by-
comparison basis. The target threshold was an adjusted p value less than 0.05; however, this 
was adjusted upwards for some comparisons depending upon their initial findings 
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2.7.2.5 Groupings for Comparison 
Multiple data and blood sample collection time points, the continuous nature of the DAS28 score - 
and the variety of different thresholds and formulae that can be used to interpret static and 
dynamic changes in the DAS28 value – could feasibly allow many different types of comparisons 
between the mRNA expression profile data and the available clinical outcomes. However, it is 
likely that a number of these comparisons would be either clinically irrelevant or pathogenetically 
tenuous. In order that the findings remain clinically relevant, expression profiles were subdivided 
into comparison groups that referred to commonly encountered phenotypes and clinical scenarios 
(i.e supervised grouping). For each comparison, participants were segregated into different 
groups using the demographic and/or clinical outcome data that was collected as part of their 
participation in the main clinical trial. Differences between each group’s pooled gene expression 
profiles were then examined using the Limma package. When participants were segregated into 
two groups, direct comparisons of mRNA expression profiles were performed. Static comparisons 
between corresponding mRNA expression profiles and phenotypic groupings were used to 
determine whether clinically recognisable, phenotypic groupings were related to differences in 
gene expression. Dynamic comparisons that correlated gene expression profiles to a subsequent 
predefined clinical state (or change in state) were used to determine whether specific gene 
expression profile patterns might discriminate between – and therefore be predictive of – future 
clinical state or treatment response.  
 
The DAS28 forms a continuous, numerical measure of disease activity. Whilst, there are 
established thresholds that differentiate between disease activity states, the threshold values do 
not relate to specific pathogenetic subsets of RA. Further, it is unlikely that there will be significant 
differences in gene expression evident in the profiles of phenotypically similar patients who fall 
either side of a DAS28 threshold. Therefore, comparator groups were created that exhibited large 
phenotypic differences since it was presumed that large phenotypic differences would most be 
most likely to be associated with evident differences in gene expression. In most cases, this 
method lead to comparator groups comprising the upper and lower quartiles of DAS28 (or its 
interpolations) at a particular time point. Prior to conducting gene expression analyses, the 
degree of difference in the phenotypic descriptor of each group (e.g median DAS28) was 
compared using non-parametric methods.  
 
The following phenotypic grouping structures, and PAXgene RNA sampling time point 
comparator, were used to segregate mRNA expression profile data into distinct groups for 
comparison: 
 
Baseline phenotypic groupings: groups defined using baseline demographic and RA-related 
phenotypic data. Baseline gene expression profiles served as the comparator set. 
 
• Sex    1. Female 
2. Male 
 
• Smoking status   1. Current smoker 
2. Former smoker 
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3. Never smoked 
 
• Rheumatoid factor status  1. Rheumatoid factor positive (titre >10iu/l) 
2. Rheumatoid factor negative (titre ≤10iu/l) 
 
• Anti-CCP Antibody status  1. Anti-CCP antibody positive (titre >10iu/l) 
2. Anti-CCP antibody negative (titre ≤10iu/l) 
 
• Baseline plain X-ray status 1. Erosive baseline x-rays 
2. Non-erosive baseline x-rays 
 
Disease activity at a single time point: defined using existing DAS28 based definitions of disease 
activity. For each time point the corresponding gene expression profiles were used as the 
comparator set 
 
• Baseline disease activity – quartiles based 1. Highest baseline DAS28 quartile 
2. Lowest baseline DAS28 quartile 
(2nd and 3rd quartiles are excluded) 
 
• 3 month disease activity – quartile s based  1. Highest baseline DAS28 quartile 
2. Lowest baseline DAS28 quartile 
(2nd and 3rd quartiles are excluded) 
 
• 3 month disease activity – threshold based 1. High - DAS28 ≥ 5.1 
2. Moderate – 3.2≤DAS28<5.1 
3. Low – 2.6≤DAS28<3.2 
4. Remission – DAS28<2.6 
 
• 3 month DAS28 < 3.2    1. 3 month DAS28 < 3.2 
(Strategic threshold for DMARD escalation) 2. 3 month DAS28 ≥	 3.2 
 
 
Change in disease activity over time: defined using existing definitions of treatment response 
based upon the change in DAS28 between two time points. Both dynamic and predictive 
analyses were conducted and the gene expression profile comparator will be listed with the 
description of each comparison 
 
Dynamic comparisons compare change in disease activity measure to corresponding change in 
gene expression profile 
 
• Measured change in expression profile vs  1. Lowest quartile change DAS28 
observed change in DAS28 – change in both 0-3 months 
variables between baseline and 3 months 2. Highest quartile change DAS28 0-3 
months 
(2nd and 3rd quartiles are excluded) 
 
Predictive comparisons determine whether gene expression profiles at a single time point 
associate with particular patterns of subsequent clinical response 
 
• Baseline profile vs 3 month DAS28  1. 3 month DAS28 < 3.2 
(profile as predictor of need for DMARD  2. 3 month DAS28 ≥	 3.2 
 escalation after 3 months monotherapy) 
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• Baseline profile vs mean DAS28 0-18 months 1. Lowest quartile mean DAS28 
(profile as predictor of disease course and over 2. Highest quartile mean DAS28 
all treatment response) 
 
Overall treatment response: the grouping definitions that underpin the analyses described in the 
preceding sections are based upon phenotypic variables from single time point and should lead to 
all participants being classified into one or other of the comparator groups. However, an individual 
patient’s treatment response or disease character may not be evident from either a single, static 
measure of disease activity nor a measure of change between two relatively closely associated 
time points. In many cases, the character of a patient’s RA will not become apparent until several 
months of therapy have elapsed by which time either the therapeutic window of opportunity may 
have passed and/or irreversible joint damage may have already occurred. It is presumed those 
patients who respond well to relatively light DMARD therapy may exhibit gene expression profiles 
that distinguish them from poorer prognosis patients who continue to display persistently active 
disease. Thus, the longitudinal clinical outcome data between baseline and 18 months will be 
used to categorise patients into groups based upon their overall treatment response. Those with 
extremes of response (e.g persistently active and persistent remission) will be compared to 
determine if there are any preceding differences in baseline gene expression profiles. The 
following grouping definitions will be used and all comparisons will be between the associated 
baseline mRNA expression profiles: 
 
• Mean DAS28 0-18 months – quartiles based 1. Worst treatment response 
   Upper quartile mean DAS28 0-18  
        2. Best treatment response 
        Lower quartile mean DAS28 0-18  
 
• Mean DAS28 0-18 months – criteria based 1. Persistently active RA 
(thresholds are arbitrary)    Mean DAS28 0-18 months > 4.2 
       2. Persistent low disease activity 
       Mean DAS28 0-18 months < 3.2 
 
As previously described (Section 1.4.1), imaging studies consistently suggest that DAS28 
remission (e.g. DAS28 < 2.6) don’t necessarily equate with total absence of inflammatory disease 
activity. Rather, the level of active synovitis has simply fallen below a threshold that is no longer 
clinically detectable. This understanding that current remission definitions don’t necessarily 
represent inactive disease has lead to the development of much stricter (Boolean) remission 
criteria which require the virtual absence of all clinical measures of RA disease activity (e.g tender 
joint count ≤ 1, swollen joint count ≤ 1, CRP ≤ 10mg/l and patient global 10 cm VAS ≤ 1) (186). 
Interestingly, and somewhat counter-intuitively, patients can return DAS28 scores upto 2.8 and 
yet still fulfil the Boolean definition of remission. Whether fulfilment of the Boolean remission 
criteria equates to total absence of inflammatory disease activity remains to be proven by further 
imaging studies; however it is still likely to be a truer approximation, given that patients can return 
DAS28 < 2.6 whilst still displaying 3-4 clinically swollen joints and/or a moderately elevated 
ESR/CRP.  In reality, increasingly stricter definitions of remission may represent further steps 
along a continuum from clinically detectable active RA, to subclinical RA that can be 
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demonstrated by MSUS to absence of both clinical and imaging evidence of active synovitis. It is 
possible that the proposed Boolean definition of remission may still not be either sensitive nor 
specific enough to truly identify all patients with inactive RA and may yet overlap somewhat with 
existing definitions of remission. However, since it is the tightest clinical definition of RA remission 
currently available, it is the most efficient means of identifying those patients at the very lowest 
end of the disease activity continuum. Hence, it will be used as an alternative phenotypic 
definition in the following analyses to be conducted using the 3 month expression profile datasets: 
 
• Differences between definitions  1. 3 month DAS28 < 2.6 but NOT Boolean  
of remission    remission 
      2. Boolean remission at 3 months 
 
• Extremes of disease activity at 3 months 1. 3 month DAS28 > 4.6 and 2 or more swollen 
joints 
2. Boolean remission at 3 months 
 
     
  
  151 
Grouping  
Variable 
mRNA Expression 
Profile  
Timepoint 
 
Groups 
Baseline Phenotypic Groupings 
 
 
Sex 
 
 
Baseline 
 
 
1. Male 
2. Female 
 
 
Smoking Status 
 
 
Baseline 
 
1. Current smoker 
2. Ex-smoker 
3. Never smoked 
 
 
Rheumatoid Factor 
Status 
 
 
Baseline 
 
1. RhF positive (titre >10iu/l) 
2. RhF negative (titre ≤10iu/l) 
 
CCP Antibody Status 
 
 
Baseline 
 
1. aCCP positive (titre >10iu/l) 
2. aCCP negative (titre ≤10iu/l) 
 
 
Baseline Erosions 
 
Baseline 
 
1. Erosions baseline x-rays 
2. Non-erosive baseline x-rays 
 
Clinical Disease Activity – Single Time Point 
 
 
Baseline Disease 
Activity - quartiles 
 
 
Baseline 
 
1. Lowest quartile baseline DAS28 
2. Highest quartile baseline DAS28  
(Middle 2nd and 3rd quartiles excluded) 
 
 
3 month Disease 
Activity - quartiles 
 
 
3 months 
 
1. Lowest quartile 3 month DAS28  
2. Highest quartile 3 month DAS28 
(Middle 2nd and 3rd quartiles excluded) 
 
 
3 month DAS28 
Disease Activity - 
thresholds 
 
 
3 months 
 
1. High - DAS28 ≥ 5.1 
2. Moderate – 3.2≤DAS28<5.1 
3. Low – 2.6≤DAS28<3.2 
4. Remission – DAS28<2.6 
 
 
3 month DAS28 < 3.2 
 
 
3 months 
 
1. 3 month DAS28 < 3.2 
2. 3 month DAS28 ≥ 3.2 
 
Table 12: Summary of phenotypic grouping structures and corresponding mRNA expression 
profile sampling time points 
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Grouping  
Variable 
mRNA Expression 
Profile 
Timepoint 
 
Groups 
Change in Clinical Disease Activity  
 
 
Change DAS28 0-3 
months 
 
 
Δ Expression profile 
0-3 months 
 
1. Lowest quartile change DAS28 0-3 months 
2. Highest quartile change DAS28 0-3 
months 
(2nd and 3rd quartiles are excluded) 
 
Predictive properties of Baseline Expression Profile 
 
 
DMARD escalation at 3 
months 
 
Baseline 
 
1. 3 month DAS28 < 3.2 
2. 3 month DAS28 ≥ 3.2 
 
 
Overall treatment 
response 
Mean DAS28 0-18 
months - quartiles 
 
 
Baseline 
 
1. Lowest quartile mean DAS28 0-18 
months 
2. Highest quartile mean DAS28 0-18 
months 
 
Overall treatment 
response 
Mean DAS28 0-18 
months – criteria 
 
 
Baseline 
 
1. Persistently active – mean DAS28 > 4.2 
2. Persistent low disease activity – mean 
DAS28 < 3.2 
3. Persistent clinical remission – DAS28 < 
2.6 on at least 6 occasions and meand 
DAS28 < 4.2 
 
Comparisons Using Boolean Definition of Clinical Remission 
 
 
Alternative definitions of 
clinical remission 
 
 
3 months 
 
1. 3 month DAS28 < 2.6 but NOT Boolean 
remission 
2. Boolean remission at 3 months 
 
 
Extremes of disease 
activity 
 
 
3 months 
 
1. 3 months DAS28 > 4.6 and 2 or more 
swollen joints 
2. Boolean remission at 3 months 
 
Table 12: Summary of phenotypic grouping structures and corresponding mRNA expression 
profile sampling time points 
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3. Practical Considerations, 
Unexpected Developments and 
Research Design Amendments   
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The methods proposed in preceding sections 2.1 to 2.7 describe the ideal means of addressing 
the clinical and transcriptomic research hypotheses. However, due to a number of unexpected 
logistical challenges it has not been possible to complete the full outcomes analysis and it will not 
be possible to present the complete results set. Rather, the results chapters of this thesis will 
describe as much of the analyses of the clinical, ultrasonographic and transcriptomic datasets as 
it was possible to present at this time. The contents of these analyses will be described in more 
detail at the start of each of the relevant chapters and the following sections will describe the 
sequences of events that led to this change in analysis plan 
 
3.1 Dates 
The clinical and transcriptomic research projects described within this submission were first 
proposed in 2008 and the first protocol outline was completed in September 2008. However, by 
the time that the appropriate funding and approvals had been confirmed and the necessary 
logistical arrangements had been made (see below), it was not possible to recruit the first 
participant until September 2009. The final, 111th, participant was recruited in November 2011; 
therefore, the participant follow-up period ran until May 2013.  
 
As the Chief Investigator, Dr Dale was the sole clinician responsible for the on-going clinical care 
of all the participating patients. In order to have sufficient time to screen, recruit and review all of 
the research participants, Dr Dale needed to 1. apply for Out-of-Programme Time for Research 
from NHS Education Scotland and the Joint Royal Colleges Post-Graduate Training Board’s 
Rheumatology Speciality Advisory Committee and 2. secure fellowship funding for the duration of 
this time. Dr Dale was awarded a 3 year Chief Scientist’s Office Clinical Academic Fellowship in 
September 2008 and took up this post (held at the University of Glasgow) on 1st April 2009 (the 
latest possible date). However, since recruitment couldn’t commence until September 2009, and 
didn’t complete until November 2011, the complete follow-up of all the study participants fell 
outwith the research time offered by the fellowship. Dr Dale completed the fellowship in April 
2012, and returned to full clinical training, initially as an NHS-funded Specialist Registrar and then 
as a University of Glasgow funded Clinical Lecturer (post commenced June 2012). Thus, from 
April 2012 until the completion of the follow-up period, Dr Dale will have been continuing to review 
research participants, conduct analyses and draft this submission whilst also working in a full time 
clinical training post.  
 
Unexpected delays in recruitment and the conduct of the transcriptomic analysis have also 
impacted upon the submission of this thesis. The original intention was that this thesis would 
detail the full sets of results relating to both the clinical and transcriptomic analyses. However, it 
became apparent that the follow-up period would extend beyond the submission deadline for the 
thesis and it did not appear possible to present the complete results set. Therefore, the interim 
analyses described in Chapter 7 were conducted. Furthermore, considerable delays were 
encountered finalising the specific arrangements for the transcriptomic analysis (described in 
section 3.8.2 below). The relevant samples did not undergo laboratory processing until June 2012 
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and the subsequent quality control and clinical-correlation analyses were conducted between July 
2012 and December 2012. 
 
3.2 Research Funding 
Research funding was provided from a variety of different sources: 
 
• Chief Scientist’s Office Clinical Academic Fellowship (ref CAF / 08 / 03): total value 
£174,422. Awarded to Dr Dale to cover all salary, superannuation, degree registration, 
clinical trial regulation, training and some consumable costs incurred over the duration of 
Dr Dale’s Out of Programme Time for Research 
 
• Investigator Initiated Research Project Grant: awarded by Wyeth Pharmaceuticals to Drs 
Dale and Porter and Professor McInnes. Total value £197,200; to cover all additional NHS 
costs incurred through the conduct of this research; including, funding of research nurse’s 
salary for the duration of the study, the use of NHS MRI and plain x-ray facilities and the 
use of NHS clinical spaces. Furthermore, Wyeth Pharmaceuticals undertook to provide a 6 
month supply of etanercept to all study participants who qualified for biologic therapy as 
part of the treatment protocol  
 
• Investigator Initiated Research Project Grant: awarded by Pfizer UK to Drs Dale and Porter 
and Professor Mcinnes. Total value £75,000; to cover the costs incurred by the proposed 
biomarker / transcriptomic analysis 
 
3.3 NHS Research Ethics and Management 
Approvals 
This study was conducted with the full approval of the West of Scotland Research Ethics Service 
and NHSGGC Research and Development department. However, whilst the applications for 
these approvals were commenced well before Dr Dale took up his research fellowship, delays in 
the granting of the final approvals led to significant delays in the commencement of recruitment 
 
West of Scotland Research Ethics Committee Approval (Ref: 09 / S0709 / 38): The initial 
research ethics application was submitted on 1st April 2009 and an initial favourable opinion was 
granted on 16th June 2009. However, this opinion was based upon a randomisation process that 
minimised using anti-CCP antibody status as a discriminating variable. The research investigators 
were then informed that, due to funding issues, NHSGGC Immunology Laboratory were unable to 
guarantee that the anti-CCP assay would be available for the duration of the recruitment period. 
Thus, in order to avoid future randomisation irregularities it was decided that randomisation 
should be minimised based upon each participant’s RhF status instead, since this test had been 
routinely available for many years. Whilst, switching to using RhF status to inform the 
minimisation process would have no impact upon what treatments a participant would receive 
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during the research it could lead to being allocated to a different assessment group and thereby, 
indirectly, a different treatment path. Hence, since this relatively minor change could potentially 
influence a patient’s randomisation allocation the research ethics committee requested that a 
substantial amendment be submitted. A second favourable opinion was granted on 4th September 
2009. 
 
Following the initial favourable opinion, two additional substantial amendments to the original 
research protocols were submitted. The first (submitted January 2011) proposed bringing clinical 
and radiological outcome data collection in line with the newly formed Scottish Early Rheumatoid 
Arthritis Inception Cohort (see section 3.7 below) and that all tissue samples donated for research 
be stored within its tissue bank. The second (submitted August 2012) proposed that two 500µl of 
serum from each patient, at each sampling time point, be sent to Crescendo Biosciences (San 
Franscisco, USA) to determine the degree of agreement between MSUS and a novel cytokine 
profile (Multibiomarker Based Disease Activity Test - MBDA) assessment of global disease 
activity.  
 
NHSGGC Research and Development Approval (Ref: GN09RH196): The application for 
NHSGGC R+D approval was first submitted on 1st April 2009. The financial funding provided by 
Pfizer UK and the Chief Scientist’s Office was paid directly to the University of Glasgow. 
However, since the participants for the research were identified and reviewed in NHSGGC out-
patient clinics and day wards the NHSGGC R+D Office acted as the main research sponsor. 
Thus a three-way agreement was negotiated between NHSGGC R+D Office and the legal 
departments of the University of Glasgow and Pfizer UK. A separate Letter of Understanding was 
agreed between the NHSGGC R+D Office and the University of Glasgow that allowed the 
NHSGGC R+D Office to act as the main research sponsor whilst the University of Glasgow 
Finance Office administered the financial accounts (including payment to NHSGGC for the use of 
its facilities). The series of negotiations that were required to finalise the funding contracts created 
a significant temporal obstacle that prevented the commencement of participant screening and 
recruitment. Furthermore, Dr Dale and the research supervisors could not participate directly in 
these discussions. Final NHSGGC R+D approval was eventually granted on 8th September 2009  
 
3.4 Participant Screening, Consent and Recruitment 
Rates 
In order to fully address the proposed hypotheses Dr Dale was required to identify an appropriate 
cohort of research participants who were willing to participate for the duration of the follow-up 
period. Potential participants could not be approached, nor consented, until they had undergone a 
screening review which confirmed their diagnosis and ensured that they fulfilled all of the 
inclusion / exclusion criteria. The sample size calculation (section 2.2.4) suggested that 110 
participants were required to provide sufficient statistical power to address the clinical research 
hypothesis. It was presumed that approximately 30 percent of patients who met the inclusion / 
exclusion criteria would prefer not to participate in clinical research and therefore at least 143 
patients with early RA would need to be ‘screened’. Furthermore, it was imperative to identify 
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potential participants at the earliest possible time after symptom onset to 1. reduce the risk of 
their first DMARD being commenced outwith the ‘window of therapeutic opportunity’ and 2. 
ensure that as few participants as possible were recruited after the commencement of first 
DMARD. To maximise recruitment rates, Dr Dale relied on local colleagues kindly agreeing to 
refer any potential participants who attended their usual new patient and early arthritis clinics. 
Over the duration of the screening and recruitment period a number of different tactics were 
employed to try and identify the research cohort as quickly as possible: 
 
Review of new rheumatology clinic referrals: All likely new patient referrals to either Gartnavel 
General Hospital or Stobhill Hospital where the diagnosis of RA was either expressly mentioned, 
or seemed likely from the provided clinical details, were seen urgently (usually within 2 weeks of 
referral) by Dr Dale during weekly research clinics at each site or on the rheumatology day-unit at 
a time convenient to the patient. Patients who fulfilled inclusion / exclusion criteria were offered 
participation in the research projects; whereas, patients who did not fulfil the inclusion / exclusion 
criteria were commenced on initial treatment and appropriate local follow-up was arranged 
 
Referrals from local NHSGGC rheumatologists: Initially, patients with new diagnoses of early RA, 
who had attended rheumatology new patient clinics at any of the participating hospitals, were 
referred to Dr Dale for research screening. Those who met inclusion / exclusion criteria continued 
to attend the research clinics and on-going follow-up at the local early arthritis clinic was arranged 
for those who declined. Later, as a means of enhancing recruitment rates, Dr Dale also accepted 
referrals of potential participants from other local rheumatology services if the patient was willing 
for their on-going care to be transferred to the closest participating hospital site. In this way, a 
further 18 research participants were identified from the Victoria Infirmary (5), Inverclyde Royal 
Hospital (1), Royal Alexandria Hospital (1) and the Private sector (11). 
 
Attendance at existing NHSGGC early arthritis clinics: Shortly after commencing recruitment it 
became apparent that not all patients with new diagnoses of early RA were being referred for 
screening. Therefore, for a 12 month period, Dr Dale attended the weekly early arthritis clinics at 
Gartnavel and Glasgow Royal Infirmary as a way of: 1. identifying any patients who might not 
have been referred previously, 2. assisting local rheumatology colleagues by making the referral 
pathway as straight forward as possible and 3. raising awareness of the research’s aims and 
inclusion / exclusion criteria 
 
Recruitment Posters: A4 posters describing the research’s aims, inclusion / exclusion criteria and 
referral pathways were posted in every clinic room, waiting area and day unit space at each of the 
participating hospitals 
 
Email Correspondence: In order to maintain awareness of the research’s aims, inclusion / 
exclusion criteria and the referral pathways, Dr Dale sent a monthly email reminder to all 
rheumatology consultants and specialist trainees working in participating and collaborating 
hospital sites. 
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The recruitment period was longer than originally anticipated. The first research participant was 
consented in September 2009 and the final, 111th participant was consented in November 2011. 
Previous, locally administered, studies of early RA, with similar follow-up periods, have recruited 
similarly sized populations over a similar 3 year period. However, these studies did not face the 
initial delays in granting of both NHS REC and NHSGGC R+D approvals. Furthermore, the 
inclusion criteria for these studies allowed patients with symptom durations up to 2 or 5 years to 
be recruited; whereas, this research limited symptom duration to 1 year thereby excluding a 
number of patients who might otherwise have helped meet the recruitment target at an earlier 
point.  
 
3.5 Musculoskeletal Ultrasound Training 
Whilst having to wait for final NHS REC and NHSGGC R+D approval did delay the 
commencement of recruitment it did allow Dr Dale several months to continue practicing and 
refining the limited MSUS joint set examination which forms the back bone of global disease 
activity assessment in the MSUS assessment group. Dr Dale received training in MSUS from 
several different sources: 
 
1. 2008 British Society of Rheumatology Basic Musculoskeletal Ultrasound Training Course. 
A three day introductory course delivered by a faculty of British expert rheumatology 
sonographers 
 
2. Glasgow Royal Infirmary Rheumatology Department Musculoskeletal Ultrasound Clinic. 
Weekly attendance for approximately 9 months for training and supervision on unselected 
rheumatology out-patients. Provided by Dr Anna Ciechomska, Associate Specialist in 
Rheumatology, and Dr Debbie Turner, Specialist Podiatrist 
 
3. 2011 Scottish Rheumatology Ultrasound Group Musculoskeletal Ultrasound Training and 
Teach the Teachers Course. A three day training course where a faculty of invited, 
international experts in MSUS delivered training and advice specifically targeted to the 
needs of the attendees. Part of this course included theoretical and practical synovitis 
grading exercises which Dr Dale co-organised 
 
4. Unsupervised Practice. Over an approximately 12 month period Dr Dale maximised his 
opportunities to practice and refine the limited MSUS joint set examination by attending the 
weekly early arthritis clinics at Gartnavel General Hospital, Glasgow Royal Infirmary and 
Stobhill Hospital as a supernumerary clinician. During these clinics, he would conduct the 
patient’s usual clinic consultation and would complete his assessment of global disease 
activity by performing the limited MSUS joint set examination. This unsupervised practice 
proved essential in refining the technique and sequence of joint examination 
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3.6 Identification of Collaborator for Transcriptomic 
Analysis 
The original intention of the biomarker analysis described in preceding Section 2.7 was to 
describe changes in expression patterns across a number of different genetic and molecular 
levels (e.g genotype – RNA / transcriptomic analysis – proteomic – metabolomic). Subsequently, 
an integrative pathway analysis was proposed, whereby the relative expressions of biomarkers at 
each level would be compared to the expression levels of corresponding biomarkers on 
preceding and following levels to determine how whether genetic pre-determinants of RA were 
transmitted forward to molecular and physical phenotype. This multi-platform analysis requires 
significant technical assistance from a scientific collaborator with expertise in both operating and 
conducting each of the different analysis platforms. From the very outset of drafting the research 
protocol a verbal agreement to collaborate was reached between Dr Dale, his research 
supervisors at University of Glasgow, and the research scientists of the Translational Medicine 
Research Collaboration (TMRC), Dundee. The TMRC was funded jointly by Pfizer UK, the 
Scottish Government and the Universities of Aberdeen, Dundee, Edinburgh and Glasgow. The 
Research Laboratory provided a state-of-the-art facility with specific expertise in conducting 
genomic, transcriptomic, proteomic and metabolomic analyses coupled to dedicated bio-
informatic support. Unfortunately in January 2010, and despite having virtually finalised a formal 
research contract and analysis plan, TMRC scientists eventually decided that they would have 
insufficient capacity to conduct the analysis following the loss of their central funding stream. A 
potential collaboration with translational immunology scientists based within Pfizer Global’s US 
research laboratories could not progress because of internal conflicts of interest. There then 
followed a protracted tendering process during which Dr Dale sought quotes from several 
independent Contract Research Organisations; including, AROS Applied Biotechnology (Aarhus, 
Denmark), Asuragen Incorporated (Austin, Texas, USA) and Expression Analysis Incorporated 
(Durham, North Carolina, USA). A potential local collaboration with colleagues at the Sir Henry 
Wellcome Functional Genomics Unit, University of Glasgow did not progress because of their 
inexperience at handling human blood samples and the potential scale of the proposed analysis. 
Eventually, in January 2012, local colleagues (Drs Martin Mcbride and John McClure) from the 
Systems Biology Group of the Institute of Cardiovascular and Medical Sciences at the University 
of Glasgow very kindly agreed to assist by performing the laboratory analysis of the stored blood 
samples and assisting with the statistical processing. RNA extraction was performed between 
February and March 2013 and, due to availability of laboratory technical staff, the microarray 
analysis was completed in August 2012. Data normalisation, quality control procedures and 
comparison of expression levels between different phenotypic groups was conducted between 
September 2012 and February 2013. 
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3.7 Recruitment to Scottish Early Rheumatoid 
Arthritis Inception Cohort 
When the TaSER Study commenced in September 2009 the original intention was that all 
participants would donate additional blood samples for the proposed multi-level biomarker 
analysis at set time-points over the duration of their participation in the study. However, whilst the 
recruitment period of this research was being conducted a further, multi-centre cohort study was 
commenced with very similar inclusion criteria and sampling requirements. The Scottish Early 
Rheumatoid Arthritis (SERA) Inception Cohort (UKCRN ID 9162, MREC No 10/S0704/20) is a 
Scotland-wide, prospective longitudinal study of 1800 patients with early RA, or undifferentiated 
inflammatory arthritis, which aims to compare changes in clinical and radiographic outcomes to 
measured changes in biomarker expression profiles to determine whether particular biomarkers 
(individually or grouped) can act as additional predictors of outcome. Since both projects are 
analysing outcomes in early RA, to solely recruit patients to the TaSER Study would have 
significantly impaired recruitment to SERA. Thus, it was agreed that the data collection and blood 
sampling procedures followed by this research should be brought into line with those of SERA so 
that participants of the TaSER study might also contribute to the longer term aims of SERA and 
recruitment to both projects could be maximised. Other than contributing outcome data and blood 
samples to the SERA study, participants who were primarily recruited to the TaSER study 
continued to be randomised, assessed and followed-up by the processes described in preceding 
sections 2.3-2.5. Altogether, of the 111 research participants 79 (study numbers 001-078 and 
083) followed the previously described data collection and blood sample donation procedures; 32 
participants (study numbers 079-082 and 084-111) contributed clinical and radiological outcome 
data and blood and urine samples to the SERA study. New study participants could not contribute 
to the SERA study until the West of Scotland Research Ethics Service had approved a 
substantial amendment to the research methods. To bring the data collection procedures in line 
with the main SERA study the following changes were made: 
 
1. Blood biomarker sampling time points switched to baseline and months 6, 12 and 18  
2. Additional urine sample collected at each sampling time point for proteomics analysis 
3. Completion of the Hospital Anxiety and Depression (HAD) Questionnaire at baseline, 6 and 
12 months 
4. Additional plain x-rays of hands and feet performed at months 6 and 12  
5. Formal documentation of distribution of tender and swollen joints in hands and feet; 
compared to Ritchie Articular Index component of DAS44 which summarises joint 
tenderness for the whole metacarpophalangeal and metatarsophalangeal joint areas 
6. Documentation of employment status at baseline, 6 and 12 months 
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3.8 Amended Analysis Plan 
The previously described delays in obtaining NHS REC and NHSGGC R+D approvals, and in 
completing the recruitment period, have led to a protracted follow-up period which means that 
completion of the follow-up period was significantly delayed. Thus, at the time of writing, it has not 
possible to report all of the final outcomes described in preceding section 2.6. However, up until 
this point a significant amount of clinical and ultrasonographic data had been collected; therefore, 
after discussion with research supervisors and University of Glasgow assessors, a detailed 
interim analysis was conducted to determine how often the MSUS disease activity findings 
altered DMARD escalation decisions.  
 
For the purposes of this thesis submission the following results sets will be presented: 
 
Chapter 4: Research cohort’s presenting demographic and disease-related characteristics. 
Including: comparison of these characteristics to those of the SERA Study Cohort and other, 
previously conducted, early RA studies in a similar geographic area 
 
Chapter 5: Description of level of agreement between DAS28 and MSUS assessments of global 
disease activity 
 
Chapter 6:Description of the impact of DAS28 and MSUS disease activity assessment on the 
ACR core set outcomes 
 
Chapter 7: Description of findings of initial transcriptomic analysis, conducted using baseline and 
3 month PAXgene RNA samples and available clinical data 
 
Chapter 8: Description of findings of comparison between baseline, 3 month and 18 month multi-
biomarker disease activity test and corresponding DAS28 and MSUS disease activity 
assessments 
 
3.8.1 Interim MSUS Data Analysis Plan 
Throughout the follow-up period DAS28 and MSUS disease activity assessment data were 
frequently recorded simultaneously. These data were interrogated to determine how often DAS28 
and MSUS assessment agreed / disagreed on the need for DMARD escalation using the 
thresholds described in Section 2.4. An estimation of how often MSUS findings were leading to 
DMARD escalation decisions which differed from those currently reached by standard care (e.g 
DAS28 assessment) started to demonstrate the likely impact of MSUS assessment upon DMARD 
treatment intensity and the practicalities of incorporating it into routine practice. 
 
Results from all occasions when there was simultaneous DAS28 and MSUS disease activity 
assessment data available were pooled. The following relationships were calculated: 
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1. Proportion of assessment visits where MSUS was indicated and the frequency of each 
indication. The indications for MSUS were defined as: 
 
i. DAS28 < 3.2 
ii. 3.2 ≤	 DAS28 < 5.1 and 0-1 swollen joints 
 
Since DMARD escalation is not indicated within 3 months of a preceding DMARD 
escalation, data for this analysis will be taken from all visits in the MSUS group occurring 
from month 3 onwards. As an internal comparison, the number of occasions that patients 
within the DAS28 assessment group might also have qualified for MSUS assessment will 
be calculated 
 
2. The degree of agreement between DAS28 and MSUS assessments of global disease 
activity. Agreement will be defined as those occasions when corresponding DAS28 and 
MSUS assessments lead to the same DMARD escalation decision based on the thresholds 
described in section 2.4. Disagreement will be defined as those occasions when MSUS 
findings lead to a DMARD escalation decision that opposes that suggested by the DAS28 
findings 
 
Agreement i. DAS28<3.2 and MSUS assessment identifies PD signal in one or no joints. 
Thus, both assessments agree that DMARD escalation is not indicated 
 ii. 3.2 ≤	 DAS28 < 5.1 and 0-1 clinically swollen joints and MSUS identifies PD 
signal in two or more joints. Thus, both assessments agree that DMARD 
escalation is indicated 
 
Overall agreement will be calculated as the proportion of occasions that either scenario i. 
or scenario ii. are satisfied out of all the occasions when there is corresponding DAS28 and 
MSUS assessment data available 
 
Disagreement i. DAS28<3.2 but MSUS identifies PD signal in two or more joints. Thus DAS28 
suggests low disease activity whereas MSUS assessment has identified in 
subclinical synovitis 
 ii. 3.2 ≤	 DAS28 < 5.1 and 0-1 clinically swollen joints but MSUS identifies PD 
signal in one or no joints. Thus, whilst DAS28 suggests moderate disease 
activity, MSUS has not identified evidence of active synovitis 
 
3. Using MSUS finding data relating to each monthly time point, the proportion of occasions 
that MSUS findings indicated DMARD escalation will be calculated to determine whether 
the impact of MSUS alters over the follow-up time period. Furthermore, median synovial 
hypertrophy and PD signal scores (sum of gradings) and indices (number of positive 
findings) will be calculated at each time point 
 
  163 
3.8.2 Amended Transcriptomic Expression Analysis Plan 
So far, it has only been possible to secure local collaborators to perform the transcriptomic 
analysis, therefore a decision was taken to focus on interrogating the transcriptomic dataset 
thoroughly before seeking collaborators to assist with analyses across additional polyomic 
platforms. Analysis was limited to 79 participants out of the whole cohort (study IDs T001 – T078 
and T083) since the remaining participants had donated blood samples to the parallel Scottish 
Early Rheumatoid Arthritis Inception Cohort Study. Furthermore, analysis of transcriptomic 
expression profiles was restricted to the baseline and 3 month PAXgene RNA samples since, at 
the time of laboratory analysis, there weren’t 18 month samples available for all participants.  
 
Demographic and clinical outcome data - that had been accrued as part of the clinical research - 
was then used to form patients into pre-defined phenotypic and treatment response groups 
representing clinical scenarios that rheumatologists were likely to encounter during routine 
practice. Statistical techniques (described in detail in Section 2.7.2.4) were used to determine 
whether there were significant differences in the mRNA expression profiles evident between the 
groups. Comparator groups were formed using the phenotypic descriptors that are described in 
Section 2.7.2.5 
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4. The TaSER Study Cohort 
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4.1 Identification of Participants  
 
The recruitment period ran between September 2009 and November 2011 and the follow-up 
period ran until May 2013. In total, 283 patients were screened and 111 agreed to participate in 
the research (recruitment rate 39%) 
 
4.1.1 Referral Sources 
Potential participants could be referred for screening by rheumatology colleagues based at a 
number of NHSGGC rheumatology units. Participants who were referred from outwith the three 
main participating sites were allocated appointments at which ever of the main hospital sites was 
most convenient for their travelling requirements. Table 13 summarises the original source of 
referral for the final 111 research participants and Table 14 summarises how their follow-up was 
distributed between each of the participating sites. If, including screening and baseline 
appointments, all participants had attended for every single monthly review appointment a total of 
2,220 consultations would have occurred 
 
Source of Referral 
 
Number of Research 
Participants 
Percentage 
Gartnavel General Hospital 49 45% 
Glasgow Royal Infirmary 24 21% 
Stobhill Hospital 20 18% 
Private Practice 11 10% 
Victoria Infirmary 5 4% 
Inverclyde Royal Hospital 1 <1% 
Royal Alexandria Hospital, 
Paisley 
1 <1% 
Table 13: Original source of referral for research participants 
 
Follow-up Site 
 
Number of Research 
Participants 
Percentage 
Gartnavel General Hospital 63 57% 
Glasgow Royal Infirmary 26 23% 
Stobhill Hospital 22 20% 
Table 14: Follow-up arrangements for research participants 
 
4.1.2 Screening Process 
 
283 patients underwent screening review; of these 170 (60%) had a clinical diagnosis of RA and 
113 (40%) had an alternative diagnosis. Of the RA patients, 111 (65%) agreed to participate in 
the research (overall recruitment rate = 39%) and 59 (35%) did not, or could not, participate. 
Table 15 summarises the reasons why RA patients were unable to participate in the research. 
Table 16 describes the range of alternative diagnoses of non-RA patients who attended 
screening. The consort diagram in Figure 12 depicts how patients and research participants have 
progressed through the screening and follow-up process to date 
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Reason Frequency 
 
Percentage 
Patient preference 19 32% 
Did not attend follow-up  2 3% 
Did not meet inclusion criteria 
 
Disease duration > 12 months 13 
(mean = 30 months) 
22% 
DAS44 < 2.4 
(after steroid therapy) 
15 
(5) 
25% 
(8%) 
Fulfilled exclusion criteria 
 
Cytopenia  
(Hb < 10g/dl, WCC < 4x109/l, 
platelet < 150x109/l) 
3 5% 
Renal failure  
(creatinine > 200 µg/l) 
1 2% 
Abnormal liver function tests 
(AST / ALT > twice ULN) 
1 2% 
Pregnant or planning 
pregnancy 
2 3% 
Aggressive DMARD escalation 
contraindicated by co-
morbidities 
3 5% 
Table 15: Frequency of reasons why patients with RA (n=59) did not participate in research 
 
Diagnosis Frequency Percentage 
 
Osteoarthritis 22 19% 
Undifferentiated inflammatory 
arthritis 
17 15% 
aCCP / RhF +ve – no arthritis 16 14% 
Psoriatic arthritis 9 8% 
Fibromyalgia 9 8% 
Arthralgia (no specific 
diagnosis) 
6 5% 
Palindromic arthritis 5 4% 
Reactive arthritis 3 3% 
Transient arthritis 3 3% 
Ankylosing spondylitis 2 2% 
Gout 2 2% 
Sarcoidosis 2 2% 
Connective tissue disease 2 2% 
Viral arthritis 2 2% 
Extensor tenosynovitis 2 2% 
Sjogren’s syndrome 2 2% 
Hypermobility syndrome 1 <1% 
CTD associated polymyositis 1 <1% 
Ulnar nerve palsy 1 <1% 
Flexor tenosynovitis 1 <1% 
Diabetic cheiroarthropathy 1 <1% 
IBD related arthritis 1 <1% 
Polymyalgia rheumatic 1 <1% 
Meniscal tear 1 <1% 
Dupuytren’s contracture 1 <1% 
Table 16: Frequency of alternative diagnoses in patients (n = 113) attending for screening review 
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Figure 12: Consort diagram depicting progress of patients and research participants through 
screening and follow-up period  
 
Ten (9%) patients withdrew before completing the full follow-up period: 5 (5%) had not attended 
for follow-up reviews; 2 (2%) had withdrawn consent and elected not to continue in the research 
and 2 (2%) were planning to conceive. Additionally, 1 patient developed an overlap syndrome 
with dermatomyositis and required such high levels of oral corticosteroids (initially prednisolone 
60mg/d) and alternative immunosuppressant therapy (azathioprine then rituximab) that it was not 
possible to continue following the DMARD escalation protocol 
 
4.2 Baseline Characteristics of Study Cohort 
 
Overall, the research cohort appeared representative of a typical early RA population. Table 17 
describes the baseline demographic and disease related characteristics of the whole cohort in 
detail. The cohort can be broadly summarised as predominantly female (68%) and middle aged 
(mean age 56 years) with recent onset symptoms (mean symptom duration 5.3 months); 
moderate-to-high disease activity (mean baseline DAS44 = 4.3), moderate functional impairment 
283 screening 
reviews 
113 non-RA  
diagnoses 
(see Table 16) 
 
170 RA 
diagnoses 
111 research 
participants 
59 didn’t 
participate in 
research 
10 didn’t complete 
research follow-up 
Reason 
Patient preference – 19 
Lost to follow-up – 2 
Disease duration > 12 
months – 13 
DAS44 < 2.4 – 15 
Cytopenia – 3 
Renal failure - 1 
Abnormal LFT – 1 
Current or planned 
pregnancy – 2 
Comorbidities - 3 
 
Reason 
Lost to follow-up – 5 (5%) 
Withdrawal of consent – 2 
(2%) 
Planning pregnancy – 2 
(2%) 
Intervening illness – 1 (<1%) 
 
101 (91%) 
completed 
follow-up period 
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(mean baseline HAQ = 1.5). The majority exhibited either positive rheumatoid factor and/or anti-
CCP antibodies (67% and 60% respectively). Despite the relatively early presentation a 
significant minority (29%) still exhibited erosive baseline x-rays. 
 
 TaSER 
 
 
 All DAS28 
 
Ultrasound p 
 (DAS28 vs US) 
Number 
 
111 57 54  
Females 
n (%) 
76 (68%) 43 (75%) 33 (61%) 0.10 (chi2) 
Age 
(years) 
56 (13) 56 (13) 57 (14) 0.68 
Disease 
Duration 
(months) 
5.3 (3.0) 5.4 (3.1) 5.1 (2.8) 0.64 
RhF +ve  
n (%) 
74 (67%) 39 (68%) 35 (65%) 0.16 (chi2) 
CCP +ve  
n (%) 
67 (60%) 35 (61%) 32 (59%) 0.81 (chi2) 
Current 
Smoker 
n (%) 
31 (28%) 17 (30%) 14 (26%)  
 
0.728 
Ex-smoker 
n (%) 
31 (28%) 18 (32%) 13 (24%) 
Never Smoked 
n (%) 
49 (44%) 22 (39%) 27 (50%) 
DAS28 
 
5.0 (1.1) 5.0 (1.2) 4.9 (1.0) 0.56 
28TJC 
 
6 (5) 6 (5) 6 (5) 0.85 
28SJC 
 
6 (4) 6 (4) 6 (3) 0.68 
DAS44 
 
4.3 (1.2) 4.4 (1.3) 4.3 (1.0) 0.59 
RAI 
 
20 (13) 20 (14) 20 (12) 0.92 
44SJC 
 
10 (6) 10 (7) 9 (5) 0.38 
Patient Global 
(100mm VAS) 
54.7 (22.3) 56.2 
(27.9) 
54.4 (21.4) 0.71 
Physician 
Global 
(Likert 0-5) 
3.2 (0.7) 3.2 (0.7) 3.2 (0.7) 0.65 
ESR 
(mm/hr) 
39 (35) 41 (43) 36 (25) 0.41 
CRP 
(mg/l) 
37 (49) 38 (57) 35 (40) 0.76 
HAQ 
 
1.5 (0.8) 1.5 (0.8) 1.5 (0.7) 0.92 
Pain VAS 
(100mm VAS) 
49.4 (22.4) 52.5 
(25.1) 
46.2 (18.9) 0.14 
Baseline 
Erosions* 
n (%) 
32 (29%) 15 (26%) 17 (32%) 0.470 
Table 17: Baseline demographic and disease related characteristics of whole research cohort, 
DAS28 and MSUS assessment groups 
Unless otherwise stated values are shown as means ± standard deviation 
*Data collected from routine NHSGGC radiology reports, formal grading of baseline xrays is 
awaited 
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Following the randomisation process, the DAS28 group was slightly larger than the MSUS group 
and contained a numerically higher proportion of female participants (75% vs 61%, p=0.10). 
Other than gender, there were no statistically significant between group differences evident in any 
of the baseline demographic features, disease characteristics or measures of disease activity.  
 
Autoantibody Status 
 
Observational studies suggest that the prevalence of anti-CCP positivity amongst European early 
RA cohorts is approximately 57 – 63% and for rheumatoid factors is approximately 54 – 63% 
(1,10); reassuringly, very similar results were observed in this cohort (60% anti-CCP positive, 
67% RhF positive). Table 18 describes the rates of separate and combined autoantibody 
positivity for all research participants. These rates are comparable to those previously described 
in 164 RA patients attending routine early arthritis clinics in Glasgow (65% anti-CCP positive, 
63% RhF positive) (J Dale – unpublished data). Additionally, the rates of combined anti-CCP 
antibody and/or rheumatoid factor status for this cohort were very similar to those described in a 
larger (n=279) Swedish early RA cohort who presented with similar symptom durations (mean = 5 
months) and disease activity levels (mean DAS28 = 5.01) (1).  
 
All patients  Anti-CCP antibody  
  Negative Positive Total 
Rheumatoid 
Factor 
Negative 32 (29%) (32%) 5 (4%) (4%) 37 (33%) 
Positive 12 (11%) (10%) 62 (56%) (53%) 74 (67%) 
 Total 44 (40%) 67 (60%) 111 
Table 18: Frequency of anti-CCP and/or rheumatoid factor positivity for the whole research 
cohort 
Values are number (percentage).  
Figures in red font show corresponding rates for the Swedish RA cohort (1) 
 
4.2.1 Fulfilment of RA classification criteria 
 
1987 ACR RA Classification Criteria 
Since the 1987 ACR classification criteria for RA are biased towards identifying established RA, 
eligible participants needed a robust clinical diagnosis of RA (based on presenting features and 
initial investigation results) rather than needing to fulfil the criteria set. Even so, data relating to 
whether or not participants fulfilled 1987 ACR classification criteria was still collected during each 
baseline assessment. Since some participants presented very early after the onset of symptoms, 
with clear features of RA, there was no requirement for criteria 1-4 to have been present before 
the criteria could be applied. Based on presenting features, 95 participants (86%) fulfilled 1987 
ACR classification criteria for RA (i.e. total score ≥ 4). Table 19 describes the frequency that each 
criterion was present and Table 20 describes how often each score was returned. Of note, the 
criterions which are most closely related to disease longevity (e.g presence of rheumatoid 
nodules, erosive baseline x-rays) were recorded much less frequently (4% and 29% respectively) 
than the other criterions which relate to presenting clinical features and fixed rheumatoid factor 
status 
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Criterion 
 
Frequency Percentage 
Early morning stiffness ≥ 1 
hour 
94 85% 
Arthritis ≥ 3 areas 102 92% 
Arthritis of hand joints 105 95% 
Symmetric arthritis 95 86% 
Presence of rheumatoid 
nodules 
4 4% 
Rheumatoid factor positive 75 67% 
Erosive plain x-rays 32 29% 
 Table 19: Fulfilment of 1987 ACR Classification Criteria – during baseline assessment 
Definitions of criterions adapted from Arnett et al (11). The ‘6 week rule’ for criteria 1-4 was not 
applied 
 
 
Score Frequency Percentage 
 
2 1 1% 
3 15 14% 
4 34 31% 
5 44 40% 
6 15 14% 
7 2 2% 
Table 20: Fulfillment of 1987 ACR Classification Criteria – total score at baseline assessment 
A score ≥ 4 classifies the presenting features as RA(11) 
 
2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis 
During the recruitment process the 2010 ACR-EULAR Classification Criteria for RA were 
proposed (13). The 2010 classification criteria were not specifically included within the original 
dataset; however, fortuitously each of the individual components was already being collected 
during the baseline assessment and it was therefore possible to retrospectively apply the 2010 
classification criteria. The distribution of large and small joint involvement was determined from 
the 44 swollen joint count and Ritchie Articular Index components of the DAS44. The Ritchie 
Articular Index summarises tenderness across all PIPj and MCPj of each hands and therefore 
doesn’t provide sufficient detail to accurately determine the extent of small joint involvement in the 
hands. In instances where the Ritchie Articular Index identified PIPj or MCPj tenderness the 
extent and pattern of joint involvement was determined by referring to the 28 tender joint count 
that was recorded independently as part of the baseline DAS28 assessment. All study 
participants displayed evidence of either clinical and/or musculoskeletal ultrasound synovitis in at 
least one joint at the baseline assessment. 
 
One hundred and seven participants (96%) scored 6 or higher and therefore satisfied 2010 ACR-
EULAR Classification Criteria for definite RA. Table 21 describes the frequency that each criterion 
was present and Table 22 demonstrates the frequency that each score was reported 
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Criterion Score Frequency Percentage 
 
A. Joint Involvement 
1 large joint 0 8 7% 
2-10 large joints 1 24 22% 
1-3 small joints*  2 12 11% 
4-10 small joints*  3 24 22% 
>10 joints (at least 1 small joint) 5 74 67% 
B. Serology 
Negative RF and negative ACPA 0 32 29% 
Low positive RF or low positive ACPA 2 7 6% 
High positive RF or high positive ACPA 3 72 65% 
C. Acute-phase Reactants 
Normal CRP and normal ESR 0 19 17% 
Abnormal CRP or abnormal ESR 1 92 83% 
D. Duration of Symptoms 
< 6 weeks 0 5 5% 
≥ 6 weeks 1 106 95% 
Table 21: Fulfilment of 2010 ACR-EULAR Classification Criteria for RA – during baseline 
assessment.  
* with or without large joint involvement 
Definitions of criterions based upon Aletaha et al (13) 
 
Score Frequency Percentage 
5 4 4% 
6 11 10% 
7 28 25% 
8 10 9% 
9 24 22% 
10 34 30% 
Table 22: Fulfillment of 2010 ACR-EULAR Classification Criteria for RA – total score at baseline 
assessment.  
A total score ≥ 6 identifies definite RA 
 
Altogether, 95 participants (86%) fulfilled the 1987 ACR criteria, 107 participants (96%) fulfilled 
the 2010 ACR-EULAR criteria and 92 participants (83%) fulfilled both sets of criteria. Three 
participants (3%) solely fulfilled the 1987 ACR criteria, 15 participants (14%) solely fulfilled the 
2010 ACR-EULAR criteria and 1 participant (approx. 1%) fulfilled neither set of criteria. Chi 
squared comparison showed no significant statistical difference between the proportion of 
participants in each randomisation group fulfilling either set of criteria (p=0.54). 
 
Taken together these results provide additional support that the screening process identified an 
appropriate study cohort to follow since the vast majority of participants satisfied current RA 
classification criteria for RA. Furthermore, the overall picture implied by the individual criterion 
does fit with a very typical description of RA. The majority of participants displayed 1. polyarticular 
involvement at presentation (67% with >10 clinically affected joints); 2. high titres of at least one 
disease associated autoantibody (65% high titre RhF and/or CCP); 3. elevated acute phase 
reactants (83% abnormal CRP and/or ESR) and 4. persistent disease outwith the expected 
window for spontaneous resolution (95% > 6 weeks symptom duration). 
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4.2.2 Distribution of Joint Involvement at Presentation 
RA is traditionally considered to involve peripheral small joints in a symmetrical distribution (4). 
However, this definition probably relates better to established disease since it is increasingly 
recognised that the earliest stages of symptoms are not always associated with symmetrical joint 
involvement. Indeed, the 2010 ACR-EULAR RA classification criteria no longer feature 
symmetrical joint involvement as a defining feature (13) and recent prediction rules for persistent, 
erosive arthritis allocate either no, or a relatively small, additional weighting to the presence of 
symmetrical joint involvement (15,16). To determine how closely participant’s presenting features 
matched the classical description of RA the distribution of clinically evident synovitis in peripheral 
joints was recorded during the baseline assessment (Table 23). Interestingly, despite the 
relatively short symptom durations, the distribution of joints involved did still suggest that 
significant numbers of the participants presented with clinical features that fitted the classical 
description of rheumatoid arthritis (e.g, symmetrical involvement of peripheral small hand and foot 
joints). The most common patterns of clinical joint inflammation were bilateral involvement of 
MCPj (70%), PIPj (64%), MTPj (53%) and wrist (49%). 
 
  No Involvement Unilateral Involvement Bilateral Involvement 
  Frequency Percentage Frequency Percentage Frequency Percentage 
 
 
Upper  
Limb 
PiPj 29 26% 11 10% 71 64% 
MCPj 25 23% 8 7% 78 70% 
Wrist 34 31% 23 21% 54 49% 
Elbow 92 83% 10 9% 9 8% 
Shoulder 65 77% 16 14% 30 27% 
 
Lower  
Limb 
MTPj 44 40% 8 7% 59 53% 
Ankle 85 77% 8 7% 18 16% 
Knee 61 55% 28 25% 22 20% 
Hip 109 98% 0 0 2 2% 
Table 23: Frequency and distribution of clinically evident synovitis at presentation 
 
4.3 Discussion 
 
Before the impact of the intervention can be assessed the ability of the research cohort to 
represent a ‘typical’ early RA population should be considered. Newly diagnosed RA patients who 
were undergoing screening were primarily considered suitable for recruitment if their presenting 
clinical and laboratory features reasonably supported a clinical diagnosis of RA. Whilst this 
approach reduces any potential restrictions to recruitment that might be caused by structured 
classification criteria it does increase the risk of diagnostic inconsistency because of clinician’s 
subjectivity.  
 
4.3.1 Baseline Clinical Features 
Overall, the baseline clinical and laboratory descriptors of the TaSER cohort seem typical of a 
newly diagnosed early RA population. At a whole cohort level, the participants presented in the 
sixth decade (mean age 56 years) and the majority (68%) were female. Participants presented 
relatively early (mean = 5.3 months) after the onset of symptoms and whilst the majority of 
presentations were from a fairly narrow central band (IQR 3 – 7 months) the overall range was 
much wider (0.5 – 12 months). Participants presented with moderate-high clinical disease activity 
  173 
(mean DAS44 4.4), moderate elevation of inflammatory markers (mean ESR 39, mean CRP 37), 
moderate functional impairment (mean HAQ 1.5) and elevated participant completed 
assessments of pain and global health (mean 10cm VAS 49/100 and 55/100 respectively). The 
majority of participants returned HAQ assessments (IQR 1-2; SD 0.77) pain 10cm VAS 
assessments (IQR 34-63; SD 22.4) and global health 10cm VAS assessments (IQR 38.5 -71; SD 
22.3) from within a narrow central range; however, the total ranges for each of these variables 
(HAQ 0-2.9; pain VAS 8-100; global health VAS 7-100) do suggest that there were small numbers 
of outlying participants at both extremes of each variable.  
 
Excepting sex, there were no statistical differences in the baseline measures between the 
assessment groups. The randomisation process lead to the DAS28 assessment group being 
slightly larger (57 vs 54) than the MSUS assessment group and containing a numerically higher 
proportion of females (75% vs 61%). It is quite likely that this imbalance has resulted from the 
minimisation processes used to ensure equal balance of DAS28, rheumatoid factor status and 
erosive status between the assessment groups. Being female does have clear prognostic 
implications (32,320)  and several population based studies have demonstrated that measures of 
disease activity and functional impairment tend to be worse in females (36,38-40). It is therefore 
possible that the DAS28 group may have been predisposed to achieving a lesser treatment 
response and poorer outcomes over the course of the follow-up period. Nevertheless, all other 
baseline prognostic markers (age, rheumatoid factor and anti-CCP antibody status, symptom 
duration at presentation, smoking status, baseline disease activity level) were equally 
represented in both assessment groups and may therefore limit any potential bias associated with 
the imbalance in female sex. In fact, an increased proportion of females within the DAS28 group 
should have increased the likelihood of identifying between group differences if the control group 
were effectively biased towards worse outcomes. Analyses performed to date have shown that 
there were no differences in DAS44 or gene expression outcomes between the gender groups, 
though male participants did tend to demonstrate earlier and greater improvements in functional 
ability. In due course, gender will be incorporated into multiple regression analyses of the clinical 
outcomes to determine whether it comes out as an independent predictor of clinical response.  
 
Analysis of the pattern of clinical joint involvement at presentation suggests that the cohort’s 
presentation was consistent with RA. There was polyarticular joint involvement (mean 44 swollen 
joint count 10) and the small peripheral joints of the hands and feet were most commonly involved 
(any involvement: MCP 77%, hand PiPj 74%; wrist 69%; MTPj 60%). Furthermore, during the 
baseline assessment there was consistently high rates of bilateral involvement for all joint areas, 
except the elbows and knees (Table 23). There is increasing recognition that patients in the very 
early stages of RA, when the disease process may be most amenable to treatment, do not 
necessarily present with symmetrical joint involvement. Indeed, a recent cohort study conducted 
on 2472 patients with early undifferentiated arthritis suggested that those who fulfilled the 2010 
ACR-EULAR RA classification criteria presented with earlier disease (mean symptom duration: 
13.4 vs 15.7 weeks; p = 0.01), were more likely to exhibit asymmetrical joint involvement (52% vs 
46%; p = 0.01) and had a higher rate of small hand and foot joint involvement (85% vs 81%; p = 
0.04) than those who fulfilled the 1987 ACR classification criteria (321). Few recent studies have 
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described the distribution of joint involvement in newly diagnosed RA patients or those with early 
undifferentiated arthritis. Compared to the cohort study, the TaSER cohort exhibited a somewhat 
higher rate of symmetrical joint involvement which could, in part, have been related to the 
inclusion criteria requiring potential participants to have a clinical diagnosis of RA. It is possible 
that this approach emphasised the need for potential participants to match the ‘classical’ 
description of RA and thus predisposed towards recruiting participants with symmetrical joint 
involvement.  
 
4.3.2 Baseline Autoantibody Status 
It is now well recognised that rheumatoid factor and (especially) anti-citrillunated protein 
antibodies (ACPA) have important diagnostic and prognostic properties in relation to RA 
(6,10,69). Therefore, the expression of these autoantibodies within an early RA research cohort 
should be comparable to both the local RA population and other previously described early RA 
cohorts. It is also understood that rheumatoid factor and/or anti-CCP antibodies are detectable for 
several years before the development of RA and that the prevalence of either autoantibody does 
vary depending upon which stage of RA is present. Prospective observational studies have 
demonstrated that i. the prevalence of rheumatoid factor and anti-CCP antibodies in the 
asymptomatic phase prior to the development of clinical RA is between 19.3 – 57% and 33.7 – 
61% respectively (7,84,85) and that ii. the prevalence of both antibodies increases sharply 
immediately before the onset of clinical RA (7). Similarly, in newly diagnosed RA the prevalence 
of rheumatoid factors and anti-CCP antibodies is significantly higher than in asymptomatic at-risk 
patients (84) and, furthermore, is higher still in patients with longer disease durations and well 
established diagnoses of RA (IgM RF 68-82%; anti-CCP 72-82%) (322-324).  
 
For the TaSER cohort the prevalence of rheumatoid factor was 67% and anti-CCP2 antibodies 
was 60%. Rheumatoid factor and anti-CCP status was concordant in 94 (85%) participants. 
These results are at least comparable to the baseline values reported in local NHSGGC early 
arthritis clinics and similar early RA cohorts.  
 
• In 2010, a retrospective analysis was conducted of the case sheets of 164 RA patients 
attending NHSGGC early arthritis clinics to determine their rate of rheumatoid factor and 
anti-CCP antibody positivity (J Dale – unpublished results). Table 24 summarises the 
results of this analysis. Overall, the rates of anti-CCP antibody (60% vs 63%) and paired 
RhF-anti-CCP positivity (56% vs 54%) were similar between the TaSER cohort and 
NHSGGC clinics. The NHSGGC clinics contained a notably higher proportion of RhF 
positive patients (67% vs 80%) which may reflect false positive results causing diagnostic 
bias since, at the time of analysis, none of the clinics were applying RA classification 
criteria to confirm the clinical diagnosis 
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  Anti-CCP 
Positive 
Anti-CCP 
negative 
Total 
TaSER Cohort 
N = 111 RhF Positive 
62 (56%) 12 (11%) 
 
74 (67%) 
NHSGGC Cohort* 
N = 164 
89 (54%) 43 (26%) 132 (80%) 
  
TaSER Cohort 
 RhF Negative 
5 (4%) 32 (29%) 
 
37 (33%) 
NHSGGC Cohort 15 (9%) 17 (10%) 
 
32 (19%) 
Table 24 - Comparison of rates of rheumatoid factor and anti-CCP antibody positivity between 
TaSER study cohort and NHSGGC early arthritis cohort 
 
• The Scottish Early Rheumatoid Arthritis Inception Cohort Study (SERA – UKCRN ID 9162) 
provides a useful parallel cohort, from a similar geographic area, against which the 
baseline features of the TaSER cohort can be compared. The following results are a 
personal communication from Dr D Porter (SERA Principal Investigator) and are presently 
unpublished. 508 (78%) SERA participants had been classified as RA by the 2010 ACR-
EULAR RA classification criteria. Overall, the incidence of RhF and/or anti-CCP antibodies 
appears similar between the TaSER and SERA cohorts. Rheumatoid factor results were 
available for 367 patients (57% of the total cohort), of whom, 322 patients (88%) are 
rheumatoid factor positive. Anti-CCP antibody results are available for 525 patients (81% of 
the total cohort), of whom, 346 patients (66%) are anti-CCP antibody positive. At present it 
is not possible to report the degree of concordance between rheumatoid factor and anti-
CCP antibody.  
 
• Several recent cohort studies have reported the incidence of RhF and anti-CCP antibody 
positivity in early and established RA populations from different geographical regions 
(1,323,324). Overall, rates of RhF and anti-CCP antibody positivity and concordance were 
relatively similar between the TaSER study and other cohorts. There was evidence of 
some geographical variation with RA patients from India (324) and Brazil (323) tending to 
have slightly higher rates of dual positive RhF and anti-CCP antibodies whilst patients from 
Sweden (i.e. another North European cohort) had very similar rates of single and dual 
antibody positivity (1) (Table 25). Of note, results reported from the Indian cohort were 
gathered from patients with established RA where the incidence of RhF and anti-CCP 
antibodies may be expected to be higher anyway. 
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  Anti-CCP 
Positive 
Anti-CCP 
negative 
Total 
TaSER Cohort 
N = 111 
RhF Positive 
62 (56%) 12 (11%) 
 
74 (67%) 
Swedish Cohort* 
N = 279 
147 (53%) 28 (10%) 
 
175 (63%) 
Indian Cohort** 
N = 129 
95 (74%) 11 (9%) 106  (82%) 
Brazilian Cohort*** 
N = 156 
95 (61%) 11 (7%) 106 (68%) 
  
TaSER Cohort 
 
RhF Negative 
5 (4%) 32 (29%) 
 
37 (33%) 
Swedish Cohort 12 (4%) 90 (32%) 
 
102 (36%) 
Indian Cohort 
 
11 (8%) 12 (9%) 23 (18%) 
Brazilian Cohort 
 
22 (14%) 18 (12%) 40 (26%) 
Table 25 – Comparison of rates of rheumatoid factor and anti-CCP antibody positivity between 
TaSER study cohort and Swedish early arthritis cohort 
* Adapted from Ronnelid et al. Annals of Rheumatic Diseases 2005 (1) 
 ** Adapted from Agrawal et al. Clinical Rheumatology 2007 (324) 
*** Adapted from Goeldner et al. Rheumatology 2010 (323) 
 
Recent evidence suggests that a patient’s anti-citrillunated protein antibody (ACPA) status is 
dynamic with the pattern of ACPA expression undergoing a two-fold change prior to the onset of 
clinical RA. Observational studies of ACPA-positive individuals without RA have demonstrated 
that, an individual’s total ACPA titre rises prior to the onset of RA(7) and also diversifies with 
expression of antibody isotypes directed against a wider range of citrillunated antigens (epitope 
spreading)(87,88). Whilst the dynamic changes in ACPA expression are extremely interesting it is 
not yet possible to discuss how ACPA isotype expression may have influenced either the 
presenting features or observed outcomes of the TaSER cohort. The anti-CCP assay used by 
NHSGGC Immunology department is a second generation test which only quantifies total anti-
CCP expression and not the expression of individual ACPA isotypes. Recently, a verbal 
agreement to collaborate has been reached with Dr Jeremy Sokolove (Division of Rheumatology, 
Stanford University Medical School) whereby baseline serum samples will be analysed using the 
Stanford custom multiplex autoantibody and cytokine array. Correlation and regression analyses 
will then be conducted to determine how strongly baseline autoantibody profile predicts 
subsequent clinical course and treatment response. 
 
4.3.3 Fulfillment of Existing RA Classification Criteria 
To determine how closely the research cohort matched existing definitions of RA the 1987 ACR 
RA classification criteria (11) and the 2010 ACR-EULAR RA classification criteria (13) were 
applied to the baseline presenting features of the TaSER cohort. Reassuringly, both the 1987 
ACR criteria and the 2010 ACR-EULAR criteria classified a high proportion of patients as RA 
(86% and 96% respectively). Furthermore, examining the individual criterions of each criteria set 
once again suggested baseline features that were compatible with the common perception of an 
RA phenotype. From the 1987 ACR criteria, the majority of patients described prolonged morning 
stiffness (>1 our) and exhibited a symmetrical arthritis (86%), frequently involving the hand joints 
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(95%) and often associated with rheumatoid factor positivity (67%) (Table 19). Markers of 
established disease, such as rheumatoid nodules (4%) and erosive baseline xrays (29%), were 
not prevalent. A similar impression is created by the 2010 ACR-EULAR classification criteria: the 
majority of participants exhibited polyarticular joint involvement (>10 joints 67%), high RhF and or 
anti-CCP antibodies (65%) and elevated acute phase reactants (83%).  
 
Most recent early arthritis intervention studies require patients to fulfil existing RA classification 
criteria (usually 2010 ACR-EULAR criteria) before they can be considered for recruitment. 
However, in validation studies the gold standard against which the performance of the 
classification criteria is compared is often either subjective (e.g. physician’s opinion) or non-
specific (e.g. need to commence DMARD therapy). Several studies have reproduced a similar 
situation to the screening and recruitment process of this research; whereby, the performance of 
the 1987 and 2010 classification criteria are compared to physician’s diagnosis of RA (325-327). 
Indeed, when both classification criteria are applied strictly to early inflammatory arthritis cohorts 
the 2010 ACR-EULAR criteria are consistently found to be more sensitive at identifying ‘definite 
RA.’ In particular, compared to the 1987 criteria, the 2010 ACR-EULAR criteria are more likely to 
classify patients with asymmetric oligoarthritis presentations as RA (325) and are more sensitive 
in patients who are seronegative for RA associated antibodies (328). Furthermore, a recent meta-
analysis of 5 classification studies has suggested that whilst the 2010 ACR-EULAR criteria are 
more sensitive for the diagnosis of RA, the 1987 ACR criteria appear to be more specific (327)  
 
For this study, very high proportions of the cohort fulfilled both the 1987 ACR and 2010 ACR-
EULAR classification criteria for RA. This provides additional supporting evidence that the 
screening and recruitment process identified an appropriate cohort of patients. In line with 
previous studies, a slightly higher proportion of participants fulfilled the 2010 ACR-EULAR criteria 
than the 1987 ACR criteria; however, this did not reach statistical significance. To ensure that 
only patients with early RA, rather than any cause of inflammatory arthritis were recruited, the 
inclusion criteria stipulated a clear clinical diagnosis of RA, or anti-CCP positive undifferentiated 
inflammatory arthritis. Therefore, it is unsurprising that a high proportion of participants fulfilled 
one or both sets of classification criteria, since the referring clinicians and study investigators will 
have been biased towards considering patients where the clinical diagnosis was apparent and in 
keeping with the ‘classical’ understanding of RA. Indeed, it is in patients with undifferentiated 
inflammatory arthritis where the 2010 ACR-EULAR classification criteria are most likely to be 
clinically useful. A high proportion of participants fulfilling the 1987 ACR criteria may suggest that 
a significant number of participants were recruited at a later stage of the disease process. In fact, 
the mean symptom duration for the whole cohort was relatively short (5.3 months) and was 
comparable (5.2 months) when considering the subset of 95 patients who fulfilled the 1987 
criteria.  
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4.3.4 Characteristics of other recent early RA treatment strategy studies 
To determine whether MSUS-driven DMARD escalation has a similar impact upon outcomes to 
other interventional strategies the presenting feature of the TaSER cohort were compared 
numerically to those of patients recruited to other strategic treatment studies (Table 26). The 
TICORA (118) and TEAR (UK) (146) studies were conducted in exactly the same geographical 
area though had notable differences of inclusion criteria. Both studies recruited participants with 
symptom durations up to 5 years, whilst the TEAR (UK) study required participants to have at 
least high disease activity (DAS28 > 5.1). The SWEFOT study (147) inclusion criteria also 
allowed symptom durations up to 1 year but did not specify a lower disease activity limit. Overall, 
allowing for differences in disease duration, the baseline disease characteristics and disease 
activity measures of the TaSER cohort appear numerically similar to previous early interventional 
cohorts 
 
Taken altogether, when the baseline features of patients recruited to the TaSER are examined 
closely it is possible to be confident that a representative population of early RA patients was 
identified by the screening and recruitment process. The baseline clinical features, demographic 
and disease related characteristics of the cohort is similar to well-established definitions of the 
presenting features of RA and very high proportions of participants fulfilled either one or both of 
the accepted classification criteria definition for RA. Excepting female sex, there were no 
significant differences in the distribution of baseline demographic or disease-related phenotypic 
variables between the DAS28 and MSUS assessment groups suggesting that the baseline 
features of either group are unlikely to negatively bias the measured impact of the assessment 
strategy. Allowing for heterogeneity of study design (in particular, variations in inclusion criteria), 
and without being able to conduct direct statistical comparisons, comparisons with other 
published studies do suggest that the baseline RA-related phenotypic variables for this research 
cohort are at least numerically similar to those of other early RA cohorts. Rates of RA-associated 
auto-antibody expression were similar to those of other locally identified and European early RA 
cohorts. Furthermore, excepting the TEAR (UK) study, this research cohort exhibited similar 
baseline demographic features and disease activity levels to those of several, previously 
published, early RA inception cohorts.  
 
The screening process also identified 59 additional RA patients who, through preference or 
presence of a contra-indication, were unable to participate in the research. If recruited these 
patients would have comprised a significant proportion of the overall cohort and their individual 
disease characteristics could feasibly have altered the baseline characteristics and treatment 
response of both the whole cohort and the individual assessment groups.  
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Table 26 -  Baseline RA disease characteristics and disease activity levels for patients recruited 
to the TASER, TICORA, TEAR (UK) and SWEFOT studies of RA treatment strategies 
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5. Impact of Musculoskeletal 
Ultrasound on DMARD 
Escalation Decisions 
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Depending upon their clinical course participants within the MSUS group underwent MSUS 
assessment of global disease activity on a highly variable number of occasions. The following 
sections will describe the degree of agreement between DAS28 and MSUS assessments of 
global disease activity and the potential impact of using the proposed indications and definitions 
for MSUS assessment on both clinical workload and treatment escalation decisions. In situations 
where MSUS and DAS28 assessment disagreed about the disease activity state, MSUS findings 
were given precedence over DAS28. Hence, it should be assumed that DMARD therapy would 
have been escalated if the MSUS escalation threshold was exceeded and provided there was no 
specific contraindication identified. Follow-up months 1 and 2 are excluded from the analyses 
since participants would have been within 3 months of commencing DMARD therapy and 
therefore would not have been eligible for consideration of DMARD escalation. 
 
5.1 Fulfilment of Indication Criteria for MSUS 
 
Table 27 summarises the different disease activity states that were used to categorise 
participants’ DAS28 findings and how these related to DMARD escalation decisions 
 
Disease Activity State 
Descriptor 
Disease State 
 
DMARD escalation 
decision 
DAS28 ≥	 5.1 High disease activity  
 
 
Escalate on clinical 
grounds 3.2 ≤	 DAS28 < 5.1 AND 28SJC ≥	 2 
Moderate disease activity and 
clinical synovitis  
3.2 ≤	 DAS28 < 5.1 AND 28SJC 
=	 0-1 
Moderate disease activity but 
minimal clinical synovitis  
 
 
MSUS assessment 
required to inform DMARD 
decision 
 
 
DAS28 < 3.2 Low disease activity  
 
DAS28 < 2.6 Clinical remission 
Table 27: Disease activity states and relationship to DMARD escalation decisions 
 
Fulfilment of MSUS Indication Criteria by Assessment Group 
 
Between follow-up months 3 and 18, participants within the MSUS assessment group underwent 
753 clinic consultations. Of these, 658 reviews fulfilled the pre-defined indications for MSUS 
disease activity assessment; on 580 occasions (88%) MSUS assessment was potentially 
indicated because DAS28 was less than 3.2 (LDAS – low disease activity) and on 78 occasions 
(12%) MSUS assessment was potentially indicated because DAS28 suggested moderate disease 
activity (3.2 ≤	 DAS28 < 5.1) with minimal clinical synovitis (28SJC≤1). Similar rates of each of the 
different disease activity states were also identified in the whole cohort and in the DAS28 
assessment group (Table 28). The most common clinical disease activity state was low disease 
activity and DAS28 remission was identified in over half of assessments in each group  
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Disease Activity 
State Descriptor 
Total number of 
assessments 
Whole cohort 
 
Number of 
assessments in 
MSUS group 
Number of 
assessments in 
DAS28 Group 
DAS28 ≥	 5.1 
 
48 
(3%) 
12 
(2%) 
36 
(5%) 
3.2 ≤	 DAS28 < 5.1 
AND 28 SJC ≥	 2 
 
156 
(10%) 
83 
(11%) 
73 
(10%) 
3.2 ≤	 DAS28 < 5.1 
AND 28SJC =	 0-1*	 
 
177 
(12%) 
78 
(10%) 
99 
(13%) 
DAS28 < 3.2* 
 
1139 
(75%) 
580 
(77%) 
449 
(73%) 
DAS28 < 2.6* 
 
852 
(56%) 
432 
(57%) 
420 
(55%) 
Total number of 
assessments 
1520 753 657 
Table 28: Frequency (percentage) that DAS28 assessments fulfilled different disease activity 
states between 3 and 18 months.  
Data compiled from all visits for each assessment group 
*MSUS indication 
 
Altogether, up until February 2013, and allowing for necessary deferment of MSUS assessment 
after DMARD escalation, 414 MSUS assessments had been conducted on MSUS group 
participants. On 369 of these occasions (89%) MSUS assessment was indicated because of 
DAS28 LDAS and on 45 occasions (11%) MSUS assessment was indicated because of 
moderate disease activity and minimal clinical synovitis. 
 
So far, relatively few sets of paired DAS28 and MSUS disease activity assessments are available 
for the 18 month time point since: 1. not all participants have completed the full follow-up period, 
2. a number of participants had undergone DMARD escalation within the preceding 3 months 
and/or 3. because participants were about to leave the close monitoring processes allowed by 
study participation. Over the whole follow-up period DAS28 LDAS was consistently the most 
frequent indication for MSUS assessment (Graph 1). During months 3 to 12 of the follow-up 
period there was an apparent spike in the total number of MSUS assessments every 3 months 
that may represent the deferment of MSUS assessments for at least 3 months following DMARD 
escalation. Between months 12 to 17 the number of MSUS assessments being conducted each 
month became relatively static (between 28-31 MSUS assessments per month) with the majority 
being indicated by DAS28 LDAS.  
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Graph 1: Frequency of MSUS indication by month – MSUS assessment group only 
 
 
5.2 Clinical Disease Activity Assessment Findings in 
MSUS Assessment Group 
 
To determine whether the proposed MSUS indications were selecting appropriate participants for 
MSUS assessment the mean values of the DAS28 component variables were compared between 
the different DAS28 disease activity states. To avoid biasing the on-going management of 
continuing study participants a similar comparison was not performed for the DAS28 assessment 
group 
 
5.2.1 Mean Values of DAS28 Component Variables 
The available data for reviews of the MSUS assessment group between months 3 and 18 was 
segregated into groups based upon the previously defined disease activity states (Table 27) and 
the mean value of each of the DAS28 components for each group was calculated (Table 29). In 
summary, as the relative severity of the DAS28 disease activity assessment increased there was 
a corresponding increase in the individual components of the DAS28. 
 
In the small number of occasions of high disease activity (DAS28>5.1) the individual mean 
DAS28 components clearly suggested active disease that was likely to be clinically evident. 
Patients exhibited the highest number of tender and swollen joints, reported the worst global 
health and pain scores and also exhibited the highest ESR. Conversely, instances of DAS28 
LDAS and DAS28 remission were both associated with very low tender and swollen joint counts, 
suggesting that there was little clinical evidence of active synovitis. As a whole group, instances 
of moderate disease activity were associated with mean values that were somewhere between 
those of the low and disease activity groups. Dividing the moderate disease activity group using a 
threshold of 2 or more clinically swollen joints did identify differences between the mean values of 
the other DAS28 components. Compared to patients with 2 or more clinically swollen joints those 
patients with minimal clinical synovitis (SJC<2) tended to exhibit higher tender joint counts (mean: 
3.55 vs 3.05), global health 10cm VAS (mean: 48.78 vs 35.33) and pain 10cm VAS (mean: 47.09 
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vs 40.45). However, even though these was no clinical evidence of synovitis the mean ESR was 
still moderately elevated providing some objective evidence of underlying active inflammatory 
disease 
 
DAS28 Disease 
Activity Assessment 
DAS28 28TJC 28SJC ESR Global 
VAS 
Pain 
VAS 
DAS28<2.6 
N = 432 
 
1.72 
(0.49) 
0.14 
(0.44) 
0.49 
(0.92) 
9.45 
(6.24) 
7.56 
(12.36) 
7.85 
(13.37) 
DAS28<3.2* 
N = 580 
 
2.02 
(0.67) 
0.36 
(0.89) 
0.69 
(1.28) 
12.50 
(10.29) 
11.27 
(15.97) 
11.84 
(17.32) 
3.2≤DAS28<5.1  
N = 161 
 
3.89 
(0.52) 
3.29 
(2.88) 
1.92 
(1.88) 
26.16 
(20.22) 
41.84 
(25.42) 
40.45 
(25.30) 
3.2≤DAS28<5.1 and 
SJC<2* 
N = 78 
3.75 
(0.48) 
3.55 
(2.95) 
0.42 
(0.50) 
21.82 
(14.46) 
48.78 
(23.07) 
47.09 
(22.22) 
3.2≤DAS28<5.1 and 
SJC ≥2  
N = 83 
4.03 
(0.53) 
3.05 
(2.82) 
3.33 
(1.60) 
30.23 
(23.80) 
35.33 
(25.92) 
34.13 
(26.55) 
DAS28 ≥5.1 
N = 12 
5.72 
(0.57) 
8.33 
(5.03) 
6.58 
(4.08) 
42.50 
(25.53) 
72.25 
(17.37) 
65.17 
(20.24) 
Table 29: Mean (SD) values of DAS28 components for MSUS assessment group participants 
between 3 and 18 months follow-up 
* MSUS Indication 
 
 
5.2.2 Frequency of Clinical Disease Activity States in MSUS Assessment 
Group by Month 
Over the course of the follow-up period there was a gradual shift in the proportion of participants 
classified as each of the different disease activity states (Graph 2). Overall, the proportion of 
participants with clinically active RA fell and was mirrored by a steady increase in the proportion 
with either DAS28 LDAS and/or remission. There were no instances of high disease activity from 
month 13 onwards. The proportion of participants with DAS28 LDAS rose from 71% at month 3 to 
93% at month 18. Similarly, the proportion of participants with DAS28 remission rose from 45% at 
month 3 to 72% at month 18. The proportion of participants with moderate disease activity but 
minimal synovitis remained relatively static, suggesting that there may be a subset of RA patients 
in whom it is not possible to fully suppress DAS28.  
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Graph 2: Percentage occurrence of each disease activity state by month – MSUS assessment 
group 
 
5.3 Potential workload implications of MSUS 
Assessment 
To quantify the potential workload implications of incorporating MSUS assessment into routine 
clinical practice the incidence of each MSUS indication, the likelihood of each indication 
identifying active disease and the relationship between the frequency of MSUS assessments and 
the incidence of active disease for each patient was calculated. 
 
5.3.1 Frequency of each MSUS indication and likelihood of identifying 
active disease 
Regardless of indication, the majority of MSUS assessments failed to identify active synovitis. 
Three-hundred and sixty-nine MSUS assessments were conducted because of DAS28 LDAS; of 
these, 92 (25%) identified active disease. Similarly, 271 MSUS assessments coincided with 
DAS28 remission; of these, 66 (24%) identified active disease. Forty-five assessments were 
conducted because participant’s DAS28 suggested moderate disease activity but with minimal 
clinical synovitis; however, only 15 of these assessments (33%) actually confirmed the presence 
of underlying active synovitis.  
 
For each MSUS indication, there was a gradual fall in the total number of MSUS assessments 
that identified active disease over the follow-up period (Graphs 3-5). The frequency of positive 
MSUS assessments varied on a month-by-month basis (Graph 6). Further, there was also 
considerable variability evident when the proportion of positive MSUS assessments was 
segregated by indication (Graph 7). The highly variable nature of these findings may, in part, be 
explained by the relatively small number of MSUS assessments performed during some months.  
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Graph 3 – DAS28<2.6 - Frequency of MSUS assessments and frequency of positive MSUS 
assessments  
 
 
 
Graph 4 -  DAS28 < 3.2 - Frequency of MSUS assessment and frequency of positive MSUS 
assessments  
 
 
Graph 5 - 3.2≤DAS28<5.1 and SJC<2 – Frequency of MSUS assessment and frequency of 
positive MSUS assessments  
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Graph 6 – Relationship between frequency of MSUS assessment and frequency of positive 
MSUS assessments  
line = frequency of positive MSUS assessment 
 
 
Graph 7 – Percentage of MSUS assessments that identified active disease by MSUS indication 
and month 
 
5.3.2 Relationship of frequency of MSUS assessment to incidence of 
active disease 
All MSUS assessment group participants underwent at least 1 MSUS assessment over the 
follow-up period. The frequency of MSUS assessment for each patient demonstrated a positively 
skewed distribution (Graph 8).The median number of assessments performed per patient was 9 
(IQR 6-10) whilst the mean was 8.2 (SD 3.5) 
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 Graph 8 – Distribution of number of MSUS assessments conducted per patient over 
follow-up period 
 
The relationship between the number of the MSUS assessments performed per participant and 
the number which actually identified active disease was not linear. As Graph 9 demonstrates the 
proportion of MSUS assessments that actually identified active disease remained highly variable 
between individual participants. Notably, a small number of participants (n = 6) underwent 
comparatively infrequent MSUS assessments (between 1 and 3 assessments per participant) that 
identified a high rate of active disease (60% of assessments). It is presumed that this reflects the 
small subgroup of participants with highly active disease in whom MSUS assessment was only 
infrequently indicated since treatment escalation decisions could be based upon clinical findings 
alone. There was also a subset of participants (N = 13) who underwent comparatively high 
numbers of MSUS assessments (between 11 and 15 assessments per participant) that identified 
relatively low rates of active disease (percentage of positive assessments 2.2-14.5%) but still 
contributed significantly to the overall workload (160 MSUS assessments; 37% of total number).  
 
 
Graph 9 – Scattergraph demonstrating the relationship between the number of MSUS 
assessments performed per patient and the number of assessments that identified active disease 
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5.3.3 Indication and findings of first MSUS assessment 
The majority of first MSUS assessments were conducted because participants exhibited DAS28 
LDAS, rather than moderate disease activity and minimal clinical synovitis (Table 29). Twenty 
three (43%) of the first MSUS assessments identified active disease. However, despite the 
evident imbalance in numbers the proportion of MSUS assessments that identified active disease 
was similar for both MSUS indications (Table 30). Chi-squared analysis suggested that there was 
no statistically significant difference in the proportion of positive first MSUS assessments between 
either of the indication groups (p=0.8174) 
 
Indication Number (%) Number (%) of positive 
MSUS assessments 
DAS28<3.2 
 
40 (76%) 17 (43%) 
3.2≤DAS28<5.1 and SJC<2* 
 
13 (24%) 6 (46%) 
Total 
 
53 23 (43%) 
Table 30  - Number of first MSUS assessments performed for each MSUS indication and number 
(percentage) that identified active disease  
 
 
5.4 Change in MSUS PD signal findings over follow-
up period 
 
5.4.1 Overall change in MSUS findings 
Despite the month-by-month variation in the rate of active disease identified by MSUS 
assessment there was a downward trend in the number and proportion of positive MSUS 
assessments over the whole of the follow-up period (Graph 6). A gradual fall in the total PD score 
and the number of joints demonstrating PD signal (the PD joint count) was observed, suggesting 
the total inflammatory burden was lessening and a positive treatment response. Mean PD score 
decreased from 2.70 to 1.34 (95% CI: 2.09, 0.63; p<0.001) between the first and last MSUS 
assessment and PD joint count decreased from 1.78 to 1.12 (95% CI-1.10, -0.22; p=0.004). Only 
5 patients had undergone MSUS assessments at both month 3 and 18 time points. For these 
patients, a downward trend was observed in the change of mean total PD score (2.60 to 1.20) 
and mean PD joint count (1.80 to 1.00); however, due to the very small number of subjects, this 
did not reach statistical significance (p= 0.21 and 0.34 respectively).  
 
For each set of monthly MSUS assessments, the interquartile ranges of the PD joint counts 
fluctuated around a relatively narrow range of values (between 0-3) suggesting that the majority 
of MSUS assessments were identifying relatively small numbers of joints with evidence of PD 
signal (Graph 10). However, for each month, the range of all the PD joint counts observed was 
more variable than the relatively narrow band implied by the interquartile range. Even in the later 
follow-up months a subset (at least 25%) of participants continued to exhibit PD joint counts of 2 
or higher that fulfilled DMARD escalation criteria. Therefore, continuing MSUS assessments up 
until this point remained worthwhile since it continued to identify evidence of active synovitis 
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Graph 10 – Box and whisker plot of dispersal of PD joint counts recorded each month – all 
results. 
 Blue box – inter-quartile range; whiskers – range; purple line – mean 
 
 
Graph 11 – Box and whisker plot of dispersal of total PD score recorded each month 
Pink box – inter-quartile range; whiskers – range; purple line – mean 
 
Graphically representing the range of total PD scores demonstrates that there was a wide 
dispersal in the range of total scores and that some outlying patients continued to exhibit 
relatively high total PD scores, even at relatively late stages of follow-up (Graph 11). Once again, 
significant variability in the total range of scores was evident throughout most of the follow-up 
period. The inter-quartile ranges suggest that, on the majority of occasions, the majority of 
participants exhibited total PD scores within a narrow band of low PD burden (range 0-3 – i.e. at 
most 3 joints affected, each with grade 1 PD signal). However, between months 3 and 14 there 
were still outlying participants (up-wards whisker) exhibiting much higher total PD scores (range 3 
– 10) suggesting a minority who experienced a much higher inflammatory burden. From month 15 
  191 
onwards the absolute and range of values relating to the outlying participants falls and narrows 
markedly (range 1 – 5), perhaps suggesting that previously high total inflammatory burdens have 
started to recede in response to increasingly aggressive DMARD therapy regimens 
 
5.4.2 Time course assessment of changes in PD findings 
Since the pattern and sequence of MSUS assessments was highly variable between participants,  
describing the change in mean PD joint count on a month-by-month basis may not fully depict the 
impact of MSUS-steered DMARD therapy on MSUS findings since, for any given month, each 
participant will have been at a different place in the sequence of MSUS assessments. By taking 
the first MSUS assessment as a reference point, against which all subsequent MSUS 
assessments are compared, it is possible to describe how MSUS findings change once global 
disease activity starts to be assessed by a standardised MSUS measure. Following the first 
MSUS assessment, there was an overall decrease in the number of positive MSUS assessments 
performed during subsequent months (Graph 12: Month 0 - 23 positive assessments; Month 15 – 
2 positive assessments, p=0.038). However, it is worth restating that there were 53 data points 
available for the first MSUS assessment but only 5 for the fifteenth month after the first MSUS 
assessment.  
 
 
Graph 12 – Number of positive MSUS assessments observed for each month after first MSUS 
assessment 
 
Following the first MSUS assessment there was a progressive fall in the total PD joint count 
between months 1 and 13 (mean PD count 1.8 vs 0.5 respectively, p<0.0001), suggesting that 
the number of joints exhibiting any PD signal had also fallen (i.e. a positive treatment response) 
(Graph 13). However, after month 13 there was a slight increase in the mean PD joint observed 
to 0.9 (month 14) and then 1.0 (month 15). For the fourteenth month after first MSUS assessment 
there were 24 data points available, which is similar to preceding months 1 to 13 (range 22-32); 
therefore, it is likely that the apparent increase does represent a slight overall increase in the rate 
of active disease. However, for the 15th month there were only 5 data points available. Such 
discordance in data group sizes will have significantly increased the risk of single abnormal 
findings skewing the overall summary statistic and will have reduced the representative value of 
the month 15 data overall. Whilst the mean PD joint count was consistently less than 2, Graph 13 
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also demonstrates that at each time point there was a subgroup of participants (essentially the 
upper quartile) who exhibited significantly higher numbers of joints with PD signal 
 
 
Graph 13 - Total PD joint count score for each month after first MSUS assessment (month 0) 
Box = interquartile range, whiskers = maximum and minimum, line = mean 
 
 
Determining the likelihood of future MSUS findings from preceding MSUS 
assessments 
Whilst the assessment and treatment protocol lead to participants undergoing a highly variable 
number of MSUS assessments, and usually for a mixture of indications, it also lead to many 
participants undergoing several consecutive negative MSUS assessments (Graph 9). By setting 
each participant’s first MSUS assessment as a reference point, the relationship between different 
sequences of MSUS findings, and the likelihood of subsequently identifying active disease could 
be calculated. Several, theoretical, but clinically likely, scenarios were devised to determine the 
relationship between patterns of MSUS findings and the risk of identifying active disease during 
subsequent assessments. Active disease continued to be defined as at least 2 or more joints 
exhibiting any PD signal. Overall, a positive MSUS assessment was associated with an increased 
likelihood of subsequent MSUS assessments identifying active disease; whilst consecutive 
negative MSUS assessments were associated with a decreasing likelihood that subsequent 
MSUS assessments would identify active disease 
 
Probability of identifying active disease following a positive MSUS assessment – applies to two 
different clinical scenarios: 
1. Three month follow-up MSUS assessment - if DMARD therapy had been escalated 
because MSUS assessment identified active disease it is likely that another MSUS 
assessment would not be performed for at least 3 months. Presuming that each positive 
MSUS assessment would have lead to DMARD escalation, the probability of any positive 
MSUS assessment being followed by another positive MSUS assessment three months 
later was calculated. Altogether, 55 positive MSUS assessments had 3 month follow-up 
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MSUS assessment data available. Of these, 30 follow-on assessments (55%) continued to 
identify active disease whilst 25 assessments (45%) did not  
 
2. One month follow-up MSUS assessment – on a small number of occasions a positive 
MSUS assessment was not followed by immediate DMARD escalation; usually due to 
patient choice, intercurrent illness or the presence of a contra-indication (e.g. blood 
monitoring abnormality). If DMARD therapy was not escalated, a further MSUS 
assessment was conducted during the subsequent month’s consultation to determine 
whether there was persistence of PD signal. Comparing the findings of both these 
assessments provided the opportunity to determine the likelihood of a single positive 
MSUS assessment being followed by another positive assessment one month later. There 
were 22 occasions when a positive MSUS assessment had follow on MSUS assessment 
data available for the next month. Eighteen follow-on assessments (82%) demonstrated 
persistence of active disease, whilst 4 follow-on assessments (18%) no longer identified 
active disease. 
 
Probability of identifying active disease following a negative MSUS assessment – applies to two 
different clinical scenarios: 
1. One month follow-up assessment – if a MSUS assessment did not identify active disease, 
the assessment protocol required that participant’s global disease activity be reassessed 
during the next monthly review to determine whether they then fulfilled the criteria for 
DMARD escalation. There were 245 occasions when a single negative MSUS assessment 
had MSUS assessment data available for the next month. In 45 follow-up MSUS 
assessments (18%) active disease was identified and DMARD therapy would usually have 
been escalated. By contrast, 200 follow-up assessments (82%) showed no evidence of 
active disease and DMARD therapy would usually not have been changed 
 
2. Risk of active disease after consecutive negative MSUS assessments – data from 
consecutive negative MSUS assessments was analysed to determine whether increasing 
numbers of consistently negative MSUS assessments were associated with an increased 
chance of future assessments also being negative (Graph 14). Overall, as the number of 
consecutive MSUS assessments increased the risk of a subsequent MSUS assessment 
identifying active disease gradually fell. Systematic between group comparisons (Fisher’s 
test) demonstrated that, compared to one negative MSUS assessment, after 4 and 5 
consecutive negative MSUS assessments there was a statistically significant reduction in 
the risk of subsequent MSUS assessments being positive (p = 0.037 and 0.0062 
respectively). All other between group comparisons did not reach statistical significance 
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Graph 14 – Risk of subsequent MSUS assessment identifying active disease following 
consecutive negative assessments.  
   
In summary, a positive MSUS assessment was associated with an increased likelihood of 
subsequent MSUS assessments identifying active disease; whilst a negative MSUS assessment 
was associated with an increased likelihood of subsequent MSUS assessments not identifying 
active disease. Compared to a single negative MSUS assessment the relative risk of a single 
MSUS assessment being followed by another positive assessment is 4.45 (95% CI 3.20 – 6.19; 
p< 0.0001). Furthermore, increasing numbers of negative consecutive MSUS assessments were 
associated with a diminishing risk of subsequent MSUS assessments identifying active disease 
(Table 31) 
 
Preceding MSUS 
assessment findings 
Relative risk of 
subsequent positive 
MSUS assessment 
95% Confidence 
Intervals 
p 
Single positive 
assessment 
4.45 3.20 – 6.19 < 0.0001 
2 consecutive 
negative assessments 
0.72 0.45 – 1.15 0.17 
3 consecutive 
negative assessments 
0.65 0.38 – 1.11 0.12 
4 consecutive 
negative assessments 
0.45 0.21 – 0.96 0.041 
5 consecutive 
negative assessments 
0.26 0.085 – 0.82 0.021 
Table 31 – Relative risk of subsequent MSUS assessments identifying active disease following 
consecutive negative MSUS assessments 
 
 
5.5 MSUS PD signal findings by joint area 
The available MSUS data were interrogated to determine how often each joint area displayed 
positive MSUS findings that contributed to the final treatment decision. The radiocarpal joint most 
frequently demonstrated PD signal. The index MCPj and middle MCPj were next most frequently 
involved. By comparison, the index PIPj, middle PIPj, second MTPj and fifth MTPj demonstrated 
PD signal very infrequently (Graph 15). The number of occasions when bilateral joint involvement 
was recorded was consistently less than the number of occasions when unilateral joint 
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involvement was identified. This asymmetrical pattern of joint involvement on MSUS is contrary to 
the traditional depiction of active RA as a symmetrical polyarthritis and may represent either very 
early disease or attenuation of the usual disease processes by DMARD therapy 
 
 
 
Graph 15 – Frequency and distribution of positive PD findings by joint area 
Data presented for right (blue) and left (red) hand side involvement combines both unilateral and 
bilateral involvement of each joint area 
 
5.5.1 Frequency of positive MSUS assessments using different joint 
sets 
Graph 15 shows that, even using the limited 14 joint set, there were certain joint areas (notably 
radio-carpal and MCP joints) that were much more likely to exhibit positive PD signal. Equally, as 
the size of the joint set increases there will be a corresponding increase in the length of time 
needed for performing the MSUS assessment. Reducing the size of the joint set will reduce the 
overall assessment time; though may also reduce its sensitivity. Using the 14 joint set as 
reference, different combinations of joints were tested to determine what impact further 
reductions in the size of the joint set would have upon the overall accuracy of MSUS assessment 
(Table 32). To varying degrees, all of the reduced joint sets proved less sensitive than the 14 joint 
set. Joint sets that retained bilateral assessment of each joint area (sets 1 – 3) performed notably 
better than unilateral joint sets (sets 4 and 5). As the bilateral joint sets became more restricted 
the accuracy of the disease activity assessment also fell. For example, by omitting the 2nd and 5th 
MTP joints the overall sensitivity of assessment fell to 90% (set 2). By contrast, retaining the 2nd 
and 5th MTP joints but omitting the index and middle PIP joints (set 3) had the smallest impact on 
overall sensitivity (97%). Omitting both the index and middle PIP joints and the 2nd and 5th MTP 
joints caused the sensitivity to fall to 86.7%. Thus, the 2nd and 5th MTP joints, which individually 
demonstrated slightly higher rates of involvement than the index and middle PIP joints, also had a 
greater impact on the likelihood of diagnosing active disease  
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Joint Set 
Name 
 Active 
Disease 
(PD Signal 2+ 
joints) 
Inactive 
Disease 
(PD Signal 0-1 
joints) 
Sensitivity 
TaSER Set 14 joints – 
bilateral RCj,  
MCP2, MCP3, 
PIP2, PIP3, 
MTP2, MTP5 
118 
(28%) 
 
311 
(72%) 
100% 
1 6 joints – 
bilateral RCj, 
MCP2 + MCP3 
100 
(23%) 
 
329 
(77%) 
86.7% 
2 10 joints – 
bilateral RCj, 
MCP2, MCP3, 
PIP2 + PIP3 
105 
(24%) 
 
324 
(76%) 
90.0% 
3 10 joints – 
bilateral RCj, 
MCP2, MCP3, 
MTP2 + MTP5 
114 
(27%) 
 
315 
(73%) 
97% 
4 All right hand 
sided joints 
 
33 
(8%) 
 
396 
(92%) 
58% 
5 All left hand 
sided joints 
 
43 
(10%) 
 
386 
(90%) 
61% 
Table 32 – Frequency (percentage) of positive MSUS assessments using different joint sets 
 
5.6 Agreement between DAS28 and MSUS disease 
activity assessments 
5.6.1 Definitions (reprise) 
Definitions of agreement (and disagreement) between DAS28 and MSUS disease activity 
assessments was based on whether the outputs of each assessment method would have 
resulted in the same decision to intensify (or not) DMARD therapy. Agreement was present if both 
methods would have produced the same treatment decision (i.e. they agreed on the disease 
activity state) and disagreement was present if both methods would have produced opposing 
treatment decisions (i.e. disease activity state assessments were discordant). Table 28 (reprinted 
below), summarises the interaction between DAS28 and MSUS disease activity assessments in 
relation to DMARD escalation decisions 
 
Disease Activity State 
Descriptor 
Disease State 
 
DMARD escalation 
decision 
DAS28 ≥	 5.1 High disease activity  
 
 
Escalate on clinical 
grounds 3.2 ≤	 DAS28 < 5.1 AND 28SJC ≥	 2 
Moderate disease activity and 
clinical synovitis  
3.2 ≤	 DAS28 < 5.1 AND 28SJC 
=	 0-1 
Moderate disease activity but 
minimal clinical synovitis  
 
 
MSUS assessment 
required to inform DMARD 
decision 
 
 
DAS28 < 3.2 Low disease activity  
 
DAS28 < 2.6 Clinical remission 
Table 28: Disease activity states and relationship to DMARD escalation decisions 
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5.6.2 MSUS disease activity assessment findings during DAS28 LDAS 
Three hundred and sixty-nine MSUS assessments were performed during DAS28 LDAS, of these 
277 (75%) showed no evidence of active disease and therefore supported the impression given 
by DAS28 that little, or no, active disease remained. Ninety two (25%) MSUS assessments 
disagreed with the DAS28 by identifying PD signal in 2 or more joints (Table 33). 
 
If the MSUS PD joint count DMARD escalation threshold was reduced to include assessments 
that identified PD signal in any joint, 219 MSUS assessments (59%) would have suggested active 
disease (Table 34). Alternatively, if the threshold had been raised to only include occasions when 
3 or more joints exhibited PD signal, 33 (9%) of the MSUS assessments would have been 
classified as active disease (Table 35). 
 
5.6.3 MSUS disease activity assessment findings during DAS28 
remission 
Two hundred and seventy-one MSUS assessments coincided with DAS28 remission. Two 
hundred and five (76%) assessments did not identify ultrasonographic evidence of active disease 
and therefore did not influence DMARD therapy. Sixty-six (24%) assessment did identify 
ultrasonographic evidence of active disease and supported further DMARD escalation even 
though participants fulfilled DAS28 remission criteria (Table 33).  
 
Using an MSUS PD joint count threshold of one, 162 assessments (60%) would have been 
classified as showing active disease (Table 34). However, if the PD joint count threshold had 
been raised to 3, only 25 MSUS assessments (9%) would have identified active disease (Table 
35) and the degree of agreement (and the number of MSUS assessments classified as inactive 
disease) would have appeared far higher 
 
5.6.4 MSUS disease activity assessment findings during moderate 
disease activity and minimal clinical synovitis 
Forty-five MSUS assessments were performed when 3.2≤DAS28<5.1 (moderate disease activity) 
and SJC<2 (minimal clinical synovitis) to determine whether the elevated DAS28 was associated 
with underlying active synovitis. Thirty (67%) MSUS assessments did not identify evidence of 
active disease and prevented further DMARD escalation on that occasion. Fifteen (33%) MSUS 
assessments confirmed the presence of active disease and supported the DAS28-based decision 
to escalate DMARD therapy (Table 33). 
 
Lowering the MSUS PD joint count threshold to 1 would have classified 25 MSUS assessments 
(56%) as active disease (Table 34). Conversely, a MSUS PD joint count threshold of 3 or more 
would have only classified 6 instances (13%) as active disease (Table 35) 
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Table 33 – Agreement (green boxes) and disagreement (red boxes) between DAS28 and MSUS 
assessments of global disease activity.  
MSUS threshold = PD signal in 2 or more joints 
PD – Power Doppler, SJC – swollen joint count 
	  
Table 34 – Agreement (green boxes) and disagreement (red boxes) between DAS28 and MSUS 
assessments of global disease activity.  
MSUS threshold = PD signal in 1 or more joints 
 
Table 35 – Agreement (green boxes) and disagreement (red boxes) between DAS28 and MSUS 
assessments of global disease activity.  
MSUS threshold = PD signal in 3 or more joints 
 
5.6.5 Overall agreement between DAS28 and MSUS disease activity 
assessments 
The degree of overall agreement between DAS28 and MSUS disease activity assessment was 
dependent upon the MSUS PD joint count threshold used to define active disease (Graph 16). 
Using the proposed joint count threshold of 2 joints, there was agreement between DAS28 and 
MSUS disease activity assessments on 292 (71%) occasions. This also infers that MSUS disease 
activity findings had the potential to alter DMARD escalation decisions on 122 (29%) occasions. 
On 92 (22% of all MSUS assessments) of these occasions, MSUS assessment lead to DMARD 
therapy intensification that had not been suggested by DAS28 and on 30 occasions (7%) MSUS 
  MSUS Assessment 
  PD signal in 0-1 
joints 
PD in 2 or more 
joints 
 
 
DAS28 
Assessment 
(N = 414) 
DAS28 <2.6 
(N= 271) 
205 (76%) 66 (24%) 
DAS28 <3.2 
(N= 369) 
277 (75%) 92 (25%) 
3.2≤ DAS28 <5.1 and SJC <2 
(N= 45) 
30 (67%) 15 (33%) 
  MSUS Assessment 
  PD signal in 0 
joints 
PD in 1 or more 
joints 
 
 
DAS28 
Assessment 
(N = 414) 
DAS28 <2.6 
(N= 271) 
109 (40%) 162 (60%) 
DAS28 <3.2 
(N= 369) 
150 (41%) 219 (59%) 
3.2≤ DAS28 <5.1 and SJC <2 
(N= 45) 
20 (44%) 25 (56%) 
  MSUS Assessment 
  PD signal in 0-2 
joints 
PD in 3 or more 
joints 
 
 
DAS28 
Assessment 
(N = 414) 
DAS28 <2.6 
(N= 271) 
246 (91%) 25 (9%) 
DAS28 <3.2 
(N= 369) 
336 (91%) 33 (9%) 
3.2≤ DAS28 <5.1 and SJC <2 
(N= 45) 
39 (87%) 6 (13%) 
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assessment prevented DMARD escalation even though DAS28 registered moderate disease 
activity 
 
A MSUS PD joint count threshold of 1 or more lead to more participants being classified as 
having active disease but a lower overall rate of agreement (42%) with DAS28 (Graph 16). 
Conversely, a MSUS PD joint count threshold of 3 or more lead to far fewer participants being 
classified as having active disease by MSUS assessment but an increased overall rate of 
agreement (83%). 
 
 
Graph 16 -  Percentage agreement between DAS28 and MSUS disease activity assessments 
based upon different MSUS PD joint count thresholds 
 
5.7 Change in MSUS synovial hypertrophy findings 
over follow-up period 
The proposed definition of active disease focuses on the presence of intra-articular PD signal as 
the primary MSUS marker of active synovitis. Assessing the presence of PD signal also allows 
direct visualisation of gray scale synovial hypertrophy, and, even though these findings did not 
influence DMARD therapy decisions directly, the available data does make it possible to describe 
how synovial hypertrophy appearances changed over the follow-up period. 
 
Whilst an overall downward trend was observed in both the total PD score and joint count over 
the follow-up period, the pattern and degree of change in the mean total synovial hypertrophy 
score and joint count was much less marked. Considerable month-by-month variability was 
observed in the mean total synovial hypertrophy score and joint count and in fact there was 
actually very little overall change (Graph 17). The greatest degree of fluctuation in both total 
synovial hypertrophy score and joint count is evident between follow-up months 11 and 18. 
Interestingly, excepting month 18, this is also the period when the number of MSUS assessments 
performed each month is most consistent (28 – 32 assessments per month). Therefore, whilst 
presumably there will have been some low level variation in which specific participants underwent 
MSUS assessment each month, it is unlikely that the observed synovial hypertrophy findings will 
have been excessively skewed by small numbers of aberrant outliers. 
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Graph 17 – Mean total synovial hypertrophy score (black line) and joint count (dotted line) by 
month 
 
Overall, a small numerical fall was observed in the mean total synovial hypertrophy scores. 
However, the degree of change did not meet statistical significance for comparisons comprising 
the mean first (4.58) and last (4.34) synovial hypertrophy score (mean difference -0.24; CI -1.23 – 
0.75; p 0.63) or the month 3 (3.20) and month 18 (2.00) values (mean difference -1.20; CI -5.96, 
3.56; p 0.52). Thus, whilst step-up DMARD therapy was associated with an apparent overall 
improvement in total PD score over the follow-up period it was not associated with a similar 
improvement in the total synovial hypertrophy score. Graph 18 demonstrates that the total 
synovial hypertrophy score recorded each month was also variable for an outlying subset of 
participants. In the majority of participants (blue box) the total synovial hypertrophy score fell 
within a relatively narrow band (0-3). However, up until month 13, MSUS assessments continued 
to record much higher total synovial hypertrophy scores in a subset (approximately 25%) of 
participants. Interestingly, from month 14 onwards, there is an apparent, and consistent, 
decrease in the maximum score recorded and a narrowing in the total range of scores. This may 
reflect prolonged DMARD therapy being eventually associated with some reduction in the total 
volume of synovial hypertrophy present in outlying participants; however, it may not yet be 
sufficient to influence the overall group mean. The follow-up period would need to be extended to 
determine whether the apparent reduction in score continued beyond month 18. 
 
A small, non-significant fall was also observed in the mean synovial hypertrophy joint counts over 
the follow-up period. Between the first and the last recording mean synovial hypertrophy joint 
count fell from 2.48 to 2.30 (mean change -0.18; CI -0.74 – 0.38; p 0.52). Similarly, between the 
month 3 and month 18 time points, mean synovial hypertrophy joint count fell from 1.60 to 1.00 
(mean change -0.60, CI -3.02 – 1.82; p 0.53).  
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Graph 18 – Box and whisker plot of range of values for total synovial hypertrophy score for each 
month 
Blue box – interquartile range; whiskers – range; purple line – mean 
  
5.8  Discussion 
The available results do suggest that a standardised MSUS assessment of global disease activity 
will alter DMARD treatment escalation decisions in a significant subset of patients. In some 
instances of DAS28 LDAS and clinical remission (approximately 25%), MSUS assessment will 
support further DMARD escalation in patients who continue to exhibit evidence of subclinical 
synovitis. Conversely, in a significant proportion of patients with moderate disease activity, but 
minimal clinical synovitis (approximately 67%), MSUS assessment will support non-escalation of 
DMARD therapy in those who exhibit no ultrasonographic evidence of active disease.   When 
considering how feasible, or appropriate, it would be to incorporate MSUS assessment into the 
routine assessment of RA patients a number of important factors should be considered: 
 
1. How to select appropriate patients for MSUS assessment 
2. What constitutes an adequate MSUS assessment of global disease activity and how best 
to define ‘active disease’ using MSUS findings 
3. The additional workload that would be created by regularly performing the MSUS 
assessment 
4. How frequently the MSUS assessment lead to altered treatment decisions 
5. Whether the treatment decisions that were influenced by MSUS assessment lead to 
meaningful improvements in clinical, functional and/or radiological outcomes 
 
5.8.1 Selection of patients for MSUS assessment 
For logistical reasons it would be impractical, and illogical, to perform MSUS disease activity 
assessment upon all RA patients during every single review. In order to balance the time required 
to perform MSUS disease activity assessment against the needs of a busy clinical service MSUS 
assessment should be targeted at those patients who are most likely to benefit from its findings. 
Therefore, there will be some situations in which MSUS assessment is superfluous since 
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decisions to alter DMARD therapy can be supported by clinical findings alone. Conversely, there 
will also be some clinical situations where clinical examination is insufficiently sensitive and/or 
specific to provide an accurate reflection of the actual disease burden and could lead to 
inappropriate therapeutic decision making. Thus, for this study, the investigators devised clinical 
scenarios where the additional disease activity information provided by MSUS assessment was 
likely to alter the DMARD escalation decision. Considering the disease activity variables of each 
of these situations individually will determine whether appropriate indications for MSUS were 
proposed: 
 
DAS28 LDAS - including DAS28 remission 
Performing MSUS disease activity assessment during instances of DAS28 LDAS (with or without 
DAS28 remission) does seem reasonable because, at a group level, a notable number of 
assessments (approximately 25%) did identify evidence of active synovitis and supported further 
DMARD escalation.  Equally, the summary values of the DAS28 components for instances of 
LDAS equated to a previously published definition of RA minimal disease activity (295,329). 
During these instances, the individual DAS28 components suggest that synovitis would not have 
been clinically evident. Therefore, MSUS assessment could provide an additional means of 
differentiating between DAS28 LDAS patients with no active synovitis (i.e. a truer definition of 
remission) and those who still have subclinical synovitis and might require further DMARD 
escalation. DAS28 LDAS was by far the most common indication (89%) for MSUS assessment; 
therefore a MSUS indication based upon DAS28 LDAS could lead to repeated negative 
assessments of patients with stable disease control. Following 4 or 5 consecutive negative MSUS 
assessments there was a low risk that further MSUS assessments would identify active synovitis 
therefore, it seems reasonable to stop performing MSUS after 4 consecutive negative 
assessments 
 
DAS28 Moderate disease activity (3.2≤DAS28<5.1)  
Until recently, any instance of DAS28 moderate disease activity was considered to reflect on-
going active synovitis. However, it is increasingly recognised that, in some instances, other 
coexistent pathologies may also contribute to elevations in DAS28 scores that can be 
misinterpreted as being RA related (154,155,204). If there is evidence of clinically swollen joints 
the clinician can be confident that at least some of the elevation in DAS28 is related to active RA 
because of the presence of clinical synovitis. If there is minimal clinical synovitis, the clinician may 
consider that alternative, non-inflammatory processes are contributing to the DAS28 score, or 
may need to seek additional evidence to support further DMARD escalation.  
 
The findings of this study support the understanding that the presence of clinically swollen joints 
is an important (but not absolute) indicator of active disease during DAS28 moderate disease 
activity. Accepting that only a limited joint set was examined by MSUS, this study suggests that 
the majority (67%) of instances of DAS28 moderate disease activity but minimal clinical synovitis 
were in fact not associated with evidence of active subclinical synovitis. Therefore, in these 
instances relentlessly escalating immunomodulatory therapy purely based on the value of the 
DAS28 may not be appropriate since alternative processes may be contributing to the patient’s 
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on going symptoms. However, participants with DAS28 moderate disease activity but minimal 
clinical synovitis were still clearly symptomatic since they reported notable elevations in global 
health and pain 10cm VAS. They also had mild elevations of ESR, suggesting underlying 
inflammatory disease. Further, there were still a notable number of instances (33%) when MSUS 
assessment did identify active disease and supported the decision to escalate DMARD therapy. 
So the absence of clinically swollen joints doesn’t totally exclude the presence of synovitis. Thus, 
during instances of moderate disease activity with minimal clinical synovitis, MSUS disease 
activity assessment does allow treatment decision to be tailored to the specific needs of the 
participants. If active synovitis is confirmed, symptomatic patients will still be considered for 
further DMARD escalation. By contrast, symptomatic patients who have no synovitis will avoid 
unnecessary (and potentially toxic) additional DMARD therapy but may benefit from being 
considered for alternative treatment approaches 
 
High disease activity (DAS28>5.1) 
Compared to other disease activity states there were comparatively fewer instances of high 
disease activity and none that underwent MSUS assessment. Further, the mean values of the 
individual DAS28 component variables suggested a clinical phenotype that is easily recognisable 
as active RA. Therefore it is unlikely that MSUS assessment would have added sufficient 
additional disease activity information to lead to a decision not to escalate DMARD therapy. 
Previous studies have reported that patients with fibromyalgia (204) and fibromyalgic-RA (155) do 
exhibit DAS28 scores that are significantly higher than other RA patients and in some instances 
reach DAS28 high disease activity. During this study, concerns relating to non-specific elevations 
of the DAS28 were focussed on the moderate disease activity band and all instances of high 
disease activity were considered RA related. Clearly, some of the instances of high disease 
activity may have been related to non-RA processes; however, since MSUS assessment was not 
performed during these instances the exact extent cannot be quantified. A significant overlap with 
fibromyalgia seems unlikely, since: 1. all instances of high disease activity were associated with 
at least 2 clinically swollen joints and 2. the tender and swollen joint counts were relatively well 
matched which is contrary to the description of fibromyalgic-RA proposed by Pollard et al (155) 
 
Overall, the proposed indications do seem to select populations of patients that are appropriate 
for MSUS assessment of global disease activity. In particular, focussing on patients with DAS28 
LDAS or DAS28 moderate disease activity but minimal clinical synovitis identified clinical 
situations where the additional MSUS findings contributed meaningfully to tailored treatment 
decisions during a significant subset of consultations. Furthermore, restricting MSUS assessment 
to occasions when there is clinical doubt about the disease activity state will avoid needing to 
perform potentially time consuming MSUS assessments during instances where there is clear 
clinical evidence of active synovitis. The results also suggest that it will be possible to stop 
performing MSUS assessment after 4 or 5 consecutive negative assessments since the risk of a 
subsequent assessment being positive is very low. 
 
The proposed indications for MSUS assessment are based heavily on the consensus DAS28 
definitions of disease activity. These definitions are relatively arbitrary and don’t always provide a 
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full representation of the true disease state. Using the DAS28 patients can exhibit high numbers 
of swollen joints (i.e polyarticular synovitis) but still be classified as DAS28 LDAS or remission. As 
an extreme illustration:  if 28SJC = 28, 28TJC = 0, ESR = 5 and global VAS = 0, DAS28 = 2.61. 
Indeed, as has previously been shown, a significant proportion of patients who meet DAS28 
definition of remission can still demonstrate evidence of synovitis on imaging studies (121) and 
patients with DAS28 remission who still exhibit clinically swollen joints also exhibit progressive 
radiographic damage (192). Furthermore, it is possible that some RA patients who achieve high 
disease activity might have additional non-RA related processes adding to their overall DAS28 
score. Nevertheless, the DAS28 score, and it’s shortcomings, is easy to apply, validated and well 
understood by most rheumatologists (272). If the presence of clinically swollen joints, and by 
extension clinical synovitis, is predictive of future radiographic progression an alternative 
approach that disregards the total DAS28 value and determines whether patients require MSUS 
assessment based upon their swollen joint count might be more appropriate. This alternative 
approach is categorical rather than linear and favours the identification of active synovitis by 
either clinical and/or MSUS assessment rather than the attainment of a predefined DAS28 value. 
MSUS assessment would then be indicated if the clinician felt there was minimal clinical synovitis 
present, or sufficient doubt relating to the clinical findings. For example, patients with DAS28 
remission but 2 clinically swollen joints would be classified as active disease, as would patients 
with moderate-high disease activity if they exhibited at least 2 clinically swollen joints; whereas, 
patients with one or no clinically swollen joints would require MSUS assessment regardless of the 
DAS28 score.  
 
5.8.2  Proposed MSUS joint set and definitions of active RA 
Whilst there is a mounting momentum of evidence arguing for the inclusion of some form of 
musculoskeletal ultrasound examination into the routine assessment of global disease activity in 
RA (129,330), there is continuing debate about which joints should be examined to assess global 
disease activity and what is the minimal level of joint involvement required to define active 
synovitis on ultrasonographic grounds. For the purposes of this research, a pragmatic joint set 
and MSUS definition of active disease were chosen:  
 
Proposed MSUS limited joint set 
So far, limited MSUS joint sets have been proposed comprising 7 joints (290-292), 12 joints (226) 
and 20 joints (293). Further, limited joint sets have been shown to have similar metric properties 
to more extensive sets (226,293,331), sensitivity to changes in disease activity (226,292,332) and 
simplified PD joint sets have demonstrated similar sensitivity to sets that also include grey scale 
synovial hypertrophy (226). Since there is no universally accepted joint set, a novel joint set was 
devised that pragmatically combined the features of previously proposed sets to be in keeping 
with the defining clinical characteristics of RA.  
 
Unlike the studies by Dougados et al(293) and Naredo et al(226), the proposed MSUS joint set 
was devised by deduction rather than being derived from the findings of an extensive joint set. 
Thus, it is not possible to report how well the reduced set would perform in relation to a more 
extensive joint set. The concern being that by omitting particular joints that frequently exhibit 
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evidence of ultrasonographic synovitis the sensitivity of the proposed joint set is reduced. Equally, 
since the proposed MSUS joint set incorporates a novel combination of joints it is not possible to 
be certain that it will have similar metrological properties to any of the previously published joint 
sets. In order to standardise the examination technique, the joint set was non-adaptive; that is, 
symptomatic areas outwith the joint set were not examined. This is unlikely to represent usual 
clinical practice where clinicians may consider scanning all symptomatic areas a more 
appropriate assessment of global disease activity. Future studies in a similar area may increase 
the sensitivity of the MSUS assessment, and therefore its effectiveness, by considering either a 
much more extensive joint set (which requires longer scanning times and greater MSUS 
expertise) or a limited joint set and any other symptomatic region. This latter approach is 
particularly interesting since a major advantage of MSUS over MRI is its ability to examine most 
joint regions using a single piece of equipment.  
 
The high incidence of PD signal identified at the wrist is striking when compared to other joints 
and will have contributed to a significant number of DMARD escalation decisions. Compared to 
other joints within the set, the wrist is significantly more complex anatomically, since it comprises 
articulations between the radius, ulnar and both carpal rows. Hence there is a greater risk that 
variability in MSUS technique will influence interpretation of synovial findings. To minimise 
inconsistencies related to MSUS technique, assessment at the wrist was limited to the 
radiocarpal joint, which is relatively easy to identify and examine in a standardise manner. 
Clearly, there may have been some instances when the adjacent inter-carpal joint displayed PD 
signal that was not evident at the radio-carpal joint and would have been recorded (perhaps 
incorrectly) as a negative assessment. In future studies, the presence of synovitis at either the 
radio-carpal, and/or the inter-carpal joint, may be a more appropriate overall assessment for wrist 
synovitis.  
 
As the frequency of PD signal at the wrist was much higher than in other joint areas it is also 
important to consider whether findings at the wrist represented true synovial pathology. Until 
recently the assumption was that any intra-articular PD signal represented underlying synovial 
vascularity and, by extension, synovitis (213). However, it is possible that some PD findings are in 
fact related to the increasing sensitivity of modern ultrasound machines. Recent observational 
studies have reported a particularly high incidence (between 56-86%) of Doppler signal in the 
wrist joints of healthy volunteers but a much lower incidence in the MCP (7-11%) and PIP (1-2%) 
joints (224,295). This higher rate of Doppler signals may reflect the wrist having a much larger 
synovial surface than other peripheral joints and may be more likely to contain larger nutrient 
vessels that are detectable during Doppler examination. Importantly, failure to differentiate 
Doppler signal related to synovitis from that which is physiological (or artefactual) could contribute 
to inaccurate classification of the overall disease activity state and an inappropriate decision to 
escalate therapy. The resistive index (the degree of flow in tissue during diastole) can be used to 
differentiate physiological flow in synovial tissue from that related to inflammation; non-inflamed 
tissues exhibit a high resistance to flow, whilst inflamed tissues exhibit a comparatively lower 
resistance (295,333,334). Unfortunately, the resistive index was not measured, therefore, it is not 
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possible to comment on what proportion of positive PD signals at the radiocarpal joint might not 
have been related to synovial inflammation.  
 
Proposed MSUS definition of active disease 
Since there is no universally accepted joint set for assessment of global disease activity it follows 
that there is no accepted ultrasonographic definition of active disease either. Therefore, for this 
study, the definition of active disease, and the threshold at which DMARD therapy would be 
escalated, was devised pragmatically to represent a situation that balanced the sensitivity of the 
assessment against the possibility of false positive findings caused by PD artefact. The proposed 
MSUS definition defines active disease in a categorical manner (i.e. active or inactive) and is 
therefore more akin to the description of Minimal Disease Activity (329) than a continuous 
composite disease activity score. Using the available results, it was possible to determine what 
impact varying the PD joint count thresholds might have upon the sensitivity of the assessment 
and overall impression of disease activity (Tables 33 – 35). Using a PD joint count threshold of 2, 
107 (26%) MSUS assessments were classified as active disease. When the PD joint count 
threshold was reduced to 1, 244 (59%) were classified as active disease; whereas, when the PD 
joint count threshold was increased to 3, only 39 assessments (9%) were classified as active 
disease. These changes were evident whether the indication for MSUS assessment was DAS28 
LDAS or moderate disease activity with minimal clinical synovitis. Clearly, if a lowered PD joint 
count threshold of 1 had been used, it is likely that the MSUS assessment group as a whole 
would have been treated even more aggressively than they were using a threshold of 2. 
However, the potential of misinterpreting PD artefact in a single joint remains, and therefore such 
a low threshold may have lead to some participants being inappropriately exposed to the risks of 
intensive combination and/or DMARD therapy. By contrast, using an increased PD joint count 
threshold of 3 clearly restricts the sensitivity of the MSUS assessment. Whilst the stricter 
definition of active disease further reduces the risk of misclassifying PD artefact, it is quite unlikely 
that so few treatment decisions being altered would make any benefits on clinical and radiological 
outcomes too small to detect. It is worth noting that these assumptions on the impact of different 
PD joint count thresholds on treatment decisions were based upon data which was collected 
when the threshold was always 2. The MSUS findings observed during any given consultation will 
have been directly influenced by the treatment decisions made during preceding consultations 
(i.e. a single treatment escalation decision impacts upon all future disease activity assessments). 
Therefore, it is quite possible that the different PD joint count thresholds would have lead to 
different sequences of DMARD escalation and different sequences of subsequent clinical and 
MSUS disease activity assessments. Thus, separate longitudinal studies may be required to fully 
understand the impact of different PD joint count thresholds on DMARD escalation decisions and 
clinical and radiological outcomes.  
 
5.8.3 Workload implications of regularly performing MSUS disease 
activity assessment 
By extrapolating the findings of this study to routine care, approximately 55% of all early RA clinic 
consultations would also need to accommodate MSUS assessment of disease activity. If the 
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average outpatient consultation takes between 10-20 minutes (335) adding MSUS examination to 
existing clinical practice will substantially prolong the consultation time required for a significant 
number of patients and may actually lead to a reduction in the number of patients it is possible to 
review in an already busy clinic. Therefore, if MSUS examination were to be used routinely 
alternative assessment models may need to be considered. In particular, if it is impractical for the 
clinician to conduct the examination during the routine appointment, reconfiguring how outpatient 
clinics operate may be required (see below)  
 
If patients do achieve a stable low disease activity state that is no longer associated with on-going 
ultrasonographic evidence of active synovitis, it may be possible to use several consecutive 
MSUS assessments to confirm attainment of a stable disease state and then only consider 
repeating the MSUS assessment if there is a change in the patient’s condition. In this way, it 
might be possible to still achieve the potential benefits of disease activity monitoring using MSUS 
(in particular the unexpected discovery of active subclinical synovitis) without having to perform 
multiple, negative assessments that are no longer contributing directly to clinical care. From the 
available results it is clear that a subset of participants underwent multiple MSUS assessments 
with relatively low rates of active synovitis being identified (Graph 9). When participants had 
undergone a lesser number of MSUS assessments the frequency that active disease was 
identified was notably higher (Table 36). Thus, by extension, as the number of MSUS 
assessments performed on a single patient increases, the probability of identifying activity 
synovitis decreases. Indeed, the risk of identifying active synovitis following 4 or 5 consecutive 
negative assessments was significantly less than after one negative assessment. Therefore, the 
results suggest that if patients have undergone 4 or 5 consecutive negative MSUS assessments 
the risk of identifying synovitis during future assessments becomes too small to justify the time 
and cost needed to perform the examination. Since there is still a small risk of identifying synovitis 
it may be prudent to perform a final MSUS assessment after a further 3-6 months to determine 
whether there has been any recurrence of active disease in the intervening period 
 
Number of MSUS 
assessments per 
participant 
Number of 
participants 
Total number of 
MSUS 
assessments 
Mean rate 
(percentage) of 
positive MSUS 
assessments 
1 – 5 11 32 66% 
6 – 10 29 240 32% 
11 – 15 13 160 9% 
Table 36 – Rate of positive MSUS assessments in relation to number of MSUS assessments 
performed per patient 
 
When the number of MSUS assessments that identified active synovitis (i.e the positive 
assessments) were compared to the number of MSUS assessments for each patient it also 
became apparent that repeatedly performing MSUS assessments on some patients was not 
contributing additional disease activity information. For participants who’d undergone between 1 
and 9 MSUS assessments the proportion of positive assessments appeared quite varied. In 
contrast, the proportion of positive MSUS assessments was substantially lower if participants had 
undergone 10 or more assessments. Interestingly, these repeated assessments were still 
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identifying evidence of synovial hypertrophy (i.e. evidence of previous joint involvement); 
however, it was frequently not associated with sufficient PD signal to meet the definition of.  
 
Proposals for integration of MSUS assessment into routine practice 
• MSUS assessment should occur of the same day as the clinical assessment to provide 
contemporaneous assessments of disease activity. The requirement for MSUS assessment 
should be decided following clinical assessment of disease activity 
• MSUS assessments can be performed by any appropriately experienced sonographer; e.g. 
rheumatologist, specialist nurse, extended scope physiotherapist, occupational therapist, 
sonographer 
• Indication for MSUS assessment should be restricted to occasions when MSUS findings will 
change both impression of disease activity and treatment decisions: eg –  
 
i. moderate disease activity but minimal clinical synovitis 
ii. DAS28 LDAS and/or remission – less clear, MSUS assessment has not been 
associated with superior clinical outcomes 
 
• MSUS joint set should contain sufficient joints to represent global disease activity, 
Infrequently affected or highly complex joints should be excluded to reduce scanning time. 
This approach could include adaptive scanning of additional symptomatic joints when 
necessary 
• MSUS definition of active disease should be sufficiently sensitive to allow impact on DMARD 
escalation to positively impact upon outcomes. Not so far demonstrated by this research 
• Grading of synovial hypertrophy findings is not necessary. PD findings to be graded semi-
quantitatively using standardised scores (e.g. Szkudlarek et al (288) or Hammer et al(289)) 
• Proposed MSUS joint sets and/or definitions of active disease may eventually be 
superseded by findings of OMERACT Imaging Working Group 
• Stop further MSUS assessment after 4 consecutive negative assessments; applied to this 
study, this would have lead to 98 fewer (23%) MSUS assessments being performed 
 
5.8.4 Impact of MSUS assessment upon DMARD escalation decisions 
Despite repeated evidence that current definitions of RA remission do not necessarily equate to 
absence of ultrasonographic evidence of synovitis (121,200,336,337), there have not yet been 
any studies that describe how MSUS findings alter treatment decisions or outcomes, as part of a 
treat-to-target strategy in early RA. Similarly, there have not yet been any studies published that 
report the rate of ultrasonographic synovitis in RA patients with either moderate disease activity 
and minimal clinical synovitis and/or those in whom clinical disease activity measures may have 
been elevated by external influences (such as fibromyalgic-RA overlap).  
 
Altogether, 292 (71%) paired sets of DAS28 and MSUS assessments ‘agreed’ on the overall 
disease activity assessment and would not have lead to substantially different DMARD escalation 
decisions (Table 33). However, pooling the results for different MSUS indications may be 
incorrect since they represent quite different clinical scenarios where the outcomes of the MSUS 
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assessment had opposing influences on DMARD treatment decisions. Therefore, for clarity of 
discussion, the following sections will address the significance of findings for each MSUS 
indication separately: 
 
MSUS assessment during DAS28 LDAS 
The majority (75%) of MSUS disease activity assessments conducted on patients with low clinical 
disease activity did not identify evidence of active disease (Table 33). Importantly, this also 
implies that a sizable minority (25%) of MSUS assessments DID identify evidence of active 
synovitis and supported additional DMARD escalation. Interestingly, similar levels of 
ultrasonographically defined disease activity were identified when the instances of DAS28 LDAS 
were subdivided into subgroups for remission and LDAS without remission. The present results 
relate to all instances of LDAS with no adjustment having been made for the small subset of 
participants who continued to exhibit 2 or more clinically swollen joints. In time, an additional 
comparison of the MSUS findings in instances of LDAS stratified by the swollen joint count (SJC 
<2 vs SJC ≥2, per Aletaha et al (192)) will be conducted to determine whether there is a 
significant difference in the rates of ultrasonographic synovitis identified between those with and 
without clinical synovitis 
 
Whenever there was discordance evident between DAS28 LDAS and the MSUS disease activity 
assessment, participants were considered for further intensification of their DMARD therapy in an 
attempt to suppress the last vestiges of subclinical synovitis. This would have lead to treatment 
changes at levels of clinical disease activity that in the DAS28 assessment group, and usual care, 
would be considered too low to justify further DMARD escalation. Hence, it is likely that, for the 
duration of the research the MSUS assessment group as a whole received more intensive 
therapy (including earlier escalation and higher rates of combination therapy and/or biologic 
therapy) than the DAS28 group. In most of these instances, patients reported relatively low levels 
of symptoms (mean global health 10cm VAS 11.27, mean pain 10cm VAS 11.84) and it does not 
appear that increasingly intense therapy was associated with significant improvements in 
outcomes. Increasingly aggressive combinations of DMARDs and/or biologic therapies are 
potentially associated with an increased risk of toxicity overall (144) and infection particularly 
(338). Therefore, it is possible that relentlessly escalating DMARD therapy in patients who have 
very low symptom burdens may become unacceptable because of: i. increasingly complicated 
treatment regimens with low symptomatic benefit: treatment burden ratios and/or ii. an 
unfavourable benefit: risk ratio. At present, the data relating to the rate and type of adverse 
events in either the MSUS or DAS28 group is not available for analysis. In due course, once the 
relevant data is available, a careful between group comparison of the number, type and severity 
of adverse events occurring in both assessment groups is planned in order to determine the 
impact of MSUS-driven DMARD escalation on adverse event rates  
 
Previously published studies have predominantly reported the incidence of MSUS findings in RA 
patients with remission and not LDAS (121,217,336,337,339). Direct comparisons between those 
studies and these results is limited because none of the studies have specifically reported the 
prevalence of PD signal in DAS28 LDAS and because there are notable methodological 
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variations, relating to differences in joint set and how PD findings are reported. Nevertheless, the 
consensus appears to be that a significant proportion of patients continue to exhibit some degree 
of PD signal, even when they fulfil existing remission criteria. Based upon published results, the 
proportion of RA patients in remission who continue to exhibit PD signal in at least one joint lies 
between 40% (217) and 62% (339). Similarly, this study found that 60% of patients in DAS28 
remission, and 59% in DAS28 LDAS, exhibited evidence of PD signal in at least one joint (Table 
33). However, whilst these rates are similar it is worth restating that the previously published 
studies used different (often subjective) definitions of remission and different MSUS joint sets. 
 
MSUS assessment during DAS28 moderate disease activity but minimal clinical synovitis 
This study has shown that the majority of MSUS assessments conducted during instances of 
DAS28 moderate disease activity but minimal clinical synovitis did not identify active synovitis 
(Table 32). Fifty six percent of MSUS assessments identified PD signal in at least one joint, 
however, this fell to 33% when defining active disease as PD signal in at least 2 joints. MSUS 
assessment identified a higher rate of active synovitis during instances of DAS28 moderate 
disease activity but minimal clinical synovitis compared to DAS28 LDAS (33% vs 25%) but this 
did not reach statistical significance (Fishers exact test; p=0.2782). It is perhaps surprising that 
there was not a higher incidence of ultrasonographic synovitis identified during instances of 
DAS28 moderate disease activity but minimal clinical synovitis, since comparisons with instances 
of DAS28 LDAS had shown the individual clinical disease activity variables (excepting swollen 
joint count) to be notably higher (Table 29) 
 
Most published research has focussed on the ultrasonographic findings in RA patients in clinical 
remission. There are very few published results against which the DAS28 moderate disease 
activity findings from this study can be compared. A single study by Brown et al did describe the 
ultrasonographic and MRI findings of a subset of 24 RA patients who qualified as DAS28 
moderate disease activity (121). However, this cohort is biased by selection since the referring 
clinician subjectively considered the patient to be in clinical remission and moderate disease 
activity was only diagnosed once the DAS28 assessment had been applied retrospectively. 
MSUS assessment of the dominant wrist and MCP joints identified synovial hypertrophy in 23 
patients (95.8%) and PD signal in 20 patients (83.3%). Clearly, these rates of PD signal are 
somewhat higher than those identified by this research which used a broader MSUS joint set but 
only identified PD signal in the joints of 56% of patients with moderate disease activity but 
minimal clinical synovitis. The participants examined by this research are biased by indication 
since MSUS examination was only performed for the subset of instances of moderate disease 
activity when there was 1 or no clinically swollen joints. By contrast, Brown et al performed MSUS 
assessment on all patients with moderate disease activity. Furthermore, the clinical features of 
the cohort examined by Brown et al do suggest a higher degree of disease activity overall. Whilst, 
the mean group DAS28 score is not specifically reported, the mean swollen joint count was 4 
(versus 0.42 for this research) suggesting that the Brown cohort exhibited a higher rate of clinical 
synovitis that could also have been associated with an increased rate of underlying MSUS 
abnormalities. 
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Despite the realisation that other joint pathologies may contribute to elevated RA disease activity 
assessments there have been few studies that describe the ultrasonographic findings in RA-
overlap syndromes. In fibromyalgia, most current imaging research is focussed on identifying 
whether or not there are specific functional MRI changes present that may be associated with 
abnormal central pain-related brain activity (340). A single study has previously compared PD 
findings at peripheral entheseal points between 30 patients with psoriatic arthritis and 30 with 
fibromyalgia (341). Any entheseal PD signal abnormalities was identified in a significantly higher 
proportion of psoriatic arthritis patients (100% vs 80%, p=0.01), who were also more likely to 
exhibit ‘inflammatory changes’ (70% vs 23%, p=0.001). Whilst fibromyalgia patients exhibited 
significantly lower rates of inflammatory entheseal changes, it is interesting that there was still 
some PD signal abnormalities identified and such a high rate of entheseal abnormalities. 
Unfortunately, it is not possible to directly compare the results of Marchesoni et al to the findings 
of this study, since different joint recesses were examined for different sonographic abnormalities 
 
Compared to fibromyalgia the presence of ultrasonographic synovial abnormalities has been 
studied more extensively in osteoarthritis. The emerging consensus suggests that osteoarthritis 
can also be associated with findings of joint effusion, synovial hypertrophy and PD signal 
(212,342,343). In the UK population the prevalence of symptomatic hand osteoarthritis is 
estimated between 12-30% (344,345) and approximately 4.4 million people are estimated to have 
radiographic hand osteoarthritis (Arthritis Research Campaign, 2002). Therefore, it is highly likely 
that a proportion of RA patients will also develop degenerative joint disease. Since joint 
osteoarthritis may also be associated with inflammatory like synovial lesions on MSUS, the 
specificity of disease activity assessment by MSUS examination in patients with RA-osteoarthritis 
overlap is potentially reduced. A number of participants in this study exhibited clinical (e.g. 
nodular PiPj and DiPj changes) and radiological features of osteoarthritis at presentation. It is 
quite possible that, during MSUS disease activity assessments PD signal related to osteoarthritis 
was attributed to RA synovitis instead and contributed to the RA disease activity state being 
classified as active. Unfortunately, it is not possible to estimate the potential impact of co-existing 
osteoarthritis on MSUS disease activity assessment findings since the rate of osteoarthritis at 
baseline was not specifically recorded. Further, the MSUS assessment focussed predominantly 
on the presence of synovial hypertrophy and (especially) PD signal. The presence of other joint 
abnormalities (e.g. osteophytes), that may allow clearer discrimination between inflammatory and 
degenerative synovial findings, were not recorded. Until recently, treatment of osteoarthritis 
focused on symptom relieving measures and medications. The increasing realisation that some 
sub-types of osteoarthritis are associated with the presence of inflammatory-like lesions has lead 
some investigators to trial treatment with immunomodulatory agents. So far, clinical trials have 
suggested that methotrexate (346), hydroxychloroquine (347), anti-TNFα blocking therapies (348) 
and systemic corticosteroids (349) can all have either symptom relieving (methotrexate, 
hydroxychloroquine, intra-muscular methylprednisolone) and/or radiographic progression limiting 
(anti-TNFα blocking agents) beneficial effects. Thus, even if participant’s DMARD therapy was 
escalated because inflammatory osteoarthritic lesions were identified during MSUS assessment it 
is possible that participants may still have experienced some symptomatic benefit from the 
therapy change. However, disentangling whether any benefit was related to improvements in 
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either RA and/or osteoarthritic inflammatory activity will not be possible using the currently 
available results. 
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6. Impact of MSUS Disease 
Activity Assessment upon 
Clinical Outcomes 
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During the process of writing this thesis the period of follow-up for the research participants was 
completed, therefore, the following chapter shall present the results of an analysis of the clinical 
outcomes for the DAS28 and MSUS assessment groups. Due to the timing of the submission 
deadline it will not be possible to present the results of any of the radiological outcomes nor the 
adverse event rates.  These data will be presented in the academic press in due course and will 
be deposited with the thesis in University records for future reference. 
 
6.1 Clarification of disposition of study participants 
Fifty-eight participants were randomised to the DAS28 (control) assessment group and 53 were 
randomised to the MSUS assessment group. By the completion of the research, 52 participants 
remained within the DAS28 group (10% dropout) and 49 participants remained in the MSUS 
group (8% drop-out). The overall drop out rate was 9% and there was no difference in the 
proportion of drop-outs from either group (p = 0.74, Fishers exact test). Based on these findings a 
continuation of the preliminary consort diagram (Figure 12) is presented below (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Continuation of consort diagram (Figure 13) to include disposition of all research 
participants between recruitment and final study visit 
 
111 Participants 
58 DAS28 
Group 
53 MSUS 
Group 
52 completed 
follow-up 
6 did not 
complete 
follow-up 
49 completed 
follow-up 
4 did not 
complete 
follow-up 
101 (91%) 
completed 
follow-up 
10 (9%) did 
not complete 
follow-up 
5 – lost to 
follow-up 
1- patient 
choice 
1 – inter 
current illness 
3 – patient 
choice 
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6.2  Comment on the statistical analysis 
The following analysis is restricted to the ACR core set variables (i.e. the clinical outcomes). All 
analyses have been conducted using Graphpad Prism Version 6 (www.graphpad.com). However, 
the data have not been subjected to the checking and quality control procedures of the Robertson 
Centre for Biostatistics, University of Glasgow that usually accompany the completion of a 
prospective clinical trial. In due course a final statistical analysis of the whole dataset will be 
conducted with the assistance of the Robertson Centre for Biostatistics statisticians prior to formal 
reporting of the research’s main clinical and radiological outcomes. 
 
For every ACR core set variable, frequency distribution analysis demonstrated quite significant 
variability in the skew and distribution at each of the 3 month assessment time points (Table 37). 
Values of skew greater than 1 suggest that the distribution of the data within a group is very 
unlikely to be symmetrical; therefore, since it appears that a significant number of the data groups 
are not distributed normally, non-parametric between-group comparisons have been conducted. 
Unless otherwise stated, a p value less than 0.05 was considered statistically significant 
 
ACR Core Set Variable DAS28 Group 
 
MSUS Group 
DAS44 
 
0.56 – 1.64 0.10 – 1.24 
HAQ 
 
-0.22 – 1.17 0.18 – 1.50 
44 Swollen Joint Count 
 
0.92 – 4.40 0.21 – 4.23 
Ritchie Articular Index 
 
1.52 – 3.53 0.57 – 4.57 
ESR 
 
1.13 – 3.59 1.03 – 3.04 
CRP 
 
2.25 - 5.0 1.71 - 5.50 
Global Health 10cm VAS 
 
0.08 – 1.86 0.02 – 1.87 
Pain 10cm VAS 
 
0.38 – 1.61 0.33 – 1.70 
Table 37 – Range of skew across the whole follow-up period for each ACR core set variable 
 
6.3 Overall change in ACR core set variables 
Table 38 describes the overall change in each ACR core set variable between baseline and 
completion of 18 months follow-up. There were no statistically significant between-group 
differences in the mean change from baseline of any variable. In the MSUS assessment group, 
for each ACR core set variable, the 18 month value tended to be lower than the corresponding 
value for the DAS28 assessment group. Furthermore, excepting ESR, the mean change from 
baseline tended to be slightly higher for the MSUS assessment group.  
 
In both assessment groups, there was a statistically significant improvement in all of the ACR 
core set variables measured between baseline and 18 months. Furthermore, the time period that 
corresponded with the fastest rate of improvement was consistently between baseline and 3 
months for both groups. Equally, for most ACR core set variables, very few additional 
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improvements were measured between 3 months and 18 months. The specific patterns of 
change of each of the ACR core set variables will be discussed in more detail in the following 
sections 6.4 to 6.6 
 
ACR Core Set 
Variable 
 
DAS28 Group 
n = 57 
MSUS Group 
n = 54 
Difference 
between means  
(95%CI) 
p 
(DAS28 vs 
MSUS) 
 DAS44 
 
Baseline 
 
4.43 
(3.19 – 5.42) 
4.32 
(3.63 – 5.25) 
 0.98  
(MW) 
18 months 
 
1.73 
(0.92 – 2.63) 
1.25 
(0.64 – 2.43) 
 0.12 
(MW) 
Mean change 
mean (SD) 
-2.58 
(1.57) 
-2.69 
(1.41) 
-0.11 
(-0.70, 0.48) 
0.72 
(t test) 
 HAQ 
 
Baseline 
 
1.63 
(0.88 – 2.13) 
1.5 
(1.0 – 2.0) 
 0.78 
(MW) 
18 months 
 
0.5 
(0.0 – 1.38) 
0.0 
(0.0 – 0.91) 
 0.062 
(MW) 
Mean change 
mean (SD) 
-0.79 
(0.70) 
-1.02 
(0.81) 
-0.23 
(-0.52, 0.07) 
0.14 
(t test) 
 44 Swollen Joint Count 
 
Baseline 
 
8 
(5 – 14) 
9 
(5 – 13) 
 0.97 
(MW) 
18 months 
 
0 
(0 – 1) 
0 
(0-0) 
 0.07 
(MW) 
Mean change 
mean (SD) 
-8.6 
(6.6) 
-8.2 
(5.3) 
0.37 
(-2.0, 1.2) 
0.76 
(t test) 
 Ritchie Articular Index 
 
Baseline 
 
17 
(10 – 28) 
18 
(11 – 28) 
 0.89 
(MW) 
18 months 
 
2 
(0 – 6) 
0 
(0 – 5) 
 0.23 
(MW) 
Mean change 
mean (SD) 
-15.7 
(13.8) 
-14.1 
(11.5) 
1.59 
(-3.4, 6.6) 
0.53 
(t test) 
 ESR 
 
Baseline 
 
25 
(11 – 52) 
35 
(16 – 43) 
 0.90 
(MW) 
18 months 
 
15 
(7 – 20) 
8 
(5 – 23) 
 0.15 
(MW) 
Mean change 
mean (SD) 
-20 
(26) 
-20 
(25) 
0.56 
(-9.4, 10.6) 
0.91 
(t test) 
 CRP 
Baseline 
 
15 
(7.4 – 44.5) 
19.5 
(5.9 – 50.5) 
 0.81 
(MW) 
18 months 
 
3.8 
(1.8 – 9.3) 
4.0 
(1.6 – 10.0) 
 0.71 
(MW) 
Mean change 
mean (SD) 
-29.4 
(60.1) 
-28.8 
(42.6) 
0.61 
(-20.0, 21.2) 
0.95 
(t test) 
Table 38 – Overall change in each ACR Core Set Variable between baseline and 18 months  
Unless stated values are medians (IQR) 
MW – Mann Whitney U test; t test = unpaired, 2 tailed t test 
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ACR Core Set 
Variable 
 
DAS28 Group 
n = 58 
MSUS Group 
n = 53  
Difference 
between means 
(95%CI) 
p 
(DAS28 vs 
MSUS) 
 Global Health 10cm VAS 
 
Baseline 
 
54 
(31 – 79) 
54.5 
(39.8 – 67.2) 
 0.74 
(MW) 
18 months 
 
6 
(1 – 29) 
2.5 
(0 – 22.3) 
 0.28 
(MW) 
Mean change 
mean (SD) 
-40.5 
(34.7) 
-43.4 
(29.0) 
-2.9 
(-15.6, 9.7) 
0.65 
(t test) 
 Pain 10cm VAS 
 
Baseline 
 
51 
(34.3 – 69.8) 
48.5 
(33.5 – 57.5) 
 0.30 
(MW) 
18 months 
 
7 
(1 – 19) 
3.5 
(0 – 23) 
 0.33 
(MW) 
Mean change 
mean (SD) 
-34.9 
(31.6) 
-32.4 
(27.0) 
2.5 
(-9.2, 14.2) 
0.68 
(t test) 
Table 38 (continued)– Overall change in each ACR Core Set Variable between baseline and 18 
months.  
 
6.4  Change in DAS44  
6.4.1 Mean Change in DAS44 from baseline 
The primary clinical outcome measure was the mean change in DAS44 exhibited by both groups. 
The original sample size calculation was based upon detecting a between group difference of 1.1 
or higher in the mean change of DAS44 after 18 months rather than a difference in the absolute 
DAS44 values. The overall difference in the mean change in DAS44 was 0.11, suggesting that 
both groups had experienced a similar improvement in DAS44. At every assessment time point, 
both groups exhibited a similar mean change in DAS44 from baseline (Graph 19). There were no 
statistically significant between-group differences in the mean change from baseline of DAS44 at 
any of the assessment time points (p 0.36-0.83) and the rate of change in DAS44 appeared 
similar for both groups. 
 
 
Graph 19 – Mean change from baseline of DAS44 
0 3 6 9 12 15 18
-3
-2
-1
0
Month
M
ea
n 
C
ha
ng
e
DAS28
MSUS
  218 
6.4.2  DAS44 at each time point 
For both assessment groups there was a significant overall improvement in DAS44 between the 
baseline and 18 months follow-up visits (Graph 20, p<0.0001). There were no statistically 
significant between group differences in the distribution of DAS44 values measured at any of the 
assessment time points (p = 0.18 – 0.71).  
 
 
Graph 20 – Median DAS44 score at each assessment time point 
 
 
The steepest rate of change of DAS44 for both groups was measured between the baseline and 
3 month assessment visits. Between follow-up months 3 and 18 there was continued 
improvement measured in the median DAS44 for both groups. In the DAS28 group, median 
DAS44 fell from 1.79 (IQR 1.04 – 2.95) to 1.73 (IQR 0.93 – 2.61) (p = 0.018). In the MSUS group, 
median DAS44 fell from 2.37 (IQR 1.22 – 3.12) to 1.25 (IQR 0.64 – 2.43) (p<0.0001). There was 
no statistically significant difference in the mean change in DAS44 between either group between 
follow-up months 3 and 18 (mean change DAS44: DAS28 group -0.39 vs MSUS group -0.72, p 
0.19) 
 
Overall, both groups appear to have been exposed to a similar cumulative inflammatory burden. 
Using each patient’s mean DAS44 between baseline and month 18 as a surrogate for 
inflammatory exposure, there was no significant difference identified between the medians 
measured in either group (DAS28 2.23 (IQR 1.55 – 3.18) vs MSUS 2.27 (IQR 1.38 – 2.85), p = 
0.64). 
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6.4.3 EULAR response rates 
Using both the final value and the absolute change from baseline of the DAS44, the EULAR 
response rates after 6, 12 and 18 months follow-up were calculated for each group (297) (Graphs 
21 and 22). At each 6 monthly assessment time point between group comparisons were 
conducted (Fisher’s exact test) of the proportion of participants in each group meeting each of the 
different EULAR response definitions. Participants were excluded from the comparison if there 
was no DAS44 data available for the follow-up visits 
 
At each time point, there was no significant difference between the proportion of participants in 
either group fulfilling any of the EULAR response definitions. Over the follow-up period there was 
an upward trend in the proportion of MSUS group participants who achieved a EULAR good 
response (6 months 52%; 12 months 70%; 18 months 73%) which was statistically significant 
between months 6 and 18 (p = 0.039). The proportion of DAS28 groups who achieved a EULAR 
good response remained relatively static over the follow-up period (6 months 69%; 12 months 
65%; 18 months 63%) 
 
 
Graph 21 – DAS28 Group – percentage of participants fulfilling EULAR response criteria 
 
 
Graph 22  - MSUS Group – percentage of participants fulfilling EULAR response criteria 
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6.4.4 Rate of Low Disease Activity and Remission 
The DAS44 results were analysed to determine what proportion of participants within each group 
met DAS44 LDAS (DAS44 <2.4) and remission (DAS44 <1.6) definitions at any point during the 
follow-up period and what proportion achieved remission on one or more occasions (e.g. 
persistent remission).  
 
Rates of DAS44 Low Disease Activity (LDAS)  
In this section, DAS44 LDAS includes the subset of participants who had also attained DAS44 
remission. After 18 months of treatment, a similar proportion of participants within both groups 
had achieved DAS44 LDAS (DAS28 67% vs MSUS 74%, p 0.51) (Graph 23). There was no 
statistically significant between group differences in the number of participants in either group 
achieving DAS44 LDAS at any of the assessment time points (p 0.32 – 1.0). Indeed, between 
follow-up months 12 until 18 the number and proportion of participants within each group 
achieving DAS44 was virtually identical.  
 
 
Graph 23 - Percentage of participants within each group achieving DAS44 LDAS (DAS44 < 2.4) 
between follow-up months 3 to 18 
 
Within the DAS28 assessment group, the number of participants achieving DAS44 LDAS 
remained relatively static between follow-up months 3 and 18 (n = 33-38). By contrast, there was 
an incremental increase in the number of participants within the MSUS assessment group who 
achieved DAS44 LDAS. In fact, there was a statistically significant increase in the number of 
MSUS participants who achieved DAS44 LDAS between follow-up months 3 and 9 (52% to 73%, 
p 0.003), months 3 and 15 (52% to 81%, p 0.0032) and months 3 and 18 (52% to 74%, p 0.04). 
 
Rates of DAS44 Remission  
 
Excepting follow-up month 18, a very similar pattern of change to that described for LDAS was 
observed for the proportion of participants in each group who achieved DAS44 remission (Graph 
24). After 18 months, a significantly higher number of patients within the MSUS group had 
achieved DAS44 remission compared to the DAS28 group (66% vs 43%, p 0.028). Prior to month 
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18, there were no significant differences observed in the proportion of participants achieving 
DAS44 remission in either group (p 0.32 – 0.84).  
 
In the MSUS group, the proportion of participants who attained DAS44 remission increased over 
the follow-up period. A statistically significant increase was observed between follow-up months 3 
and 9 (34% to 57%, p 0.030), months 3 and 15 (33% to 58%, p 0.017), months 3 and 18 (33% to 
66%, p = 0.0016) months 6 and 15 (38% to 58%, p = 0.047) and months 6 and 18 (38% to 66%, 
p = 0.0057). By contrast, there was no increase in the proportion of DAS28 group participants 
who attained DAS44 remission between months 3 and 18.  
 
 
Graph 24 – Percentage of participants within each group achieving DAS44 remission (DAS44 
<2.4)  
 
Rates of ACR-EULAR Boolean Remission 
A very stringent definition of remission has been proposed by the ACR and EULAR based on all 
the common components of composite disease activity measures being virtually normal (TJC≤1, 
SJC≤1, Global Health VAS ≤1cm, CRP ≤1mg/dl)(186). This Boolean definition of remission is 
perhaps a more appropriate outcome since it seems to much more closely represent the virtual 
absence of clinically detectable synovitis. Applying the ACR/EULAR Boolean definition of 
remission to the clinical outcomes of this study does attenuate the apparent impact of MSUS 
assessment on the DAS44 remission rates of the MSUS group (Graph 25). For both groups, the 
pattern of attainment over the time course is unchanged; the DAS28 group ACR/EULAR 
remission rate remains relatively static between months 3 and 18, whilst for the MSUS group the 
remission rate increases gradually. However, the proportion of participants within each group 
achieving ACR/EULAR remission is consistently less in both groups than the proportion who 
attained DAS44 remission. Further, whilst the ACR/EULAR remission rates for the MSUS group 
once again appear numerically higher than the DAS28 group between follow-up months 9 and 18 
there is no statistically significant between group difference in the proportion of participants 
achieiving ACR/EULAR remission at any of the time points (p = 0.11 – 0.84)  
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Graph 25 – Percentage of participants attaining ACR/EULAR remission follow-up period  
(* DAS28 vs MSUSp<0.05) 
 
Rates of sustained DAS44 remission  
Forty-four participants (76%) within the DAS28 group and 41 participants (77%) within the MSUS 
group attained DAS44 remission on at least one occasion. Further, participants within either 
group were equally likely to achieve DAS44 remission on at least one occasion (OR 0.9, 95%CI 
0.4, 2.2).  
 
Since the persistence of a remission state may be more suggestive of inactive disease than an 
assessment relating to a single time point, the odds of participants within either group attaining 
DAS44 remission on more than one occasion (Table 39) and on more than one consecutive 
occasion (Table 40) were calculated. There was no statistically significant differences in the 
likelihood of participants in either group attaining DAS44 remission on multiple separate 
occasions or consecutive occasions. Though the odds suggested participants within the MSUS 
group were slightly more likely to have achieved DAS44 remission on 5 or more separate 
occasions and 5 or more consecutive occasions.  
 
Number of 
occasions of 
remission (not 
consecutive) 
Odds Ratio 
(95% CI) 
p 
(Fisher’s exact 
test) 
1 or more 
 
0.9 
(0.4, 2.2) 
1 
2 or more 
 
1.1 
(0.5, 2.3) 
1 
3 or more 
 
1.4 
(0.7, 2.9) 
0.45 
4 or more 
 
1.1 
(0.5, 2.3) 
1 
5 or more 
 
0.7 
(0.3, 1.7) 
0.5 
6 
 
0.6 
(0.2, 1.6) 
0.47 
Table 39 - Odds of participants within DAS28 group attaining DAS44 remission on separate 
occasions compared to MSUS group 
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Number of 
consecutive 
occasions of 
remission 
Odds Ratio 
(95% CI) 
p 
(Fisher’s exact 
test) 
1 or more 
 
0.6 
(0.2, 1.5) 
0.36 
2 or more 
 
1.4 
(0.6, 2.9) 
0.45 
3 or more 
 
1.2 
(0.6, 2.6) 
0.70 
4 or more 
 
0.9 
(0.4, 2.1) 
1 
5 or more 
 
0.7 
(0.3, 1.8) 
0.51 
6  
 
0.6 
(0.2, 1.6) 
0.47 
Table 40 –Odds of participants within DAS28 group attaining DAS44 remission on consecutive 
occasions compared to MSUS group 
 
6.5  Change in HAQ  
At baseline, very similar levels of functional impairment were measured in both groups by the 
Health Assessment Questionnaire. Both groups experienced a significant improvement in 
functional ability between baseline and 18 months (Graph 26). In the DAS28 group median HAQ 
fell from 1.63 to 0.5 (p<0.0001, Wilcoxon matched-pairs signed rank test) and in the MSUS group 
median HAQ fell from 1.50 to 0.0 (p<0.0001, Wilcoxon matched-pairs signed rank test). Eighteen 
month median HAQ levels were numerically lower in the MSUS group though the between group 
difference only reached borderline statistical significance (p 0.062, Mann Whitney U test). 
Patients in the MSUS group tended to experience a greater overall mean change in the HAQ 
(DAS28 -0.79 vs MSUS -1.02). The difference of the mean change from baseline of HAQ (-0.23) 
was not statistically significance (p 0.14) but , interestingly, was greater than the minimum 
clinically important difference (0.22).  
 
 
Graph 26 – Median HAQ at each assessment time point 
 
Measures of skew suggested that the distribution of HAQ data for each group at each 
assessment time point was highly asymmetrical (range -0.22 – 1.499); hence, non-parametric 
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statistical tests were used to compare between group differences at each time point. The median 
HAQ values for the MSUS group at months 12, 15 and 18 were very low (0.25, 0.063 and 0.0 
respectively) suggesting that at least 50% of the group reported a HAQ that was essentially 
normal. Indeed, the difference in median HAQ between the groups at months 15 (0.38 vs 0.063) 
and month 18 (0.5 vs 0.0) is greater than the minimal clinically important difference (300). 
However, reporting median HAQ values alone may under-estimate and mis-represent the level of 
functional impairment experienced by the upper half of the MSUS group. Calculating the mean 
HAQ for each group at each assessment time point reveals a slightly different pattern (Graph 27). 
The pattern of improvement in HAQ remains similar and both groups continue to demonstrate 
significant overall improvements. However, in the later follow-up months, the mean HAQ (0.52) 
for the MSUS group is slightly higher than indicated by the median value (0.0) suggesting that at 
least some of the MSUS group were still experiencing low level function impairment. Interestingly, 
there is virtually no between group difference in the mean HAQ value, or the rate of improvement, 
at any of the assessment time points.  
 
 
Graph 27 - Mean HAQ at each assessment time point 
 
6.6  Change in Other ACR Core Set Variables 
Both groups exhibited significant improvements from baseline of all other ACR core set variables 
with the steepest change evident between baseline and follow-up month 3. For each variable, 
between group comparisons were conducted at each time point, though none of these 
comparisons suggested a statistically significant difference. Similarly, none of the between group 
comparisons for mean change from baseline of a variable were statistically significant either. 
Graphs 28 to 33 depict the change from baseline of each variable by group 
 
6.6.1 44 Swollen Joint Count 
At the baseline assessment, both groups exhibited a similar median number of clinically swollen 
joints (8 vs 9, p 0.97) which fell, and remained at a very low level (0-1) from month 9 onwards for 
both groups (Graph 28). There were no significant between group differences in the median 
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44SJC at any time point (p = 0.1 – 0.91). Nor was there a significant differences in the mean 
change in 44SJC observed between either group (DAS28 -8.6 vs MSUS -8.2, p 0.76).  
 
 
Graph 28 – Median 44SJC at each assessment time point 
 
6.6.2  Change in Ritchie Articular Index  
There were no statistically significant differences in the RAI identified between either group at any 
of the assessment time points (p 0.29-0.87) (Graph 29).  At baseline, median RAI for the DAS28 
group was 17 and had fallen to 2.0 after 18 months follow-up (p <0.0001). For the MSUS group, 
median baseline RAI was 18.0 and fell to 0.0 after 18 months (p <0.0001). There was no 
statistically significant difference in the mean change of RAI between either group (DAS28 -15.7 
vs MSUS -14.1, p=0.53).  
 
Graph 29 – Median Ritchie Articular Index at each assessment time point 
 
6.6.3  Change in ESR  
There were no significant difference identified in the mean overall change in ESR between 
baseline and 18 months in either group (p 0.91) (Graph 30). There were no statistically significant 
differences in the ESR values between the groups at any of the assessment time points (p 0.067–
0.85). Median ESR values at 18 months for both groups were almost within the normal range 
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(DAS28 15 (IQR 7– 20) vs MSUS 8 (IQR 5-23)). However, the interquartile ranges suggest that 
the distribution of values was broad.  
 
 
Graph 30 – Median ESR at each assessment time point 
 
6.6.4  Change in CRP  
At a group level, participants in both groups exhibited moderate elevation of CRP at baseline 
(median CRP: DAS28 15, MSUS 19.5; p 0.81) (Graph 31); however, the interquartile ranges were 
heavily negatively skewed (IQR: DAS28 7.4-44.5; MSUS 5.9-50.5) and there were notable 
outliers in both groups (maximum baseline CRP: DAS28 314; MSUS 191). There were no 
significant between group differences in the CRP values at any time point (p= 0.08-0.81) nor in 
the mean change from baseline (p = 0.95). By follow-up month 18, the range of the CRP values 
for each group appeared to have narrowed (IQR: DAS28 1.8-9.3; MSUS 1.6-10.0), though there 
remained notable outliers in both groups (maximum 18 month CRP: DAS28 126, MSUS 67.0).  
 
  
Graph 31 – Median CRP at each assessment point 
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6.6.5  Change in Global Health 10cm VAS  
The median Global VAS at baseline was 54mm for the DAS28 group and 54.5mm for the MSUS 
group. After 18 months follow-up, the median Global VAS had fallen to 6mm in the DAS28 group 
and 2.0mm in the MSUS group (Graph 32). There were no statistically significant between group 
differences measured in Global VAS values at any of the assessment time points (p = 0.29-0.89) 
or in the mean change from baseline (p = 0.65) 
 
 
Graph 32 – Median Global Health 100mm Visual Analogue Score at each assessment time point 
 
 
6.6.6  Change in Pain 100mm VAS  
Participants in both groups reported similar levels of moderate to high pain 100mm visual VAS 
scores at baseline (median baseline pain 100mm VAS: DAS28 51 MSUS 48.5; p 0.30) that had 
virtually normalised after 18 months (DAS28 7.0, MSUS 3.5, p 0.33) (Graph 33). There were no 
significant between group differences in pain 100mm VAS at any time point (p = 0.23 – 0.90), nor 
in the change from baseline (p = 0.68) 
 
Graph 33 – Median Pain VAS at each assessment time point 
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6.7 Impact of gender on treatment response and 
remission rates 
 
Female gender may have adverse prognostic implications, having been previously associated 
with lesser treatment responses, worse functional outcomes and greater rates of functional 
decline (38,40,45,320). The randomisation process allocated a significantly higher number of 
females into the DAS28 group (78% vs 60%, p 0.031) and clearly this may have adversely 
impacted the measured outcomes of the DAS28 group and attenuated the true between group 
difference. To estimate the potential impact of gender on observed outcomes, gender-based 
analyses comparing the median DAS44, median HAQ and median change in DAS44 from 
baseline were conducted at a whole cohort and assessment group level. 
 
6.7.1 Impact of gender on DAS44 and HAQ – whole cohort 
Outcome data were pooled for the whole cohort and divided by gender rather than allocation 
group. At baseline, participants of both sexes reported similar scores for DAS44 and HAQ. 
Furthermore, both sexes exhibited significant improvements in DAS44 and HAQ over the whole 
of the follow-up period. At every time point, there was virtually no difference in the median DAS44 
level (Graph 34). The pattern of mean change from baseline of DAS44 was similar for both sexes. 
There appeared to be a slightly higher rate of change measured in the Male group; however, 
there was no significant between group difference in the mean change from baseline measured at 
any time point (p 0.21-0.97). Furthermore, linear regression analysis did not identify any 
significant differences in the equation of the line representing mean change in DAS44 from 
baseline (Slope of line: Females  -0.031 vs Males -0.042, p 0.46). DAS44 remission rates for both 
sexes were very similar for follow-up months 3 to 12 (Graph 35). For follow-up months 15 and 18 
the proportion of participants attaining DAS44 remission tended to be higher in the male group 
(15 months Female 49% vs Male 61%: 18 months 49% vs 68%); however, neither of these 
differences were statistically significant (p 0.29 and 0.09 respectively) 
 
 
Graph 34 – Median DAS44 over follow-up period – segregated by gender 
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Graph 35 - Percentage of participants attaining DAS44 remission, stratified by gender 
 
Dividing participants by gender did identify a different pattern of improvement in the median HAQ 
over the follow-up period. Baseline HAQ levels were similar for both gender groups (median 
HAQ: Females 1.5 vs Males 1.375, p 0.25). However, at every other time point, male participants 
reported HAQ scores that were consistently numerically lower than their female counterparts 
(Graph 36). The between group difference in HAQ was statistically significant at months 9 
(Females 0.63 vs Males 0.063, p 0.02) and months 15 (Females 0.50 vs Males 0.0, p 0.038). At 
every time point, the mean change from baseline of HAQ was consistently higher for male 
participants, though there was no difference measured in the mean overall change after 18 
months follow-up (Females -0.88 vs Males -1.0, p 0.66) 
 
 
Graph 36 – Median HAQ at each assessment time point, segregated by gender 
* p<0.05 
 
6.7.2 Impact of gender on DAS44 and HAQ – by assessment group 
Subdividing randomisation groups by gender created small and numerically imbalanced 
comparator groups. In the DAS28 group there were 43 females and 14 males, whilst in the MSUS 
group there were 33 females and 21 males. Neither randomisation group exhibited significant 
* * 
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between-gender differences in the value of DAS44 at any of the assessment time points (Graph 
37 – DAS28 group; Graph 38 – MSUS group) (p 0.13 – 0.98). 
 
Group 37 – DAS28 group: median DAS44 at each assessment time point, segregated by gender 
(Males n = 14, Females n = 43) 
 
 
 
Graph 38 – MSUS group – median DAS44 at each assessment time point, segregated by gender 
(Males n = 21, Females n = 33) 
 
Comparing the change in DAS44 between same-gender subgroups of the randomisation groups 
did not identify any significant differences in the pattern of change of DAS44 over the follow-up 
period. Female participants in the MSUS group exhibited slightly higher DAS44 scores at follow-
up months 3 and 6 (median DAS44: DAS28 1.72 vs MSUS 2.26 and DAS28 1.75 vs 2.26 
respectively) (Graph 39); however, neither of these differences reached statistical significance (p 
0.72 and 0.61 respectively). There were no other notable differences over the rest of the follow-up 
period. Male participants in both groups exhibited virtually identical DAS44 scores for most of the 
follow-up period except month 12 when the DAS44 was numerically lower in the MSUS group 
(median DAS44: DAS28 2.97 vs MSUS 0.1.51) (Graph 40), however, this was not statistically 
significant (p 0.62) 
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Graph 39 – Median DAS44 for female participants, stratified by assessment group 
 
 
 
Graph 40 – Median DAS44 for male participants, stratified by assessment group 
 
In the MSUS group, there was no significant difference in the HAQ score reported by either sex at 
any of the time points (Graph 41) (p 0.25-0.94). In the DAS28 group, where the gender 
distribution was less well balanced, the male participants consistently reported lower HAQ scores 
than the female participants with a statistically significant between sex difference evident at 
follow-up month 6 (median HAQ: Females 0.86 vs Males 0.0, p 0.035), month 9 (0.75 vs 0.0, p 
0.032) and month 15 (median HAQ: Females 0.56 vs Males 0.0, p 0.029) but not at any other 
time point (Graph 42) 
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Graph 41 – MSUS group: Median HAQ score at each assessment time point, segregated by 
gender 
 
 
Graph 42 – DAS28 group: Median HAQ score at each assessment time point, segregated by 
gender 
* = p <0.05 
 
6.8  Multiple Regression Analyses 
To determine whether individual baseline variables were significant predictors of 18 month 
outcomes, multiple backward linear regression analyses were conducted using SPSS v19. The 
dependent variables were change in DAS44 between baseline and 18 months and 18 month 
HAQ. The independent (predictor) variables included: ordinal variables – randomisation group, 
gender, anti-CCP antibody status, smoking status; continuous variables – age, symptom duration, 
baseline HAQ, baseline DAS44, baseline CRP 
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Change DAS44 baseline-18 months 
R2 = 0.33, F = 17.2, p<0.001 
 
Predictor Variable Beta Co-efficient p 
Baseline DAS44 -0.57 <0.001 
Baseline CRP -0.20 0.021 
 
(Randomisation group, gender, anti-CCP antibody status, smoking status, age, symptom duration 
and baseline HAQ were not significant predictors in this model) 
 
18 month HAQ 
R2 = 0.24, F = 34.8, p<0.001 
 
Predictor Variable Beta Co-efficient p 
Baseline HAQ 0.49 <0.001 
 
(Randomisation group, gender, anti-CCP antibody status, smoking status, age, symptom 
duration, baseline DAS44 and baseline CRP were not significant predictors in this model) 
 
6.9 Discussion 
Based upon the available results it is possible to make the following conclusions about the 
potential role for MSUS disease activity assessment in the management of early RA:  
 
1. In early RA, the proposed indications would lead to MSUS disease activity assessments 
being conducted during approximately 55% of consultations during months 3 to 18 of 
follow-up 
2. The majority of MSUS disease activity assessments are indicated by DAS28 LDAS (89% of 
all MSUS assessments, 49% of all consultations). A small minority (11%) of MSUS disease 
activity assessments are indicated by DAS28 moderate disease activity but minimal 
synovitis 
3. RA patients require a highly variable number of MSUS disease activity assessments when 
being managed using a MSUS guided step-up DMARD escalation regimen 
4. MSUS assessments of synovitis activity (i.e. PD signal findings) seem to improve when RA 
patients are treated using a step-up DMARD escalation regimen 
5. Using the proposed MSUS definitions of active disease, and a limited MSUS joint set, the 
majority (approximately 71%) of MSUS disease activity assessments agreed with the 
findings of the DAS28 . . . . 
6. . . . . however, in a substantial minority of occasions (approximately 29%), MSUS 
assessment provided disease activity findings that changed the perception of disease 
activity and supported an alternative treatment decision.  
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7. In DAS28 LDAS and remission, MSUS assessment provided additional disease activity 
information that supported further DMARD escalation in approximately 25% of 
examinations 
8. In DAS28 moderate disease activity but minimal clinical synovitis, MSUS assessment 
identified active disease, and therefore supported DMARD escalation, in approximately 
33% of examinations 
9. From the proposed joint set, the radiocarpal and index MCP joints were most likely to 
exhibit PD signal 
10. Early RA patients treated using either a DAS28 or MSUS-guided step-up DMARD 
escalation experience significant, and similar, improvements in measures of disease 
activity, functional ability, pain and the inflammatory response up until 18 months of follow-
up. 
11. MSUS guided DMARD escalation was not associated with any significantly better, or 
faster, improvements in ACR core set variables up until 18 months of follow-up . . . . 
12.  . . . . but was associated with accrual of EULAR good responses and a higher rate of 
DAS44 remission after 18 months 
13. MSUS guided DMARD escalation may be associated with a greater improvement in 
functional ability (HAQ) 
14. Both DAS44 and ACR/EULAR definitions of remission demonstrated similar patterns of 
change in remission over the follow-up period. The between group differences were less 
marked when the more stringent ACR/EULAR Boolean definition was applied compared to 
the DAS44 threshold definition 
 
Thus, these results seem to suggest that MSUS disease activity assessment might achieve 
additional benefits in some patients. Specifically, by increasing the likelihood of attaining 
remission, MSUS-guided DMARD escalation is in line with recent guidelines advocating that 
treatment targets should be remission (111,124,129,350). However, whilst attaining a marginally 
lower level of disease activity (i.e. DAS44< 1.6 vs DAS44 < 2.6) could theoretically be associated 
with better functional and radiographic outcomes this has yet to be demonstrated in a clinical trial. 
The results also suggest that the MSUS group experienced a slightly greater overall improvement 
in functional ability. Indeed, by completion the majority of the MSUS group reported HAQ scores 
that were essentially normal and, arguably, improving functional ability should be a very important 
goal of treatment. Whilst there was no statistically significant between group difference in the 
mean change in HAQ the difference (0.23) was greater than the minimally clinically important 
difference (0.22) so it may be that the study was underpowered to detect a significant difference 
in change in HAQ. 
 
Virtually identical clinical outcomes were achieved by the DAS28 group without having to use 
quite such aggressive DMARD combinations nor conduct time consuming MSUS examinations. If 
MSUS were to be incorporated into routine clinical practice, clinicians would need to consider 
whether the additional benefits experienced by patients were sufficient to justify the additional 
time (and training) required to conduct the assessment. Unfortunately, it is not yet possible to fully 
answer this important question, since it has not yet been shown that regular MSUS assessment is 
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associated with significantly better radiographic outcomes, nor whether the small increase in 
remission rates translate into significantly better medium-long term benefits. If MSUS driven 
DMARD escalation is not shown to significantly improve medium-long term outcomes, it is quite 
possible that its impact on clinic appointments may outweigh its relatively modest benefits. 
Particularly when very similar benefits can still be gained through DAS28 driven DMARD 
escalation. In this context, MSUS assessment of global disease activity may remain a useful 
additional method of quantifying global disease activity, to be considered for patients in whom 
there may be doubt about the accuracy of clinical disease activity assessment 
 
Over the course of the follow-up period, patients in both assessment groups experienced a 
significant improvement in all of the disease activity measures. For each ACR core set variable, 
the greatest rate of improvement was observed between baseline and follow-up month 3. That is, 
the intervention that had the greatest impact on disease activity was the commencement of first 
DMARD and the initial, early administration of corticiosteroids. In both groups, the values for each 
ACR core set variable remained relatively static between follow-up months 3 and 18. Routinely 
incorporating MSUS assessment into global disease activity assessment did not result in the 
MSUS assessment group exhibiting significantly better (i.e. lower) measures of either disease 
activity, functional ability or the acute phase response at any point during the follow-up period. In 
fact, the summary values of each ACR core set variable were similar, if not virtually identical, at 
each assessment time point and both groups exhibited very similar patterns of improvement over 
the whole of the follow-up period. Whilst it is not (yet) possible to specifically describe either the 
DMARD or corticosteroid treatment exposure of each group over the course of the study it is 
highly likely that the MSUS group will have received more aggressive therapy than the DAS28 
group. It is likely that this would have been evident as both an increased, and earlier, use of 
combination DMARD therapy and an increased use of etanercept therapy either at an earlier 
point in the disease course or at a level of disease activity not normally associated with requiring 
biologic therapy. However, this greater intensity of DMARD therapy over the duration of the 
follow-up period did not seem to translate into significantly better values of ACR core set 
variables at any point.  The condition of individual patients may have improved significantly; 
however, the additional time spent conducting MSUS disease activity assessments in addition to 
the DAS28 may not necessarily lead to better clinical outcomes that can be measured at a group 
level  
 
Even though the MSUS group did not exhibit significantly better measures of disease activity at 
any time point, there was some evidence that the group overall did accrue additional moderate 
benefits that were not evident in the DAS28 group. For example, for the MSUS group there was 
an increase in the proportion of participants attaining EULAR good responses between months 6 
and 18 (55% to 74%) that was statistically significant (p 0.04). By contrast, in the DAS28 group, 
there was no additional improvement in the rate of EULAR good responses between months 6 
and 18 and, if anything, there was actually a slight decline (month 6 = 67%, month 18 = 63%).  
 
DAS44 remission rates were similar for both groups between follow-up months 3 to 15; however, 
by month 18, the MSUS group were exhibiting a statistically higher rate of DAS44 remission than 
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the DAS28 group (66% vs 43%, p 0.028). The proportion of DAS28 group participants who 
attained DAS44 remission remained static overall between follow-up months 3 and 18 (42% to 
43%), and if anything declined between months 6 and 18 (48% to 43%). By contrast, the MSUS 
group demonstrated an overall increase in the proportion of participants achieving DAS44 
remission between months 3 and 18 (34% to 66%, p 0.0016). From the shape of the associated 
graph (Graph 24), it is tempting to suggest that this was a step-wise incremental increase. 
However, there was no statistical difference in the DAS44 remission rates between DAS28 and 
MSUS groups at any assessment point until month 18. Excepting month 6, the DAS44 remission 
rates for both groups are closely matched and follow similar patterns. It is only really at month 18 
that there is any divergence evident between the groups. Participants within the MSUS group 
were most likely to commence etanercept within the last few months of the follow-up period and 
this may partly explain some of the divergence in month 18 DAS44 remission rates. However, a 
longer follow-up would be needed to determine whether there is continued divergence in the 
remission rates and whether separation in any of the other ACR core sets becomes apparent. 
Taken altogether, it is possible that MSUS assessment assisted a subset of MSUS group 
participants to achieve a tighter level of disease control than may have been possible had therapy 
been guided by DAS28 alone. This is best suggested, by the continued increase in DAS44 
remission rates, accumulation of participants with a EULAR good response and the MSUS group 
experiencing a slightly greater overall mean change in HAQ. Whilst the randomisation process 
lead to groups with unequal gender distributions, it is unlikely that this could have significantly 
biased the observed results since: 1. within each randomisation group, male and female 
participants exhibited similar patterns of change in DAS44, 2. there were no significant 
differences in the pattern of change of DAS44 between female participants of each group and 3. 
there were no significant differences in HAQ values at any time point between male and female 
subgroups.  
 
Previous studies have shown that the persistence of PD signal in asymptomatic patients predicts 
the risk of future disease flare (217). The MSUS group treatment strategy proposed by this 
research used the persistence of PD signal as a marker of continuing disease activity and the 
primary trigger for DMARD escalation. Whilst this did not lead to the MSUS group achieving 
significantly higher overall DAS44 remission rates (except at month 18), it may have lead to an 
overall lower rate of PD signal (i.e. more complete suppression of synovitis), a lower likelihood of 
fluctuations in disease activity and an increased likelihood of MSUS group participants achieving 
DAS44 remission on a higher number of occasions. Long term follow-up is required of both 
assessment groups to determine whether the subtle short term difference translate into an altered 
medium-long term disease course for either group (i.e. lesser rate of acute flare between 18 and 
60 months). However, this partly assumes that patients receiving MSUS guided DMARD therapy 
will also exhibit lower long term levels of PD signal than those receiving DAS28 guided therapy. 
This assumption cannot be supported since there is no comparator PD signal data available from 
the DAS28 group. Previous observational studies have suggested that PD findings do improve in 
response to escalations of DMARD and biologic therapy (351,352). The available results did 
show improvements in both the total PD score and PD joint count; however, it is not possible to 
determine whether this is related to the additional influence of MSUS on treatment intensity or 
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whether similar changes would have been evident in the DAS28 group. Ideally, future studies of 
the impact of MSUS guided DMARD therapy would also collect MSUS findings data for their 
control arms too. Even if these data were not used to influence treatment decisions it would serve 
as a useful comparator to determine whether MSUS guided DMARD therapy results in lesser 
rates of PD signal positivity and to determine how this relates to corresponding changes in 
disease activity 
 
So far, the reported results have taken a short-term view of the participant’s response to step-up 
DMARD therapy. It is possible that the follow-up period was too short, and the treatment 
response in the DAS28 group too good, to expect a between group difference to become evident 
within the time available. Further, an important predictor of long term prognosis, and therefore 
and important marker of the likely long term efficacy of the treatment strategy, is the development 
of radiographic erosions (3). Even though there was no significant difference in clinical response 
observed it is possible that the more aggressive treatment regimen received by the MSUS 
assessment group was associated with a lesser rate of progression in radiographic damage. This 
relationship will be clearer once the plain x-ray outcomes have been formally graded. Equally, 
comparisons of the change in MRI RAMRIS outcomes between baseline and 18 months will 
provide an additional measure of the impact of each group’s DMARD therapy on several very 
sensitive, and often sub-clinical, measures of RA activity. It is possible that grading of the MRI 
RAMRIS images will demonstrate favourable changes in the MSUS group with a lesser change in 
the RAMRIS erosion score (i.e. lesser destructive progression), a greater change in the RAMRIS 
synovitis score (i.e. a greater treatment response), and a greater change in the RAMRIS bone 
marrow oedema score (i.e. a lesser risk of developing future erosions). In this way, it may be 
possible to demonstrate that MSUS-guided step-up DMARD therapy is associated with 
favourable short-medium term radiological outcomes that are likely to be associated with a lesser 
long-term risk of developing joint destruction and chronic disability. Thus, even though there 
appears to be no short-medium term benefit in clinical response it may yet be possible to 
demonstrate a potential benefit in medium-long term radiological benefits that justifies the routine 
use of MSUS monitoring of global disease activity in early RA. 
 
 
 
 
 
 
 
 
 
  238 
 
 
 
 
 
 
 
 
 
7. The Relationship Between RA 
Phenotype and Gene 
Expression Profile 
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To increase cohort size and microarray sensitivity expression profile datasets for DAS28 and 
MSUS assessment groups were pooled. Certain participants were excluded if they had either 
withdrawn from on going follow-up or had not provided sufficient information for analysis at a 
particular time point. Comparison groups were formed by segregating participants into groups 
based upon clinical, or treatment response phenotype as previously described in sections 2.7.2 
and 3.8.2. However, as the analysis progressed additional comparisons were conducted that 
were either based upon the outputs of pre-planned comparisons and/or were an attempt to 
maximise the likelihood of identifying a significant finding.  
 
When comparing expression levels of individual genes between different clinical groupings an 
adjusted p value (false discovery rate) less than 5% was considered significant. In many 
comparisons the lowest adjusted p value observed was actually greater than 5%. In these 
instances, the acceptable adjusted p value for that comparison was adjusted arbitrarily depending 
upon the values returned for that comparison. However, there were some comparisons where the 
adjusted p value were so high (greater than 20%) it was unlikely that it would be possible to 
confidently describe a significant between group difference in gene expression. In the following 
sections, comparisons that identified significant between group differences in gene expression 
will be presented in conjunction with detailed gene lists taken directly from the Limma 
comparison. Conversely, for the sake of space and brevity, comparisons that failed to identify 
significant evidence of differential gene expression will be presented with a description of the best 
observed (i.e. lowest) adjusted p value but not the full gene lists. 
 
7.1 Clinical Features of Gene Expression Analysis 
Cohort 
79 participants provided PAXgene RNA samples and clinical data for the gene expression 
analysis.  76 of these participants (96%) fulfilled the 2010 ACR classification criteria for RA. For 
73 participants (92%) methotrexate was the first choice of DMARD monotherapy, the remaining 6 
patients all received sulfasalazine monotherapy. Forty participants (51%) were randomised to the 
DAS28 assessment group and 39 (49%) were randomised to the MSUS assessment group. 
Table 41 summarises the baseline features of the cohort. Overall, the baseline features of the 
gene expression analysis cohort closely matched the baseline features of the whole TaSER 
cohort (also shown in Table 41).  
 
Overall, the transcriptomic analysis cohort experienced a good response to step-up DMARD 
escalation therapy (Table 42). There was a clear numerical fall in DAS28 between baseline and 
month 3 and a lesser fall between month 3 and month 18. There were a statistically significant 
falls in DAS28 between baseline and month 3 (paired t test: p<0.0001), baseline and month 18 
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(paired t test: p<0.0001) and between month 3 and month 18 (paired t test: p<0.0001). 
Furthermore, the mean improvement in DAS28 between baseline and month 3 and baseline and 
month 18 (mean change DAS28: -2.1 and -2.7 respectively) were both greater than the minimum 
clinically important change (1.2). Statistically significant improvements in ESR and CRP were also 
measured between baseline and month 3 and baseline and month 18 (paired t test: p<0.0001 for 
each comparison). 
 
 Transcriptomic Analysis 
Cohort (n=79) 
Whole TaSER Cohort 
(n=111) 
Female Sex – n (%) 
 
54 (68%) 68% 
Age (years) 
 
56 (SD 13) 56 (SD 13) 
Disease Duration (months) 5.3 (SD 3.1) 
 
5.3 (SD 3.0) 
Rheumatoid Factor Positive 
- n (%) 
51 (65%) 
 
67% 
Anti-CCP Antibody Positive 
- n (%) 
43 (54%) 
 
60% 
DAS28 5.0 (SD 1.1) 
 
5.0 (SD 1.1) 
HAQ 1.5 (SD 0.80) 
 
1.5 (SD 0.80) 
ESR 36 (SD 26) 
 
39 (SD 35) 
CRP 42 (SD 55) 
 
37 (SD 49) 
Plain X-ray erosions – n (%) 26 (33%) 
 
29% 
Table 41 – Baseline features of transcriptomic analysis cohort in comparison to the whole 
research cohort.  
Unless otherwise stated values are means (standard deviation) 
 
 
 DAS28 Mean change 
from baseline 
DAS28 
ESR CRP 
Baseline 5.0 
(SD 1.1) 
 36 
(SD 26) 
42 
(SD 55) 
Month 3 2.9 
(SD 1.2) 
-2.1 
(SD 1.4) 
21 
(SD 21) 
14 
(SD 26) 
Month 18 2.3 
(SD 1.0) 
-2.7 
(SD 1.5) 
15 
(SD 12) 
9 
(SD 12) 
Table 42 – Disease activity measures at baseline, 3 months and 18 months for the transcriptomic 
analysis cohort.  
All values are mean (standard deviation) 
 
Comparator groups were formed based upon the available DAS28 data, though this was 
recorded in a manner that was not blinded to the participant’s randomisation group. Towards the 
end of the data analysis period, the DAS44 data also became available. Whilst the DAS44 data 
could not be used to form comparator groups, it could be used to demonstrate that the gene 
expression analysis cohort had experienced a similar level of disease activity and treatment 
response to the whole TaSER cohort (Table 43). The mean values of DAS44 for the gene 
expression and TaSER cohorts were similar at each of the time points and the mean change from 
baseline for both cohorts were similar between baseline and month 3 and baseline and month 18. 
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The proportion of gene expression analysis participants categorised as different DAS44 disease 
activity states are shown in Table 44 
 
 
 
 DAS44 
 
Mean change from baseline of 
DAS44 
 Transcriptomics 
Cohort 
Whole Cohort Transcriptomics 
Cohort 
Whole Cohort 
Baseline 4.5 
(SD 1.2) 
4.4 
(SD 1.1) 
  
Month 3 2.4 
(SD 1.3) 
2.2 
(SD 1.3) 
-2.1 
(SD 1.4) 
-2.1 
(SD 1.3) 
Month 18 1.7 
(SD 1.2) 
1.7 
(SD 1.1) 
-2.7 
(SD 1.5) 
-2.6 
(SD 1.5) 
 Table 43 – DAS44, and change from baseline of DAS44, at baseline, 3 months and 18 months 
for transcriptomics analysis cohort and whole research cohort.  
Values are mean (standard deviation) 
 
 Baseline Month 3 Month 12 Month 18 
 
High 
DAS44 >3.7 
57 (72%) 13 (17%) 7 (10%) 5 (7%) 
Moderate 
2.4≤DAS44 <3.7 
22 (28%) 23 (30%) 15 (21%) 17 (24%) 
Low 
DAS44 <2.4 
0 41 (53%) 50 (69%) 49 (69%) 
Remission 
DAS44 <1.6 
0 28 (26%) 39 (54%) 39 (55%) 
Table 44 – Number (percentage) of transcriptomic analysis cohort attaining DAS44-defined 
disease activity states at each time point 
 
7.2 Baseline Phenotypic Groupings 
Participants were divided into phenotypic comparator groups based upon their presenting 
characteristics. Between group comparisons of differences in gene expression were then 
conducted using the baseline, pre-treatment gene expression profiles. Pre-treatment expression 
profiles were chosen to minimise any influence DMARD therapy might have upon the observed 
gene expression patterns 
 
7.2.1 Gender 
Segregating participants by sex identified the highest number of differentially expressed genes. In 
total, 66 genes exhibited differential expression between female and male groups (FDR range 
2.26E-34 – 0.0458). In females, 25 genes were down-regulated and 36 genes were up-regulated 
relative to males. Genes were associated with a range of different loci (chromosomes 1, 2, 3, 5, 
6, 10, 11, 12, 14, 18 , 19 and 20). All 14 genes associated with the X chromosome were up 
regulated whereas all 16 genes associated with the Y chromosome were down regulated. Four 
genes (EIF1AY, RPS4X, UTY, EIF1AX) were each identified at more than one microarray 
location. Additionally four probe identifiers (LOC100133662, 38961, LOC644670, LOC647322) 
were not associated with recognised genes by the online Genes database 
(www.ncbi.nlm.nih.gov/gene). Table 45 (see over) lists the expression levels and chromosomal 
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location of all genes that exhibited differential expression between females and males in this 
analysis 
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Table 45 - Genes exhibiting differential expression in baseline samples between female and male 
RA patients. Ranked by adjusted p value 
 Adjusted p values < 0.05 are considered significant 
*denotes duplicate gene; α denotes unrecognised gene 
  
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
RPS4Y1 ribosomal protein S4, Y-linked 1 -3.90 2.3E-34 Yp11.3 
LOC100133662 
α 
? -2.56 2.1E-30 X 
EIF1AY*1 eukaryotic translation initiation factor 1A, 
Y-linked 
-1.65 2.6E-27 Yq11.223 
JARID1D lysine (K)-specific demethylase 5D -1.20 2.6E-27 Yq11 
PRKY Protein kinase, Y-linked -1.20 7.0E-27 Yp11.2 
CYORF15A chromosome Y open reading frame 15A -0.67 3.0E-23 X 
XIST X inactive specific transcript 1.26 1.5E-22 Xq13.2 
EIF1AY*1 eukaryotic translation initiation factor 1A, 
Y-linked 
-0.70 2.7E-21 Yq11.223 
RPS4Y2 ribosomal protein S4, Y-linked 2 -1.13 1.3E-19 Yq11.223 
CYORF15B taxilin gamma 2, pseudogene -0.38 1.0E-15 Yq11.222 
PRKX Protein kinase, X-linked 0.35 2.4E-12 Xp22.3 
UTX lysine (K)-specific demethylase 6A 0.37 1.0E-11 Xp11.2 
LOC391777 ribosomal protein S4X pseudogene 6 0.38 6.6E-09 5p13.2 
EIF2S3 eukaryotic translation initiation factor 2, 
subunit 3 gamma 
0.37 3.3E-08 Xp22.2-p22.1 
ZFY Zinc finger protein, Y-linked -0.23 1.4E-07 Yp11.3 
RPS4X *2 ribosomal protein S4, X-linked 0.54 1.9E-06 Xq13.1 
UTY *3 ubiquitously transcribed tetratricopeptide 
repeat containing, Y-linked 
-0.23 4.0E-06 Yq11 
RPS4X *2 ribosomal protein S4, X-linked 0.53 4.3E-06 Xq13.1 
UTY *3 ubiquitously transcribed tetratricopeptide 
repeat containing, Y-linked 
-0.24 5.4E-06 Yq11 
ZBED1 zinc finger, BED-type containing 1 -0.27 1.3E-05 Xp22.33 
38961 α ? 0.42 0.00018  
CA5B carbonic anhydrase VB, mitochondrial 0.33 0.00077 Xp21.1 
TMSB4Y thymosin beta 4, Y-linked -0.18 0.00092 Yq11.221 
SOCS2 suppressor of cytokine signaling 2 0.34 0.00096 12q 
LOC441550 ribosomal protein S4X pseudogene 11 0.27 0.0023 10p11.22 
PURA purine-rich element binding protein A 0.27 0.0026 5q31 
EIF1AX *4 eukaryotic translation initiation factor 1A, 
X-linked 
0.21 0.0035 Xp22.12 
EIF1AX *4 eukaryotic translation initiation factor 1A, 
X-linked 
0.28 0.0036 Xp22.12 
ZRSR2 zinc finger (CCCH type), RNA-binding 
motif and serine/arginine rich 2 
0.22 0.0038 Xp22.1 
ZNF548 Zinc finger protein 548 0.23 0.0044 19q13.43 
CSF2RA colony stimulating factor 2 receptor, alpha, 
low-affinity (granulocyte-macrophage) 
-0.23 0.0068 Xp22.32 and 
Yp11.3 
HDHD1A haloacid dehalogenase-like hydrolase 
domain containing 1A 
0.22 0.0070 18 
LOC220433 ribosomal protein S4X pseudogene 16 0.34 0.0072 13q14.3 
LOC644670 α ? 0.23 0.0088  
LOC390183 ribosomal protein S4X pseudogene 13 0.28 0.0088 11q12.1 
DOCK10 dedicator of cytokinesis 10 0.31 0.0090 2q36.2 
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Table 45 (continued): Genes exhibiting differential expression in baseline samples  
between female and male RA patients. Ranked by adjusted p value 
 Adjusted p values < 0.05 are considered significant 
*denotes duplicate gene; α denotes unrecognised gene 
 
7.2.2 Rheumatoid Factor Status 
Segregating patients based upon RF status identified 3 genes which exhibited differential 
expression between rheumatoid factor positive and negative groups when the adjusted p value 
threshold was less than 0.05. However, the microarray location (prode ID 7650093) with the 
lowest adjusted p value was not associated with a recognised gene. Increasing the adjusted p 
Illumina Gene Symbol Gene Name log Fold Change Adjusted p 
Value 
Chromosomal 
Location 
CXORF45 UDP-N-
acetylglucosaminyltransferase 
subunit 
0.24 0.0090 Xq23 
TFRC transferrin receptor (p90, CD71) 0.23 0.0096 3q29 
SLITRK3 SLIT and NTRK-like family, 
member 3 
-0.13 0.011 3q26.1 
LOC554203 JPX transcript, XIST activator 
(non-protein coding) 
0.22 0.011 Xq13.2 
USP9Y ubiquitin specific peptidase 9, Y-
linked 
-0.15 0.012 Yq11.2 
BCORL2 BCL6 corepressor pseudogene 
1 
-0.14 0.013 Yq11.222 
ZNF248 zinc finger protein 248 0.18 0.014 10p11.2 
LOC647322 α ? 0.20 0.016  
LRRC58 leucine rich repeat containing 58 0.21 0.02 3q13.33 
TNNI2 troponin I type 2 (skeletal, fast) -0.17 0.022 11q15.5 
CLTB clathrin, light chain B -0.16 0.023 5q35 
BACH2 BTB and CNC homology 1, 
basic leucine zipper transcription 
factor 2 
0.28 0.023 6q15 
SLC20A1 solute carrier family 20 
(phosphate transporter), 
member 1 
0.19 0.025 2q13 
ZNF512 zinc finger protein 512 0.20 0.025 2p23 
IL7R Interleukin 7 receptor 0.53 0.026 5p13 
BCL2 B-cell CLL/lymphoma 2 0.35 0.030 18q21.3 
EDG1 sphingosine-1-phosphate 
receptor 1 
0.31 0.030 1p21 
LRIG1 leucine-rich repeats and 
immunoglobulin-like domains 1 
0.18 0.031 3p14 
ITK IL2-inducible T-cell kinase 0.34 0.031 5q31-q32 
NANP N-acetylneuraminic acid 
phosphatase 
-0.14 0.040 20p11.1 
C6ORF190 thymocyte selection associated 0.35 0.042 6q22.33 
ZCCHC24 zinc finger, CCHC domain 
containing 24 
-0.15 0.042 10q22.3 
DRD3 Dopamine receptor D3 -0.18 0.045 3q13.3 
ZNF540 Zinc finger protein 540 0.17 0.046 19q13.12 
CD2 CD2 molecule 0.36 0.046 1p13.1 
LBH limb bud and heart development 0.32 0.046 2p23.1 
MAPK14 mitogen-activated protein kinase 
14 
-0.26 0.046 6p21.3-p21.2 
NAP1L1 nucleosome assembly protein 1-
like 1 
0.26 0.046 12q21.2 
MBIP MAP3K12 binding inhibitory 
protein 1 
0.14 0.046 14q13.3 
LOC387820 DnaJ (Hsp40) homolog, 
subfamily B, member 7 
pseudogene 
-0.13 0.046 11q24.3 
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value threshold to 0.15 identified a further 5 differentially expressed genes. Of these, one gene 
duplicated a previously identified gene (NAIP) and one gene (LOC648984) was not associated 
with a recognised chromosomal location. All five of the remaining genes were up-regulated in 
baseline samples of rheumatoid factor positive participants. Two up-regulated genes duplicated 
the same chromosomal location (NAIP and LOC728519, Chr 5q13.2) Table 46 lists the 
expression levels and chromosomal location of all genes that exhibited differential expression 
using the adjusted value threshold of less than 0.15 
 
Table 46: Genes exhibiting differential expression between baseline samples of rheumatoid 
factor positive and negative patients 
Adjusted p values < 0.15 are considered significant 
 
7.2.3 Anti-CCP Antibody Status 
Segregating participants by baseline anti-CCP antibody status did not identify significant between 
group differences in gene expression. Whilst many genes exhibited highly significant p values 
during t-testing (down to p= 2.24E-05), correcting for multiple testing returned consistently high 
adjusted p values (lowest adjusted p value = 0.51). Since expression of anti-CCP antibodies is 
strongly associated with tobacco smoke exposure, which in turn can also influence gene 
expression (353,354), the comparison of gene expression between anti-CCP comparator groups 
was rerun whilst also adjusting for the participant’s smoking status. However, this corrected 
analysis also failed to identify any new differences in gene expression (lowest adjusted p value = 
0.999).  
 
7.2.4 Baseline Erosive Status 
The presence or absence of erosions at first presentation was not associated with significant 
between group differences in gene expression. Simple t-testing returned highly significant p 
values for multiple genes; however, correcting for multiple testing suggested that there were no 
significant between group differences (lowest adjusted p value = 0.999) 
 
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
NA (7650093) Not recognised -0.17 0.0092  
SRI Sorcin 0.18 0.035 7q21.1 
NAIP NLR family, apoptosis 
inhibitory protein 
0.30 0.04 5q13.2 
LOC648984 Similar to Baculoviral 
IAP repeat-containing 
protein 1 
0.38 0.13 
 
 
Not known 
LOC728519 NLR family, apoptosis 
inhibitory protein 
pseudogene 
0.39 0.13 5q13.2 
AP1S1 Adaptor-related protein 
complex 1, sigma 1 
subunit 
0.15 0.13 7q22.1 
BCS1L BC1 (ubiquionol-
cytochrome c 
reductase) synthesis 
like 
0.17 0.13 2q33 
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7.2.5 Smoking Status 
The impact of smoking status on gene expression in baseline samples was examined by dividing 
participants into groups based upon whether they were current, former or never smokers. Gene 
expression in each group was then compared in a step-wise fashion against gene expression in 
each of the other two smoking status groups. An adjusted p value threshold was initially set at 
0.05. Current smokers exhibited up-regulation of the gene LRRN3 in relation to both never 
smokers (adjusted p value = 0.0021) and former smokers (adjusted p value = 0.0031). In both 
comparisons, there was evidence of LRRN3 up-regulation at 2 separate microarray locations. 
There was no evidence of differential LRRN3 expression between former and never smokers. 
Former smokers did exhibit up regulation of HIATL1 (adjusted p value = 0.040) in relation to 
never smokers. Furthermore, using an adjusted p value threshold of 0.15, former smokers also 
exhibited up-regulation of gene MBD2 in relation to never smokers. Table 47 describes the 
differences in gene expression levels between the different smoking status groups.  
 
Table 47 - Genes exhibiting differential expression in baseline samples between current, former 
and never smokers 
Adjusted p values < 0.15 are considered significant 
*denotes duplicate gene 
 
7.3 Gene Expression Profiles as Measures of Global 
Disease Activity 
Participants were divided into comparator groups based upon the numerical value of the DAS28 
at baseline and three months. Between group comparisons of differences in gene expression 
were then conducted using the corresponding mRNA expression profiles. The presumption being 
that different disease activity states might associate with specific gene expression patterns. In 
order to try and maximise the sensitivity of the comparisons the numerical value of DAS28 was 
used in a variety of different permutations either as a stand alone value or in relation to 
predefined, disease activity classification thresholds. 
 
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
Current smoker vs Never Smoked 
LRRN3 Leucine rich repeat 
neuronal 3 
0.74 0.0021 7q31.1 
LRRN3 Leucine rich repeat 
neuronal 3 
0.43 0.0070 7q31.1 
Current smoker vs Former smoker 
LRRN3 Leucine rich repeat 
neuronal 3 
0.82 0.0031 7q31.1 
LRRN3 Leucine rich repeat 
neuronal 3 
0.48 0.0075 7q31.1 
Former smoker vs Never smoked 
HIATL1 Hippocampus 
abundant transcript-
like 1 
0.25 0.040 9q22.32 
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7.3.1 Baseline Gene Expression Profile and Baseline Disease Activity – 
DAS28 Quartiles 
Categorising participants into groups based upon baseline disease activity level failed to identify 
significant differences in baseline gene expression profiles between those with the highest and 
lowest levels of disease activity. Participants were subdivided into groups based upon baseline 
DA28 quartiles. To increase the likelihood of identifying clear between group differences, gene 
expression comparisons were limited to the upper and lower quartile groups. There were 19 
participants in the lower quartile group where the DAS28 scores ranged from 2.83-3.95 (median 
3.57). There were 18 participants in the upper quartile group where the DAS28 scores ranged 
from 5.85-8.21 (6.48). Mann-Whitney U test confirmed that there was a statistically significant 
difference in the distribution of the DAS28 scores between the upper and lower quartile groups 
(p<0.0001). However, despite the evident differences in clinical phenotype, there were no 
significant differences in gene expression profiles (lowest adjusted p value = 0.40) 
 
7.3.2 Three Month Gene Expression Profile and Three Month Disease 
Activity – DAS28 Quartiles 
Categorising participants into groups based upon 3 month disease activity also failed to identify 
any differences in gene expression profile between the groups. Participants were divided into 
groups based upon quartiles of their 3 month DAS28 score and between group comparisons of 
gene expression profile were limited to the upper and lower quartile groups. There were 19 
participants in the lower quartile group (DAS28 range: 1.049 – 2.025, median 1.73) and all fulfilled 
clinical remission criteria. There were 18 participants in the upper quartile group (DAS28 range: 4 
– 6.3, median 4.46) with disease activity ranging from moderate to high. Mann Whitney U test 
confirmed that the distributions of DAS28 scores for each group were statistically distinct 
(p<0.0001). However, despite the evident differences in clinical phenotype, no significant 
differences in gene expression profile could be demonstrated between the groups (lowest 
adjusted p value = 0.78). 
 
7.3.3 Three Month Gene Expression Profile and Three Month Disease 
Activity – DAS28 Thresholds 
Participants were divided into comparator groups based upon the numerical value of their 3 
month DAS28 score in relation to existing DAS28-based definitions of clinical disease activity 
(e.g. high / moderate / low / remission). The 3 month expression profiles of the high disease 
activity and clinical remission groups were chosen for comparison since these were likely to be 
the most widely separated clinical phenotypes and therefore also most likely to exhibit differences 
in gene expression. However, the eventual groups were significantly imbalanced in size and 
therefore any attempted comparisons would have been significantly biased. Thirty five patients 
fulfilled clinical remission criteria (DAS28 range: 1.049 – 2.599, median 2.008) whereas only 4 
patients displayed high disease activity (DAS28 range: 5.474 – 6.3). 
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7.3.4 Three Month Gene Expression Profile and Clinical Threshold for 
DMARD Escalation 
To determine whether or not specific gene expression profiles were associated with an adequate 
treatment response after 3 months of DMARD monotherapy participants were subdivided into 
comparator groups depending on whether or not their 3 month DAS28 fell below the strategic 
threshold of 3.2. Fifty-three participants demonstrated a DAS28 less than 3.2 (range 1.049 – 
3.161, median 2.35) and therefore would not ordinarily have been considered for DMARD 
escalation. Twenty five patients demonstrated a DAS28 score greater than 3.2 (i.e. range 3.205 – 
6.3, median 3.70) and would have qualified for DMARD escalation. Mann-Whitney U testing 
confirmed that the distributions of DAS28 scores for both groups were statistically distinct 
(p<0.0001). Despite the differences in phenotype, there was only evidence of borderline 
differential expression of one single gene. The HS.515967 gene, which relates to a transcribed 
locus, was down regulated in patients who failed to achieve a 3 month DAS28 less than 3.2 
 
Table 48 - Characteristics of a single gene which was down regulated in participants who failed to 
achieve 3 month DAS28 < 3.2 
 
7.4 Baseline Gene Expression Profile as Predictor of 
Clinical Course 
 
The relationship between baseline expression profiles and subsequent clinical outcomes was 
examined to determine whether baseline profiles had any predictive ability for short-medium term 
outcomes 
 
7.4.1 Baseline Gene Expression Profile and Three Month Threshold for 
DMARD Escalation 
To determine whether specific baseline gene expression patterns were present in those patients 
who were likely to require DMARD escalation (a surrogate for persistently active disease) after 3 
months of DMARD monotherapy, baseline expression profiles were compared in participants 
grouped according to whether or not 3 month DAS28 fell below or above 3.2. Comparison groups 
were identical to those described in preceding section 7.3.4; however, on this occasion the 
baseline expression profiles were compared. No differentially expressed genes were associated 
with an adjusted p value threshold of less than 0.05. Using an adjusted p value threshold of 0.15, 
3 genes were found to be up-regulated in baseline samples of participants exhibited a DAS28 
greater than 32 after 3 months of DMARD monotherapy. The expression levels and chromosomal 
locations of these genes are described in Table 49. 
  
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
HS.515967 ? – transcribed locus -0.13 0.052 ? 
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Table 49 - Genes which were up-regulated in baseline samples of patients with 3 month DAS28 
greater than 3.2 
Adjusted p value threshold < 0.15   
 
7.4.2 Baseline GeneExpression Profile and Three Month Disease 
Activity Level – DAS28 Quartiles 
Baseline expression profiles were not associated with, and therefore are unlikely to be predictive 
of, participants subsequently achieving particular levels of disease activity. Participants were 
separated into quartile groups based upon their 3 month DAS28 score. Between group 
comparisons of differences in baseline expression profiles were then conducted. The composition 
of the comparator groups was identical to those described in preceding section 7.3.1 However, 
despite the evident differences in clinical phenotype there was no demonstrable difference in 
baseline gene expression in participants with different levels of disease activity after 3 months 
monotherapy (lowest adjusted p value = 0.50). 
 
7.4.3 Baseline Gene Expression Profile and Clinical Course – Mean 
DAS28 between 0 and 12 months 
The relationship between baseline expression profile and subsequent clinical course was 
examined to determine whether baseline expression profile patterns might have any ability to 
predict how patients fare over a period of time, regardless of treatment method. The presumption 
being, that particular patterns of treatment response (e.g. persistently active disease or 
persistently inactive disease) might be associated with distinct differences in underlying gene 
expression. Clinical course was characterised by calculating each participant’s mean DAS28 
between baseline and 12 months. Those participants with the highest mean DAS28 0-12 months 
would have experienced the most persistently active disease and, by extension the weakest 
treatment response, whilst those with the lowest mean DAS28 0-12 months would have 
experienced a much lesser overall disease burden and should be at a much lower risk of long 
term complications. The baseline expression profiles of the upper and lower quartile mean 
DAS28 0-12 months groups were compared. There were 18 participants in each group. In the 
lower quartile group mean DAS28 0-12 months ranged from 1.33 to 2.42 (median 1.93), whilst in 
the upper quartile group mean DAS28 0-12 months ranged from 3.72 to 5.67 (median 4.0). Mann 
Whitney U testing confirmed that the distribution of mean DAS28 0-12 months for each group 
were statistically distinct (p<0.0001). Baseline expression profiles did not appear to associate with 
particular patterns of clinical course since there were no differences in gene expression identified 
that were also associated with acceptable adjusted p values (lowest adjusted p value = 0.38). 
 
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
TBC1D22B TBC1 domain family, 
member 22B 
0.22 0.088 6p21.2 
TMCC2 Transmembrane and 
coiled-coil domain 
family 2 
0.27 0.088 1q32.1 
USP46 Ubiquitin specific 
peptidase 46 
0.14 0.088 4q12 
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7.4.4 Dynamic Changes in Gene Expression Profile in Relationship to 
Changes in Disease Activity 
Neither gene expression nor inflammatory disease activity levels are static therefore the 
relationship between dynamic changes in gene expression and dynamic changes in disease 
activity measures was examined. Changes between baseline and 3 months for both gene 
expression and DAS28 were described by subtracting the baseline values from the 3 month 
values. The resulting values were then compared as continuous variables. This crude comparison 
did not identify evidence of differential gene expression (lowest adjusted p value = 0.43); 
however, the continuous nature of the comparator variables may have limited the comparison’s 
ability to identify between group differences by not creating clearly separated phenotypic groups.  
 
7.5 Additional Unplanned Phenotypic Groupings 
Sections 7.2 – 7.4 describe the outcomes of gene expression comparisons that were planned in 
advance of the laboratory analysis. However, the results so far do not suggest that there is any 
consistent evidence of differential gene expression within the peripheral blood of these clinically 
relevant phenotypic groupings. Potential reasons why this may be the case will be discussed in 
Section 7.6. Several comparisons (most notably groupings based upon gender) did identify 
differential gene expression between the comparator groups. Furthermore, following completion 
of the original analysis, the 3 month MSUS findings data became available for the subset of 
participants within the MSUS assessment group. The information provided by both of these 
developments was used separately to define several post hoc phenotypic groupings that 
underpinned additional comparisons of gene expression profiles 
 
7.5.1 Correcting for Influence of Gender on Gene Expression Profiles 
To correct for any potential skew that gender may have had on gene expression profiles in other 
comparisons a number of comparisons were rerun using only clinical outcome and gene 
expression data from female participants (n = 51, the larger gender group). 
 
Baseline Gene Expression Profile and Rheumatoid Factor Status – Females 
Only 
When the baseline gene expression profiles of rheumatoid factor positive (n = 31, 61%) and 
negative (n = 20, 39%) female participants were compared a single gene was differentially 
expressed (down regulated) using an adjusted p value threshold of 0.05. The microarray ID 
(7650093) was not associated with a recognised Gene ID and therefore it may be that this 
microarray location represents a control probe. Using an adjusted p value threshold of 0.15, one 
additional gene (CCDC28B), that had not been identified when the whole cohort was examined, 
appeared to be up-regulated in rheumatoid factor positive participants. The chromosomal 
locations and expression levels of these 2 genes are shown in Table 50  
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Table 50 -  Genes which were differentially expressed in baseline samples of female participants 
grouped by rheumatoid factor status 
Adjusted p value threshold = 0.15 
 
Baseline Gene Expression Profile and Anti-CCP Antibody Status – Females 
Only 
Twenty-six (51%) female participants were anti-CCP antibody positive and 25 (49%) were anti-
CCP antibody negative. Separating female participants into groups based upon anti-CCP 
antibody status did not identify any significant differences in gene expression profile though did 
reduce slightly the adjusted p values of the genes with the highest rankings. Nevertheless, the 
lowest adjusted p value was still extremely high (0.94) 
 
Baseline Gene Expression Profile and Erosion Status – Females Only 
Nineteen (37%) female participants exhibited plain x-ray erosions at presentation. Comparing 
baseline gene expression profiles between female participants with, and without, erosive x-rays 
also did not identify significant differential gene expression. Overall, adjusted p values were 
slightly lower than the whole cohort comparison, though did still remain extremely high (0.92). 
 
Baseline Gene Expression Profile and Baseline Disease Activity Level – 
DAS28 Quartiles in Females Only 
Groups were formed based upon quartiles of the baseline DAS28 and between group gene 
expression comparisons were conducted between the upper and lower quartile groups. There 
were 13 participants in each group. The DAS28 range in the lower quartile group was 3.24 to 
4.32 (median 3.66) and in the upper quartile group was 5.85 – 7.21 (median 6.47). Mann Whitney 
U testing confirmed that the distributions of DAS28 values in both groups were statistically distinct 
(P<0.0001). Even though there were clear differences in the measure of disease activity the 
adjust p values remained above any reasonable threshold that would have supported a significant 
between group difference in gene expression (lowest adjust p = 0.79). 
 
7.5.2 Dynamic Change in Gene Expression Profile Between Baseline 
and 3 Months 
To determine, whether there was likely to be any dynamic change in gene expression profiles a 
paired analysis, comparing the baseline and 3 month expression profiles for all the participants 
was conducted. This analysis was not restricted by any phenotypic denominator or level of 
response. Overall, the whole cohort exhibited a significant improvement in DAS28. Median 
baseline DAS28 was 5.01, falling to 2.94 after 3 months (p<0.0001). Using an adjusted p value 
threshold of 0.05, paired comparisons of gene expression profile identified 19 genes whose 
expression patterns changed significantly between baseline and 3 months (Table 51). Five genes 
became upregulated and 14 genes became down regulated. All 19 differentially expressed 
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromosomal 
Location 
7650093 ? -0.19 0.048 ? 
CCDC28B Coiled-coil domain 
containing 28B 
0.22 0.11 1p36.11-p34.2 
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microarray locations were associated with previously identified human genes. Two genes that 
were down regulated were not listed as having a known chromosomal location (LOC651751 and 
LOC652493). Further, down regulated genes LOC647450 and LOC647506 were both associated 
with the same gene ID. 
 
7.5.3 Incorporation of MSUS Disease Activity Assessment Findings into 
Phenotypic Groupings 
At low disease activity levels it is possible that the DAS28 will be insufficiently sensitive to identify 
those patients with truly quiescent disease since it has been consistently demonstrated that 
significant numbers of patients with DAS28 LDAS still exhibit evidence of synovitis on either 
clinical examination or imaging (121,192,200). Hence, the previously described comparisons 
(sections 7.3.2 - 7.3.4) may have been underpowered to identify differences in gene expression 
because the presumed LDAS / remission groups may still have contained some participants with 
active subclinical synovitis. With the availability of 3 month MSUS disease activity data it was 
possible to identify a further subgroup (n=5) of patients who had absolutely no ultrasonographic 
evidence of synovitis (total PD joint count = 0). This MSUS remission sub-group could be 
assumed to represent the very lowest level of inflammatory disease activity it was possible to 
identify using the available clinical and MSUS disease activity data. The three-month gene 
expression profiles of the MSUS remission sub-group were then compared to those of the 10 
participants with the highest 3 month disease activity levels (who all had clinically evident 
synovitis). The DAS28 range in the MSUS remission sub-group was 1.049 to 3.581 (median 2.31)  
and 4.425 to 6.3 (median 5.0) in the high DAS28 sub-group. Mann Whitney U testing compared 
that the distribution of DAS28 values in both groups was statistically distinct (p=0.0007). The 
previously employed method of multiple t tests between both groups did not identify any 
significant differences in gene expression between the comparator groups (lowest adjusted p 
value = 0.54).  
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Table 51 – Genes which underwent changes of expression between baseline and 3 months 
Adjust p value threshold = 0.05 
 
7.5.3 Comparison of Differences Between Baseline and 3 Month Gene 
Expression Profiles in Patients Who Achieved DAS28 Remission 
After 3 Months 
Changes over time of microarray analyses are often correlated to corresponding changes in a 
designated disease state and are interpreted as being causally associated with the change in the 
disease state under investigation. However, peripheral blood gene expression profiles do not 
simply relate to a single disease state and may be influenced by multiple additional intrinsic 
factors; such as, environmental exposures, drug therapy, intercurrent illness, co-morbidities and 
Illumina Gene 
Symbol 
Gene Name log Fold 
Change 
Adjusted p 
Value 
Chromoso
mal 
Location 
Up-regulated Genes 
RNU1G2 U1 small nuclear 4 0.22 0.0088 1p36.1 
RNU1-5 Variant U1 small nuclear 18 0.20 0.011 1q21.2 
FCER1A Fc fragment of IgE, high 
affinity I, receptor for alpha 
polypeptide 
0.33 0.018 1q23 
RNU1-3 U1 small nuclear 3 0.19 0.048 1p36.1 
BCL11A B-cell/lymphoma 11A (zinc 
finger protein) 
0.13 0.057 2p16.1 
Down-regulated Genes 
IGJ Immunoglobulin J 
polypeptide 
-0.53 0.016 4q21 
MGC29506 Marginal zone B and B1 
cell-specific protein 
-0.29 0.018 5q31.2 
SMN1 Survival of motor neuron 1 0.088 0.044 5q13.2 
LOC653618 Similar to hypothetical 
protein LOC349196 
-0.093 0.0022 8p23.1 
TXNDC11 Thioredoxin domain 
containing 11 
-0.11 0.018 16p13.13 
TAF15 TAF15 RNA polymerase II 0.28 0.00042 17q11.1-
q11.2 
C17ORF79 Chromosome 17 open 
reading frame 
0.20 0.0055 Chr 17 
IGLL1 Immunoglobulin lambda-
like polypeptide 1 
-0.11 0.016 22q11.23 
MIAT Myocardial infarction 
associated transcript 
-0.66 0.0004 22q12.1 
LOC651751 Similar to Ig kappa chain V-
II region RPMI 6410 
precursor 
-0.20 0.0044 Not known 
LOC647450 Similar to Ig kappa chain V-
I region HK101 precursor 
-0.39 0.0022 Chr 2 
LOC652493 Ig kappa chain V-I region 
HK102-like 
-0.54 0.0032 Not known 
LOC647506 Similar to Ig kappa chain V-
I region HK101 precursor 
-0.58 0.0036 Chr 2 
LOC642113 Ig kappa chain V-III region 
HAH-like 
-0.45 0.0053 Chr 2 
LOC652694 Similar to Ig kappa chain V-
I region HK102 precursor 
-0.53 0.0055 Chr 2 
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genetic predisposition. At a patient level, many of these potential influences will remain constant; 
however, at a group level they may not be equally distributed amongst all the patients. To 
minimise the influence of patient related factors on the observed gene expression profiles, the 
baseline and 3 month gene expression profiles of participants who achieved DAS28 remission 
after 3 months were compared. Participants required at least moderate disease activity to enter 
the study; therefore, those patients who achieved DAS28 remission after 3 months were likely to 
have undergone a profound clinical change which should increase the likelihood of observing a 
corresponding dynamic change in gene expression. Results from 34 participants were included in 
the analysis and a clear clinical response to 3 months of DMARD monotherapy was observed. 
Median DAS28 score fell from 4.40 (IQR 3.71 – 5.44) to 2.00 (IQR 1.59 – 2.30) and Wilcoxon 
Signed-Ranks test confirmed a statistically significant change between the two time points 
(p<0.0001). However, despite the clear change in clinical state, there were no statistically 
significant differences in gene expression profile evident between the 2 time points (lowest 
adjusted p value = 0.99). Repeating the comparison using more widely spaced samples (e.g 
baseline and 18 months) may allow more time for shifts in gene expression to become apparent 
and may determine whether any lead bias was present 
 
A similar comparison was conducted using the subset of 14 participants whose MSUS disease 
activity assessment at 3 months identified PD signal in one or no joints since, under the proposed 
MSUS definitions of disease activity, this state effectively equates to MSUS LDAS and/or 
remission and was not felt to justify DMARD escalation. Since at baseline all participants had 
exhibited evidence of active synovitis (either clinically and/or ultrasonographically) those who 
exhibited a MSUS PD joint count of 1 or zero after 3 months were presumed to have experienced 
the biggest swing in overall inflammatory disease activity. Of the participants who underwent 
MSUS disease activity assessment after 3 months follow-up, 9 had a PD joint count of 1 and 5 
had no evidence of PD signal in any joint. Of these 14 fourteen patients, 6 (43%) also fulfilled the 
ACR-Boolean definition for remission. Overall, this subgroup of participants had experienced a 
good response to initial DMARD monotherapy as measured by DAS28; median DAS28 at 
baseline was 4.79 (IQR 4.34-5.45) falling to 2.34 (IQR 2.05-2.99) after 3 months. The median fall 
in DAS28 was 2.29 (IQR 2.29) and a Wilcoxon Signed Rank comparison confirmed that there had 
been a significant change in the distribution of DAS28 values between the two time points 
(p=0.001). Despite the clear improvements in clinical and MSUS disease activity assessments 
there was no evidence of differential gene expression between the two sample time points 
(lowest adjusted p value = 0.99) 
 
7.5.4 Relationship of Interferon Response Gene Expression to Disease 
Activity Levels  
Whilst conducting this study, two linked papers were published describing how expression of 
interferon response genes changed in response to rituximab therapy and suggesting that 
elevated pre-treatment interferon response gene levels were predictive of treatment non-
response (355,356). Both papers attempted to manipulate gene expression data, to produce a 
single, numerical score that was both objective and easily understood. In the first paper, the 3 
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month mean expression level of 6 type I interferon response genes (IRG) (RSAD2, IFI44, IFI44L, 
HERC5, LY6E, Mx1) increased in patients who experienced a good 6 month response to 
rituximab (356). In the second paper, an elevated pre-treatment mean expression level of 8 type I 
IRG (LY6E, HERC5, IFI44L, ISG15, MxA, MxB, EPSTI1, RSAD2) was predictive of non-response 
to rituximab after 6 months (355). Using the available clinical outcome and expression profile 
datasets from this research, an analysis was conducted to determine whether the IRG signatures 
either 1. exhibited the same changes of expression in response to DMARD therapy and/or 2. 
were predictive of response to DMARD monotherapy after 3 months and overall response to 
step-up DMARD therapy after 12 months. 
 
Analysis 1 – relationship between change in IRG score and disease activity 
following commencement of DMARD therapy (after Vosslamber et al, 2011 
(356)) 
Methods 
 
1. Comparisons groups defined based upon DAS28 score 
 
i. After 3 months – ΔDAS28<1.2 vs ΔDAS28 ≥1.2 
ii. After 6 months - ΔDAS28<1.2 vs ΔDAS28 ≥1.2 
iii. After 12 months - ΔDAS28<1.2 vs ΔDAS28 ≥1.2 
iv. After 3 months – DAS28<3.2 vs DAS28 ≥3.2 
v. After 6 months - DAS28<3.2 vs DAS28 ≥3.2 
vi. After 12 months - DAS28<3.2 vs DAS28 ≥3.2 
 
2. Calculation of IRG score using baseline and month 3 gene expression data for each 
participant 
IRG score = mean of expression levels of RSAD2, IFI44, IFI44L, HERC5, LY6E, Mx1 
 
3. Calculation of IRG ratio (IRG T3:T0) between month 3 and baseline mean IRG score for 
each participant 
 
4. Between group comparison of pooled IRG T3:T0 values: participants segregated by 
treatment response comparator groups. Between group comparisons conducted using 
Mann-Whitney-U test and represented graphically using boxplot of median, interquartile 
range, minimum and maximum values 
 
Results 
 
Paired sets of gene expression and DAS28 data were available for 74 participants between 
baseline and follow-up month 3 and between baseline and follow-up month 6 and for 69 
participants between baseline and follow-up month 12. Overall, the dynamic change in the mean 
IRG score between baseline and 3 months was not associated with either a significant 
improvement in DAS28, nor likelihood of attaining low disease activity, after 3, 6 or 12 months of 
follow-up. The summary statistics suggest that the majority of 3 month IRG T3:T0 ratio values 
were closely associated with the value 1.0 (mean 1.0, ±SD 0.18) implying that for the majority of 
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patients there was very little change in the overall expression levels of IRG genes between 
baseline and month 3.  
 
1. Response to DMARD monotherapy after 3 months 
 
After 3 months of DMARD monotherapy, 61 participants were classified as responders and 
13 participants were classified as non-responders. For responders, the median change in 
DAS28 was -2.27 and for non-responders the median change was 0.12; there was a 
statistically significant difference in the degree of change between the groups (Mann-
Whitney p<0.0001). However, the IRG T3:T0 ratios for both groups were very similar (Graph 
43). Between group comparisons showed that there was no statistically significant difference 
between the groups (Mann-Whitney p 0.16). A correlation analysis comparing the 3 month 
IRG T3:T0 ratio to the corresponding change in DAS28 suggested a positive correlation 
between the values (Pearson’s co-efficient: r = 0.33, 95%CI 0.11-0.52, p=0.0045) 
 
After 3 months, 51 participants exhibited a DAS28 score < 3.2 (low disease activity) and 23 
participants exhibited a DAS28 of 3.2 or higher (moderate disease activity above); between 
group comparisons suggested that the distribution of DAS28 scores were statistically distinct 
for each group (median DAS28 2.3 vs 4.2 respectively, p <0.0001). The distribution of IRG 
T3:T0 ratios for both these groups were statistically similar (Graph 44). The median IRG 
T3:T0 ratio for both groups was 1.0 (Mann Whitney, p =0.68) 
 
 
  
Graph 43 – IRG T3:T0 ratio according to 3 month clinical response.  
Clinical response defined as change in DAS28 > 1.2 
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Graph 44 – IRG T3:T0 ratio between patients with low disease activity (DAS28 <3.2) and 
moderate disease activity or higher (DAS28 >3.2) at 3 months 
 
2. Response to step-up DMARD therapy after 6 months 
 
This comparison most closely resembled the analysis described by Vosslamber et al (356). 
After 6 months of treatment, 56 participants were classified as responders and 18 were 
classified as non-responders. In the responder group, the median fall in DAS28 was -2.4 and 
in the non-responder group the median fall in DAS28 was -0.19; the between group 
comparison confirmed a statistically significant difference in the mean fall in DAS28 between 
both groups (Mann Whitney p <0.0001). Whilst there was considerable overlap in the 
distribution of values, between group comparisons did suggest that there was a statistically 
significant difference between the IRG T3:T0 ratios for both groups (Graph 45). However, the 
pattern observed for this research was contrary to that described in the original paper. 
Participants defined as non-responders tended to have higher median IRG T3:T0 ratios than 
responders (median IRG T3:T0 ratio: responders 1.0 vs non-responders 1.2, p =0.0046). 
Correlation analysis identified a weak positive correlation between 3 month IRG T3:T0 ratio 
value and change in DAS28 between baseline and 6 months (Pearson’s co-efficient: r=0.29, 
95%CI 0.021-0.45, p =0.033).  
 
After 6 months of DMARD therapy, 43 participants had attained a DAS28 LDAS (median 
DAS28 = 2.1), whilst 31 participants continued to exhibit a DAS28 of 3.2 or greater (median 
DAS28 = 4.1). The distribution of DAS28 values between both groups was significantly 
different (Mann Whitney p<0.0001). However, there was very little difference evident in the 3 
month IRG T3:T0 ratios between the groups (Graph 46). The median IRG T3:T0 ratio for the 
DAS28 <3.2 group was 1.0 and the median IRG T3:T0 ratio for the DAS28 >3.2 or greater 
group was 0.97; Mann Whitney test between the groups returned a p value of 0.97. 
Therefore, no association between 3 month IRG T3:T0 ratio and 6 month disease activity 
level was identified in this comparison 
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 Graph 45 – Association between 3 month IRG T3:T0 ratio and clinical response at 6 
months.  
Clinical response defined as a fall in DAS28 of 1.2 or greater 
 
 
Graph 46 – IRG T3:T0 ratio between patients with low disease activity (DAS28 <3.2) or moderate 
disease activity or higher (DAS28 >3.2) at 6 months 
 
3. Response to step-up DMARD therapy after 12 months 
 
After 12 months of step-up DMARD therapy, 57 participants were classified as responders 
(median change in DAS28 = -2.6) and 12 were classified as non-responders (median 
change in DAS28 = -0.60). Mann Whitney testing confirmed that there was a statistically 
significant difference in the degree of change in DAS28 between the groups (p <0.0001). 
However, there was no statistically significant difference evident in the 3 month IRG T3:T0 
ratio between either group (Graph 47). Median IRG T3:T0 ratio for both groups was 1.0 and 
between group comparisons returned a non-significant p value (Mann-Whitney p =0.62). 
Correlation analysis suggested that there was a weak positive correlation between 3 month 
IRG T3:T0 ratio and change in DAS28 between baseline and 12 months (Pearson’s co-
efficient: r=0.24, 95%CI 0.00053-0.44, p =0.050) 
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After 12 months of follow-up, 48 participants had attained a DAS28 <3.2 and 21 participants 
exhibited a DAS28 > 3.2. Once again, the distribution of DAS28 scores between both groups 
was statistically distinct (median DAS28 1.8 vs 4.0 respectively, p<0.0001), though there 
was no association evident between 3 month IRG T3:T0 ratio and disease activity state at 12 
months (Graph 48). The median 3 month IRG T3:T0 ratio for both groups was 1.0 and 
between group comparisons returned a non-significant p value (Mann Whitney p = 0.70). 
 
Graph 47 – Association between 3 month IRG T3:T0 ratio and clinical response at 12 months.  
Clinical response defined as change in DAS28 of 1.2 or greater 
 
 
Graph 48 - IRG T3:T0 ratio between patients with low disease activity (DAS28 <3.2) or moderate 
disease activity or higher (DAS28 >3.2) at 12 months 
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Analysis 2 – relationship between baseline IRG score and clinical response 
following commencement of DMARD therapy (after Raterman et al, 2012 
(355)) 
Methods 
 
1. Comparison groups defined based upon DAS28 score 
 
i. After 3 months – ΔDAS28<1.2 vs ΔDAS28 ≥1.2 
ii. After 12 months - ΔDAS28<1.2 vs ΔDAS28 ≥1.2 
iii. After 3 months – DAS28<3.2 vs DAS28 ≥3.2 
iv. After 12 months - DAS28<3.2 vs DAS28 ≥3.2 
 
2. Calculation of IRG score using baseline expression data for each participant 
- IRG score = mean of expression levels of LY6E, HERC5, IFI44L, ISG15, MxA, MxB, 
EPSTI1 and RSAD2 
 
3. Between group comparison of pooled IRG scores; participants segregated by treatment 
response comparator groups. Between group comparisons conducted using Mann-
Whitney-U test and represented using boxplot of median, interquartile range, minimum and 
maximum values 
 
Results  
 
Overall, no significant differences in baseline IRG scores were observed when patients were 
stratified by either change in DAS28 or absolute DAS28 value at either 3 months or 12 months.  
 
1. Response to DMARD monotherapy after 3 months.  
 
Using both definitions of treatment response created comparator groups with statistically 
different levels of measured treatment response. After 3 months of DMARD monotherapy, 61 
participants were classified as responders and 13 participants were classified as non-
responders (median change DAS28: -2.77 vs +0.12, p<0.0001). However, the median and 
distribution of mean IRG scores was very similar for both groups (median IRG score: 8.91 vs 
8.93, p 0.88) (Graph 49). Similarly, 51 participants exhibited a 3 month DAS28 less than 3.2 
and 23 exhibited a DAS28 of 3.2 or higher (median DAS28: 2.34 vs 4.18, p<0.0001). 
However, despite the differences in disease activity levels, there was no statistically 
significant difference evident in the distribution of IRG scores between the groups (median 
IRG score: 9.09 vs 8.66, p 0.45) (Graph 50) 
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Graph 49 – Baseline IRG score in relation to 3 month clinical response 
Clinical response defined by change in DAS28 from baseline 
 
 
Graph 50 – Baseline IRG score in relation to 3 month clinical response 
Clinical response defined by value of DAS28 at 3 months 
 
2. Response to step-up DMARD therapy after 12 months 
 
After 12 months follow-up, 57 participants were classified as responders and 12 were 
classified as non-responders (median change DAS28: -2.64 vs -0.60, p<0.0001). Both 
groups exhibited a very similar distribution in the change if IRG after 12 months (median IRG 
score: 8.86 vs 8.94, p 0.63) though the total range for the positive response group was 
higher (Graph 51). Forty eight participants attained a DAS28 less than 3.2 and 21 
participants didn’t (median DAS28: 1.79 vs 3.96, p<0.0001). However, despite the 
differences in clinical response, there was no statistically significant difference identified in 
the associated distribution of IRG scores (median IRG score: 8.93 vs 8.50, p 0.34) (Graph 
52). 
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Graph 51 – Baseline IRG score in relation to 12 month clinical response 
Clinical response defined by change in DAS28 from baseline 
 
  
Graph 52 – Baseline IRG score in relation to 12 month clinical response 
Clinical response defined by value of DAS28 at 12 months 
 
7.6 Discussion 
Previous studies describing the relationship between gene expression and RA have tended to 
focus on either disease pathogenesis and/or a limited aspect of disease phenotype. So far, no 
studies have attempted a comprehensive phenotypic / genotypic approach such as that described 
herein. As a complex disease, whose clinical course is often heterogenous and dynamic, RA 
phenotype can be considered from a number of different angles: 1.as a single fixed factor at a 
single time point (e.g. RhF status, anti-CCP antibody status); 2. as a static measure of disease 
activity at a single time point (e.g. DAS28), 3. as a dynamic change in a measure between time 
points and 4. as the overall level of disease activity over a given time period (e.g. mean DAS28). 
Therefore, the relationship between gene expression profiles and RA phenotype can also be 
considered from a variety of angles: 1. the relationship between gene expression profile and RA 
phenotypic factor at a single time point; 2. the relationship between gene expression patterns at a 
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single time point and a future RA phenotype (i.e. the predictive ability) and 3. how well dynamic 
changes in RA phenotype (most commonly a measure of disease activity) are reflected in 
corresponding changes in gene expression.  
 
Taken together the following conclusions can be drawn from the analyses: 
 
Baseline gene expression profile and baseline disease phenotype 
1. Participant gender was associated with the highest number of differentially expressed 
genes. In females, 25 genes were down-regulated and 36 genes were up-regulated in 
relation to males. Accounting for gender did not identify any new evidence of differential 
gene expression between the phenotypic comparator groups 
2. Five genes were up-regulated in RhF positive patients compared to RhF negative patients 
3. Current tobacco smoking was associated with up-regulation of a single gene (LRRN3) in 
relation to former smokers and non-smokers. In former smokers, one gene (HIATL1) was 
up-regulated in relation to non smokers.  
 
Gene expression profiles in relation to disease activity 
4. There was no evidence of differential gene expression between upper and lower quartile 
groups of DAS28 at either baseline or follow-up month 3; despite the groups appearing 
phenotypically different at both time points 
5. The expression pattern of 19 genes changed following three months of DMARD 
monotherapy. Five genes became up-regulated and 14 genes became down-regulated. 
However, the subgroups of participants who experienced the biggest improvement in 
disease activity did not exhibit evidence of changing gene expression patterns 
6. There was no evidence of differential gene expression between the subgroups of patients 
with the greatest phenotypic difference in disease activity after 3 months of DMARD 
therapy. In particular, there was no evidence of differential gene expression between 
MSUS-defined remission and patients with clinically active disease 
 
Baseline gene expression as a predictor of future disease activity 
7. At baseline, three genes were up-regulated in participants who subsequently qualified for 
treatment escalation after 3 months of DMARD monotherapy 
8. Baseline gene expression patterns did not appear predictive of disease activity status after 
3 months of DMARD monotherapy nor clinical course over 12 months 
9. Mean baseline interferon response gene score neither predicted treatment response nor 
disease activity state after 3 months and 12 months of treatment 
 
7.6.1 Relationship between baseline phenotypic characteristics and 
gene expression profile 
There has been very little work that has systematically considered differences in peripheral blood 
gene expression based upon RA-associated phenotypic factors. In this study, participant’s 
gender, rheumatoid factor status and smoking status were associated with differential expression 
  264 
of small numbers of genes. Conversely, anti-CCP antibody status and baseline erosive status did 
not appear to be associated with any significant differences in gene expression.  
 
Gender 
Unsurprisingly, segregating participants by gender identified the highest number of genes with 
differential expression between the groups. Sixty six genes exhibited differential expression; 36 
were up-regulated in females and 25 were down regulated. All 14 X chromosome related genes 
were up-regulated in females and all 16 Y chromosome related genes were down-regulated. This 
pattern is partly explained by the analysis method, since gene expression levels of male 
participants were compared relative to female participants. The pattern identified for differential 
gene expression between gender groups bore similarities to the patterns described in other 
studies of gender associated differences in gene expression. Four of the X chromosome related 
genes (EIF1AX, EIF2S3, RPS4X, XIST) and 4 of the Y chromosome related genes (RPS4Y1, 
EIF1AY, CYorf15B, USP9Y) had previously been shown to be differentially expressed in a 
comparison between healthy gender groups (357,358); though that data had been analysed using 
the Significance Analysis of Microarrays technique, and a slightly higher adjusted p value 
threshold (0.065). Four of the 66 differentially expressed genes identified by this study (XIST, 
EIF1AX, EIF2S3, RPS4X) were included within the 19 genes exhibiting gender related differential 
expression in peripheral blood from another study conducted on normal subjects (359-361). 
Similarly, a recent study by Xu et al, which used a stringent adjusted p value threshold (p<0.01), 
identified 105 differentially expressed genes between gender groups (362). Interestingly, all of the 
top 10 gender-associated genes were sex chromosome related and 8 of these were also 
identified as being differentially expressed by this study (XIST, RPS4Y1, EIF1AY, CYorf15A, 
CYorf15B, USP9Y, UTY, PRKY). Using an adjusted p value threshold of 0.01, eleven of the 37 
differentially expressed genes identified by this study (CA5B, CYorf15A, CYorf15B, EIF1AY, 
HDHD1A, PRKX, PRKY, RPS4Y1, UTY, XIST, ZFY) were also identified within the 104 
differentially expressed genes identified by Xu et al. Further, the expression patterns of sex 
chromosome related marker genes (XIST and RPS4Y1) for this study were similar to those 
reported by Wu et al (i.e. XIST was up-regulated in females whilst RPS4Y1 was up-regulated in 
males).  
 
These findings are similar, but not identical, to those of previous studies in healthy subjects. In 
fact, the results reported herein seem to be the first reported description of gender related gene 
expression differences in RA. It seems likely that the majority of observed differences in gene 
expression are gender rather than RA related. It also seems unlikely that differences in gender 
related gene expression will have had a sufficient impact on overall gene expression to confound 
the observations of other RA-related comparisons; especially since the 66 gender-related genes 
comprise a very small proportion of the 47,000 gene probes on the Illumina HumanHT Beadchip. 
Nevertheless, additional analyses were conducted using data from female participants in an 
attempt to account for the potential influence of gender on gene expression when participants 
were grouped according to RA-related characteristics. In fact, focusing on female participants 
alone did not identify any new differences in gene expression and also altered the previous 
observation that RhF status was associated with some differential gene expression. Whilst this 
  265 
suggests that the inclusion of males in the original analysis may have influenced the observed 
gene expression profiles, it was not related to an imbalance in the proportion of males in either 
group since there was no statistical difference in sex distribution between the RhF status groups 
(Percentage males - RhF +ve 37% vs RhF –ve 29%, p=0.62). Similar comparisons conducted in 
female participants grouped according to their anti-CCP antibody status, erosive status of 
baseline DAS28 disease activity did not identify any significant between-group differences of 
gene expression.  
 
Tobacco smoking status 
Several previous studies have shown that tobacco smoking affects gene expression systemically 
(353,363) and within the small airways (354). Further, the relationship between tobacco smoking 
and increased risk of developing rheumatoid arthritis, particularly RhF and anti-CCP antibody 
positive RA, is now well established (364) and may in part be initiated by smoking-induced 
activation of citrillunation within the respiratory epithelium (97). Given the known complexities of 
RA pathogenesis and the increasing recognition of its link to tobacco smoke exposure it is 
surprising that this research did not identify a greater number of differentially expressed genes. 
The differential expression of the LRRN3 gene between current smokers and non-smokers and 
current smokers and former smokers replicates a previously identified association (353) and is 
therefore more likely due to the influence of tobacco smoke exposure on whole blood gene 
expression generally, rather than RA per se. It seems reasonable to presume that RA patients 
whose disease development has been influenced by tobacco smoke exposure might feasibly 
exhibit differences in gene expression that are not present in RA patients with a different 
aetiological background. However, the cohort investigated by this study may have been too small 
and prone to the influence of confounders to accurately reflect the complexities of the interactions 
between genetic predisposition, tobacco smoke exposure and RA pathogenesis. Furthermore, it 
is possible that the gene expression changes induced by tobacco smoke exposure might be 
better demonstrated in alternative target tissues (such as synovium or respiratory epithelium) 
rather than whole peripheral blood which is more exposed to the influence of external factors and 
co-existing illness. 
 
Rheumatoid factor status 
From this study, an adjusted p value threshold of 0.05 identified 2 genes (SRI, NAIP) that were 
up-regulated in RhF positive participants compared to RhF negative patients. Increasing the 
adjusted p value threshold to 0.15 identified a further 4 up-regulated genes (LOC648984, 
LOC728519, AP1S1, BCS1L) in RhF positive participants. Interestingly, the same genes were not 
found to be differentially expressed when the comparison was restricted to female participants. 
These initial findings do suggest that RhF status might be associated with a specific pattern of 
gene activation. However, it is worth re-iterating that the gene list was not apparent until the 
adjusted p value threshold had been arbitrarily raised. Equally, it is well recognised that RhF 
expression is not specific to RA. Several other conditions (e.g. chronic hepatitis C infection, 
Sjogrens syndrome, systemic lupus erythematosus) have also been associated with RhF 
positivity and approximately 11% of healthy subjects may also exhibit rheumatoid factors without 
having RA (365,366). Therefore, even if the gene signature tentatively reported by this research 
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were to be confirmed by qRT-PCR, and in an independent validation cohort, its relevance to RA 
pathogenesis would need to be carefully explored.  
 
Very few studies have so far described the relationship between gene expression profile and RhF 
status. A small study of 8 RhF positive and 6 RhF negative RA patients suggested that there 
were no differences in PBMC gene expression between the groups nor between sub-groups of 
patients with the three highest and three lowest RhF titres (367). Van Baarsen et al described 
gene expression profiles in auto-antibody positive arthralgic patients who had not yet developed 
frank RA (368). Within a subset of 9 RhF positive patients, a small (unspecified) number of genes 
were differentially expressed compared to 6 healthy control subjects. Interestingly, within a larger 
cohort of 109 auto-antibody positive arthralgic patients, the gene expression profiles of those 
patients who subsequently progressed to clinical inflammatory arthritis tended to cluster with the 
gene expression profiles of patients with established RA.  
 
Anti-CCP antibody status 
Despite a positive anti-CCP antibody status being highly specific, and predictive, for RA, this 
analysis did not identify any differential gene expression between anti-CCP antibody positive and 
anti-CCP antibody negative participants. This is particularly surprising since the development of 
ACPA antibodies is at least partly genetically determined (90,322). Further, it seems feasible to 
presume that differences in whole blood (i.e. systemic) gene expression might arise from the 
interaction between environmental (i.e. smoking) and genetic (HLA-DRB4, PTPN22) factors that 
culminate in the expression of ACPA antibodies. It is possible that the characteristics of the anti-
CCP antibody comparator groups may have confounded the gene expression analysis. Whilst the 
groups were similarly sized (anti-CCP positive 41, anti-CCP negative 36) and balanced for 
gender distribution (%females: anti-CCP positive 69%, anti-CCP negative 63%), the anti-CCP 
positive group unsurprisingly contained a significantly higher number of current smokers (anti-
CCP positive 39% vs anti-CCP negative 17%, p=0.045). Given existing evidence that tobacco 
smoking does influence gene expression in peripheral blood (353,363) it is possible that the gene 
expression influence of tobacco smoke may have modulated the gene expression changes 
observed in relation to anti-CCP status. Nevertheless, correcting for tobacco smoking status 
between the anti-CCP comparator groups and rerunning the gene expression comparison did not 
identify any new differentially expressed genes. Further, it is possible that the anti-CCP antibody 
comparator group was too small to account for all the potential confounding factors that might 
also influence gene expression and ACPA antibody expression (e.g. smoking status, gender and 
hormone status, weight, alcohol intake, presence of periodontal disease, HLA-DRB4 and 
PTPN22 genotype). It is also important to consider that a significant subset of RA patients do not 
develop ACPA antibodies but do still develop a clinical and histological expression of synovitis 
that is very similar to ACPA positive RA patients (369). Therefore, if the eventual histological and 
clinical expression phenotypes of ACPA positive and negative RA patients are similar (i.e. a 
common pathway) it is perhaps less surprising that there were no differences in whole blood gene 
expression identified either. It is possible that ACPA expression may be associated with 
differential gene expression within the target tissues (such as respiratory epithelium or synovial 
tissue); however, this requires further investigation and targeted tissue sampling 
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Several studies have used gene expression data to perform hierarchical clustering exercises that 
cluster patients into distinct sub-groups based upon gene activation state and pathway analysis 
(for example: van der Pouw Kraan et al 2003 (229)). Their findings need to be carefully 
interpreted, and often inferred, since in many cases the original studies were not designed to 
investigate the relationship between RA phenotype and gene expression profile and any reported 
findings in relation to ACPA status are often supplementary. Taken together the available results 
of previous studies provide a signal that ACPA status might be associated with detectable 
differences in gene expression. Junta et al reported differential expression of 101 genes between 
anti-CCP positive and negative RA patients (370), van Baarsen et al reported that RA patients 
with high levels of synovial inflammation exhibited different patterns of gene expression within 
synovial tissue and also tended to have higher ACPA titres than patients with low levels of 
synovial inflammation (371). Further, van Baarsen et al have also reported that auto-antibody 
patients who develop RA have similar gene expression profiles to patients with established RA 
(i.e. they can be differentiated from auto-antibody positive patients who do not develop RA); 
though they do not specifically describe whether there are differences between different subsets 
of autoantibody patients nor whether gene expression in auto-antibody negative RA patients 
differs at all from auto-antibody positive RA patients (368). The combined findings of these 
studies is not conclusive. Furthermore, due to relatively small sample sizes, heterogeneity of 
design and study population and the potential for external confounders their clinical relevance is 
uncertain. Their results are also directly contrary to those reported herein. Even though this study 
was conducted on a notably larger population than any of the previously reported studies it still 
did not identify any evidence of differential gene expression between anti-CCP positive and 
negative participants. This could be partly explained by the cohort being too small to minimise the 
influence of all other confounders and by not having optimised the statistical analysis sufficiently 
to account for external confounders.  
 
Baseline x-ray status 
The emergence of radiographic erosions is an important step during the time course of RA. 
Whether certain patients are inherently predisposed to the development of erosions because of 
pathogenetic characteristics of their RA, or whether the development of erosions represents a 
point where the burden of joint destruction exceeds the bone’s ability to repair remains unclear. 
Either way, since the development of erosions has long-term prognostic implications it seemed 
prudent to determine whether their presence at presentation might be associated with differences 
in gene expression. Overall, the available results suggest that the presence of plain x-ray 
erosions at presentation is not associated with evidence of underlying differences in gene 
expression. When considering these findings it is important to consider the characteristics of the 
grouping variable used to construct the comparator groups. Since the formal grading of the 
radiology outcomes has not yet occurred the baseline plain x-ray images have not yet been 
systematically graded for the presence of erosions. Rather, in order to allow a preliminary 
analysis, participants were grouped depending on whether the routine reporting (but not grading) 
by NHSGGC staff radiologists described the presence of erosions. All plain x-ray images 
collected within NHSGGC radiography departments undergo verbal reporting by staff radiologists 
  268 
with a large variety of experience in musculoskeletal radiography and this process may have lead 
to inconsistencies in how baseline x-rays were categorised. Once the formal grading of the plain 
x-ray images has been completed the comparison will be rerun with participants categorised 
based upon the componenets of the van-der-Heijde/Sharp score. An additional comparison is 
also planned to determine whether future deterioration in plain x-ray appearances is in anyway 
associated with baseline gene expression profile. 
 
A single study has already reported on the association between erosive plain x-ray damage and 
differences in baseline PBMC gene expression profile in 96 African-American early RA patients 
(372). Using a relatively generous adjusted p value threshold (0.30), 1138 genes were shown to 
exhibit differential expression between patients with mild and severe erosive change on plain x-
rays of hands and feet. There was far les striking evidence of differential gene expression 
between patients who did, and did not, exhibit progressive radiographic damage.  
 
In fact it may not be possible to identify a single gene expression pattern that associates strongly 
with either the presence or future development of erosions since their development may instead 
represent the end-outcome of several overlapping pathogenetic processes associated with the 
presence of inflammatory synovitis (inflammatory cell activation and migration, pannus formation 
and proliferation, cytokine and osteolytic enzyme release, synovial fluid exudation, 
angioneogenesis, apoptosis) (373). The activation states of each of these different processes 
may themselves be associated with differential gene expression; therefore, it may be that the 
gene expression profile for each process must be first described and correlated with the profiles 
of all other associated processes before a specific gene expression profile relating to the 
presence or development of plain x-ray erosions can be proposed.  
 
7.6.2  Relationship between RA disease activity state and gene 
expression profile 
The clinical phenotype of RA patients with persistently active disease is very different from those 
with persistent LDAS or remission, even if the presenting substrates have been similar. Therefore 
it was hypothesised that differences in disease activity state, representing different stages of 
immune activation, might also be associated with differences in underlying gene expression. 
Whilst differences in gene expression might provide interesting insights into the activity of 
underlying inflammatory pathways for the findings to be clinically useful they must also relate to 
recognisable clinical scenarios. Therefore participants were formed into comparator groups based 
upon permutations of the DAS28 score, a widely used composite measure with well recognised 
thresholds for different disease activity states. At presentation, most participants had not yet 
commenced immunomodulatory therapy and the distribution of their DAS28 scores was skewed 
towards moderate-high disease activity. Likewise after 3 months follow-up, most participants were 
starting to experience the benefits of commencing DMARD therapy, so the distribution of their 
DAS28 score was skewed towards moderate-low disease activity. Therefore, in order to include 
the whole spectrum of disease activity comparisons were performed using both the baseline and 
3 month data. A comparison combining the 2 datasets, to encompass the whole range of possible 
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disease activity states, was not performed since most participants would be represented twice 
within a single dataset and statistical corrections for multiple inclusions of some participants 
would become exceedingly complicated.  
 
The DAS28 provides a continuous measure of disease activity; therefore, even though closely 
related DAS28 measures for 2 patients might fall either side of an arbitrary threshold they might 
actually relate to patients who are phenotypically very similar. Presuming that comparisons of 
groups with the greatest phenotypic difference would be most likely to elicit differences in 
underlying gene expression profile, the baseline and 3 month DAS28 scores were used to form 
participants into sub-groups with clear, statistically distinct, differences in the DAS28 score. 
Overall, none of the comparisons of different levels of disease activity were associated with 
differences in whole blood gene expression at either baseline or after 3 months of DMARD 
monotherapy. However, this may have been due to the grouping structures chosen for each 
comparison. In order to fulfil the inclusion criteria, participants at baseline had to display at least 
moderate disease activity (DAS44 >2.4). Hence, the comparison of baseline gene expression 
profiles in relation to disease activity is actually between the lowest quartile of participants, who 
all had moderate disease activity (median DAS28 3.57), and the highest quartile of participants, 
who all had high disease activity (median DAS28 6.48). Despite the distribution of DAS28 scores 
between the two groups being statistically distinct (p<0.0001) the moderate and high disease 
activity states might still have been too close to each other to exhibit clear differences in gene 
expression.  
 
After 3 months of DMARD therapy, the remaining participants exhibited a much wider range of 
DAS28 scores that encompassed the whole range of potential disease activity states (DAS28 
range 1.049 – 6.3). Ideally, the 3 month gene expression profiles of participants in DAS28 LDAS 
and/or clinical remission would have been compared to those of participants who were still in 
DAS28 high disease activity. However, after 3 months of follow-up the majority of participants had 
experienced some benefit from their initial treatments and the DAS28 scores were strongly 
positively skewed towards DAS28 LDAS and remission. In fact, nearly half had already attained 
DAS28 remission. Thus comparing groups of participants with high disease activity (n=4) and 
participants with DAS28 remission (n=35) would have been substantially imbalanced. Therefore, 
to allow a comparison between 3 month disease activity states participants were separated into 
comparator groups using the upper and lower quartiles of the 3 month DAS28. This did produce 
comparator groups that appeared phenotypically distinct. Patients in the lower quartile group all 
had DAS28 remission (DAS28 median 1.73), whilst patients in the upper quartile group all had 
moderate-high disease activity (DAS28 median 4.46). Nevertheless, despite clear phenotypic 
differences there was no evidence of differential gene expression between the comparator 
groups. Further attempts were made to increase the sensitivity of the gene expression analysis 
by forming comparator groups comprising participants with even wider differences in clinical 
phenotype. Several different manipulations of the available DAS28 and MSUS disease activity 
data were made to allow the formation of several different phenotypic extreme comparator 
groups. None of these approaches however identified evidence of differential gene expression 
despite the comparator groups exhibiting clearly different levels of disease activity. 
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An alternative method of performing comparisons of phenotypic extremes would have been to 
form a comparator groups comprising patients who had attained the stringent ACR-Boolean 
definition of remission (186), since this may be a more clinically relevant for the majority of 
rheumatologists who cannot perform MSUS assessments. However, this comparison was 
deferred since: 1. the preceding two comparisons based upon DAS28 remission and MSUS 
LDAS/remission had failed to identify any signal that extremes of disease activity would be 
associated with gene expression differences and 2. ACR-Boolean Remission did not necessarily 
equate to absence of disease activity. Twelve participants attained ACR-Boolean Remission and 
also underwent MSUS disease activity assessment at the 3 months time point. Of these 
participants, only 3 (25%) exhibited total absence of PD signal; 3 had a PD joint count of 1 and 6 
(50%) had evidence of active disease with a PD joint count of 2 or higher (range 2-4) (data not 
shown). 
 
Clinically, at a cohort level, there was a positive response to initial DMARD monotherapy, best 
evidenced as a statistically significant fall in the mean DAS28 score between baseline and 3 
months. However, not all participants exhibited a significant improvement in DAS28; in 5 
participants DAS28 fell by less than 1.2 (the minimum clinically important change) and in 8 
participants DAS28 actually increased. It is possible that differences in magnitude, and direction, 
of treatment response may also have been reflected in out-of step changes in gene expression 
that skewed the outputs of comparisons involving the whole cohort. A crude, unadjusted, 
comparison was conducted between baseline and 3 month gene expression profiles using data 
from all participants and demonstrated that 19 genes underwent changes of expression between 
baseline and the 3 month time point. It is possible that the differential expression of these genes 
represents a true dynamic change in response to treatment. However, similar differences were 
not identified when the baseline and 3 month gene expression patterns were compared in the 
subgroup of participants who exhibited the greatest phenotypic change over the same time period 
(i.e. DAS28 remission, MSUS LDAS/remission). Since these participants had experienced the 
biggest change in disease activity it was presumed that they would be most likely to also 
demonstrate a dynamic change in gene expression. Further restriction of the comparison to the 
63 participants who exhibited a significant improvement in DAS28 between baseline and 3 
months (i.e. fall in DAS28 of 1.2 or greater) may reveal additional changes in gene expression 
profile that are not evident at the cohort level. Given the breadth of the microarray and the size of 
the cohort it is quite possible that the interplay between the various external factors that might 
also influence gene expression (e.g. initial DMARD therapy, corticosteroid use, variations in 
clinical course, intercurrent illness) caused certain genes appearing to appear to undergo 
expression changes which, whilst temporally associated with the commencement of treatment, 
were not strictly disease activity related.  
 
Whilst the early treatment regimen was standardised, differences in DMARD escalation threshold 
meant that treatment was not applied uniformly to all participants. Equally, the quantity and 
frequency of corticosteroid administered to each participant varied quite considerably depending 
upon their clinical course and month-by-month disease activity level. Since differences in gene 
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expression have been reported in relation to methotrexate (374,375), sulphasalazine (357) and 
corticosteroids (359,361) it is possible that the variable treatment exposure amongst participants 
contributed to additional variations in gene expression patterns that obscured any expression 
patterns that were directly related to disease activity. It is possible to correct for some of the 
treatment-related influence on gene expression by limiting comparisons to participants who solely 
received methotrexate. However, it would still be difficult to fully correct for the influence of 
concomitant corticosteroid exposure and to disentangle whether any measured changes in gene 
expression were related to changes in disease or the treatment exposure.  
 
The principle findings of previously published studies comparing RA disease activity and gene 
expression can be summarised thus: 
  
1. Treatment with either rituximab (356) or anti-TNFα blocking (376) therapy induces 
detectable changes in peripheral blood gene expression 
2. Characteristic patterns of gene expression from within fibroblast synovial-like cells (377) 
and synovial tissue (371) correlate with different disease activity states, as measured by 
either HAQ, DAS28, ESR or CRP 
3. Specific PBMC gene expression signatures have been associated with different levels of 
disease activity based upon either an absolute DAS28 threshold (370) or subjective 
assessment of need to escalate therapy (378). 
4. Non-response to both methotrexate and infliximab has been individually associated with 
specific PBMC gene expression patterns that are not present in responders (375) 
 
Therefore, the indications are that synovial tissue and peripheral blood gene expression patterns 
might in some way correlate to RA disease activity and could feasibly serve as an alternative 
disease activity measure in certain circumstances. However, this tentative consensus is not in 
keeping with the findings of this research which found that: 
  
1. Whilst there was evidence of change in peripheral blood gene expression profile between 
baseline and after 3 months of initial DMARD therapy, it could not be reproduced in the 
specific subsets of participants who experienced the greatest phenotypic improvement  
2. Comparisons between upper and lower DAS28 quartile groups at baseline and 3 months 
did not identify significant evidence of differential gene expression in PBMCs 
  
Allowing for the limitations of the chosen comparator groups these findings do not suggest that it 
is presently possible to describe a consistent association between peripheral blood gene 
expression and clinically relevant RA disease activity subtypes. A potential role for gene 
expression profiling might be to differentiate between patients with active and inactive RA or to 
confirm response to a particular therapy. The main role for such measures is usually in patients 
with low levels of inflammatory disease activity where clinical assessments are equivocal and it is 
difficult to differentiate between those with inactive disease (who do not require DMARD 
escalation) and those with subclinical active disease (who may require DMARD escalation). 
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However, if the gene expression measure is no different between patients with the widest 
phenotypic difference it is unlikely to be sufficiently sensitive or specific to differentiate between 
those with much subtler differences in disease activity. Junta et al have reported that there was 
evidence of differential gene expression between relatively small groups of RA patients who fell 
either side of an arbitrary DAS28 threshold of 5.0. Whilst this is suggestive that higher disease 
activity is associated with specific patterns of gene expression there is no clear biological reason 
why the threshold should be a DAS28 of 5.0. Given the size of the study it is possible that a small 
number of aberrant gene expression data sets could have skewed the overall findings. Galligan et 
al and van Baarsens et al have also demonstrated that particular gene expression patterns from 
synovial tissue (van Baarsen (371)) and synovial tissue derived fibroblast-like cells (Galligan et al 
(377)) do correspond to particular histological and clinical measures of disease activity. However, 
importantly, van Baarsen et al could not identify corresponding evidence of differential gene 
expression in simultaneous peripheral blood samples (371). This strongly suggests that synovial 
tissue, which directly represents the main inflammatory lesion of RA, may be a more appropriate 
tissue in which to identify evidence of an association between gene expression and disease 
activity. Whilst peripheral blood is more readily accessible than synovial tissue it may be exposed 
to too many additional external influences to provide an accurate representation of the nature of 
gene expression patterns in RA. Equally, RA-related variations in gene expression that occur 
within the synovium may be either isolated from the systemic circulation or of too small a 
magnitude to be apparent in whole blood.  
 
In the hunt to identify additional disease activity measures, there remains a tension between 
identifying a tissue whose gene expression patterns accurately and consistently reflect disease 
activity and the need for the necessary tissue collection procedures to be acceptable to the 
patient. Ultimately, it may be that specific patterns of synovial tissue gene expression are found to 
serve as accurate measures of RA disease activity; however, the clinical relevance of the 
measure will be significantly limited if patients consider the need for synovial biopsy excessively 
invasive. Peripheral blood provides an ideal medium for identifying additional disease activity 
measures since it is readily accessible and favours repeated sampling to track fluctuations in 
disease activity. However, the results from this research suggest that, despite its accessibility, 
peripheral blood may not be an appropriate tissue to investigate since, so far, differences in 
disease activity have not been consistently associated with evidence of differential gene 
expression. Taken together the inherent limitations of both synovial tissue and peripheral blood 
gene expression analysis suggest that it might not be possible to develop a reliable and accurate 
RA disease activity measure based upon gene expression patterns; though they may still 
continue to contribute important information to the understanding of disease pathogenesis and 
subtyping.  
 
Unfortunately, due to evident skew in the distribution of DAS28 values at baseline (negative skew 
towards moderate and high disease activity) and follow-up month 3 (positive skew towards low 
disease activity and/or remission) it was not possible to create a single comparison that 
represented the whole range of DAS28-defined disease activity at a single time point. Whilst a 
clinical trial environment is a very good setting for analysing change in gene expression in 
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response to a specific intervention (because the influence of potential confounders can be 
anticipated and minimised) it does inevitably lead to skew in the distribution of disease activity 
measures at baseline and after commencement of treatment because the overriding treatment 
aim is to suppress inflammatory disease activity as quickly as possible. An alternative approach 
would be to either 1. investigate a longitudinal early RA cohort  or 2. recruit and assess patients 
attending routine follow-up clinics in the hope of capturing the whole spectrum of RA disease 
activity. However, both these approaches were outwith the logistical scope of this research.  
 
7.6.3 Relationship between treatment response and baseline gene 
expression profile 
This research identified 3 genes (TBC1D22B, TMCC2, USP46) that were up-regulated in 
baseline samples of participants who failed to achieve DAS28 LDAS after 3 months of DMARD 
monotherapy. However, these genes were not identified until the adjusted p value threshold had 
been increased to 0.15. Furthermore, differential expression of the same genes was not identified 
when the participants were grouped according to quartiles of the 3 month DAS28 value. In fact, 
there was no apparent association between baseline gene expression profile and any particular 
categorisation of 3 month disease activity. Overall, on the basis of this study it is not possible to 
conclude that a particular baseline gene expression profile is neither associated with, nor 
potentially predictive of, disease activity level after 3 months of DMARD monotherapy. The up-
regulation of 3 genes at baseline may differentiate between those patients who are likely to 
require DMARD escalation after 3 months of DMARD monotherapy; however, this would require 
validation through quantitative PCR analysis of residual samples from this cohort and prospective 
validation in an independent RA cohort.  
 
Participant’s mean DAS28 between baseline and follow-up month 12 was used as a surrogate 
measure of their disease course during the first year of treatment. The upper and lower quartile 
groups had evidently experienced quite different inflammatory disease burdens; for the lower 
quartile group the median DAS28 0-12 months was 1.93 (suggesting persistent LDAS, if not 
remission), whilst for the upper quartile group the median DAS28 0-12 months was 4.0 
(suggesting moderate – high disease activity). Even so, the evident differences in disease course 
were not associated with differences in baseline gene expression profile. Therefore, based on 
these results, it is not possible to use baseline whole blood gene expression profile to predict a 
patient’s likely disease course, nor their potential requirement for a specific intensity of DMARD 
therapy. The EULAR response criteria for RA (297) do provide a categorical measure of 
treatment response over time and could have been used as an alternative grouping variable for 
disease course. However, they are based upon the final value of DAS28/DAS44 and the relative 
change from another point and can only represent the change in disease activity level between 
those two time points. In RA, where month-by-month disease activity levels can be dynamic and 
highly variable, the relative change between the two points may not actually reflect the overall 
disease activity burden in the intervening month. Hence, for this comparison, the mean DAS28 
value was chosen as the comparator variable since it does incorporate all of the intervening 
DAS28 values.  
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To date, most studies have correlated pre-treatment gene expression profiles to short term 
clinical outcomes in relation to single drug interventions. Previous studies have demonstrated that 
specific patterns of pre-treatment gene expression in the whole peripheral blood, PBMC and 
synovial biopsies predict the likelihood of response to either infliximab (234,236,370,371,379), 
adalumimab (239,380), rituximab (355,356,381) and anakinra (382). Several studies have also 
attempted to maximise the practical application of gene profile assessment by identifying either 
single genes (CD11c, (239)), reduced gene profiles (234,355,356) or mean gene expression 
scores based upon a small number of candidate genes (355,356). However, the generalizability 
of these results remains uncertain. The findings of most studies require further validation through 
replication of the gene signature by qRT-PCR and/or further testing in a larger, prospective 
cohort. 
 
Two studies have described how changes in gene expression profile after commencement of 
anti-TNFα blocking therapy may also predict the likelihood of attaining a favourable response 
(238,383,384). Whilst both studies identified changes in gene expression profile that were 
associated with subsequent treatment response it is unclear whether this approach will be 
clinically useful since: i. it requires patients to undergo a two step tissue sampling process to 
assess the change in gene expression profile from baseline and ii. it still requires patients to be 
exposed to an agent, which may ultimately still prove ineffective, whilst the gene expression 
response is being assessed.  
 
Both the studies by Raterman et al and Vosslamber et al have suggested that pre-treatment 
interferon response gene scores, and an increase in interferon response gene expression after 3 
months, are potentially predictive of achieving a good response to rituximab and that dynamic 
early changes in interferon gene expression may reflect clinical response (355,356). The clinical 
applicability of these scores is evident, since the mean interferon response gene score is both 
objective and easily interpreted. However, the findings of the studies by Raterman et al and 
Vosslamber et al are so far isolated to treatment with rituximab and therefore of restricted clinical 
value. Interestingly, in this study, pre-treatment mean interferon response gene score and the 3 
month IRG T3:T0 ratio were not found to have the same relationships with clinical response to 
step-up DMARD therapy after either 3, 6 or 12 months. In fact, the value of 3 month IRG T3:T0 
ratio for the majority of participants in this research was very close to 1.0, suggesting that there 
was virtually no change in interferon gene expression following commencement of DMARD 
monotherapy. Therefore, the results from this study suggest that interferon response gene 
expression scores, are unlikely to serve as either predictive markers of short-medium term 
response or additional measures of disease activity in RA patients receiving step-up DMARD 
therapy.  
 
The majority of the studies that have so far described gene expression profiles that are potentially 
predictive of treatment response, have been conducted using relatively small patient cohorts 
(n=4-62) where there is a higher risk that aberrant results may skew the findings. By contrast, the 
cohort investigated by this study was notably larger (n=79) than that used in most previous 
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studies. Whilst this increases the risk of multiple testing introducing false positive results it should 
also attenuate the risk of aberrant results adversely influencing the overall results. However, 
despite the cohort’s size, this study has not identified a consistent relationship between pre-
treatment gene expression profile and either 3 month disease activity level or clinical course over 
12 months. Interestingly, a similar pattern was observed in comparisons between synovial tissue 
gene expression and treatment response. The smaller studies reported by Badot et al and van 
der Pouw Kran et al (n= 18 and 25 respectively) had identified evidence of differential gene 
expression between responder and non-responder patients (236,380). However, a subsequent 
larger study by Lindberg et al (n= 62) did not identify any differential gene expression in the 
baseline profiles, except in a subset of patients with histological evidence of synovial lymphoid 
aggregates (235).  
 
The disconnect between the findings of small and large gene expression cohort studies was also 
evident when this study tested whether the mean interferon response gene scores proposed by 
Raterman et al and Vosslamber et al exhibited the same relationship to short-medium term 
response in patients receiving step-up DMARD therapy (355,356). Admittedly the parameters of 
the comparison were different since 1. DAS28 data from several different follow-up time points 
was used instead of just 6 months; 2. participants in this research had early RA, rather than 
established RA, and 3. they were treated with step-up DMARD rather than rituximab. 
Nevertheless, interferon mediated pathways have recently been implicated in the development of 
symptomatic disease in ACPA and RhF positive RA patients (240,385,386) so it is reasonable to 
presume that the importance of interferon response genes will not be solely confined to the 
likelihood of achieving a response to rituximab. Eitherway, this research was unable to replicate 
the findings of either study since there was no significant difference in baseline mean interferon 
gene scores between participants categorised as responders and non-responders after either 3 
or 12 months follow-up and there was little evidence of a dynamic change in interferon response 
gene expression following commencement of DMARD therapy. The influence of intercurrent 
illness and co-morbidities on peripheral blood gene expression profiles may also ultimately limit 
the value of the interferon response gene signature in RA, particularly since elevated expression 
of interferon response genes has been reported in systemic sclerosis (387), juvenile idiopathic 
arthritis (388), systemic lupus erythematosus, multiple sclerosis and type 1 diabetes 
mellitus(389). 
 
All previously published studies have described the association between treatment response and 
pre-treatment gene expression profile in RA patients commencing a single immunomodulatory 
agent (usually a biologic agent). Thus, the results of individual studies can at present only be 
interpreted in relation to the associated therapeutic agent. Whilst there appears to be very little 
overlap between the various gene profiles that have been reported it cannot be presumed that the 
temporal association with treatment response is confined to either that agent or indeed RA. Prior 
to routine clinical use, the extended performance characteristics of individual gene profiles will 
require testing in alternative clinical circumstances (e.g in relation to alternative diagnoses and/or 
drug treatments) to determine their specificity and sensitivity to different clinical scenarios, and 
therapeutic agents, rather than the restrictive inclusion criteria of a clinical study. Feasibly, it may 
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be possible to identify pre-treatment gene expression profiles that reliably predict response to 
each individual immunomodulatory agent. Provided there is minimal overlap of the constituent 
genes, the predictive profiles for several different agents could be combined in a single 
microarray that could be used to estimate an individual’s likelihood of responding to a range of 
potential therapeutic options; therefore, facilitating the clinician choosing the agent with the 
greatest likelihood of success. Microarrays that comprise separate predictive gene profiles for 
several immunomodulatory agents are more likely to be clinically relevant since they will 
maximise the number of occasions that the microarray is indicated, rather than being confined to 
single occasions when only one agent is being considered.  
 
Since the majority of PAXgene RNA samples were collected prior to the commencement of 
DMARD treatment, variations in the choice of first DMARD and use of corticosteroid could not 
have influenced the baseline gene expression profiles. The 3 month assessment point allowed 
investigation of the ability of pre-treatment gene expression profiles to predict response to initial 
DMARD monotherapy (predominantly methotrexate). For clinical and societal reasons, a number 
of participants initially commenced sulphasalazine instead of methotrexate. Hence, a further, truer 
pharmacogenomic analysis comprising only the pre-treatment gene expression profiles of the 
subset of participants who commenced methotrexate monotherapy (n=74 of 79) is also planned. 
Comparisons of 12 month disease activity level and mean DAS28 to pre-treatment gene 
expression profiles can not be related to a single agent; instead the gene expression profile must 
be considered in the context of the overall treatment strategy which could potentially include 
several different non-biologic and biologic DMARD agents. A 12 month assessment point was 
chosen since it fitted conveniently within the timescale available to conduct the analysis and the 
longer period increased the likelihood of changes of the DAS28 being able to represent the 
overall effectiveness of the strategy. However, the complexity of the escalation strategy, and the 
length of the follow-up period also increased the likelihood of variability within the DMARD 
therapy received by each patient. Variations in application of the DMARD protocol caused by 
unexpected adverse events, intercurrent illness and/or patient choice, could have produced 
variations in disease activity and clinical response in some patients that lead to their pre-
treatment gene expression profile data being classified within an alternative comparator group, 
thereby, potentially skewing the whole group’s gene expression data set. 
 
The maximum follow-up period for the transcriptomic analysis (12 months) was longer than that 
generally reported by previous studies (usually 4-6 months). In previous studies, it is possible that 
relatively short follow-up periods may have prevented the full extent of the treatment response 
becoming apparent (particularly in relation to rituximab), and may have lead to individual patients 
treatment response being misclassified. The longer follow-up period of this study may have 
increased the sensitivity of the clinical assessment to detect change in disease activity following 
commencement of treatment. However, the differences in follow-up period between this research 
and previous studies do address slightly different clinical scenarios. Being able to accurately 
predict short-term treatment failure of a single agent (especially biologic agents) may steer a 
treatment decision towards alternative agents that are more likely to produce a beneficial 
response. Alternatively, using baseline factors to predict medium term response to a treatment 
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strategy may have important prognostic properties and could lead to patients being stratified 
towards different intensities of treatment based upon their prognostic assessment.  
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8.  Disease Activity Assessment 
Using a Multi-Biomarker 
Disease Activity Test 
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8.1 Introduction 
 
This chapter will discuss how a cytokine-based measure of disease activity relates to 
corresponding MSUS and DAS28 disease activity assessments. The laboratory analysis was 
conducted in collaboration with Crescendo Biosciences, San Franscisco, California 
(www.crescendobio.com).  
 
8.1.1 The Multi-Biomarker Disease Activity Test 
The Multi-Biomarker Disease Activity Test (MBDA was devised on the premise that the level of 
inflammatory biomarkers within the blood would be directly related to the level of inflammatory 
disease present (383). It was hypothesised that it would be possible to create a single objective 
score of RA disease activity, based on the expression levels of inflammatory biomarkers, that was 
proportionate to RA disease activity and would allow longitudinal monitoring of disease activity. 
Serum samples for 649 RA patients (early and established disease) were collected from the 
collections of 4 existing inception cohort RA studies. Samples were screened for the presence of 
130 candidate biomarkers that had previously been associated with either RA disease activity 
and/or pathogenesis. Univariate and multivariate analyses were conducted for each study 
individually to determine which markers most closely related to RA disease activity. 
Subsequently, additional multivariate algorithm development techniques were applied to the 
biomarker ranks to generate summative formulae that predicted each of the individual 
components of the DAS28, except CRP. Eventually, a 12-biomarker model was proposed based 
upon the following biomarkers: 
 
 Adhesion molecules  Vascular cell adhesion molecule-1 (VCAM-1_ 
 Growth factors   Epidermal growth factor (EGF) 
    Vascular endothelial growth factor A (VEGF-A) 
 Cytokine-related  Interleukin-6 
     Tumour necrosis factor receptor, type 1 (TNF-RI) 
 Matrix metalloproteinases Matrix metalloproteinases-1 (MMP-1) 
     Matrix metalloproteinase-3 (MMP-3) 
 Skeletal proteins  YKL-40 
 Hormones   Leptin 
     Resistin 
 Acute-phase proteins  Serum amyloid (SAA) 
     C-reactive protein (CRP) 
 
The expression levels of the 11 candidate biomarkers (excepting CRP) were combined in 
summative formulae that estimated the value of the corresponding 28 tender joint count, 28 
swollen count and patient 10cm global VAS (390): 
 
predicted 28 tender joint count = -26.72+3.243 *[YKL-40]1/10-11.97*[EGF]1/10+15.72*[IL6]1/10 
+0.4594*[Leptin]1/10 +3.881*[SAA]1/10+0.7388*[TNF-RI]1/10-0.2557*[VCAM1]1/10+0.7003*[VEGF-
A]1/10 
 
predicted 28 swollen joint count = -26.63+3.232*[YKL-40]1/10-11.93*[EGF]1/10+15.67*[IL-
6]1/10+0.4578*[Leptin]1/10 +3.868*[SAA]1/10+0.7363*[TNF-RI]1/10-0.2548*[VCAM-1]1/10 
+0.6979*[VEGF-A]1/10 
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predicted global 10cm VAS = -13.489+5.474*[IL-6]1/10+0.486*[SAA]1/10+2.246*[MMP-1]1/10 
+1.684*[Leptin]1/10+ 4.14*[TNF-RI]1/10+2.292*[VEGF-A]1/10-1.898*[EGF]1/10+0.028*[MMP-3]1/10-
2.892* [VCAM-1]1/10-0.506*[Resistin]1/10 
 
Thereafter, the outputs of each of these formulae were incorporated with the CRP into a 
derivation of the established DAS28 formula to provide the final MBDA score: 
 
MBDA = round [max (min((0:56√pTJC28 + 28√pSJC28 + 14pPGAz + 36 ln(CRP+1)+0:96) x 
10:53+1,100),1)] 
 
The MBDA calculation outputs a single numerical value in the range 0-100 and MBDA thresholds 
have been proposed that correspond to existing DAS28-CRP disease activity thresholds (Table 
52). At present there is no accepted definition of minimal clinically important difference. 
 
Disease Activity Category DAS28-CRP Definition MBDA Definition 
Remission <2.3 ≤25 
Low ≥2.3 and ≤2.7 >25 and ≤29 
Moderate >2.7 and ≤4.1 >29 and ≤44 
High >4.1 >44 
Table 52 - Disease activity category definitions based upon DAS-CRP and MBDA  
(after Centola et al 2013 (383)) 
 
Validation of the Multi-Biomarker Disease Activity Test 
 
During its initial derivation, the performance of the MBDA was tested in an independent study of 
24 RA patients who were receiving treatment with methotrexate and infliximab and underwent 
serial assessment of disease activity using DAS28, MSUS (MCP joints only) and the MBDA 
(391). Overall, the MBDA performed favourably compared to other measures of disease 
activity(383). There was significant positive correlation between the MBDA and corresponding 
DAS28-CRP (Spearman’s r=0.82, p<0.001), MSUS evidence of synovial hypertrophy 
(Spearman’s r = 0.46, p<0.001), MSUS PD area (Spearman’s r = 0.47, p<0.001) and change in 
DAS28 (Spearman’s r = 0.62, p<0.001). Furthermore, baseline MBDA score showed a stronger 
correlation (Spearman’s r = 0.52) with 12 month change in total Sharp score than DAS28-CRP 
(Spearman’s r = 0.43, p=0.006). 
 
The performance of the MBDA has been tested in an independent validation exercise conducted 
using samples from an additional 230 RA patients who were participating in 3 existing RA 
prospective cohort studies (390). Correlation analyses demonstrated that the MBDA score 
correlated positively with DAS28 in both sero-positive and sero-negative RA patients (Pearson’s r 
= 0.56 and 0.43 respectively, p<0.001 for both). There was fair-moderate agreement between the 
DAS28-CRP and MBDA categorization of disease activity state for both sero-positive (kappa 
0.44, p<0.001) and sero-negative (kappa 0.33, p<0.001) patients. In sero-positive and sero-
negative patients, the MBDA correlated significantly with other composite disease activity 
measures; however, the strength of the correlation appeared consistently stronger in sero-
positive patients.  
 
The MBDA score’s responsiveness to changes in disease activity following treatment has been 
tested in an independent analysis of 45 RA patients who were all treated with methotrexate and 
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infliximab. A positive response was defined as a fall in DAS28-CRP of 1.2 or more. In treatment 
responders, the MBDA score demonstrated significant improvements between baseline and week 
12 of treatment, with the greatest rate of change occurring in the first 2 weeks. In non-responders, 
the changes in MBDA score were much less marked. The change in MBDA between baseline 
and week 2, positively correlated with the corresponding change in DAS28-CRP (Spearman’s p = 
0.51, p<0.001) and showed a fair ability to discriminate between DAS28-CRP responders and 
non-responders after 2 weeks (AUROC = 0.72, p=0.02) and 12 weeks (AUROC = 0.77, p=0.002) 
of follow-up.  
 
Two previously discussed DMARD strategy studies have also recently described the correlation 
between the MBDA score and DAS28 defined disease activity in patients with RA. In both cases, 
MBDA was calculated using stored serum samples and was compared to existing clinical 
outcome datasets. Bakker et al compared the relationship between MBDA and DAS28-CRP in 72 
patients recruited to the CAMERA study (392). Seventy-two sample sets were available at 
baseline; however, only 48 samples were available after 6 months follow-up. The MBDA score 
correlated strongly with the DAS28-CRP (Pearson’s r = 0.72, p<0.001) and could distinguish 
between remission/LDAS and moderate/high disease activity (AUROC 0.86, p<0.001). However, 
there was only fair agreement between the MBDA and DAS28-CRP disease classification for 
each disease activity subtype (kappa 0.34, 95%CI 0.19-0.49) and MBDA was not shown to be a 
strong predictor of subsequent radiographic progression over the next 2 years. In a similarly 
designed study, Hirata et al described the correlation between DAS28-ESR and MBDA in a 
subset of 125 RA patients recruited to the BeST study (393). Follow-up data after one year was 
available in 54 patients (43%) who had been selected from all of the original studies treatment 
strategy arms. Once again, the MBDA score correlated positively and strongly with DAS28-ESR 
(Spearman’s r = 0.66, p<0.0001), SDAI (Spearman’s r = 0.67, p<0.0001) and CDAI (Spearman’s 
r  = 0.56, p<0.0001). Further, the change in MBDA after 1 year’s follow-up correlated positively 
with the change in DAS28-ESR (Spearman’s r = 0.55, p<0.0001) and SDAI (Spearman’s r = 0.35, 
p=0.016), but not CDAI (Spearman’s r = 0.18, p = 0.23), over the same time period. 
 
As previously discussed, DAS28 assessment of disease activity is insensitive to some subclinical 
synovitis and DAS28 remission does not necessarily predict non-progression of radiographic 
damage (121,200). Further, whilst the DAS28-CRP and MBDA have demonstrated positive 
correlations at a single time point, and in relation to treatment changes, it is possible that the 
MBDA might provide a more accurate marker of ongoing subclinical synovitis. Therefore, it is also 
possible that MBDA remission might prove a better marker of true remission, and radiographic 
non-progression, than DAS28 remission. To an extent this has been borne out in an 
observational study of 163 patients with established RA receiving standard DMARD therapy 
(394). Patients who were in MBDA remission at baseline exhibited lower rates of radiographic 
progression compared to patients who were not in MBDA remission. Conversely, patients with 
high MBDA disease activity had the highest rate of radiographic progression. Furthermore, rates 
of radiographic progression were consistently higher in patients who achieved alternative 
definitions of remission (e.g. DAS28 or ACR-EULAR Boolean remission) suggesting that MBDA-
remission is a stronger predictor of radiographic remission than current composite definitions.   
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All of the previous studies have suggested that the MBDA test score correlates reasonably well 
with the DAS28-CRP as either a static measure of disease activity or a dynamic measure over 
time. The implicit meaning being that if the scores are closely correlated they must also be 
measuring the same factor. Indeed, several studies have also reported favourable results from 
receiver operating curve analyses (range AUROC = 0.76 – 0.89) (383,395,396) in relation to 
DAS28-CRP thresholds. Interestingly though, no studies have yet reported the sensitivity and 
specificity of the MBDA test in relation to DAS28 or any other disease activity measure. 
 
The potential impact on clinical practice of the additional disease activity information provided by 
the MBDA test has been tested in a theoretical and real world setting. Eighty-one rheumatologists 
were asked to comment on the management of 3 simulated RA patients; 37 (46%) of the 
rheumatologists were randomized to also receive the corresponding MBDA score (397). The 
quality of the clinician’s performance in different domains of treatment decision making was 
quantified using a standardized clinometric tool, the Clinical Performance and Value vignettes.  
Overall, clinicians with knowledge of the MBDA score improved their ‘quality scores’ by a 
significantly greater amount than those with no knowledge of the MBDA. However, abstract 
theoretical decisions can often differ significantly from real-world clinical practice. Six 
rheumatologists were surveyed regarding their opinion of RA disease activity and need for 
treatment escalation before and after being made aware of the MDBA result (398). Knowledge of 
the MBDA result was associated with changes to the treatment plan in 38 of 101 patient’s cases. 
In most cases, changes lead to therapy escalation with either addition of new DMARDs, dose 
changes and/or changes to the route of administration.  
 
8.1.2 Objective 
To determine the performance characteristics of the MBDA test in relation to corresponding 
DAS28 and, where available, MSUS assessments of global disease activity in RA patients 
recruited to the TaSER study 
 
8.2 Methods 
Study Cohort: All 79 research participants who had contributed serum samples to the TaSER 
study tissue bank were included in the MBDA analysis. This cohort was identical to the cohort 
included in the previously described gene expression analysis (Chapter 7). Paired clinical and 
MBDA data were available for 79 participants at baseline, 76 participants at follow-up month 3 
and 71 participants at follow-up month 18. 
 
Disease Activity Assessments: All clinical and MSUS assessments of disease activity, relating to 
the baseline, 3 month and 18 month time points were collated from the TaSER study data set. 
The DAS28-ESR was chosen as the main measure of clinical disease activity, since it had been 
the main factor about which DMARD escalation decisions were based during the study period. 
Whilst the MBDA had mostly been tested in relation to the DAS28-CRP, a nested analysis within 
the BeST study had shown good, positive correlation (r=0.66) between the DAS28-ESR and the 
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MBDA test result (393). Table 53 summarises the disease activity thresholds for the MBDA, 
DAS28 and MSUS assessments: 
 
 MBDA DAS28 MSUS 
High >44 
 
>5.1 grade 1 or higher PD 
signal in 2 or more 
joints Moderate >29 and ≤ 44 
 
>3.2 and ≤ 5.1 
Low >25 and ≤ 29 
 
>2.6 and ≤ 3.2 PD signal in 1 joint 
Remission ≤25 
 
≤2.6 No PD signal in any 
joint 
Table 53 – Comparison of thresholds for MBDA, DAS28 and MSUS definitions of RA disease 
activity 
 
MDBA Analysis: The laboratory analysis and calculation of MBDA test scores was kindly 
performed by collaborating colleagues at Crescendo Biosciences. For each participant, 2 of the 
stored 0.5ml SST serum samples were shipped frozen to the Crescendo Biosciences laboratory. 
All samples were defrosted simultaneously and analysed en batch according to standard 
laboratory procedures using the Meso Scale Discovery Multi Array multiplex kits manufactured by 
Crescendo Bioscience. Array analysis initially returns the concentration of each of the 12 protein 
markers which are then used to calculate the final MBDA test score using the formulae described 
in Section 8.1.1. 
 
Statistical Analysis: Following laboratory analysis Crescendo Biosciences provided the final 
MBDA score, and the individual concentrations of each component marker, for analysis. All 
statistical analyses were conducted in Graphpad Prism Version 6 (www.graphpad.com). The 
distribution of the difference in MBDA values between baseline and 3 months and baseline and 
18 months did follow a Gaussian distribution, therefore paired t tests were used to compare the 
difference in MBDA between two time points. At each time point the MBDA scores did not 
demonstrate a Gaussian distribution, therefore correlations between the MBDA and DAS28 were 
calculated using Spearman’s rank correlation. The ability of MBDA to recognise comparable 
disease activity states to both the DAS28-ESR and MSUS assessments was calculated as the 
percentage agreement at each time point and over the whole time course. The potential 
predictive ability of MBDA was estimated by calculating the correlation between baseline MBDA, 
to mean DAS28 over 12 months. Participants were stratified by randomisation group to determine 
whether intensity of therapy impacted on the overall change in MBDA score after 18 months. 
 
8.3 Results 
Results are presented showing the correlation between DAS28-ESR and MBDA at a single time 
point and also the correlation between change in DAS28-ESR and MBDA over time. The 
demographic and disease characteristics of the cohort has been previously described in Section 
7.1 
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8.3.1 Change in DAS28-ESR and MBDA Score  
Both DAS28-ESR and MBDA score showed significant improvement over the follow-up period 
(Graph 53). At baseline mean DAS28 was 5.01 (SD 1.14), after 3 months mean DAS28 was 2.94 
(SD 1.21) and after 18 months mean DAS28 was 2.32 (SD 1.03). At baseline, mean MBDA score 
was 57 (SD 17), after 3 months it was 46 (SD 15) and after 18 months it was 41 (SD 15). 
Statistical comparisons showed highly significant changes in the values of DAS28 and MBDA 
between each time point (p<0.001 for each comparison). The highest rate of change in DAS28 
and MBDA was observed between baseline and 3 months. 
 
 
Graph 53 – Mean DAS28 and MBDA values at baseline, 3 months and 18 months 
 
For both assessment methods, the proportion of participants classified as high disease activity fell 
between baseline and 18 months, whilst the proportion of participants classified as low disease 
activity increased. At each time point, there were striking differences evident in the proportion of 
participants classified as each disease activity state by DAS28-ESR and MBDA (Graphs 54A and 
54B). At follow-up months 3 and 18, the DAS28-ESR classified higher proportions of participants 
as either LDAS and/or remission whilst the MBDA test was more likely to classify participants as 
having high or moderate disease activity.  
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Graphs 54 – Distribution of disease activity state classification by DAS28-ESR (54A) and MBDA 
(54B) at baseline, 3 months and 18 months 
NB – Low disease activity bar includes remission subgroup 
 
8.3.2 Relationship of DAS28-ESR to MBDA Score  
Spearman’s rank correlation analyses demonstrated that there was a positive correlation between 
the DAS28-ESR and MBDA at each time point with the strongest correlation evident between the 
baseline datasets. At baseline, a moderate positive correlation was observed (rs= 0.51, 
p<0.0001). At 3 and 18 months, low-moderate positive correlation were observed (3 months: rs= 
0.37, p =0.001. 18 months: rs= 0.48, p <0.0001).  
 
In order to allow a comparison that covered the whole range of DAS28-ESR, various 
combinations of the baseline, month 3 and month 18 datasets were tested until a combination 
that most closely resembled a Gaussian distribution of the DAS28-ESR scores was identified. All 
combinations displayed a degree of positive skew and none matched the typical Gaussian 
distribution. A combination comprising all available paired sets of DAS28-ESR and MBDA 
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covered the widest range of DAS28-ESR (0.49 – 8.21) with an acceptable measure of skew 
(0.39) and the lowest measure of kurtosis (-0.64). The subsequent Spearman’s rank correlation 
analysis between all paired sets of DAS28-ESR and MBDA demonstrated moderate positive 
correlation (rs= 0.58, p<0.0001) (Graph 55) 
 
 
Graph 55 – Relationship between DAS28-ESR and MBDA – all sets of paired BAS28-ESR and 
MBDA values pooled from each time point  
 
The correlation of the change in DAS28-ESR to change in MBDA was calculated for the time 
periods between baseline and 3 months, baseline and 18 months and 3 months. Between 
baseline and 3 months, the mean fall in DAS28-ESR was 2.05 (SD 1.38), the mean fall in MBDA 
was 12 (SD 16.0) and a moderate positive correlation (rs = 0.48, p <0.0001) was evident. 
Between baseline and 18 months, the mean fall in DAS28 was 2.68 (SD 1.36), the mean fall in 
MBDA was 18 (SD 17.6) and a moderate positive correlation was evident (rs = 0.54, p <0.0001). 
Between, follow-up months 3 and 18 a weaker positive correlation was observed, the mean fall in 
DAS28 was 0.65 (SD 1.22), the mean fall in MBDA was 5.7 (SD 15.9) and a low-moderate 
correlation was observed (rs = 0.39, p =0.0007). However, it is evident in all comparisons that the 
distribution of the data points was not entirely linear; a notable number of outliers corresponded to 
participants where there was disparity in the degree of change represented by the DAS28-ESR 
and MBDA (i.e. outlying participants exhibited a marked change in DAS28-ESR but a much 
lesser change in MBDA). Pooling all of the paired DAS28-ESR and MBDA results together 
suggested a moderate-strong positive correlation between the change in both measures over the 
whole follow-up period (rs = 0.56, p <0.0001) (Graph 56). Importantly, a linear regression analysis 
suggested that the line of best fit passed through the origin. 
 
  287 
 
Graph 56 – Relationship between change in DAS28 and corresponding change in MBDA. 
The presented results are pooled for the following time periods: baseline-3 months, baseline-18 
months and 3-18 months 
 
 
8.3.3 Percentage agreement between DAS28-ESR and MBDA 
There was significant disparity evident in how each measure was categorising disease activity 
state for certain participants (Graphs 54A and 54B). Therefore, an analysis was conducted to 
determine how often the measures agreed on the disease activity state at each time point and 
over the whole time course. Agreement was defined as both disease activity measures 
categorising a participant at a comparable level of disease activity. 
 
At every time point, there was significant disparity evident when considering exact agreement 
between DAS28-ESR and MBDA categorisation of disease activity (e.g. both measures identified 
high disease activity). Furthermore, the degree of disparity evident increased over the follow-up 
period (Graph 57). At baseline, there was exact agreement in 43 of 79 assessments (54%), after 
3 months there was absolute agreement in 13 of 76 assessments (17%) and after 18 months 
there was absolute agreement in 20 of 71 assessments (28%). Overall, there was exact 
agreement in 76 of 226 paired assessments (34%) 
 
 
Graph 57 – Percentage exact agreement between DAS28-ESR and MBDA at each time point 
and pooled for all available results 
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The majority of instances of disagreement occurred because MBDA identified a higher level of 
disease activity than initially suggested by the DAS28 (i.e. MBDA was more sensitive than 
DAS28-ESR). At baseline, there were 36 instances of disagreement; 29 (81%) occurred because 
MBDA identified a higher disease activity state than DAS28-ESR. At month 3, there were 63 
instances of disagreement, in 60 (95%) of these instances the MBDA identified a higher disease 
activity state than the DAS28. At month 18, there were 51 instances of disagreement, all of which 
corresponded to the MBDA identifying a higher disease activity state than the DAS28-ESR. 
Overall, out of 150 instances of disagreement, 140 instances (93%) corresponded to the MBDA 
test identifying a higher disease activity state than the corresponding DAS28-ESR. Graph 58 
summarises the distribution of MBDA disease activity assessment findings when data were 
grouped based upon the DAS28-ESR disease activity assessment. Similar graphs were produced 
when the analysis was restricted to each time point (not shown). Of 114 instances of DAS28-ESR 
low disease activity, 94 (82%) were associated with a higher MBDA disease activity assessment 
(MBDA moderate = 54, MBDA high = 40) and could potentially have supported DMARD 
escalation. Of 69 instances of DAS28-ESR moderate disease activity, 46 (67%) were associated 
with MBDA high disease activity, but would not have altered treatment decisions, and 8 (12%) 
were associated with MBDA low disease activity. The highest degree of agreement was evident 
during instances of DAS28-ESR high disease activity since, in all instances, knowledge of MBDA 
score would not have altered treatment decisions. All 43 instances of DAS28 high disease activity 
corresponded to either high (41) or moderate MBDA disease activity (2) (i.e. above the treatment 
escalation threshold).  
 
Graph 58 – Distribution of MBDA disease activity findings when participants were grouped by 
DAS28-ESR disease activity state. (Results pooled for all time points)  
 
The degree of agreement between DAS28-ESR and MBDA increased when each measure was 
converted into dichotomous definitions by pooling the findings for closely allied disease activity 
states (i.e high and moderate disease activity vs low disease activity) (Graph 59). This analysis 
was based upon the common presumption that moderate disease activity or higher is a suitable 
threshold at which to consider further DMARD escalation (i.e. DAS28 >3.2). For clarity, 
comparable DAS28-ESR and MBDA disease activity definitions are shown in Table 54. Using 
  289 
dichotomous definitions of disease activity states, 72 of 79 assessments (91%) agreed at 
baseline, 27 of 76 assessments (36%) agreed at 3 months and 25 of 71 assessments (35%) 
agreed at 18 months. Overall, there was agreement in dichotomous definitions of disease activity 
states in 124 of 226 assessments (55%). Using DAS28-ESR as reference, the calculated 
sensitivity of MBDA is 93%, the specificity is 18%, the positive predictive value is 53% and the 
negative predictive value is 71%. 
 
 DAS28-ESR 
 
MBDA 
High-Moderate 
 
> 3.2 > 29	  
Low-Remission 
 
≤ 3.2 ≤ 29 
Table 54 – Comparable dichotomous disease activity states as defined by DAS28-ESR and 
MBDA 
 
 
Graph 59 – Percentage agreement of dichotomous disease activity assessments by DAS28-ESR 
and MBDA at each time point. 
 
An important aspect of any RA disease activity measure is the ability of the measure to define 
and detect remission, since this is increasingly the target at which treatment strategies are aimed. 
At baseline, no participants qualified as DAS28-ESR remission; however, interestingly, 5 
participants were classified by the MBDA as remission (DAS28-ESR range = 2.82 – 4.55). At 3 
months, 34 participants qualified as DAS28-ESR remission, though only 4 of these participants 
(12%) also qualified as MBDA remission. Similarly, at 18 months, 44 participants were classified 
as DAS28-ESR remission, however, only 10 of these (23%) were also classified as MBDA 
remission. Overall, between months 3 and 18, 78 participants were classified as DAS28-ESR 
remission, of these 14 (18%) were classified as MBDA remission, 3 (4%) were classified as 
MBDA low disease activity, 39 (50%) were classified as moderate disease activity and 22 (28%) 
were classified as high disease activity. 
 
8.3.4 Percentage agreement between DAS28-ESR and MSUS 
assessment 
The availability of some concurrent MSUS disease activity information provided an opportunity to 
test whether the suggestion of on-going inflammatory disease activity by the MBDA was also 
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reflected in ultrasonographic evidence of active synovitis. This analysis was restricted to the 
month 3 and month 18 time points. Altogether, there were 35 sets of corresponding DAS28-ESR, 
MBDA and MSUS data available. Pooled together, the range of DAS28-ESR values were 
between 0.50 and 4.40. The dataset was skewed towards LDAS and remission; there had been 
22 (63%) instances of DAS28-ESR remission, 9 instances of DAS28-ESR LDAS (26%) and 4 
(11%) instances of DAS28-ESR moderate disease activity. As before, the MSUS definition of 
active disease was evidence of grade 1 (or higher) PD signal in at least 2 of the examined joints.  
 
Graph 60 depicts the distribution of MSUS findings when data were stratified by the MBDA 
disease activity definition. Summaries of the MSUS findings for each MBDA group are shown in 
Table 55. 
 
 
Graph 60 – Musculoskeletal ultrasound findings when participants are stratified by MBDA 
disease activity definition.  
 
MBDA Disease 
Activity 
High 
 
Moderate Low 
Number 
 
12 17 6 
MBDA 
 
54 
(IQ 47 – 67) 
35 
(IQ 35 – 38) 
17 
(IQ 16.25 – 21.5) 
DAS28-ESR 
 
2.9 
(IQ 2.6 – 3.1) 
2.1 
(IQ 1.7 – 2.5) 
1.9 
(IQ 1.5 – 2.2) 
PD Score 
 
3 
(IQ 0.75 – 6.25) 
1 
(IQ 1 – 5) 
2.5 
(IQ 0.5 – 3) 
PD Joint Count 
 
1.5 
(IQ 0.75 – 4) 
1 
(IQ 1 – 3) 
2 
(IQ 0.5 – 2) 
Synovial 
Hypertrophy Score 
4.5 
(IQ 2.75 – 7) 
3 
(IQ 3 – 5) 
4 
(IQ 2.5 – 4.75) 
Synovial 
Hypertrophy Count 
2.5 
(IQ 1.75 – 4) 
2 
(IQ 2 – 3) 
2.5 
(IQ 1.25 – 3) 
Active MSUS 
Disease – n (%) 
5 
(42%) 
7 
(41%) 
4 
(67%) 
PD Joint Count ≥	 1 – 
n (%) 
9 
(75%) 
14 
(82%) 
4 
(67%) 
Table 55 – Summary of MSUS disease activity findings by MBDA disease activity group.  
Unless stated, values represent median (IQR) 
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The high and moderate MBDA groups were combined to differentiate between high-moderate 
MBDA disease activity and low disease activity in a dichotomous manner. There were 29 
instances of MBDA high-moderate disease activity, 13 (45%) of these instances also coincided 
with active disease during MSUS assessment. There were 6 instances of MBDA low disease 
activity, 4 (67%) of which corresponded to active MSUS disease. Overall, there was complete 
agreement between the dichotomous MBDA assessment and MSUS assessment on 15 (43%) 
occasions. Using the MSUS assessment as reference, the calculated sensitivity of the MBDA as 
a dichotomous measure was 76%, the specificity was 11%, the positive predictive value was 45% 
and the negative predictive value was 33%. 
 
The degree of agreement between all of the disease activity measures discussed thus far was 
tested in the subset of 35 instances when there was concurrent DAS28-ESR, MBDA and MSUS 
disease activity assessment data available. The assessment methods were tested to determine 
how well they agreed on the need to escalate DMARD therapy based on existing escalation 
thresholds that differentiate between low and moderate disease activity (i.e. DAS28 >3.2, MBDA 
> 29, MSUS PD joint count ≥	 2). Separately, there were 4 instances (11%) when DAS28-ESR 
supported DMARD escalation, 29 instances (83%) when MBDA supported DMARD escalation 
and 17 instances (49%) when MSUS assessment supported DMARD escalation. There were 2 
occasions (6%) when none of the assessment methods supported DMARD escalation, 17 
occasions (49%) when only 1 assessment supported DMARD escalation, 15 occasions (43%) 
when 2 assessment methods concurrently supported DMARD escalation and 1 occasion (3%) 
when all 3 assessment methods agreed. On the 17 occasions that only 1 assessment method 
support DMARD escalation, 13 (76%) were because the MBDA test identified moderate disease 
activity (or higher) and 4 occasions (24%) were because MSUS assessment identified active 
disease. There were no occasions when DAS28-ESR alone supported DMARD escalation. On 
the 15 occasions that 2 assessment measures both supported DMARD escalation, 3 (20%) 
occurred because of agreement between DAS28-ESR and MBDA and 12 (80%) occurred 
because of agreement between MBDA and MSUS assessment. There were no instances when 
DAS28-ESR and MSUS assessments agreed 
 
8.3.5 Relationship between MBDA score and subsequent disease 
activity 
To determine whether MBDA test values possessed any ability to predict subsequent disease 
course, the relationship between MBDA score and mean DAS28 was investigated. As before, 
mean DAS28-ESR between baseline and 12 months was used to represent disease course. This 
analysis relates to a sub-group of 72 participants, since participants were excluded if there were 
less than 10 DAS28-ESR data-points available between baseline and follow-up month 12. The 
mean DAS28-ESR 0-12 months was 3.05 (SD 0.93).  
 
Overall, only weak relationships were identified between MBDA and subsequent disease course. 
Baseline MBDA score correlated very weakly with mean DAS28-ESR 0-12 months (rs = 0.14, 
=0.24) and the scattergraph depicting the relationship revealed significant dispersal of data-points 
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(Graph 61). Similarly, there was no relationship identified between change in MBDA between 
baseline and 3 months and mean DAS28-ESR 0-12 months (rs = 0.07, p = 0.58). 
 
 
Graph 61 – Scattergraph depicting relationship between baseline MBDA and mean DAS28-ESR 
between baseline and follow-up month 12 
 
Subdividing participants into quartile groups of the mean DAS28-ESR 0-12 months did not 
identify significant differences in baseline MBDA between those with the highest and lowest 
disease burden between baseline and 12 months. The medians of the (mean) DAS28-ESR 0-12 
months for each quartile group were very similar: 1st quartile 56 (IQ 45 – 66), 2nd quartile 61 (IQ 
54 - 68), 3rd quartile 60 (IQ 46 – 73) and 4th quartile 57 (IQ 50 – 67). Furthermore, stepwise 
comparisons between each quartile group demonstrated there was no statistical difference in the 
baseline MBDA between any of the groups (p = 0.35 – 0.88). Similarly, there were no statistically 
significant (p = 0.13 – 0.83) differences in median DAS28 0-12 months when participants were 
subdivided into groups based upon quartiles of the baseline MBDA score; for the lowest quartile, 
the median DAS28-ESR 0-12 was 2.88 (IQ 1.91 – 3.71), for the 2nd quartile - 3.05 (IQ 2.03 – 
3.81), for the 3rd quartile - 2.70 (IQ 2.44 – 3.62) and for the 4th quartile - 3.42 (IQ 2.57 – 3.76).  
 
Stratifying participants by MBDA disease activity group at baseline and 3 months did not reveal 
any new associations between MBDA score and subsequent disease course. The analysis was 
limited because using the MBDA disease activity definition as a grouping variable created 
significance imbalance in the size of each group. At baseline, 4 participants were classified as low 
MBDA disease activity, 6 were classified as moderate MBDA disease activity and 62 were 
classified as high MBDA disease activity. Each participant’s mean DAS28 between baseline and 
12 months was used as an estimate of overall inflammatory disease activity. A specific pattern in 
the overall inflammatory exposure could not be identified. For the low baseline MBDA group, the 
median of the (mean) DAS28-ESR 0-12 months was 3.47 (IQ 1.8 - 4.1), for the moderate 
baseline MBDA group - 2.43 (IQ 1.69 – 2.71) and for the high MBDA group - 3.11 (IQ 2.44 – 
3.79). Tentative between group comparisons revealed a statistically significant difference 
between the moderate and high baseline MBDA groups (p = 0.02) only. Given the imbalance in 
group sizes, further statistical comparisons were not conducted. Three month MBDA exhibited a 
similar relationship to subsequent disease course (data not shown).  
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Participants categorised as high and moderate MBDA disease activity at baseline did experience 
a significantly greater change in DAS28 between baseline and 12 months than participants 
classified as low MBDA disease activity. The median change in DAS28-ESR between baseline 
and follow-up month 12 was -0.88 (IQ -1.67, -0.32) in the low MBDA group, -2.45 (IQ -2.73, -2.08) 
in the moderate MBDA group and -2.57 (IQ -3.67, -1.52) in the high MBDA group. Allowing for 
notable differences in group sizes, there was a statistically significant difference demonstrated in 
the change in DAS28-ESR between the low and moderate baseline MBDA groups (p = 0.016) 
and low and high baseline MBDA groups (p = 0.014) but not between the moderate and high 
MBDA groups (p = 0.81).  
 
Stepwise comparisons on how MBDA disease activity states at 3 months and 18 months 
compared to the preceding MBDA disease activity state suggested that a proportion of patients 
classified as high MBDA disease activity at either baseline or 3 months continued to be classified 
as moderate or high MBDA disease activity during follow-up assessments (Graphs 62 and 63). At 
baseline, 64 participants were classified as MBDA high disease activity. After 3 months of 
DMARD monotherapy, 3 participants (5%) were classified as low MBDA disease activity, 26 
(41%) were now classified as moderate MBDA disease activity and 35 (55%) were still classified 
as high disease activity (Graph 62). Similarly, of the participants classified as MBDA high disease 
activity at 3 months, 2 (6%) were classified as low MBDA disease activity at 18 months, 14 (41%) 
were classified as moderate MBDA disease activity and 18 (53%) were still classified as high 
disease activity (Graph 63) 
 
 
Graph 62 – Outcome of 3 month MBDA disease activity categorisation based upon baseline 
MBDA disease activity state 
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Graph 63 – Outcome of 18 month MBDA disease activity categorisation based upon 3 month 
MBDA disease activity state 
 
Multiple regression analyses incorporating MBDA 
To determine whether baseline MBDA was an independent predictor of disease course, the 
previously described multiple regression analyses (Section 6.8) were rerun using MBDA as an 
independent (predictor) variable instead of baseline CRP for the subset of participants who 
contributed to the MBDA analysis. All other independent variables were unchanged 
 
Change DAS44 0 – 18 months 
R2 = 0.285, F = 15.2, p<0.001 
 
Predictor Variable Beta Co-efficient p 
Baseline DAS44 -0.39 <0.001 
Baseline MBDA -0.25 0.017 
 
(Randomisation group, gender, anti-CCP antibody status, smoking status, age and symptom 
duration were not significant predictors in this model) 
 
Mean DAS44 0-18 months 
R2 = 0.31, F = 16.7, p<0.001 
 
Predictor Variable Beta Co-efficient p 
Baseline DAS44 0.59 <0.001 
Baseline MBDA -0.21 0.049 
 
(Randomisation group, gender, anti-CCP antibody status, smoking status, age and symptom 
duration were not significant predictors in this model) 
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8.3.6  Change in MBDA score by randomisation group 
For the MBDA analysis results described so far, all participants have been pooled together, 
regardless of their randomisation group allocation. Since the assessment protocols will have lead 
to each group receiving differing intensities of DMARD therapy it is possible that this may have 
been reflected in differences in the change on MBDA result over the follow-up period. Therefore, 
participants were reformed into comparator groups based upon their original randomisation 
allocation; 38 participants were included within the DAS28 assessment group and 38 were 
included within the MSUS assessment group. For each group, the median DAS28-ESR was 
similar at baseline (DAS28 group 5.03 vs MSUS group 5.00), follow-up month 3 (DAS28 group 
2.96 vs 2.63) and follow-up month 18 (DAS28 group 2.57 vs MSUS group 1.88) (Graph 64). 
There were no significant between group differences evident in the DAS28-ESR at either baseline 
and month 3 (p = 0.98 and 0.45 respectively) though the difference was statistically significant at 
month 18 (p = 0.028). 
 
 
Graph 64 – Median DAS28-ESR by randomisation group for participants included within the 
MBDA analysis  
(* p = 0.035 – no other comparisons were significant) 
 
Overall there were no statistically significant differences evident in the MBDA scores between 
either randomisation group at any of the time points and the MBDA scores appeared to follow a 
very similar pattern (Graph 65). Indeed, median MBDA scores were very similar for both groups 
at baseline and follow-up month 3 (57.5 vs 59 and 43.5 vs 43 respectively). At follow-up month 
18, the median MBDA score was slightly lower in the MSUS assessment group (DAS28 group 42 
vs MSUS group 37). There were no significant between group differences identified in the mean 
change in MBDA between either baseline and 18 months (mean change MBDA: DAS28 group -
15.7 vs MSUS group -20.9, p = 0.22) or follow-up months 3 and 18 (mean change MBDA: -5.1 vs 
-7.4, p = 0.54).  
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Graph 65 – Median MBDA score by randomisation group at baseline, 3 months and 18 months. 
There were no statistically significant between group differences 
 
8.3.7 Change in MBDA score in response to anti-TNFα blocking therapy 
A small subset of participants commenced etanercept during the follow-up period and provided 
additional serum samples for analysis. Nine serum samples corresponded to participants 
commencing etanercept, 8 samples corresponded to 3 months of etanercept and 6 samples 
corresponded to 6 months (i.e. completion) of etanercept. Overall, commencement of etanercept 
coincided with a further decrease in MBDA (Graph 66). The median MBDA scores at each time 
point were: commencement of etanercept = 45 (IQ 34 – 61); 3 months of etanercept = 27 (IQ 16 – 
36) and 6 months of etanercept = 30 (IQ 16 – 40). There was a statistically significant difference 
in median MBDA scores between commencement and month 3 of etanercept (p = 0.016), but not 
between commencement and month 6 (p = 0.125) nor month 3 and month 6 (p = 0.75). The 
distribution of MBDA defined disease activity states in relation to etanercept is depicted in Graph 
67. Overall, etanercept was associated with a reduction in the number of participants with high 
MBDA disease activity and increase in the number of participants with low MBDA disease activity 
or MBDA remission. However, given the relatively small group sizes, further statistical 
comparisons have not been performed. 
 
 
Graph 66 – Median MBDA score in relation to etanercept therapy 
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Graph 67 – Distribution of MBDA-defined disease activity in relation to etanercept therapy 
 
8.4 Discussion 
The MBDA analysis described in this section continues the central theme of this research; 
namely, how do novel methods of global RA disease activity compare to established measures, 
such as the DAS28. Indeed, the MBDA test represents several steps further along in the 
development of a biomarker based objective measure of global disease activity than might be 
possible with the outputs of the gene expression analysis described in Chapter 7. Therefore, of 
the assessment methods tested in this study, the MBDA test is perhaps the one closest to being 
used outwith a research environment and in general clinical practice.  
 
From the results of this analysis it is possible to make the following conclusions about the 
possible role of the MBDA test as a disease activity measure in RA: 
 
1. The MBDA score falls following commencement of DMARD therapy and the steepest rate 
of change occurs in the months immediately following commencement of therapy. 
2. MBDA at a single time point demonstrates a moderate positive correlation with DAS28-
ESR at the same time point (rs = 0.58). The change in MBDA between two time points has 
a moderate positive correlation with the change in DAS28-ESR over the same time period 
(rs = 0.56) 
3. There is significant disagreement evident between classification of disease activity state by 
DAS28-ESR and MBDA. For moderate and low DAS28-ESR states, MBDA classifies the 
majority of patients as a higher disease activity state  
4. The degree of agreement between DAS28-ESR and MBDA disease activity classification 
increases when the measures are used as dichotomous descriptors of disease activity (e.g. 
high/moderate disease activity vs low/remission) 
5. A substantial number of instances that MBDA classifies as either high or moderate disease 
activity are not associated with MSUS evidence of active synovitis 
6. Baseline MBDA score may be an independent predictor of change in DAS44 and mean 
DAS44 up until 18 months of follow-up 
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7. MBDA score and disease activity classification improves following commencement of 
etanercept therapy 
 
MBDA as a disease activity measure 
The correlation of the pooled results between DAS28-ESR and MBDA at a single time point (rs = 
0.58), and the correlation between the changes in DAS28-ESR and MBDA over time (rs = 0.56), 
reported by this study are similar to those reported in previous studies. In the original validation 
paper, Curtis et al reported a moderate-strong positive correlation between the two measures at a 
single time point (rp = 0.57) and a moderate positive correlation between the change in DAS28-
CRP and MBDA after 6-12 weeks (rs = 0.51, p <0.001) (390).  In a subgroup analysis of the 
BeST study, Hirata et al reported a moderate-strong positive correlation between DAS28-ESR 
and MBDA at a single time point (rs = 0.66, p <0.0001) and a moderate positive correlation 
between the change in DAS28-ESR and MBDA after 12 months of treatment (rp = 0.55, p 
<0.0001) (393). In a subgroup analysis of the CAMERA study, Bakker et al reported a strong 
positive correlation between DAS28-CRP and MBDA at a single time point (rp = 0.72, p<0.001) 
(396). However, whilst Bakker et al have reported that patients treated using an intensive 
DMARD escalation regimen demonstrate a greater improvement in MBDA score, the relationship 
between the change in DAS28-CRP and MBDA scores is not specifically described.  
 
Taken together, the consensus of the available results seems to suggest that the MBDA test 
shares a positive, linear relationship with DAS28-ESR and DAS28-CRP. That is, they represent 
similar static and dynamic changes in disease activity, even though their output values are not 
numerically comparable. Therefore, if the MBDA measures and reacts to disease activity in a 
similar manner to DAS28-ESR and DAS28-CRP it is feasible to presume that it might also be 
used as an alternative (though not interchangeable) disease activity measure. However, whilst 
the quoted correlation coefficients between static and dynamic DAS28-ESR, DAS28-CRP and 
MBDA values are consistently positive and statistically significant, it is clear that there is frequent 
disagreement between how each measure categorises disease activity in individual patients 
(Graph 57). Indeed, there were frequent occasions when the MBDA test had classified disease 
activity at a higher level than suggested by the DAS28-ESR (Graph 58) and there were a number 
of occasions when changes in the MBDA failed to reflect the same degree of improvement in 
disease activity as suggested by the DAS28-ESR. Interestingly, the highest degree of agreement 
between DAS28-ESR and MBDA in disease activity classification was recorded during the 
baseline assessments (Graph 57) but declined significantly during subsequent assessments. It is 
unlikely that this can be wholly explained by the influence of immunomodulatory therapy on the 
expression levels of the independent biomarkers that contribute to the MBDA calculations since 
immunomodulatory agents should cause a decline in the expression levels of pro-inflammatory 
biomarkers, resulting in lower final MBDA scores and, if anything, categorisation of disease 
activity at a lower level.  
 
The MBDA is calculated using formulae that are derived from the DAS28-CRP. Whilst this leads 
to the DAS28-CRP and MBDA scores having a consistently positive relationship, it is clear from 
the correlation analyses that the relationship is not perfectly proportional. Hence, each measure 
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may not change by the same proportion in response to changes in overall disease activity. 
Indeed, interpolations made using the linear regression of the correlation between DAS28-ESR 
and MBDA (Graph 68 and Table 54) estimate that the corresponding MBDA thresholds for each 
disease activity state for this cohort are somewhat higher than in the previously published studies. 
Similarly, the MBDA score remained elevated in the majority of participants after 18 months of 
treatment despite them having attained DAS28-ESR LDAS. At baseline, 61 participants were 
categorised as high disease activity by the MBDA test; after 18 months of treatment, 52 of these 
participants had attained DAS28-ESR LDAS. Conversely, after 18 months, 25 participants each 
continued to be categorised as moderate and high MBDA disease activity (Graphs 69A+B). Thus, 
either the MBDA continues to detect on-going subclinical synovitis in patients with low disease 
activity, its rate of change over 18 months is not proportionate to the corresponding change in 
DAS28-ESR and/or there is a subset of RA patients whose MBDA score remains elevated 
despite an adequate clinical response to DMARD therapy. 
 
 
Table 56 and Graph 68 – MBDA disease activity definition thresholds for this cohort – estimated 
by interpolating linear regression of correlation between all DAS28-ESR and MBDA 
(x axis intercepts correspond to DAS28 = 2.6, DAS28 = 3.2, DAS28 = 5.1) 
 
 
  
 
 
 
 
 
 
 
 
 
Graphs 69A + 69B – Relationship of baseline MBDA disease activity to 18 month DAS28-ESR 
and MBDA disease activity grouping 
 
Comparisons between DAS28-ESR and MBDA disease activity categorisation for this study have 
consistently shown that MBDA frequently categorises disease activity at a higher level than the 
corresponding DAS28-ESR (Graph 58). Most notably, 82% of the instances of DAS28-ESR LDAS 
were classified by the MBDA as either moderate or high disease activity. This may have 
DAS28-ESR Corresponding 
MBDA 
Remission 
DAS28 <2.6 
42 
Low 
DAS28 <3.2 
45 
High 
DAS28 >5.1 
58 
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treatment implications, since identifying high or moderate disease activity encourages DMARD 
escalation, whereas identifying low disease activity does not. A similar disagreement was not 
identified in relation to high DAS28-ESR disease activity since virtually all instances (95%) of 
DAS28-ESR high disease activity were also categorised as high MBDA disease activity. This 
raises several interesting points. Either: 1. MBDA scores are related to RA pathogenesis and are 
independent of disease activity, 2. MBDA is more sensitive than DAS28-ESR at low levels of 
disease activity and/or 3. MBDA is less specific than DAS28-ESR. It seems likely that the MBDA 
score is responsive to changes in disease activity since this study, and several of the previous 
validation studies, have demonstrated that the MBDA score correlates positively with existing 
measures of global disease activity (such as DAS28-CRP, DAS28-ESR, SDAI) across their whole 
range of values and that changes in global disease activity measures are matched by 
corresponding changes in MBDA (390,393,396). So far, the MBDA has been validated against 
existing global disease activity measures that rely upon clinical detection of painful and swollen 
joints. However, as previously discussed, there remains concern about the sensitivity of these 
composite measures to detect subclinical active synovitis and their specificity in patients with 
multiple causes of joint pain. Therefore, it may be difficult to estimate the specificity of a new 
measure (MBDA) if the existing validation measure (DAS28) against which it is being compared is 
less sensitive at low disease activity levels (i.e. the MBDA will appear to generate a high 
proportion of false positive results) 
 
The insensitivity of composite measures to low level active synovitis may partly explain why the 
MBDA consistently reported a higher level of disease activity than the corresponding DAS28-ESR 
measure; that is, MBDA may ‘reveal’ subclinical disease when clinical examination is otherwise 
unremarkable. By extension, if composite disease activity measures are insensitive to low levels 
of active synovitis, it may be more appropriate to test the performance of the MBDA against 
modern imaging techniques (such as MRI or MSUS). The availability of corresponding MSUS 
disease activity findings for a subset of occasions has allowed the relationship between MBDA 
and subclinical synovitis to be partially investigated. Overall, the available results suggest that, 
within the limitations of the MSUS joint set and definitions of active disease, high and moderate 
MBDA scores are not always associated with ultrasonographic synovitis (Graph 60 and Table 
55). Indeed, only 42% of the occasions classified as high disease activity by MBDA demonstrated 
active synovitis during MSUS assessment. Similarly, 41% of the occasions of moderate MBDA 
disease activity and 67% of the occasions of low MBDA disease activity also had evidence of 
active synovitis during MSUS assessment. The number of instances when any joint exhibited PD 
signal (i.e. PD joint count ≥	 1) were notably higher for all MBDA disease activity groups (high 
75%, moderate 82%, low 67%); hence it may be that the elevation of MBDA is related to the 
presence of any active synovitis rather than the total number of joints that are affected. 
Nevertheless, the frequent absence of ultrasonographic evidence of synovitis in participants with 
moderate and high MBDA scores also raises additional points to consider. Either: 1. MBDA is 
even more sensitive than MSUS at detecting synovitis, 2. MBDA measures aspects of systemic 
inflammation that are not visible at the joint and/or 3. elevation of MBDA is related to an additional 
external factor and therefore may not be specific to RA disease activity. The present results 
represent a relatively small cohort of participants so should be considered preliminary at best; 
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however, the absence of ultrasonographic synovitis in participants with high and moderate MBDA 
scores inevitably does raise questions about the specificity of the MBDA. Additional analyses will 
be possible once the results of the 18 month MRI RAMRIS assessments are available. Indeed, a 
further analysis will be performed that correlates the 18 month MBDA score to the presence (or 
absence) of MRI synovitis and bone marrow oedema. However, once again, it is unlikely that this 
additional analysis will be large enough to fully define the specificity of the MBDA test. During the 
original development studies, Centola et al did attempt to determine the influence of potential 
confounders by comparing the MBDA scores between RA patients with and without each of 
several common comorbidities (hypertension, osteoarthritis, osteoporosis, diabetes mellitus, 
asthma) (383). Overall, the presence of an additional comorbidity was not associated with a 
significant difference in the measured MBDA scores. However, the list of confounders is relatively 
limited and, other than asthma, does not contain any other inflammatory conditions (e.g. 
intercurrent infection, psoriasis, inflammatory bowel disease) that could also feasibly influence the 
expression of pro-inflammatory markers and the final MBDA score.  
 
At present, it may be difficult to incorporate the MBDA test into routine clinical practice, until its 
true sensitivity and specificity in relation to RA activity have been clarified. The balance between 
sensitivity and specificity will be crucial to the long term clinical usefulness of the MBDA test. An 
objective and sensitive additional blood marker of joint inflammation could provide extremely 
useful additional disease activity information that helps target DMARD treatment against 
persistent active synovitis in patients who no longer demonstrate clear clinical synovitis. However, 
for the test to be clinically useful its specificity for active synovitis will need to be high enough to 
prevent unnecessary, and potentially toxic, DMARD escalation in patients who have no on going 
inflammatory joint disease. Eventually a prospective study will be required to demonstrate that 
DMARD escalation regimens targeting MBDA low disease activity, and/or remission, produce 
significantly better outcomes than current, DAS28 and SDAI based regimens without also causing 
additional adverse effects. 
 
The predictive properties of the MBDA 
So far, several studies have addressed the potential predictive ability of MBDA in relation to 
radiographic progression, though their findings have not been consistent. In a subgroup analysis 
of the BeST study, the baseline MBDA score was not predictive of radiographic progression after 
2 years (392). By contrast, in the SWEFOT study, there was significant positive correlation 
between baseline MBDA score and the change in radiographic damage score after 1 year (399). 
Similarly, Van-der-Helm-van-Mil et al have demonstrated that the persistent elevation of MBDA 
score in some patients may be pathogenetically relevant since it is associated with an increased 
risk of radiographic progression after 1 year (394). Fewer patients who attained MBDA remission 
experienced radiographic progression compared to patients who’d attained either DAS28-CRP 
and/or ACR-EULAR Boolean remission (proportion of radiographic progression after 12 months = 
7% vs 20% vs 17% respectively). Furthermore, the risk of radiographic progression was 
proportional to the MBDA disease activity grouping and, importantly, the subset of patients with 
DAS28-CRP remission but high MBDA disease activity were at a significantly increased risk of 
radiographic progression (relative risk 2.28; 95CI 1.13, 3.68) compared to all patients in DAS28-
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CRP remission. The implication being that persistent elevation of MBDA is associated with active 
disease because it is also associated with progressive joint damage.  
 
The results of this study do suggest that MBDA may be an independent predictor of disease 
course. Linear correlations suggested that baseline and 3 month values of MBDA had a very 
weak positive correlation with subsequent disease course. However, multiple regression analysis 
did suggest that baseline MBDA was a significant, independent predictor of both change in 
DAS44 and mean DAS44 between baseline and 18 months. However, it appeared to have a 
similar influence on the statistical model as the cheaper (and widely available) baseline CRP 
value. The ability of baseline MBDA to predict future radiographic progression remains to be 
determined for this study 
 
 
 
 
 
  
  303 
 
 
 
 
 
9. Final Discussion and 
Considerations 
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The TaSER study was originally devised to investigate whether using a MSUS measure of global 
disease activity in early RA would improve patients short-medium term clinical, functional and 
radiological outcomes. Since blood samples were collected at set time points throughout each 
participant’s follow-up period it has been possible to broaden the scope of the study to consider in 
general the potential value of several alternative methods of assessing global disease activity. 
Interestingly, the results have been somewhat mixed: musculoskeletal ultrasound provided 
additional disease activity findings (and often altered treatment decisions) during a notable 
proportion of assessments but was not associated with significantly better clinical outcomes; 
peripheral blood gene expression analysis did not have any relationship with either RA disease 
phenotype or disease activity state; however, an inflammatory protein based MBDA score was 
more sensitive than DAS28-ESR and MSUS assessments but may be non-specific and is yet to 
be tested in an interventional treatment strategy study. Taken together, these results start to 
suggest that novel, technology dependent, methods of assessing (and monitoring) global disease 
activity may provide minimal additional benefit to existing, largely clinical, assessment methods. 
 
The wide spread use of quantitiative, composite disease activity scores is now accepted as 
having improved the sensitivity and objectivity of clinical assessments of global disease activity 
and contributes significantly to the efficacy of current early RA treatment strategies 
(124,170,350). Indeed, several interventional treatment strategy studies have associated 
systematic assessment of global disease activity with improved clinical and radiological outcomes 
(118,119,128). Though whether the measured improvements in outcomes were related directly to 
the method of disease activity assessment, or simply reflected the impact of using more 
aggressive therapy, will be difficult to disentangle since they comprise one component of a 
complex intervention that also includes early DMARD initiation, aggressive intensification of 
treatment, early (often generous) use of corticosteroids and early multidisciplinary team input. 
Regardless, formalised assessment of global disease activity has clearly enabled clinicians to 
gain better short-medium outcomes and is now accepted as a routine care standard. However, 
evidence from recent imaging studies has started to suggest that current thresholds for LDAS 
and/or remission do not necessarily correspond to either inactive synovitis (121,150,400,401) nor 
an absent risk of disease progression (200,217). Therefore, there has been a mounting 
momentum of opinion that DMARD escalation strategies should target a stricter definition of 
remission rather than clinical remission, since existing composite disease activity assessment 
methods are relatively insensitive compared to modern imaging techniques (129). However, 
whether even tighter control of inflammatory joint disease is associated with significantly better 
outcomes, and an acceptable risk:benefit ratio, has not yet been demonstrated in a randomised 
clinical trial. Equally, the additional benefits associated with novel methods of disease activity 
assessment will need to be striking in order to be distinguishable at a group level from the 
benefits that can be achieved using existing treatment strategies and disease assessment 
methods.  
 
The TaSER study is the first clinical trial to report the influence of MSUS disease activity 
assessment on any outcome measure in early RA. Whilst the OMERACT Imaging Group 
continues to debate which joints will comprise the limited joint set of the Global Ultrasound 
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Synovitis Score (294), the results reported herein provide the first indication that regularly 
assessing global disease activity using MSUS may not significantly improve clinician’s ability to 
monitor and treat early RA, at least in the short-medium term. Therefore, the wide spread up take 
and use of MSUS by rheumatologists, at least for disease activity monitoring purposes, is not 
supported. Indeed, DAS28-driven DMARD escalation was still associated with very good, and 
similar, clinical and laboratory outcomes to MSUS-driven DMARD escalation without having to 
use quite such aggressive combinations of DMARDs and biologics, nor spend additional time 
during busy clinics conducting MSUS assessments.  
 
During DAS28 LDAS and remission states, MSUS did frequently identify evidence of on going 
disease activity, but aiming to achieve imaging remission by suppressing this synovitis does not 
appear to have produced significantly better short-medium term clinical outcomes. However, 
whether this approach is associated with lesser rates of damage progression on plain x-rays and 
MRI images and/or better medium-long term clinical, functional and radiographic outcomes 
remains unanswered. It is important to consider that the current conclusions are based upon an 
incomplete dataset. The potential impact of MSUS-driven DMARD escalation on adverse event 
rates and DMARD intensity has not yet been specifically reported. It may become even harder to 
justify the additional costs (equipment, treatment burden and financial cost) of regular MSUS 
disease activity assessments if MSUS group participants also appear to experience a higher rate 
of treatment associated adverse events for no additional benefit. Similarly, a number of 
outstanding factors need to be clarified before concluding that MSUS assessment conferred no 
additional benefits on the MSUS group. Firstly, the MSUS assessment group did experience 
incremental increases in DAS44 remission and EULAR good response rates over the follow-up 
period and did also demonstrate a higher DAS44 remission rate at the 18 month follow-up point. 
It is possible that these findings reflect emerging divergence of outcomes between the 
assessment groups that would have become more apparent over a longer follow-up period. 
Secondly, the MSUS assessment group may yet demonstrate lesser rates of progression in MRI 
and plain x-ray measures of joint damage. If this is the case, the lack of clinical benefit may be 
counter-balanced by evidence that aggressive early suppression of active synovitis does 
attenuate (if not halt) progression of joint damage that should be associated with improved 
medium-long term clinical and functional outcomes. These additional benefits may not have been 
immediately apparent during the relatively restricted initial follow-up period.  
 
Interestingly, during instances of DAS28 moderate disease activity, MSUS disease activity 
assessment did still contribute useful, additional information regarding disease activity. In fact, 
MSUS assessment may yet prove most useful in the assessment of symptomatic patients with 
equivocal, or absent, examination findings. It may not be possible to use MSUS disease activity 
assessment to improve the treatment outcomes of RA patients with DAS28 LDAS and/or 
remission but it may be possible to use MSUS to ensure that patients with DAS28 moderate 
disease activity but minimal clinical synovitis are considered for the most appropriate therapeutic 
intervention, especially if there is minimal clinical evidence of synovitis. In patients with evident 
clinical synovitis MSUS is unlikely to add any additional information to the assessment of disease 
activity unless there is concern that joint swelling represents chronic synovial hypertrophy rather 
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than active synovitis. Similarly, patients with DAS28 moderate disease activity but minimal clinical 
synovitis will benefit from MSUS assessment if it differentiates between patients with active 
subclinical synovitis, who may benefit from DMARD escalation, and patients with no active 
synovitis, who may not benefit from DMARD escalation, but may benefit from an alternative 
treatment approach. In all these instances, MSUS findings will have contributed to individual 
patients being offered the most appropriate treatment for their specific needs. Those with active 
synovitis can still be considered for DMARD escalation; whereas those without active synovitis 
can be spared the risks of unnecessary DMARD escalation but can be considered for alternative 
treatment approaches instead. Admittedly, it appears that MSUS assessment will influence 
treatment decisions for instances of DAS28 moderate disease activity much less often than for 
instances of DAS28 LDAS. Therefore, whilst it may remain a useful additional assessment 
method for symptomatic patients with equivocal clinical examination findings it may prove difficult 
to prove the efficacy in an adequately powered clinical trial. 
 
This study has found conflicting evidence about the potential value of using biomarker panels to 
assess RA phenotype and disease activity. It does not appear that specific patterns within 
peripheral blood gene expression profiles associate with particular RA disease characteristics nor 
extremes of RA disease activity. Therefore, it is unlikely that, in its present guise, peripheral blood 
gene expression profile assessment will be able to add useful additional information to current 
methods of describing either phenotype and/or disease activity. This conclusion may appear 
excessively pessimistic and in due course it may well be shown that particular gene expression 
patterns do consistently associate with particular phenotypic features. The comparator groups 
used during the gene expression analysis were deliberately devised to reflect common clinical 
scenarios so that the clinical relevance of any positive findings would be immediately evident. 
However, these common scenarios were not associated with clear evidence of differential gene 
expression. Further analysis is required to determine whether specific phenotypic sub groups do 
exhibit evidence of differential gene expression (e.g. restricted to autoantibody positive patients, 
limited to a single drug therapy); however, as the cohort is split into smaller and smaller 
subgroups the potential for skew within the statistical analysis processes increases and the 
clinical relevance of any positive findings diminishes. Ultimately, specific gene expression profiles 
that relate to very strictly defined clinical scenarios may prove too costly to develop and 
commercially unviable. It is possible that gene expression profiles may provide important 
pharmacogenomics information relating to an individual patient’s risk of developing a drug related 
adverse effect (such as thiopurine methyltransferase genotype in relation to azathioprine (402)). 
However, it is unlikely that the TaSER cohort was large enough, nor had a high enough event 
rate, to have sufficient power for this to be analysed adequately. Several studies have reported 
associations between tissue (usually peripheral blood or synovial tissue) gene expression profile 
and RA phenotype; however, in most cases these studies have been either relatively small and/or 
have not yet validated the findings in independent cohorts. There is perhaps a little more 
evidence to support an association between synovial tissue gene expression profile, disease 
activity and treatment response (236,241). However, since patients are required to undergo a 
synovial biopsy the clinical usefulness of synovial tissue analysis remains unclear. Altogether, the 
findings of the TaSER gene expression analysis are largely in step with the findings of other 
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published studies in RA (403,404). That is, almost all recent studies have described the 
association between gene expression profile and phenotype; however, until robust relationships 
between specific gene expression patterns and clinical phenotype are identified (and validated) it 
won’t be possible to ‘test’ the clinical value of the profile in a clinical trial setting 
 
The available results suggest that the inflammatory protein based MBDA test is perhaps closer to 
being adopted as an additional measure of disease activity than gene expression based 
assessments. Indeed, the MBDA test remains a very attractive alternative disease activity 
measure since it is relatively easy to obtain, fits with the understanding of RA as a systemic 
disease and removes any subjectivity related to patient reported outcomes and clinician 
interpretation of clinical findings. The findings of the TaSER study are very similar to previous 
comparisons between MBDA and DAS28 measured disease activity (383,390,392-394) and 
confirm that there is a significant positive correlation between DAS28ESR and MBDA at a single 
time point and a significant positive correlation in the degree of change of both measures over 
time. Therefore, it seems reasonable to conclude that the outputs of the DAS28 and MBDA are 
measuring similar disease states, even if they are not directly interchangeable. Even though the 
correlation analyses suggest that changes in DAS28 and MBDA are ‘in step’, comparison of how 
disease activity states are categorised has demonstrated disagreement between the different 
measures. The MBDA test tends to categorise disease activity at a higher level than the DAS28 
and, in part, this suggests that the MBDA may be a more sensitive measure of very low levels of 
inflammatory joint disease than DAS28. However, over half (approximately 58%) of high and 
moderate MBDA assessments were not associated with MSUS evidence of active synovitis and 
there were a subset of participants who continued to exhibit high MBDA disease activity even 
though they had attained a good clinical response. Both these latter findings raise questions 
about the MBDA test’s specificity in relation to the presence of active synovitis. In due course, 
being able to correlate 18 month MRI RAMRIS synovitis score to corresponding MBDA score will 
help clarify some of the issues relating to both sensitivity and specificity, though it must be 
accepted that the available MRI images will correspond to an even more limited joint set than the 
MSUS assessment. Once again, all of the published results merely describe the numerical 
relationship between DAS28 disease activity and MBDA; the potential value (and safety) of the 
MBDA as an alternative disease activity measure will not be fully apparent until it has been used 
to steer DMARD therapy in a controlled clinical trial setting. It is worth considering that persisting 
elevation of the MBDA score during DAS28 LDAS may be akin to the persistence of PD signal 
during MSUS assessment. This study has shown that both MBDA score and PD signal remain 
elevated in a significant subset of RA patients with DAS28 LDAS and previous studies have also 
shown that this is predictive of future radiographic progression (200,394). However, this study has 
also shown that attempting to fully suppress ultrasonographic evidence of active synovitis is not 
necessarily associated with improved clinical outcomes and it may be that there are similar 
findings from attempts to normalise MBDA using aggressive DMARD therapy. 
 
Taken altogether the results of this study suggest that MSUS assessment and the MBDA test do 
provide additional disease activity information to the DAS28 in a subset of RA patients that could 
be used to modulate DMARD treatment decisions. However, so far, the available results do not 
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suggest that these novel methods necessarily lead to improved clinical outcomes. It may be that 
novel assessment methods are unable to improve upon the already clear benefits associated with 
DAS28 driven DMARD therapy and there will be little value in attempting to alter current practice 
if there are no additional benefits for patients. If MSUS-driven DMARD therapy is associated with 
improved radiological outcome, and/or better medium-long term outcomes, it may yet be possible 
to create an argument for incorporating some form of MSUS assessment into current practice. 
However, it is possible that many patients may find the associated increased treatment burden 
unacceptable if, symptomatically, they fell no different. Until the safety and efficacy of MSUS 
driven DMARD therapy has been fully described it is likely that DAS28 will remain the most 
commonly used method of assessing global disease activity in RA.  
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Considerations 
The research described herein has tried to address a number of related issues relating to 
assessment of RA disease activity. The structure of the TaSER study aimed to replicate routine 
clinical practice, deliver high quality care for participants as well as providing a structure for 
collection of clinical outcome data and tissue samples. Since this was a ‘real world’ setting and 
the assessment of disease activity and DMARD treatment protocol constituted a complex 
intervention there were a number of important factors that should be considered since they may 
have impacted upon the observed results of the clinical study and the findings of both the gene 
expression and MBDA test analyses. 
 
9.1 The TaSER study 
Length of follow-up period 
Previous trials of different DMARD regimens in early RA have been able to demonstrate 
significant differences in outcome after 12 (120,123,143,147), 18 (118) and 24 (149) months. A 
follow-up period of 18 months was chosen since this fitted with the time available to conduct the 
study and previous, similarly designed studies (the TICORA study) had demonstrated very 
significant differences over a similar time period. Both groups received the same DMARD 
monotherapy for the first 3 months; therefore, the first point that randomisation group could have 
influenced DMARD treatment and future outcomes was actually follow-up month 3 and, in effect, 
the follow-up period is actually foreshortened to 15 months. Whilst there was no significant 
difference overall in ACR core set variables at any of the assessment time points the MSUS 
group did demonstrate an incremental increase in the proportion of participants achieving EULAR 
good responses, DAS44 and ACR/EULAR remission. Optimistically, all other factors appearing 
equal between the groups, this does suggest that a divergence of the disease activity measures 
may have become apparent had the follow-up period been longer.  
 
MSUS disease activity assessments continued to identify active synovitis over the whole of the 
follow-up period. However, the majority of MSUS assessments did not identify active synovitis 
and did not lead to additional DMARD escalation. In fact, out of 414 MSUS assessments, only 
107 (26%) fulfilled the proposed definition of active synovitis. Further, these 107 positive MSUS 
assessments comprise a small minority (14%) of the total number of assessments that the MSUS 
group underwent between follow-up months 3 and 18. Hence, the positive influence of MSUS 
disease activity assessment on DMARD escalation may have been too infrequent to produce a 
significant improvement in the measured outcomes over the duration of the follow-up period.  
 
Group Size 
The previously described sample size calculation (section 2.2.4) aimed to provide sufficient 
statistical power to detect a clinically significant difference in the mean change of DAS44 (≥1.1). 
This was based on previously published studies that had demonstrated that the standard 
deviation of the fall in DAS44 was 0.7 (405). In fact, the standard deviation of the mean change in 
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DAS44 overall and for both groups was higher than 0.7 (Overall 1.49, DAS28 1.47, MSUS 1.51), 
suggesting that the research’s sample size may not have been large enough to identify a clear 
between group difference. However, the 95% confidence intervals of the mean change in DAS44 
for both groups overlap significantly (DAS28 -2.92, -2.10; MSUS -3.20, -2.33) and the boundaries 
of the 95% confidence interval (-0.84, 0.33) provided by the t test comparing the mean change in 
DAS44 between the groups are less than the minimally clinically significant difference. 
Considering both these facts, it is unlikely that increasing the group sizes would have 
substantially increased the chances of identifying a significant between group difference 
 
The measured standard deviation of the mean change in DAS44 (1.49) is similar to that reported 
in the TICORA study (1.1-1.4). The TICORA study also based its sample size estimation of the 
previously reported standard deviation of DAS44 being 0.7. However, in both the TICORA and 
TaSER studies, the same research nurse (Sr Anne Stirling) conducted the DAS44 assessments 
and therefore it may have been more appropriate to use a standard deviation of the change in 
DAS44 which more closely matched her previously measured variability. 
  
Baseline characteristics of assessment groups 
Overall, the randomisation process produced groups that were well matched for most baseline 
disease activity, inflammatory marker and functional ability variables. The minimisation process 
did lead to a numerical imbalance in the proportion of females in each group (DAS28 75% vs 
MSUS 61%, p=0.10) which may have predisposed the DAS28 group to exhibiting a lesser initial 
treatment response, and a lesser rate of remission. The DAS28 group functioned as a control 
group, so a higher proportion of female participants should have made it easier to detect a 
between group difference since it may have predisposed the DAS28 group to exhibit a lesser 
treatment response and therefore higher disease activity measures. In fact, the available results 
suggest that the sex distribution is unlikely to have adversely influenced the observed results. At 
a whole cohort level and a group level, there was no between sex difference in DAS44 values at 
any time point, nor the mean change in DAS44 from baseline and multiple regression analyses 
did not suggest that gender was an independent predictor of either DAS44 or HAQ at 18 months. 
Therefore, it does not appear that an imbalance in gender distribution between the groups 
adversely affected the primary outcome. In line with previously reported results, male participants 
overall, and males within the DAS28 group, did return lower HAQ scores than females. However, 
comparisons between gender subgroups of the randomisation groups did not suggest that males 
or females in either randomisation group experienced significantly worse functional outcomes 
than same-sex members of the other randomisation group. In summary, in uncorrected analyses 
participant’s gender did not appear to be associated with a significant difference in DAS44 levels 
at either a cohort or group level. Therefore it seems unlikely that the unequal allocation of female 
participants between the groups has caused a significant bias in the whole group outcomes.  
 
Proposed MSUS definition of active disease 
As discussed in the preceding section, there remains no universally agreed definition of active 
synovitis which incorporates MSUS PD findings. Nor is there a universally agreed limited MSUS 
  311 
joint set that is thought to accurately represent global disease activity. The proposed definition of 
active disease was pragmatically chosen to represent a level of synovitis that was sufficiently 
suggestive of polyarticular joint inflammation to justify DMARD escalation, but also minimised (but 
did not totally remove) the potential influence of PD artefact on disease activity perceptions. A 
higher PD joint count threshold for DMARD escalation would have further reduced the risk of 
misclassifying disease activity but may have restricted the impact of MSUS assessment on 
DMARD escalation. A lower PD joint count threshold would have lead to a much higher rate of 
DMARD escalation within the MSUS assessment group, which might have been reflected as 
much clearer benefits over the follow-up period. Whilst, in a limited joint set a PD threshold of 1 
for DMARD escalation would be more sensitive to the presence of active disease it is also more 
likely to be biased by the presence of PD artefact; such that, failure to differentiate PD artefact 
from true PD signal could lead to inappropriate DMARD escalation in patients who do not have 
active synovitis. Coincidentally, the performance characteristics of the proposed MSUS set, and a 
number of similar variations, are currently under investigation by the OMERACT Musculoskeletal 
Ultrasound Working Group to reach a consensus agreement on the best performing Global 
Synovitis Score (GloSS) (294)  
 
The proposed indications for MSUS assessment aim to identify 2 opposing clinical scenarios and 
could have had competing influences on overall DMARD exposure in the MSUS group.  During 
instances of DAS28 LDAS, MSUS assessment aims to identify subclinical synovitis with the 
intention of supporting DMARD escalation if active disease is confirmed. During instances of 
DAS28 moderate disease activity and minimal synovitis, MSUS assessment will support DMARD 
escalation if active disease is identified, but is more likely to prevent escalation in patients who 
would otherwise have qualified based upon the DAS28 findings. There were 92 instances of 
DAS28 LDAS when additional DMARD escalation was supported and there were 30 instances of 
moderate disease activity when further DMARD escalation was prevented by MSUS assessment. 
So, the net overall impact of MSUS assessment was to support additional DMARD escalation in 
the MSUS group. Equally, the proposed MSUS examination is confined to a limited joint set and 
may, in some instances of DAS28 moderate disease activity, have missed ultrasonographic 
synovitis by not examining the relevant joint areas. Thus, the positive impact of DMARD 
escalation in DAS28 LDAS states may have been tempered somewhat by restriction of DMARD 
escalation during instances of DAS28 moderate disease activity but minimal clinical synovitis if 
the MSUS assessment did not include the correct joint(s). Either way, MSUS examination failed 
to identify PD signal in only 30 instances of DAS28 moderate disease activity but minimal clinical 
synovitis. This accounts for a small proportion (7%) of all the MSUS assessments and an even 
smaller proportion of the total number of consultations attended by the MSUS group (4%). So, 
whilst failure to identify ultrasonographic synovitis may have restricted the impact of DMARD 
therapy, it is unlikely to have occurred sufficiently often to have significantly altered the measured 
outcomes. 
 
Choice and performance of clinical outcome measures 
Most of the ACR core set measures (excepting HAQ and laboratory measures of the acute phase 
response) rely on clinical assessments to identify the presence of swollen and/or tender joints. 
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However, this thesis has argued that clinical assessment alone may be insufficiently sensitive to 
accurately describe very low levels of disease activity, especially when sub clinical synovitis may 
only be detected by advanced imaging techniques. Since the MSUS intervention focussed on the 
detection of clinically undetectable disease, the chosen DAS44 outcome measure may have been 
insufficiently sensitive to differentiate between those participants with true remission and those 
with persisting subclinical synovitis. Thus, participants in both groups would be categorised by 
DAS44 as LDAS and/or remission when in fact some still had active, subclinical disease. Despite 
these concerns, the DAS44 has clearly shown that both assessment groups experienced 
significant improvements in clinical disease activity over the follow-up period. Whilst there was no 
consistent difference identified in the degree of clinical treatment response it is possible that the 
use of MSUS guided DMARD escalation, which aimed to abrogate all PD activity within the 
limited joint set, was associated with lesser rates of persisting PD signal, and therefore a lesser 
risk of subsequent flare and radiographic progression. The DAS44 will not represent this 
difference, nor is there MSUS data available for comparison with the DAS28 assessment group. 
However, the awaited analysis of the MRI RAMRIS outcomes may demonstrate that MSUS-
guided DMARD therapy was associated with greater improvements in MRI measures of erosion, 
synovitis and bone marrow oedema (see below) 
 
To maximise validity, all of the main clinical outcomes for this study were measured 
independently by an experienced metrologist who was blinded to each participant’s 
randomisation group and DMARD regimen. Therefore, the clinical outcomes for this research are 
considered to be single blinded with the potential for inter-observer variability reduced through the 
use of a single metrologist. Feasibly, the ability of the study to identify a between group difference 
may have been restricted if either group had contained a higher proportion of participants with 
overlapping causes of joint pain that contributed to elevated DAS44 assessments. However, 
based on analyses of the individual DAS44 components this seems extremely unlikely. The 
summary statistics and distribution of all DAS44 components were virtually identical at each of 
the assessment time points and it is therefore unlikely that there was a significant sub-set in 
either assessment group that contributed to skewed DAS44 measurements. 
 
Radiographic outcomes  
At the time of writing the extraction of the baseline and 18 month DICOM files for the plain x-ray 
and MRI images from NHSGGC PACS system had just been completed. Once all the files have 
been anonymised, relabelled and catalogued, they will be forwarded to the collaborating 
radiologists for formal grading. Each image will be graded independently by two radiologists in the 
manner described in Section 2.6.5 and it will thus become possible to report whether MSUS 
guided DMARD escalation is associated with slower rates of radiographic damage progression. 
 
Even if plain x-ray assessment of joint damage does not show any significant differences in rates 
of progression between the assessment groups, it is possible that differences in MRI measures of 
disease activity and damage will be present. At a single time point the three components of the 
MRI RAMRIS scoring system provide separate markers of i. current disease activity (synovitis), ii. 
joint damage up until that point (erosion) and iii. risk of future erosive damage (bone marrow 
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oedema) (303,406). However, conjecting, it is possible that the apparent increases in 
ACR/EULAR remission, DAS44 remission and EULAR good responses rates observed in the 
MSUS group will also be associated with more favourable underlying MRI findings. It will be 
particularly interesting to determine whether MSUS guided DMARD escalation is associated with 
lesser total RAMRIS synovitis (i.e. a better treatment response as measured by MRI) and/or bone 
marrow oedema scores (i.e. a lower risk of future erosive progression) than the DAS28 group.  
 
Adverse events rate 
Since there appears to be only a modest additional clinical benefit from using MSUS disease 
activity assessment it is particularly important to ensure that the greater number of DMARD 
escalation steps is not also associated with an increased risk of DMARD related adverse effects. 
Adverse event data were collected prospectively and was categorised according to nature, 
severity and likely relationship to DMARD therapy. At present, the adverse event data is being 
validated by the biostatisticians at the Robertson Centre for Biostatistics. In due course, an 
adverse events analysis will be conducted. Individual adverse events will be classified according 
to severity (as described in Section 2.6.6) and category (e.g. gastrointestinal, haematological, 
respiratory etc). Adverse event rates will be reported as the total number per group, the mean 
number per patient and the number per category in each group. 
 
DMARD escalation protocol  
A step-up DMARD escalation regimen was used for both groups because it matched closely 
current local practice and fitted best with the ‘treat-to-target’ ethos of DMARD escalation. In order 
to avoid being disadvantaged through participation in a clinical study, the DAS28 group were 
treated using a DMARD escalation approach that has consistently been shown to produce 
significant clinical benefits (118,146,149,407). Thus, any additional clinical benefits provided by 
MSUS assessment would have needed to be substantial in order to be measurable at a group 
level, and significantly different from the benefits experienced by the DAS28 group.  
 
Current UK guidelines restrict the prescription of anti-TNFα blocking therapies to RA patients with 
persistent high disease activity (DAS28>5.1) despite taking 2 non-biologic DMARDs for at least 6 
months each (272). In certain circumstances, these guidelines are counter to the concept of 
aggressively treating until a LDAS or remission target is reached since patients can exhibit clear 
evidence of active synovitis but may still not qualify for addition of anti-TNFα blocking therapy if 
the DAS28 score is too low. In order, that the DMARD escalation protocol of this research 
followed ‘tight control’ principles the disease activity threshold at which participants in either group 
could potentially qualify for anti-TNFα blocking therapy was substantially lowered (DAS28 group: 
DAS28<3.2; MSUS: i. PD signal 2 or more joints or ii. 3.2<DAS28≤5.1 AND SJC≤2). However, to 
ensure that participants had taken two DMARDs for at least 6 months each they were required to 
convert to subcutaneous methotrexate for a further 3 months if disease activity assessment still 
exceeded the DMARD escalation threshold despite 3 months of treatment with triple DMARD 
therapy. Thus, whilst the inclusion of a subcutaneous methotrexate step did ensure study 
participants had taken 2 non-biologic DMARDS for at least 6 months each before being 
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considered for anti-TNFα blocking therapy, it may also have delayed commencement of anti-
TNFα blocking therapy in the subset of participants who were unlikely to respond. Subsequently, 
delays in commencement of anti-TNFα blocking therapy may have reduced the studies ability to 
detect the positive clinical and radiological benefits of anti-TNFα blocking therapy within the 
remainder of the follow-up period. Most anti-TNFα therapy treated study participants continued to 
be reviewed until they had completed the 6 months of etanercept therapy they qualified for under 
the DMARD protocol. However, Sr Stirling, who conducted the outcomes assessment, was 
blinded to both DMARD treatment regimen and randomisation group so was unable to conduct 
further disease activity assessments when participants returned for additional reviews that fell 
outwith the usual 18 month follow-up period.   
 
It is unlikely that the findings of this research will be applicable to all rheumatology services. 
Some rheumatology centres favour a parallel and step-down DMARD approach (120,143) and in 
some countries prescribing guidelines allow for the prescription of anti-TNFα blocking therapy at a 
much earlier stage in the disease process. In both these contexts, MSUS disease activity 
assessment is very unlikely to alter management since a decision has already been made to 
commence patients on the highest tier of treatment.  In parallel and step-down DMARD regimens, 
MSUS disease activity assessment may serve an opposite purpose to that proposed by this 
study; to identify those patients who no longer exhibit evidence of active synovitis in whom it may 
be possible to reduce DMARD therapy. However, the efficacy of this approach requires to be 
proven in a randomised trial. 
 
In several countries, after methotrexate failure, the addition of biologic therapy (particularly anti-
TNFα blocking therapy) is favoured rather than the addition of sulphasalazine and 
hydroxychloroquine. Whilst this approach ensures that patients with persistently active disease 
are offered anti-TNFα blocking therapy at a very early point in their treatment sequence it could 
potentially lead to unnecessary, and expensive, exposure of patients to the risks of anti-TNFα 
blocking therapy when they might have responded adequately to triple DMARD therapy instead. 
Further, this approach would not be feasible under current UK anti-TNFα blocking therapy 
prescribing restrictions. Following on from the previously described SWEFOT (147,252) and 
TEAR studies (146), the recent RACAT study has examined whether choosing to add 
sulphasalazine and hydroxychloroquine instead of etanercept disadvantages RA patients who 
have experienced an inadequate response to methotrexate monotherapy (408). Overall, there 
was no significant difference in the change of any of the clinical, functional and radiographic 
outcome measures after 48 weeks. There was a tendency for the etanercept-methotrexate group 
to exhibit slightly better mean change in DAS28 after 24 weeks, mean change in HAQ after 48 
weeks and higher rates of both DAS28 LDAS and DAS28 remission. Interestingly, therapy 
switching rates were equal between both groups and patients who switched therapy tended to 
gain additional clinical response. The RACAT study has carefully reproduced a common clinical 
scenario (i.e. what is the most appropriate treatment decision after methotrexate monotherapy 
failure?) in the setting of a randomised, controlled clinical trial. The results support the DMARD 
escalation regimen chosen for this study, and also support local practice. That is, using triple 
DMARD therapy following methotrexate monotherapy failure as an interim measure in 
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methotrexate non-responders should not disadvantage the patient since, in the short term, it does 
not appear to be associated with worse clinical, functional or radiographic outcomes. Further, the 
majority of patients (75%) who use triple DMARD therapy following methotrexate monotherapy 
failure will experience improvements that are similar to those that are experienced by the addition 
of etanercept but without the additional expense or risk of treatment associated adverse effects. 
 
Bias of investigator 
The disease activity assessments and DMARD escalation decisions for all research participants 
were conducted by a single researcher. Indeed, Dr Dale was the sole rheumatologist that 
research participants met for the duration of their participation in the research. Consequently, Dr 
Dale was not blinded to participant’s randomisation groups and, through monthly calculation of 
the DAS28, had insight into how well each participant’s RA was responding to treatment. A single 
investigator should reduce the inherent variability of subjective disease activity assessments and 
ensure consistency of DMARD escalation decisions. However, there is also a risk that awareness 
of both group’s disease activity levels might introduce an inadvertent bias that favours DMARD 
escalation in the MSUS group and restricts DMARD escalation in the DAS28 group (especially 
when the disease activity assessment is on the borderline of the DMARD escalation threshold). 
Potential bias will have been partly limited by the DMARD escalation protocol which pre-defined 
DMARD escalation thresholds and the sequence of DMARD escalation. It may have been 
possible to limit bias further by blinding the Dr Dale to the method of disease activity assessment 
(i.e. an additional researcher conducts all the MSUS activity assessments) or by having separate 
clinicians responsible for the assessment and management of each group. However, at the time 
the research was being devised there was neither the staff, nor the resources, available to make 
such an arrangement 
 
Incomplete DAS28 vs MSUS dataset 
For this thesis, the results pertaining to the agreement between DAS28 and MSUS (Chapter 5) 
and those pertaining to the impact of MSUS disease activity assessment on ACR core set 
outcomes (Chapter 6) refer to different datasets. The DAS28 and MSUS comparison was 
conducted using an incomplete set of data since not all participants had completed the full follow-
up period. The available data did provide simultaneous DAS28 and MSUS disease activity 
assessment data from a substantial number of consultations which, when pooled together, 
allowed the degree of agreement between both assessment methods to be calculated. Attempts 
were made to describe the change in MSUS findings over time; however, there was only 
complete data available for MSUS group participants until follow-up month 15 since a small 
number of participants (approximately 7, 13% of MSUS group) had not yet attended for later 
reviews. Thus the presented results for follow-up months 16-18 do not represent a complete 
dataset and the final findings may be altered (marginally) by the inclusion of all missing data. By 
comparison, the results presented for the ACR core set comparison were gathered by analysing 
the complete data set and can reasonably be assumed to be an accurate representation of the 
response to MSUS guided DMARD escalation. Thus, since the data sets used by the two MSUS 
comparisons relate to slightly different numbers and sequences of consultations they may not be 
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directly compared; though, there will be considerable overlap in the implications of the findings 
from both.  
 
Absence of MSUS data for DAS28 group 
Several previous studies have demonstrated that MSUS findings do improve in response to 
changes in immunomodulatory therapy (220,373,409-413). For this research, MSUS disease 
activity assessment was only conducted on participants randomised to the MSUS assessment 
group. It is assumed that the observed changes in MSUS findings of synovial hypertrophy and PD 
signal relate to the positive influence of escalating doses of DMARD therapy and, by extension, 
the influence of the preceding disease activity assessment method. However, there is no parallel 
group against which the changes in MSUS findings can be compared. Furthermore, MSUS 
assessments were not performed on all patients at regular intervals and therefore the description 
of the change in MSUS findings over time is based on a patchy and incomplete dataset. In future 
studies, it would seem appropriate to perform MSUS disease activity assessment on all 
participants (even those who do not receive MSUS guided DMARD escalation) at every single 
consultation to: i. determine more clearly how MSUS findings change in response to changes in 
DMARD therapy and steroid administration; ii. determine whether there is any difference in the 
rate of change in MSUS findings in the control (non-MSUS assessed) group and iii. determine 
how often positive clinical responses are associated with persistence of ultrasonographic PD 
signal. 
 
It is not wholly accurate to report the same MSUS findings as both a disease activity measure 
and as a separate marker of treatment response since, even though they are clearly linked, they 
are not independently recorded. For this research, the change in MRI RAMRIS appearances of 
synovitis and bone marrow oedema between baseline and follow-up month 18 will serve as 
independent, radiographic measures of treatment response. If a MSUS measure of treatment 
response were to have been included as an outcome measure, the examination would need to 
have been performed independently of the disease activity assessment examination and, ideally, 
over a much more extensive joint set so that the ability of the limited set to represent global 
disease activity could be determined.  
 
Despite, an incomplete dataset, an irregular frequency of MSUS assessment for some 
participants, and the preceding concerns relating to the use of MSUS disease activity findings as 
a surrogate outcome measure, there did seem to be some improvement in MSUS PD findings 
over time. At the time of analysis, there was only 5 sets of paired 3 and 18 month MSUS data 
available for analysis; therefore, it was not possible to demonstrate a significant improvement in 
the MSUS findings over the whole time period. It was possible to demonstrate a significant 
improvement in PD findings between each participant’s first and last MSUS assessment (PD joint 
count: 1.78 to 1.12, p 0.004); however, this does not represent a constant time period for all 
participants, and doesn’t account for the number of MSUS assessments each participant had 
undergone. Further, the sensitivity of the MSUS assessment to describe large changes in 
inflammatory disease activity will have been restricted because the most marked clinical 
improvements occurred between baseline and follow-up month 3. Comparing changes from 
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baseline may demonstrate a much larger change in MSUS findings since it also corresponds to a 
much greater overall change in overt clinical disease activity. MSUS synovial hypertrophy joint 
count and total score did not show the same degree of improvement as PD findings over the 
follow-up period. In fact, there was no apparent reduction in either synovial hypertrophy joint 
count or total score identified. This is contrary to previous longitudinal studies that have 
suggested synovial hypertrophy findings improve in response to changes in treatment 
(220,292,332,351,413). There was considerable variation in the size, design, choice of joint set 
and treatment intervention employed by these studies. Nevertheless, even studies utilising small 
limited joint sets (such as the previously described US7 count) were able to identify significant 
reductions in total synovial hypertrophy score in patients undergoing a variety of different 
treatment changes (including step-up DMARD escalation and commencement of biologic 
therapy) (292,375).  
 
9.2 The Gene Expression Analysis 
It is perhaps odd that the findings of the gene expression analysis are so inconsistent. As an 
example, the findings suggest that 5 genes were up-regulated in rheumatoid factor positive 
patients; whereas, there was no evidence of differential expression based upon anti-CCP anti-
body status, a phenotypic trait which arguably has a much stronger link to RA pathogenesis 
(398,414). Furthermore, the analysis was unable to recreate previously reported associations 
between gene expression pattern and particular disease activity states; such as, the identification 
of a peripheral blood gene expression pattern associated with high disease activity (370,393). 
The TaSER cohort was considerably larger than many of those in previous studies that have 
suggested a positive relationship between gene expression and RA phenotype. Furthermore, a 
very high percentage (96%) of the cohort fulfilled 2010 ACR-EULAR RA classification criteria at 
first presentation. Therefore, it seems likely that the results represent gene expression profiles 
from a population of patients who would currently be recognised as suffering from RA. Since the 
results in relation to disease activity are inconsistent it is possible the multiple testings involved in 
the statistical analysis techniques will have generated some results by chance, despite prior 
attempts to normalise the data. Nevertheless, a number of the comparisons did identify 
suggestions of differential gene expression between comparator groups that were similar to 
previously reported results (e.g. differential gene expression between gender groups, gene up-
regulation in RhF positive participants, up-regulation of LRRN3 (but no other genes) in smokers). 
Altogether, a number of important additional factors must be considered in relation to these initial 
findings: 
 
Choice of target tissue  
The majority of studies comparing gene expression profile to treatment response have been 
conducted using either whole peripheral blood (239,355,390,415), PBMCs (234,382-384) from 
peripheral blood or synovial biopsy tissue (235,236,371). Examining synovial tissue seems 
sensible since it focuses on the end-target tissue of RA and will not be prone to the same external 
influences (such as comorbid illnesses and environmental exposures) that may also alter gene 
expression findings in peripheral blood. Unfortunately, the collection of synovial biopsy samples 
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continues to require a percutaneous biopsy which many patients may find either unpleasant, 
and/or unacceptable, and could limit the longitudinal assessment of changes in gene expression 
over serial synovial tissue samples.  
 
Peripheral blood provides an ideal candidate tissue in which to identify potential new and clinically 
useful markers since it is relatively easy to obtain and allows repeat testing to track longitudinal 
changes. Since RA is a systemic disease and activated immune cells are known to migrate 
between synovial sites and lymphoid organs in peripheral blood and lymph it has been presumed 
that some features of synovial differential gene expression will also be apparent in peripheral 
blood. However, the continued circulation of blood also exposes it to processes within every other 
organ system within the body. Therefore, it is quite likely that any gene expression patterns 
identified in peripheral blood will represent the collective influence of many different simultaneous 
physiological and disease-related processes. Clearly, multiple overlapping influences on 
peripheral blood will increase the potential for variability within the gene expression patterns 
whilst also reducing its overall specificity. Multiple external influences on peripheral blood gene 
expression have been identified including physiological factors (such as age, gender, body mass 
index (358,362), sampling-related factors (such as time of day and relative proportion of blood 
cell lines(358,362), environmental exposures (such as tobacco smoking, diet (353), and 
concurrent illness (such as cancer, cardiovascular disease, diabetes mellitus, or infection (416-
418). Given the potential for multiple environmental exposures and/or co-morbidities it will be 
impossible to design a sufficiently large study which accounts for every potential confounder and 
therefore there may always remain a concern that gene expression patterns identified in 
peripheral blood are related to a co-existing factor rather than the condition under investigation. 
Further, two studies, that conducted paired analyses between blood and synovial tissue samples, 
have demonstrated that evidence of differential gene expression in synovial tissue was not 
present in peripheral blood gene expression analyses (371,419). Therefore, peripheral blood may 
not be a suitable tissue for analysis if i. differential gene expression is confined to synovial tissue; 
ii. the degree of overlap in gene expression patterns between the two tissues is too small to allow 
peripheral blood gene expression to act as a surrogate for synovial tissue and iii. the specificity of 
peripheral blood is restricted through exposure to multiple external influences on gene 
expression. 
 
Potential impact of laboratory technique on gene expression  
Inherent variability within the laboratory technique may also contribute to variability in the findings 
of gene expression experiments. This is important because increased variability in the gene 
expression patterns will reduce the analyses power to identify true gene expression differences 
between groups. It is well recognised that differences in technique relating to either laboratory 
condition, reagent usage or personnel (420,421) contribute to variability in gene expression 
findings (i.e. batch effect).  Crucially, the impact of batch effect on gene expression patterns can 
produce confounded experiments where it is not possible to distinguish real biological differences 
in gene expression from variability caused by the experimental technique. Attempts are made to 
minimise the impact of technical variability on the final gene expression results by standardising 
the experimental technique: i.e. a small number of laboratory workers, analysing all samples 
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simultaneously in a single laboratory and using reagants and microarray chips from a single 
batch. Whilst the laboratory analysis technique can be standardised to minimise variability, 
additional technical factors, that often cannot be controlled, may also contribute to variability in 
gene expression findings. Commercially available RNA collection tubes (such as PAXgene RNA 
or Tempus tubes) stabilise whole blood RNA by lysing cells and preventing further transcript 
synthesis immediately after blood samples are collected. Indeed, both systems have been shown 
to deliver RNA transcripts of similar quality, breadth and abundance. However, direct comparison 
of final gene expression data has consistently shown that there is relatively little overlap in 
expression patterns identified by either system (422,423). Further, even the use of a single brand 
of RNA collection tube does not totally prevent variability of gene expression whilst the sample is 
in transit. When all other factors are equal, the length of period that the PAXgene RNA tubes are 
kept at room temperature prior to freezing has also been shown to influence final gene 
expression patterns even though it had no impact upon extracted RNA quality or quantity (424).  
 
The potential impact of non-biological variability (i.e technical factors) needs to be considered in 
relation to the gene expression analysis outputs of this research in case it had obscured evidence 
of RA-related differential gene expression. Where possible attempts were made to limit variability 
in the blood collection and analysis processes by 1. using a single batch of PAXgene RNA 
collection tubes, 2. using a single batch of Illumina HumanHT-12 v4 Beadchips and 3. performing 
the RNA extraction, microarray hybridisation and analysis on as few occasions as possible using 
a standardised workflow. Overall, the blood collection and RNA extraction processes produced 
RNA of sufficient quality for analysis. Indeed, Aglent Bioanalyser quality control analysis showed 
that only a single sample returned a RNA integrity number (RIN) less than the acceptable 
threshold of 7. However, despite these findings and attempts to standardise the experimental 
technique, a number of additional factors were present that may have influenced the final gene 
expression outputs: 
 
1. Due to the timing of consultations, and the need to travel between hospital and university 
laboratory, the period between blood sample collection and final storage was not uniform. 
The length of time was not specifically recorded though it is estimated that most PAXgene 
RNA samples remained at room temperature for between 2 and 6 hours 
2. Three different members of laboratory staff conducted the RNA extraction and microarrary 
hybridisation; therefore, there was potential for inter-operator variability in laboratory 
technique 
3. Due to the number of samples it was not possible to conduct RNA extraction or 
hybridisation on a single day; therefore laboratory conditions may not have been identical 
during the processing of each sample 
 
Previous studies have suggested that gene expression outputs may also be affected by the 
presence of excess, reticulocyte derived globin (421,423) and the relative proportion of different 
cell lines within the blood sample (425). Prior to microarray hybridisation, globin reduction 
techniques may increase the sensitivity of the analysis at the risk of reducing the variability of 
gene expression. However, for this research, globin reduction was not performed because: 1. it 
  320 
adds expense to the analysis, 2. it has not been shown to confer any advantages in relation to 
Illumina Beadchips (http://www.expressionanalysis.com/images/uploads / tech_notes/ Illumina_ 
Globin_Tech_Note_v2.pdf) and 3. risks inducing further variations in gene expression (426).  
 
Considering the complexity of the experimental technique, the multiple different potential sources 
of biological and technical variability and the inconsistency of current results it seems unlikely that 
any aspect of whole blood gene expression analysis in its present guise will be adopted into 
common rheumatological practice. The need to batch samples may prevent the eventual gene 
expression outputs providing a timely assessment of disease state and the need to carefully 
standardise laboratory techniques may prove prohibitive in busy clinical laboratories. However, it 
is unlikely that the necessary laboratory techniques will be optimised for wide spread use until 
robustly validated gene expression patterns have been identified, that relate to important clinical 
scenarios and meaningfully influence clinical practice. That being said, gene expression analysis 
by microarray serve to identify candidate gene profiles for further investigation that are then 
validated and incorporated within stable and commercially viable analysis techniques (e.g. 
ELISA) 
 
Choice of microarray platform  
Commonly used microarrays have gene probes either fixed to a static plate (e.g. Affymetrix 
Human Genome U133a Array) or attached to microscopic beads (e.g. Illumina HumanHT 
Beadchip). Each platform contains a large number of well characterised human genes, 
recognised variants and gene candidates. However, there is significant variability in the number 
and breadth of gene probes present on different microarrays. As an illustration, the Affymetrix 
Human Genome U133a 2.0 Array represents 14,500 human genes, whilst the Illumina HumanHT-
12 v2.0 Beadship represents at least 47,000 genes. Thus, the findings of gene expression 
experiments can be heavily influenced by the choice of microarray platform. Microarrays with 
lesser numbers of gene probes risk being insensitive, whereas platforms with very large numbers 
of probes risk being non-specific. Previous studies have clearly shown that analysing tissue 
extracts on different microarray platforms on different microarray platforms produces markedly 
different gene expression patterns (427-429). Therefore, it is difficult to directly compare gene 
expression findings between experiments if they have been performed on different platforms.  
 
Choice of statistical analysis technique  
Studies that describe the relationship between gene expression pattern and RA phenotype have 
been conducted using a variety of different statistical analysis techniques. Studies with small 
numbers of patients have tended to use differences in gene fold change to identify differential 
gene expression, whereas larger studies have tended to use a variety of different techniques 
based around either t-tests (e.g. significance analysis of microarrays), ANOVA or the Empirical 
Bayes method (such as Limma). Once again, the choice of statistical analysis technique 
increases the risk of variability, and therefore reduces the reproducibility, between different 
experiments. Previous studies that have applied different statistical analysis techniques to the 
same gene expression data set have shown that there is relatively little overlap (approximately 
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21%) in the gene lists identified by each technique (430,431). For this research, limma was 
chosen in preference to other techniques because of its proven performance characteristics. 
Compared to alternative techniques, limma analysis has been shown to perform consistently for 
small and large sample sizes, to have a favourable false-positive gene identification rate and to 
facilitate more complicated analyses between 2 or more comparison groups (431,432). However, 
clearly, applying an alternative statistical analysis technique may have identified different gene 
expression findings. 
 
Given the size of the cohort and the number of gene probes on the Illumina HumanHT Beadchip 
uncontrolled comparisons of expression levels of individual genes between every single 
participant would lead to a high risk of identifying evidence of differential gene expression by 
chance (i.e. a false discovery). By using an adjusted p value to correct for multiple comparisons it 
is possible to control the number of incorrectly identified incidents of differential gene expression, 
thereby reducing the likelihood of false positive findings and the risk of type I errors (319). 
Conventionally, an adjusted p value threshold of 5% (0.05) is considered evidence of significant 
differential gene expression between comparator groups. It is worth noting for this study that a 
number of the comparisons reported as positive were not achieved until the adjusted p value 
threshold had been arbitrarily increased to 15% (0.15). Thus increasing the risk that the observed 
results are not biologically relevant. This particularly relates to the comparisons between baseline 
expression profile and RhF status and baseline expression profile and 3 month DAS28<3.2. 
Differences in statistical analysis techniques may be relevant when considering that this research 
was unable to replicate the findings of previous studies describing the relationship of interferon 
response gene expression to disease activity in patients treated with rituximab (355,356). The 
experimental techniques of both studies and this research appear similar and all analysed blood 
gene expression profiles using the Illumina HumanHT-12 Beadchip (v3 for Vosslamber et al and 
Raterman et al, v4 for this research). Importantly, whilst this study employed the limma statistical 
analysis technique, the previous studies both chose the significance analysis of microarray 
technique instead. The study by Vosslamber et al did identify evidence of differential gene 
expression using a conventional false discovery threshold of 5%. However, Raterman et al did 
not identify any evidence of differential gene expression at that threshold and used a 2 fold-
difference in expression levels to define differential expression instead. Comparison of gene-fold 
changes does not take account of variance within the data set and is therefore prone to the 
influence of outliers and type 1 errors. Clearly the influence of outliers may also be exaggerated 
in a small cohort, such as the one studied by Raterman et al. However, the proposed interferon 
gene scores are based upon mean gene expression levels, and not the adjusted p value; 
therefore, the differences in statistical technique should not have influenced the calculation or 
application of interferon gene scores.  
 
Choice of comparator group descriptors  
This study chose to use DAS28 as the main descriptor of RA global disease activity and 
treatment response since it is well understood, validated and responsive to changes in disease 
activity state. Therefore, if this study had identified clear associations between RA phenotype and 
gene expression profile the potential clinical implications would be readily apparent to everyday 
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clinicians. However, as previously discussed (Section 1.4), the DAS28 can be relatively 
insensitive at very low levels of disease activity and also skewed by external, non-inflammatory 
influences. Therefore, the DAS28 may not have been a specific enough denominator and could 
have lead to grouping inconsistencies. Participants may have been classified as DAS28 
remission when in fact they still had active subclinical disease and, similarly, participants may 
have also been classified as having active disease without evidence of underlying synovitis. In 
both instances, the disconnect between the presumed and actual disease activity states may also 
have been reflected in differences of gene expression that biased the overall group gene 
expression signatures. In fact, the available results suggest that this concern may be unfounded 
since there was no evidence of differential gene expression between the sub-group of 
participants with no evidence of synovitis on MSUS and the sub-group with clear, clinically active 
disease. If there was no significant differences between participants with very evident differences 
in disease activity phenotype it is unlikely that misclassifying a small number of patients, with 
closely matched phenotypes, would have significantly skewed the overall gene expression 
findings for the group. 
 
Previous studies have demonstrated an association between gene expression profile and a 
number of different methods of classifying both disease activity and treatment response. So far, 
gene expression profiles in blood and synovial tissue have been correlated to the following 
disease activity descriptors at a single time point HAQ (377), CRP (371,377), ESR (371) and 
DAS28 (370,371). Comparisons with treatment response have been more consistent, with 
previous studies tending to use either change in DAS28 following treatment 
(234,236,238,355,356,381,382) or EULAR response criteria (241,380,381,415) to form gene 
expression comparator groups. The most commonly used definition of a good clinical response to 
treatment has been a fall in DAS28 of at least 1.2 (234,236,238,355,356,381,433) since this is the 
threshold of the minimally important difference in DAS28. For an individual patient, the gene 
expression analysis adds little to the perception of disease activity since the DAS28 (which can 
be calculated during the consultation), has already ‘detected’ a change. Equally, since current 
treatment guidelines advocate escalating treatment until patients achieve either low disease 
activity and/or clinical remission (124,169) accepting the minimally detectable change is 
inappropriate if patients continue to exhibit moderate (or higher) disease activity and/or clinically 
active disease. However, it is also worth considering that most studies describing the relationship 
between gene expression and RA treatment response were conducted in patients with 
established disease as they commenced biologic therapy whilst recent ‘treat-to-target’ treatment 
guidelines relate to the management of the very earliest stages of RA.  
 
Each of the individual components of the DAS28 is subject to variation and external influences 
and, as discussed previously, may also be associated with specific patterns of gene expression. 
Thus, whilst clinically useful, it cannot be presumed that the gene expression patterns identified 
when patients are grouped according to DAS28 are confined to the DAS28 since there are many 
additional factors that might influence its calculation. Grouping by single variables (such as 
number or distribution of swollen joints or CRP level) focuses on a single aspect of phenotype 
and presumes that the expression of this particular phenotype is related to a restricted number of 
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pathogenetic pathways that, in turn, are related to the activation states of a restricted number of 
genes. Hence, groupings based upon single variables may increase the chance of identifying 
between group differences in gene expression. In due course, the gene expression dataset for 
this study will undergo further interrogation using comparator groups based upon the levels of 
alternative, single feature, disease activity measures (such as: CRP level, ESR level, number and 
distribution of swollen joint, number and distribution of tender joints). 
 
Validation 
It is acknowledged that the gene expression analysis results presented herein represent an 
incomplete analysis. Given the nature of the findings - particularly the scarcity of significant 
positive findings - there has not (yet) been the opportunity to conduct additional analyses that are 
commonly reported in other studies of gene expression. In particular, there has not been any 
attempt to validate the presence of differential gene expression by quantitative real-time PCR 
(qPCR). Equally, there has been no attempt to determine whether any of the genes that did 
exhibit differential expression between groups is biologically plausible since, so far, none of the 
gene list data has been entered into either existing pathway analysis software or gene ontology 
databases. To ensure that no clinically relevant gene signatures are missed, additional analyses 
are planned whereby comparator groups will be formed based upon single factor disease activity 
(e.g. CRP) and phenotypic (e.g. tender + swollen joint counts) variables. Equally, since the 
individual chemical components of the VECTRA-DA relate directly to the recognised 
pathogenesis of RA, additional gene expression analyses will be performed whereby comparators 
groups are formed based upon the expression levels of the individual cytokines. Eventually, once 
the process of identifying clinical scenarios with evidence of differential gene expression has 
been exhausted, the expression levels of candidate genes will be confirmed by qPCR. Thereafter, 
the performance of the proposed gene signature will be tested prospectively in an independent 
validation cohort. If the proposed gene signature maintains the same relationship to clinical 
phenotype in both training and validation cohorts it is likely that it represents a ‘true’ finding which, 
depending upon the clinical context, may be applicable to the routine assessment of RA.  
 
9.3 The Multi-Biomarker Disease Activity Test 
Analysis 
The results of the comparison between the MBDA test, DAS28-ESR and MSUS assessments of 
global disease activity suggest that the MBDA may provide additional, useful disease activity 
information in RA patients. It is encouraging that the degree of correlation between MBDA and 
DAS28-ESR at a single time point, and change over time, is similar to those published by other 
groups. However, there are several important factors that need should be considered to place the 
results in context: 
 
Temporal relationship of disease activity to DAS28-ESR and MBDA test 
The results for this analysis were collected in parallel to an interventional study that used 
alternative disease activity measures to guide therapy escalation. Therefore, it is only possible to 
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describe the correlation between the DAS28-ESR and MBDA and presume that fluctuations in the 
MBDA test score are in part related to DMARD escalation decisions that were based upon the 
value of the DAS28-ESR. From these results it is possible to describe the degree of agreement 
and disagreement between the MBDA test and the corresponding DAS28-ESR. However, given 
the high prevalence of high MBDA disease activity in participants with low DAS28-ESR disease 
activity, it is possible that the two measures are not entirely representing the same disease 
activity states. Further, since the MBDA test was used as an accessory measure of disease 
activity, it is not possible to comment how the test score will react when DMARD escalation 
decisions are made on the basis of the MBDA. It is extremely interesting that there is a 
consistent, significant positive correlation between the MBDA test score and the DAS28-ESR; 
however, the clinical value (and safety) of the MBDA may not become apparent until it’s impact 
on disease outcomes and adverse event rates is tested in a prospective interventional study that 
uses the MBDA test score to drive DMARD escalation. It is quite possible that targeting low 
MBDA disease activity leads to a treatment burden or adverse event rate that patients, and 
clinicians, find unacceptable.   
 
Due to the time points at which research samples were taken it has only been possible to 
describe the relationship between MBDA score and DAS28-ESR at baseline and after 3 and 18 
months of follow-up. Overall, the results suggest that the steepest fall in MBDA occurs between 
baseline and 3 months of treatment, after which the rate of change is noticeably slower. This may 
be because the fastest rate of change in disease activity also occurs between baseline and 3 
months as patients are established on DMARD therapy and usually also receive frequent doses 
of systemic and/or intra-articular corticosteroids. Unfortunately, the absence of any intervening 
MBDA test results between follow-up months 3 and 18 means that it is not possible to discuss in 
detail how the MBDA fluctuates over time once a stable disease activity state has been attained.  
 
Use of DAS28-ESR rather than DAS28-CRP 
The majority of the published studies that have tested the MBDA in clinical practice  
(383,390,392,394,399) have used the DAS28-CRP as a comparator variable because the CRP is 
also a component of the MBDA biomarker set. So far, a single study (393) has described the 
relationship between DAS28-ESR and MBDA test score and demonstrated similar correlations to 
those described for the DAS28-CRP. For this study the DAS28-ESR was chosen as the 
comparator variable, since throughout the duration of the clinical study treatment decisions were 
based upon the DAS28-ESR and these results were more readily available. Overall the 
correlations between DAS28-ESR and MBDA test score are similar to those of previously 
published research, so it seems unlikely that the use of DAS28-ESR will have significantly biased 
the findings. Further, the results suggest that the relationship between MBDA and disease activity 
persists when the interdependence on the C-reactive protein level was removed. 
 
Sensitivity of MBDA in relation to alternative disease activity measures 
As previously discussed, the findings of this study have been consistent with other previous 
research; that is, during DAS28-ESR LDAS and remission the MBDA consistently detects a 
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higher level of disease activity in a subset of patients. In addition, this study also found that the 
MBDA continues to report moderate-to-high disease activity in a significant proportion of 
participants who did not have MSUS evidence of active synovitis. This suggests that the MBDA 
may be more sensitive even than MSUS for the detection of on-going synovitis. However, it 
should be noted that there was only a relatively small number of occasions (n = 35) when there 
was simultaneous DAS28-ESR and MBDA data available for comparison and the finding should 
be tested in a larger cohort. Furthermore, once the 18 month MRI outcomes become available, it 
will be extremely interesting to determine whether the incidence of MBDA moderate-high disease 
activity continues to exceed the incidence of on-going synovitis detected in corresponding MRI 
images. Equally, if MBDA does demonstrate the presence of active synovitis the presumption is 
that there should be a greater degree of agreement between MRI and MBDA findings than 
presently demonstrated between DAS28-ESR and MSUS. MRI may prove a more appropriate 
validation measure against which to test the MBDA since it is the most sensitive imaging 
technique currently available for the identification of synovitis and may help differentiate between 
how many of the elevated MBDA scores are false positives and how many of the DAS28 LDAS 
scores are in fact false negatives 
 
MSUS joint set 
All of the comparisons between MSUS and MBDA disease activity assessments have been 
conducted using the findings from the limited MSUS joint set of the main clinical study. This relies 
heavily upon the presumption that the proposed 14 joint set provides an accurate representation 
of global disease activity. Certainly, the results of the MSUS analysis demonstrate that the 
proposed joint set was a more sensitive measure of global disease activity than the 
corresponding DAS28-ESR. However, the ability of the joint set to fully represent global 
ultrasonographic activity has not been specifically tested against a much more extensive joint set. 
The degree of disagreement between the MBDA and MSUS assessments is strikingly high 
(especially in participants with high-moderate MBDA disease activity) and does question how 
much of the MBDA elevation is due to the presence of synovitis. However, the degree of 
disagreement can only be considered in relation to MBDA and the joint set proposed by this 
research; it can not relate to all methods of MSUS disease activity assessment. An alternative 
explanation for the disagreement between MBDA and MSUS assessments may be that the 
MSUS assessment was limited to too few joints and that in many cases of inactive MSUS disease 
the elevation of the MBDA was related to active synovitis within joints that were not included by 
the MSUS examination. The available results provide a useful initial assessment of the degree of 
agreement between MBDA and imaging evidence of active synovitis. A more accurate 
assessment may have been gained by using a much more extensive joint set to give a much 
clearer view of overall inflammatory joint disease activity rather than trying to extrapolate from an 
untested, limited set. 
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10. Conclusions 
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All of the results presented within this thesis are based upon one small population of patients with 
newly diagnosed rheumatoid arthritis. The initial intention of the TaSER Study had been to test 
the impact of musculoskeletal ultrasound disease activity assessment on DMARD escalation 
decisions and short-medium term outcomes in a randomised clinical trial setting. The systematic 
collection of clinical, functional and radiological outcome data has allowed a very detailed 
description of how each randomisation group has responded to the DMARD therapy administered 
over the course of the follow-up period. The routine collection and storage of a variety of 
additional blood samples at set points throughout the follow-up period has provided an 
opportunity to also compare how certain blood profiles respond to DMARD therapy at important 
decision points during a participant’s treatment sequence (i.e. after the first 3 months of DMARD 
monotherapy and after 18 months of step-up DMARD therapy). Further, the coexistence of 
corresponding clinical data has provided an opportunity to integrate the various clinical, 
ultrasonographic, gene expression and MBDA data sets to determine whether particular clinical 
and ultrasonographic features of RA phenotype (particularly disease activity state) are also 
associated with specific patterns of expression within blood. Whilst the list of analyses has not 
been exhaustive it has lead to the scope of the research evolving to consider whether novel blood 
analysis methods might provide additional means of assessing RA phenotype and/or disease 
activity.  
 
Based upon the available results it is possible to make the following conclusions in the following 
subject areas:  
 
Study cohort  
• The cohort recruited to the study were recognisable as a modern early RA population, 
having typical presenting clinical features and a very high percentage of participants who 
fulfilled ACR-EULAR 2010 classification criteria.  
 
• Compared to previous early arthritis strategic treatment studies from the same area, the 
TaSER cohort reported generally shorter disease durations and exhibited lesser levels of 
disease activity 
 
The impact of MSUS assessment on workload  
• The incorporation of MSUS disease activity assessment into routine rheumatological practice 
has the potential to significantly impact upon clinical workload by lengthening assessment 
time and altering clinical work patterns 
 
• Patients with high disease activity, or moderate disease activity and clinically evident 
synovitis, require relatively few MSUS assessments. The majority (89%) of MSUS 
assessments are performed for disease monitoring purposes in patients with DAS28 LDAS 
and a small minority (11%) are performed in patients with moderate disease activity but 
minimal clinical evidence of synovitis 
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Agreement between MSUS and DAS28ESR and impact on treatment decisions 
• DAS28 and MSUS disease activity assessments agreed on the disease state, and lead to 
the same treatment decision, on 71% of occasions. In the remaining 29% of occasions, 
MSUS disease activity findings suggested a disease activity state, and supported a 
treatment decision, that was contrary to that suggested by the DAS28 
 
• In DAS28 LDAS and remission states, approximately one quarter of MSUS disease activity 
assessments identified evidence of active disease and therefore supported DMARD 
escalation. Conversely, in instances of DAS28 moderate disease activity but minimal clinical 
synovitis, approximately two-thirds of MSUS assessments did not identify evidence of active 
disease. Therefore, in DAS28 LDAS states regular MSUS disease activity assessment will 
lead to patients receiving a higher burden of immunomodulatory therapy and, in DAS28 
moderate disease activity states without clinical synovitis regular MSUS disease activity 
assessment will lead to patients receiving a lesser burden of immunomodulatory therapy 
 
• A significant proportion of participants in both DAS28 LDAS and moderate disease activity 
will exhibit persistently negative MSUS disease activity assessments and could be 
considered as being in ultrasonographic low disease activity, if not remission 
 
• The radiocarpal and index MCP joints were most likely to exhibit evidence of PD signal 
 
Change in MSUS findings over time 
• Power Doppler joint counts and total PD scores continue to fall from follow-up month 3 
onwards.  
 
• The degree of improvement of synovial hypertrophy joint count and total score is much less 
marked than the degree of improvement of PD joint count and total PD score over the same 
time period 
 
Impact of MSUS assessment on clinical outcomes  
• Clinical and laboratory measures of disease activity and functional ability improved 
significantly in both groups. However, compared to DAS28 steered DMARD escalation, 
MSUS steered therapy was not associated with significantly better disease activity 
assessments at any time point nor a statistically greater mean improvement in DAS44 over 
the whole of the follow-up period. There were no statistically significant between group 
differences in DAS44, 44 swollen joint count, Ritchie articular index, ESR, CRP, pain 10cm 
VAS nor global health 10cm VAS at any of the time points. At 18 months follow-up, the 
MSUS group reported marginally, but not statistically significant, lower HAQ scores and had 
experienced a mean change in HAQ that was greater than the minimally important difference 
 
• The proportion of participants achieving DAS44 LDAS was similar for both assessment 
groups at each time point. After 18 months follow-up, MSUS steered DMARD therapy was 
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associated with a significantly higher rate of DAS44 remission than DAS28 steered therapy. 
The MSUS group exhibited a marginally higher rate of EULAR good responses and were 
marginally more likely to have exhibited DAS44 remission on 5 or 6 separate, and/or 
consecutive, occasions 
 
• On the basis of the clinical outcome results, it is not possible to support the routine use of 
MSUS disease activity assessment in regular practice since it is has not been associated 
with significantly better short-medium term outcomes. MSUS disease activity assessment 
may continue to have an important role in the subset of RA patients where there remains 
doubt about the clinical assessment of disease activity 
 
• The impact of MSUS driven DMARD therapy on adverse event rates, the individual 
components of the MRI RAMRIS score and the modified Sharp Score remains to be 
determined. The preceding statement about the routine use of MSUS disease activity 
assessment may be revised if MSUS steered DMARD therapy is shown to be associated 
with either lesser progression of damage on MRI RAMRIS and plain x-rays and/or greater 
improvements in RAMRIS measures of synovitis and bone marrow oedema. 
 
Relationship between whole blood gene expression profile and baseline phenotype 
• Gender groupings were associated with the most evidence of differential gene expression. 
Baseline rheumatoid factor status and smoking status was associated with differential 
expression of small numbers of genes  
 
• Baseline anti-CCP antibody status and plain radiology erosion status were not associated 
with evidence of differential gene expression 
 
Relationship between whole blood gene expression and disease activity 
• Extremes of DAS28 defined disease activity were not associated with evidence of differential 
gene expression at any of the time points 
 
• There was no evidence of differential gene expression between groups of patients with 
clinically active disease and either DAS28 remission or MSUS remission. Therefore, whole 
blood gene expression profiles do not appear to differentiate between active and inactive 
disease activity states 
 
• DMARD monotherapy was associated with dynamic changes in gene expression profile 
between baseline and month 3.  
 
• Continuing to exhibit a DAS28 of 3.2 or higher after 3 months of DMARD monotherapy was 
associated with up-regulation of 3 genes in baseline samples. There were no other predictive 
associations identified between gene expression profile and subsequent clinical course 
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• The baseline interferon response gene signature was not predictive of 3 or 12 month DAS28 
response to DMARD therapy. Furthermore, there was no relationship between the change in 
the score and the corresponding change in DAS28 between 3, 6 or 12 months. These 
findings are contrary to previously reported findings in relation to rituximab therapy 
 
• It is not currently possible to conclude that whole blood gene expression profile has a 
consistent relationship with either RA phenotype, disease activity or clinical course. 
Therefore, at present, it is unlikely that whole blood gene expression profiling could be used 
in clinical practice to provide additional, useful prognostic or disease activity information. 
Nevertheless, it is likely that whole blood gene expression profiling may continue to be used 
as an investigative technique in the attempt to better understand RA pathogenesis and the 
systemic manifestations of the disease  
 
Relationship of MBDA to DAS28-ESR and MSUS disease activity 
• The MBDA score improved significantly following commencement of step-up DMARD 
therapy and in parallel to the DAS28-ESR. Commencement of etanercept coincided with 
further improvements in the MBDA score 
 
• The MBDA score correlates positively with the corresponding DAS28-ESR at a single time 
point. Furthermore, the change in the MBDA test score also correlates positively with the 
change in the DAS28-ESR score over the same time period. These findings were similar to 
previously published results comparing the MBDA score and the DAS28-CRP 
 
• The MBDA test may be more sensitive than DAS28-ESR and MSUS assessment for the 
detection of on-going synovitis. The relationship of the MBDA test score to MRI measures of 
synovitis and bone marrow oedema remains to be determined 
 
• Baseline MBDA test score may be an independent predictor of short-medium term clinical 
response in RA patients commencing DMARD 
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Areas for Future Work 
The results generated by this research have gone someway to addressing several important 
clinical questions in relation to the assessment and management of early rheumatoid arthritis. 
However, there inevitably remain additional areas that require further investigation and 
consideration. Following on from the completion of this thesis, it is my intention to continue 
investigating the following areas: 
 
Study Cohort 
• Statistical comparison of baseline presenting features between the TICORA, TEAR and 
TaSER cohorts to describe how the characteristics of patients recruited to clinical studies of 
early RA in a single centre have changed over 14 years 
 
The impact of MSUS assessment on outcomes 
• Additional review of all participants to the TaSER study 5 years after recruitment to 
determine if there is divergence in clinical and radiological outcomes over medium-long term 
follow-up. Data to be collected includes – clinical disease activity assessment (DAS44), 
functional and quality of life assessments (HAQ and EQ-5D), estimation of work ability, plain 
radiographs of hands and feet (for grading by modified Sharp Score), assessment of co-
morbidity (including serious illness) and mortality, incidence of orthopaedic surgery and 
assessment of DMARD / biologic therapy burden. If there is evidence of divergence of 
outcomes at 5 years, further follow-up will be conducted at 10 years. 
 
• Completion of grading of radiological outcomes: baseline and 18 month plain radiographs to 
be graded according to modified Sharp Score and baseline and 18 month MRI images to be 
graded according to OMERACT RAMRIS system. Additional comparisons to include 
correlation between baseline RAMRIS synovitis and bone marrow oedema score and 
subsequent change in RAMRIS synovitis score and total modified Sharp score.  
 
Relationship between whole blood gene expression and RA phenotype 
• Subgroup comparisons restricted to participants with particular phenotypic descriptors to 
determine whether correcting for potential confounders of gene expression increases the 
likelihood of identifying evidence of differential gene expression. Potential comparisons to 
include: 
 
- limited to anti-CCP antibody positive participants, grouped by DAS28-ESR disease 
activity at a single time point (baseline and/or 3 months) with between group 
comparisons of gene expression conducted between high/low and upper/lower quartile 
DAS28 groups 
 
- limited to RhF positive participants, grouped by DAS28-ESR disease activity at a single 
time point (baseline and/or 3 months) with between group comparisons of gene 
expression conducted between high/low and upper/lower quartile DAS28 groups 
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- limited to participants initially treated with methotrexate, grouped by DAS28-ESR 
disease activity at a single time point (baseline and/or 3 months) with between group 
comparisons of gene expression conducted between high/low and upper/lower quartile 
DAS28 groups 
 
• Gathering of additional peripheral blood biomarker datasets, to include:  
- DNA genotyping (potential for targeted Immunochip analysis) – baseline samples 
- serum metabolomics – baseline, 3 month and 18 month samples 
- fine-specificity anti-CCP isotyping (verbal agreement to collaborate with Dr J Sokolove, 
University of Stanford) – baseline samples 
 
The resulting outputs of these analyses will allow a very detailed description of the genetic 
and metabolic layers that are measurable in the peripheral blood of patients with early RA. 
The relationship of each dataset will be compared to RA baseline phenotype, disease activity 
at a single time point and clinical course to determine whether any of the datasets provide 
consistent additional information regarding phenotype or disease state. Eventually, once all 
datasets are available an integrative analysis across all baseline layers of the dataset will be 
conducted to determine whether panels of biomarkers associate with short-medium term 
treatment outcome. The integrative analysis will be conducted with assistance from the 
Biostatisticians of the Glasgow Polyomics Facility 
 
Relationship of MBDA to RA disease activity 
• Comparison between 18 month MRI RAMRIS findings and 18 month MBDA score to 
determine degree of agreement. Particular focus on the relationship between high and 
moderate MBDA scores and MRI RAMRIS synovitis score 
 
• Additional future areas of interest could include: 
- gene expression profile comparison between participants with different levels of MBDA 
disease activity 
- interventional clinical trial in early RA to determine if treating to MBDA low disease 
activity is associated with improved clinical and radiological outcomes. Participants 
would be randomised to either MBDA or DAS28-CRP disease activity assessment 
groups and would all receive a step-up DMARD-biologic escalating regimen aiming for 
either low MBDA or DAS28-CRP disease activity 
 
It has been an enormous, and highly enjoyable, privilege to spend time conducting the TaSER 
Study. Hopefully, the results described herein will provide a meaningful contribution to the on-
going debate on how best to assess, monitor and treat patients with early rheumatoid arthritis. 
Taking part in this research has provided a vast number of additional experiences which I hope 
will remain with me throughout the rest of my clinical career. I have received training in the 
design, conduct and analysis of clinical trials and have also developed a degree of understanding 
of the use and limitations of musculoskeletal ultrasound. I have received extremely valuable 
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training in how best to manage patients with new diagnoses of rheumatoid arthritis: including - the 
use of aggressive step-up DMARD regimens, the inherent problems and concerns relating to 
combination DMARD therapy, the management of intercurrent illness and adverse events and 
how best to counsel and manage the expectations of patients during their treatment course. 
Throughout this I have also developed a better understanding of the natural course of rheumatoid 
arthritis and its impact on patient’s daily lives. Ultimately, I hope to apply all of these experiences 
to improve the care that I offer all patients with rheumatoid arthritis throughout the rest of my 
career. I also hope to build upon my initial research experience and remain as a research-active 
clinician with a focus on performing clinically focussed clinical trials that address pertinent issues 
relating to the disease course and management of inflammatory arthritidies. 
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Appendix A - Abbreviations 
ACR   American College of Rheumatology 
ACPA   Anti-Citrillunated Protein Antibodies 
ANA   Anti-nuclear antibody 
AUC   Area Under the Curve 
CCP   Cyclic-citrillunated peptide 
CD   Colour Doppler MSUS Examination 
CDAI   Clinical Disease Activity Index 
COMB   Combination DMARD Therapy 
CRP   C-Reactive Protein 
DAS28   28 joint Disease Activity Score 
DAS44   44 joint Disease Activity Score 
DMARD  Disease Modifying Anti-Rheumatic Drug 
ESR   Erythrocyte sedimentation rate 
EULAR   European League Against Rheumatism 
FBC   Full blood count 
FDA   Federal Drugs Agency 
HAQ   Health Assessment Questionnaire 
HAQ-DI   Health Assessment Questionnaire Disability Index 
IRG   Interferon response genes 
LDAS   Low disease activity score 
LFT   Liver function tests 
MBDA   Multibiomarker Disease Activity Test 
MCPj   Metacarpophalangeal Joint 
MRI   Magnetic Resonance Imaging 
MSUS   Musculoskeletal Ultrasound 
MTPj   Metatarsophalangeal Joint 
MTX   Methotrexate  
NHSGGC  NHS Greater Glasgow and Clyde 
OMERACT  Outcome Measures in Rheumatology 
OA   Osteoarthritis 
PD   Power Doppler MSUS Examination 
PAS / PASII  Patient Activity Scores 
PBMC   Peripheral blood mononuclear cell 
PiPj   Proximal Interphalangeal Joint 
RA   Rheumatoid Arthritis 
RADAI   Rheumatoid Arthritis Disease Activity Index 
RAI   Ritchie Articular Index 
RAPID   Routine Assessment of Patient Index Data 
RF   Rheumatoid Factor 
ROC   Receiver Operating Characteristics 
SASP   Sulfasalazine 
SERA   Scottish Early Rheumatoid Arthritis Inception Cohort 
SDAI   Simplified Disease Activity Index 
SNP   Single nucleotide polymorphism 
TFT   Thyroid function test 
TMRC   Translational Medicine Research Collaboration 
UE   Urea and Electrolytes 
UIA   Undifferentiated Inflammatory Arthritis 
ULN   Upper limit of normal 
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Appendix B – Recruitment Poster 
 
 
 
TaSER 
Targeting Synovitis in Early Rheumatoid Arthritis
Objective     to compare the effectiveness of using musculoskeletal  
      ultrasound or DAS28 to assess global disease activity   
      and guide DMARD escalation in early rheumatoid   
      arthritis using a tight control regimen
Sites     Gartnavel General Hospital, Glasgow Royal Infirmary,   
      Stobhill Hospital
Patient            Monthly reviews at local early arthritis clinic for 18 months. 
Involvement    
MIS 204630
Inclusion Criteria
1.  Patients attending Early RA clinics with newly diagnosed RA or anti-        
     CCP +ve Undifferentiated Arthritis (with 3 or more swollen joints)
2.  Symptom duration <12 months
3.  Active disease (DAS44>2.4)
4.  DMARD naïve or DMARD monotherapy for less than 6 weeks
5.  Aged 18 or more
Exclusion Criteria
1.  significant liver disease and/or abnormality of liver function tests  
     - baseline AST / ALT > x2 normal, Alkaline Phosphatase > x2.5 normal
2.  baseline renal impairment - serum creatinine > 200 µmol/l, eGFR < 30
3.  cytopaenias - white cell count < 4.0, haemoglobin < 10, platelet <  150
4.  pregnancy, planned pregnancy or breast feeding
5.  contraindication to MRI
6.  any co-morbid condition that would preclude the use of 
     combination DMARD therapy
If you meet any patient with a new diagnosis of early rheumatoid arthritis who wishes to be 
considered for inclusion please contact Dr James Dale on either 0141 211 3008 (53008) 
or 07855 823 209 or by emailing  james.dale@ggc.scot.nhs.uk
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Appendix C – Patient Information Leaflet 
 
 
 
 
Targeting Synovitis in Early Rheumatoid Arthritis (TASER) 
 
We would like to invite you to participate in the Targeting Synovitis in Early Rheumatoid 
Arthritis study. 
 
BACKGROUND 
 
Rheumatoid arthritis causes chronic inflammation in the joints, which results in pain, stiffness and 
restriction of movement. Over a period of time, this can lead to joint damage and restriction of day 
to day activities. Usually, patients with rheumatoid arthritis commence disease modifying drugs 
(methotrexate, sulfasalazine and/or hydroxychloroquine) to reduce any pain or stiffness and 
protect the joints from joint damage by dampening down the inflammation. Unfortunately, they do 
not cure the arthritis and many patients still experience some joint symptoms.  
 
AIM 
 
We are trying to improve our treatment so that as many patients as possible experience complete 
control of their arthritis. If a single disease modifying drug does not work, adding one or more 
additional drugs can be effective (although this does mean taking more medicines). In this 
research trial we are exploring whether using an ultrasound scanner (similar to the type used to 
look at babies in the womb) will improve the way that we make decisions on the treatment of the 
early stages of rheumatoid arthritis.  
 
YOUR PARTICIPATION 
 
We invite you to participate in this study and, if you agree, your treatment will be allocated 
randomly (by chance, like the toss of a coin) to either a standard assessment group or an 
ultrasound assessment group. You will be asked to attend clinic every month for 18 months. At 
each clinic visit we will take a further blood test (about two teaspoonfuls) and we will assess how 
active your arthritis is. If you are allocated to the routine group the activity of your arthritis will be 
measured by examining your joints. If you are allocated to the ultrasound group, you will still have 
your joints examined, but you may also have an ultrasound scan to look at the lining of the joint. 
This is a painless technique and usually takes about 15 minutes. In either group, if your arthritis is 
still active we will offer you additional treatment – either by increasing the dose of your tablets, by 
adding in a new treatment and/or by offering a steroid injection. 
 
TREATMENT 
 
Initial treatment will follow guidelines that are similar to current practice using medications that are 
very commonly used to treat rheumatoid arthritis. You will initially be prescribed either 
methotrexate or sulfasalazine and we will discuss which you feel is the most suitable. If you 
continue to show evidence of joint inflammation we will prescribe a combination of methotrexate, 
sulfasalazine and hydroxychloroquine. At the end of the study you will likely continue on your final 
combination of methotrexate, sulfasalazine and/or hydroxychloroquine and your on going care will 
transferred to the usual rheumatology follow-up clinic 
 
During the study period, if you continue to have joint inflammation despite the use of the 
methotrexate, sulfasalazine and hydroxychloroquine you will be offered treatment with 
etanercept, which is a ‘biologic’ or ‘anti-TNF’ drug. These drugs have been found to be more 
effective than ordinary disease modifying drugs. At present, the use of these drugs is restricted to 
patients who have very active disease, and they have usually been used in patients after several 
years of disease. However, there is evidence that they work well in patients with milder disease, 
and earlier on in the course of arthritis.  
 
Patients in this trial could be offered etanercept at an earlier stage, and in milder disease than 
would otherwise be possible. If you are considered for etanercept you will need to undergo an 
additional chest x-ray and blood test before the treatment can commence. This is to find out if you 
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have ever been exposed to tuberculosis which, occasionally, can be reactivated by etanercept. 
Furthermore, as a result of its action on the immune system etanercept can make you more 
prone to other common infections. Therefore, if you are started on etanercept and develop a sore 
throat, a fever or other features of infection you should consult the investigators urgently. Patients 
who are doing very well on etanercept, and have no joint inflammation, will have their treatment 
discontinued after six months to see if the initial benefit persists. If the joint inflammation recurs 
you may be reconsidered for either etanercept or a similar medication.  
 
You should remember that all drugs can cause side effects as well as benefits. Before you are 
prescribed any new disease modifying drug treatment, you will be given verbal and written 
information about the possible side effects and allowed time to discuss any questions that may 
arise. You are free to decline any drug treatment offered to you during the study, you are also 
free to withdraw from the study at any point. If you are prescribed methotrexate or sulfasalazine 
you will need to undergo regular blood tests (usually fortnightly at first) to monitor the effects of 
treatment. These blood tests are routine and are usually arranged through your General 
Practitioner’s surgery 
 
ASSESSMENTS 
 
At the start and the end of the trial we will take X-rays of your hands and feet and MRI scans of 
your dominant hand to determine what impact your treatment is having upon your arthritis’ 
progress. In order to perform the MRI scans we will require you to attend for two additional 
appointments; one at the start and one at the end of the study. Every 3 months (for 18 months) 
you will be reviewed by a research nurse who will assess how active your arthritis is but will not 
know which group you have been allocated. You should not discuss with the nurse which 
treatment group you have been allocated to 
 
ADDITIONAL TESTS 
 
In each group we will ask you to provide some extra blood tests (about 8 teaspoonfuls) at the 
very start, and at intervals throughout the study. Altogether, we could ask for extra blood samples 
up to 6 times throughout the course of the study. These additional blood tests will be performed 
during your regular clinic consultation. Furthermore, if we offer you a joint injection, and we drain 
some fluid from the joint, we will send the fluid for similar testing. All additional blood tests and 
fluid samples will be transported to the Translational Medicine Research Collaboration Core 
Laboratory in Dundee for analysis and storage. We plan to assess the levels of particular proteins 
and genetic factors to see if these help us predict which patients do best in the long term. All 
blood and fluid samples will be stored at the Translational Medicine Research Collaboration and 
could be used in future research projects, including genetic analysis. All stored samples will be 
anonymised and any new research projects will seek all relevant approvals and authorisations 
before starting 
 
Your participation in this trial is entirely voluntary and may not be of direct benefit to you. The 
study could result in improved treatment for patients with similar problems. If you do not wish to 
participate in the study, or choose to withdraw at any point, the standard of your care will in no 
way be affected and you need not provide a reason. If you agree to take part in this study, your 
GP will be kept informed about your participation and all your treatments. The usual NHS 
complaints and compensation scheme will be available to you. You must not take part in this 
study if you are breast feeding, pregnant, planning to become pregnant or are not using a reliable 
method of contraception. 
 
If you have any problems or queries please contact Dr Duncan Porter (0141 211 3262) or Dr 
James Dale (0141 211 3008 / 07855 823 209) 
 
Kind regards 
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Please initial 
each statement 
Appendix D – Patient Consent Form 
 
Consent Form 
 
 
Study Title: Targeting Synovitis in Early Rheumatoid Arthritis – TASER 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Participant   Print Name     Date 
 
 
Signature of Person    Print Name     Date 
taking Consent 
 
 
Signature of Researcher   Print Name     Date  
  
1.  I confirm that I have read and understood the information sheet (v6) for the 
above study and have had sufficient opportunity to ask questions 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving reason, and without my medical care or legal 
rights being affected 
 
3. I understand that sections of my medical notes may be looked at by 
responsible individuals who are either working on this study or from 
regulatory authorities where it is related to my taking part in this study. I give 
permission for these individuals to have access to my medical records 
 
4. I understand that my General Practitioner will be informed that I have 
agreed to participate in this study 
 
5. I do / do not agree to the storage of any tissue samples obtained during the 
course of this study for future medical research purposes. Any future 
research will receive additional Research Ethics approval before 
commencing 
 
6. I agree to take part in the above study 
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Appendix E – Recording Instrument for MSUS Findings 
    
Disease Activity Score:     
 
ESR   ; Tender JC   ; Swollen JC   ; Global VAS    
 
 
 Right Left 
 
Synovial 
Hypertrophy 
 
Doppler 
Signal 
Synovial 
Hypertrophy 
Doppler 
Signal 
 
 
 
 
 
Hands 
 
Index MCPj 
 
(0-3) (0-3) (0-3) (0-3) 
Index PiPj 
 
(0-3) (0-3) (0-3) (0-3) 
     
Middle MCPj 
 
(0-3) (0-3) (0-3) (0-3) 
Middle PiPj 
 
(0-3) (0-3) (0-3) (0-3) 
     
Radiocarpal 
 
(0-3) (0-3) (0-3) (0-3) 
      
 
Feet 
2nd MTPj 
 
(0-3) (0-3) (0-3) (0-3) 
5th MTPj 
 
(0-3) (0-3) (0-3) (0-3) 
      
Total Score 
 
 (0-21) (0-21) (0-21) (0-21) 
Total Index 
 
 (0-7) (0-7) (0-7) (0-7) 
 
Active RA = total Power Doppler index ≥	 2 across all joints 
 
 
Grading: per Szkudlarek et al. Arthritis Rheum 2003 
 
Synovial Hypertrophy – non-compressible hypoechoic intra-articular area (synovial thickening) 
 
Grade 0  no synovial thickening 
Grade 1 minimal synovial thickening; filling the angle between the periarticular bones, 
without bulging over the line linking tops of the bones 
Grade 2 synovial thickening bulging over the line linking tops of the periarticular bones but 
without extension along the bone diaphysis 
Grade 3 synovial thickening bulging over the line linking tops of the periarticular bones 
and with extension to at least one of the bone diaphysis 
 
Doppler Signal – extend of Power Doppler signal identified within the synovium 
 
Grade 0 no flow in the synovium 
Grade 1 single vessel signals 
Grade 2 confluent vessel signals in less than half the area of the synovium 
Grade 3 vessel signals in more than half the area of the synovium 
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Appendix F: The Health Assessment Questionnaire 
 
We are interested in learning how your illness affects your ability to function in daily life. 
 
Please mark with an X the response which best describes your usual abilities OVER THE PAST 
WEEK:  
 
1. DRESSING AND GROOMING Without With  With 
ANY  SOME  MUCH 
 UNABLE 
Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Dress yourself, including 1 q  2 q  3 q  4 q  
 shoelaces and buttons? 
 
b Shampoo your hair?  1 q  2 q  3 q  4 q  
 
2. ARISING    Without With  With 
ANY  SOME  MUCH 
 UNABLE 
Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Stand up from an armless 1 q  2 q  3 q  4 q 
 straight chair? 
 
b Get in and out of bed?  1 q  2 q  3 q  4 q 
 
3. EATING    Without With  With 
ANY  SOME  MUCH 
 UNABLE 
Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Can you cut meat?   1 q  2 q  3 q  4 q  
 
b Lift a full cup or glass   1 q  2 q  3 q  4 q  
to your mouth? 
 
c Open a new carton of milk? 1 q  2 q  3 q  4 q 
 
WALKING    Without With  With 
ANY  SOME  MUCH 
 UNABLE 
Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Walk outdoors on flat ground?  1 q  2 q  3 q  4 q  
 
b Climb up five steps?   1 q  2 q  3 q  4 q 
 
4. Please mark with an X any AIDS OR DEVICES that you usually use for any of these 
activities: 
 
1 q Walking stick  5 q Devices used for dressing (button hook, zipper 
pull, long handled shoe horn, etc.) 
 
2 q Walker   6 q Built-up or special utensils 
 
3 q Crutches   7 q Special or built-up chair 
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4 q Wheelchair   8 q Other 
 
5. Please mark with an X any categories for which you usually need HELP FROM 
ANOTHER PERSON:  
 
9 q Dressing and Grooming 11 q Eating 
 
10 q Arising   12 q Walking 
 
Please mark with an X the response which best describes your usual abilities OVER THE 
PAST WEEK: 
 
6. HYGIENE   Without With  With 
ANY  SOME  MUCH  UNABLE 
    Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Wash and dry your body? 1 q  2 q  3 q  4 q  
 
b Take a tub bath?     1 q  2 q  3 q  4 q 
 
c Get on and off the toilet?   1 q  2 q  3 q  4 q 
 
7. REACH   Without With  With 
ANY  SOME  MUCH UNABLE 
    Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Reach out and get down a  1 q  2 q  3 q  4 q  
 5-pound object (such as a  
 bag of potatoes) from just  
 above your head? 
 
b Bend down to pick up        1 q  2 q  3 q  4 q  
 clothing from the floor 
 
8. GRIP   Without With  With 
ANY  SOME  MUCH  UNABLE 
    Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Open car doors?          1 q 2 q  3 q  4 q  
 
b Open jars which have been    1 q 2 q  3 q  4 q  
 previously opened? 
 
c Turn taps on and off?          1 q 2 q  3 q  4 q 
 
9. ACTIVITIES  Without With  With 
ANY  SOME  MUCH UNABLE 
    Difficulty  Difficulty Difficulty to do 
Are you able to: 
 
a Run errands and shop?   1 q  2 q  3 q  4 q  
 
b Get in and out of a car?   1 q  2 q  3 q  4 q  
 
c Do chores such as vacuuming or 1 q  2 q  3 q  4 q  
 or garden work? 
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10. Please mark with an X any AIDS OR DEVICES that you usually use for any of these 
activities: 
 
 1 q Raised toilet seat   4 q Bathtub bar 
 
 2 q Bathtub seat   5 q Long-handled appliances for reach 
 
 3 q Jar opener (for jars   6 q Long-handled appliances in bathroom 
  previously opened) 
      7 q Other 
 
11. Please mark with an X any categories for which you usually need HELP FROM 
ANOTHER PERSON: 
 
 1 q Hygiene    3 q Gripping and opening things 
 
 2 q Reach    4 q Errands and chores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  374 
Appendix G: The EQ-5D Questionnaire 
 
By placing a tick in one box in each group below, please indicate 
which statements best describe your own health state today. 
 
Mobility 
I have no problems in walking about q 
I have some problems in walking about q 
I am confined to bed q 
 
Self-Care 
I have no problems with self-care q 
I have some problems washing or dressing myself q 
I am unable to wash or dress myself q 
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities q 
I have some problems with performing my usual activities q 
I am unable to perform my usual activities q 
 
Pain/Discomfort 
I have no pain or discomfort q 
I have moderate pain or discomfort q 
I have extreme pain or discomfort q 
 
Anxiety/Depression 
I am not anxious or depressed q 
I am moderately anxious or depressed q 
I am extremely anxious or depressed q 
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To help people say how good or bad a 
health state is, we have drawn a scale 
(rather like a thermometer) on which the 
best state you can imagine is marked 100 
and the worst state you can imagine is 
marked 0. 
 
 
 
We would like you to indicate on this 
scale how good or bad your own health is 
today, in your opinion. Please do this by 
drawing a line from the box below to 
whichever point on the scale indicates 
how good or bad your health state is 
today. 
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Appendix H: Materials for Transcriptomic Analysis 
The following lists describe the materials required to process and analyse a single PAXgene RNA 
sample using the methods described in sections 2.7.2.1 – 2.7.2.3 
 
Standard Laboratory Equipment 
 
Centrifuge 
Single chamber pipette: volumes ranging from 1µl to 4ml 
Incubation unit and thermal cycler 
Orbital shaker 
Rocker mixer 
Hybex waterbath 
Staining dish 
Slide rack holder 
Fine forceps and tweezers 
Nanodrop 1000 spectrophotometer 
Agilent Technologies Bioanalyser 
 
RNA Concentration and Purification 
 
PAXgene RNA tube containing whole blood 
PAXgene spin column 
PAXgene shredder spin column 
PAXgene processing tubes 
RNase-free water – 4ml 
Proteinase K - 350µl 
Re-suspension buffer - 350µl 
Binding buffer - 300µl 
96-100% Ethanol - 350µl 
Wash buffer 
Elution buffer - 40µl 
DNase incubation mixture: 10µl DNase I 
     70µl DNA digestion buffer 
 
cDNA Hybridisation and RNA Amplification 
 
Nuclease-free water 
Reverse transcription master mix: 1µl T7 Oligo(dT) primer 
     2µl 10X first strand buffer 
     4µl dNTP mix 
     1µl RNase inhibitor 
     1µl Arrayscript 
 
Second strand master mix: 63µl nuclease-free water 
     10µl 10X second strand buffer 
     4µl dNTP mix 
     2µl DNA polymerase 
     1µl RNase HI 
cDNA binding buffer - 250µl 
cDNA filter cartridge 
Wash buffer 
IVT master mix:   2.5µl T7 10X reaction buffer 
     2.5µl T7 enzyme mix 
     2.5µl Biotin-NTP mix 
 
cRNA binding buffer - 350µl 
ACS reagent grade 100% ethanol - 250µl 
cRNA filter cartridge 
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Illumina Beadchip Microarray Analysis 
 
Illumina HumanHT-12v4.0 Beadchip microarray chip 
Illumina BeadArray Reader 
Hybridisation chamber: comprising hybridization chamber, chamber gasket, chamber insert 
and lid 
Hybridisation tube 
Beadchip wash tray and cover 
 
Hybridisation buffer - 10µl 
Humidity control buffer – 200µl 
RNase-free water 
E1BC buffer – 3ml (dissolved in 1L RNase-free water) 
100% ethanol – 250ml 
Block E1 buffer – 6ml 
Cy3-Streptavidin – 1: 1,000 dilution 
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